Document Type: Protocol and amendments

Official Title: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

NCT Number: NCT02075840

Document Date(s): Protocol version 5: 10-Feb-2017
Protocol version 4: 15 April 2016
Protocol version 2: 8 October 2014
Protocol version 1: 10 Feb 2014
PROTOCOL

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 5 (Canada)
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: 
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: 
SPONSOR: F. Hoffmann-La Roche Ltd
DATE FINAL: Version 1: 10 February 2014
DATE AMENDED: Version 2: 8 October 2014
Version 4: 15 April 2016
Version 5 (Canada): See electronic date stamp below.

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.
PROTOCOL AMENDMENT, VERSION 5 (CANADA): RATIONALE

Protocol BO28984 has been amended to include information related to gastrointestinal perforation in order to be aligned with the approved Canadian product monograph (Section 5.1.2.4). The guideline for the management of specific adverse events has also been updated to include gastrointestinal perforation (Section 5.1.3).
PROTOCOL AMENDMENT, VERSION 5 (CANADA):
SUMMARY OF CHANGES

SECTION 5.1.2.4: Gastrointestinal Disorders

In pivotal clinical trials, one case of GI perforation (0.4%) occurred and had a fatal outcome. In the post-market setting, cases of GI perforation were also reported with alectinib.

TABLE 2: Guidelines for Management of Specific Adverse Events with Alectinib

Table 2 has been updated to include guidelines around GI perforation.
# TABLE OF CONTENTS

PROTOCOL AMENDMENT ACCEPTANCE FORM ......................................................... 11

PROTOCOL SYNOPSIS ........................................................................................................ 12

1. BACKGROUND .......................................................................................................................... 23
   1.1 Background on Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer .................. 23
   1.2 Background on Alectinib ................................................................................................. 25
   1.3 Study Rationale and Benefit-Risk Assessment .................................................................... 30

2. OBJECTIVES ........................................................................................................................... 32
   2.1 Efficacy Objectives ......................................................................................................... 32
   2.2 Safety Objectives ............................................................................................................. 33
   2.3 Pharmacokinetic Objectives ............................................................................................. 33
   2.4 Patient-Reported Outcome Objectives ............................................................................. 33
   2.5 Exploratory Objectives .................................................................................................. 33

3. STUDY DESIGN ......................................................................................................................... 34
   3.1 Description of Study ......................................................................................................... 34
   3.2 End of Study ..................................................................................................................... 36
   3.3 Rationale for Study Design ............................................................................................... 37
      3.3.1 Rationale for Alectinib Dosage .................................................................................. 37
      3.3.2 Rationale for Patient Population ................................................................................ 38
      3.3.3 Rationale for Control Group ..................................................................................... 38
      3.3.4 Rationale for Open-Label Design ............................................................................. 39
      3.3.5 Rationale for Primary Endpoint Selection ................................................................. 40
      3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression .................................. 41
      3.3.7 Rationale for PK Sample Collection Schedule ........................................................... 42
      3.3.8 Rationale for Biomarker Assessments ....................................................................... 42
      3.3.9 Rationale for PRO Assessments ............................................................................... 43
   3.4 Outcome Measures ............................................................................................................ 44
      3.4.1 Efficacy Outcome Measures ...................................................................................... 44
      3.4.2 Safety Outcome Measures ........................................................................................ 44
      3.4.3 Pharmacokinetic Outcome Measures ........................................................................ 45
3.4.4 Patient-Reported Outcome Measures .......................................................... 45
3.4.5 Exploratory Outcome Measures .................................................................. 46

4. MATERIALS AND METHODS ......................................................................... 46

4.1 Patients .......................................................................................................... 46

4.1.1 Inclusion Criteria ....................................................................................... 46

4.1.2 Exclusion Criteria ....................................................................................... 48

4.2 Method of Treatment Assignment and Blinding ........................................... 49

4.3 Study Treatment ............................................................................................. 49

4.3.1 Formulation, Packaging, and Handling ..................................................... 49

4.3.1.1 Alectinib ................................................................................................. 49

4.3.1.2 Crizotinib .............................................................................................. 50

4.3.2 Dosage, Administration, and Compliance .............................................. 50

4.3.2.1 Alectinib ................................................................................................. 50

4.3.2.2 Crizotinib .............................................................................................. 50

4.3.3 Investigational Medicinal Product Accountability ...................................... 51

4.3.4 Post-Trial Access to Alectinib ................................................................... 51

4.4 Concomitant Therapy ..................................................................................... 52

4.4.1 Permitted Therapy ....................................................................................... 52

4.4.2 Prohibited Therapy ..................................................................................... 53

4.4.3 Prohibited Food .......................................................................................... 54

4.5 Study Assessments ......................................................................................... 54

4.5.1 Informed Consent Forms and Screening Log ............................................. 54

4.5.2 Medical History and Demographic Data ................................................... 55

4.5.3 Corticosteroid Use for CNS Metastases .................................................... 55

4.5.4 Physical Examinations ............................................................................... 55

4.5.5 Vital Signs ................................................................................................... 55

4.5.6 ECOG Performance Status ....................................................................... 56

4.5.7 Tumor and Response Evaluations ............................................................. 56

4.5.8 Laboratory, Biomarker, and Other Biological Sample ............................. 57

4.5.8.1 Laboratory Assessments ......................................................................... 57

4.5.8.2 Pre-Treatment Tumor Samples (Mandatory) ......................................... 57
4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies
(Optional) .............................................................................. 58
4.5.8.4 Blood and Plasma Samples .............................................. 59
4.5.8.5 Samples for Pharmacokinetic Assessments ....................... 60
4.5.9 Electrocardiograms............................................................. 61
4.5.10 Patient-Reported Outcomes .............................................. 61
4.5.11 Samples for Roche Clinical Repository ................................ 62
4.5.11.1 Overview of the Roche Clinical Repository ...................... 62
4.5.11.2 Approval by the Institutional Review Board or Ethics Committee .............................................. 62
4.5.11.3 Sample Collection .......................................................... 62
4.5.11.4 Confidentiality ............................................................... 63
4.5.11.5 Consent to Participate in the Roche Clinical Repository .......... 63
4.5.11.6 Withdrawal from the Roche Clinical Repository ............... 64
4.5.11.7 Monitoring and Oversight .............................................. 64
4.6 Patient, Treatment, Study, and Site Discontinuation ...................... 64
4.6.1 Patient Discontinuation ....................................................... 64
4.6.2 Study Treatment Discontinuation ........................................ 65
4.6.3 Study and Site Discontinuation ......................................... 65
5. ASSESSMENT OF SAFETY .......................................................... 66
5.1 Safety Plan ............................................................................. 66
5.1.1 Adverse Events Collection ................................................. 66
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data ......................................................... 66
5.1.2.1 Interstitial Lung Disease .................................................. 66
5.1.2.2 Hepatotoxicity ............................................................... 66
5.1.2.3 Anemia .......................................................................... 67
5.1.2.4 Gastrointestinal Disorders ............................................. 67
5.1.2.5 Skin Disorders ............................................................... 67
5.1.2.6 Vision Disorders ........................................................... 68
5.1.2.7 Edema .......................................................................... 68
5.1.2.8 Bradycardia ................................................................. 68
5.1.2.9 Abnormal Renal Function ........................................ 69
5.1.2.10 Severe Myalgia and CPK Elevations ......................... 69
5.1.3 Management of Specific Adverse Events with Alectinib ............................................................................. 70
5.1.4 Safety of Crizotinib and Management of Adverse Events .................................................................................... 73
5.2 Safety Parameters and Definitions .................................... 76
5.2.1 Adverse Events .................................................................. 76
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor) ........................................................................... 77
5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor) ........................................ 77
5.3 Methods and Timing for Capturing and Assessing Safety Parameters ................................................................. 78
5.3.1 Adverse Event Reporting Period .................................... 78
5.3.2 Eliciting Adverse Event Information ............................... 78
5.3.3 Assessment of Severity of Adverse Events ..................... 78
5.3.4 Assessment of Causality of Adverse Events .................... 79
5.3.5 Procedures for Recording Adverse Events ....................... 80
5.3.5.1 Diagnosis Versus Signs and Symptoms .................... 80
5.3.5.2 Adverse Events that are Secondary to Other Events ................................................................. 80
5.3.5.3 Persistent or Recurrent Adverse Events ..................... 80
5.3.5.4 Abnormal Laboratory Values ..................................... 81
5.3.5.5 Abnormal Vital Sign Values ....................................... 82
5.3.5.6 Abnormal Liver Function Tests ................................... 82
5.3.5.7 Deaths ........................................................................ 82
5.3.5.8 Preexisting Medical Conditions ................................. 83
5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer ................................................................. 83
5.3.5.10 Hospitalization or Prolonged Hospitalization ............... 83
5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration ............................................ 84
5.3.5.12 Patient-Reported Outcome Data ................................ 84

Alectinib—F. Hoffmann-La Roche Ltd
7/Protocol BO28984, Version 5 (Canada)
Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196 1962
5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study .....................................................................................84

5.4 Immediate Reporting Requirements from Investigator to Sponsor .......................................................... 84

5.4.1 Emergency Medical Contacts ........................................................................................................... 85

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest ........................................................................................................... 85

5.4.2.1 Events That Occur Prior to Study Drug Initiation ............................................................................... 85

5.4.2.2 Events That Occur After Study Drug Initiation ...................................................................................... 85

5.4.3 Reporting Requirements for Pregnancies ............................................................................................ 86

5.4.3.1 Pregnancies in Female Patients ........................................................................................................ 86

5.4.3.2 Pregnancies in Female Partners of Male Patients ............................................................................. 86

5.4.3.3 Abortions ........................................................................................................................................... 87

5.4.3.4 Congenital Anomalies/Birth Defects ............................................................................................... 87

5.5 Follow-Up of Patients After Adverse Events .......................................................................................... 87

5.5.1 Investigator Follow-Up ............................................................................................................................ 87

5.5.2 Sponsor Follow-Up .................................................................................................................................. 87

5.6 Post-study Adverse Events ....................................................................................................................... 88

5.7 Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Ethics Committees ............................................................................................................................ 88

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN .............................................................................. 88

6.1 Determination of Sample Size .................................................................................................................. 89

6.2 Summaries of Conduct of Study ................................................................................................................ 90

6.3 Summaries of Treatment Group Comparability .......................................................................................... 90

6.4 Efficacy Analyses ...................................................................................................................................... 91

6.4.1 Primary Efficacy Endpoint .................................................................................................................... 91

6.4.2 Secondary Efficacy Endpoints ................................................................................................................ 92

6.4.2.1 Sensitivity Analyses .......................................................................................................................... 94

6.4.2.2 Subgroup Analyses .......................................................................................................................... 94

6.5 Safety Analyses .......................................................................................................................................... 94

6.6 Pharmacokinetic Analyses ....................................................................................................................... 95

6.7 Patient-Reported Outcome Analyses ....................................................................................................... 96
Alectinib—F. Hoffmann-La Roche Ltd
9/Protocol BO28984, Version 5 (Canada)
Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms ................................................................. 96
6.7.2 Additional Patient-Reported Outcomes ...............................................97
6.8 Exploratory Analyses ...........................................................................97

7. DATA COLLECTION AND MANAGEMENT .................................................98
7.1 Data Quality Assurance .........................................................................98
7.2 Electronic Case Report Forms ...............................................................98
7.3 Electronic Patient-Reported Outcome Data ..........................................99
7.4 Source Data Documentation ....................................................................99
7.5 Use of Computerized Systems ..............................................................100
7.6 Retention of Records ..........................................................................100

8. ETHICAL CONSIDERATIONS ..................................................................100
8.1 Compliance with Laws and Regulations .................................................100
8.2 Informed Consent .................................................................................100
8.3 Institutional Review Board or Ethics Committee .....................................102
8.4 Confidentiality .......................................................................................102
8.5 Financial Disclosure ............................................................................102

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION ...................................................................................103
9.1 Study Documentation ............................................................................103
9.2 Protocol deviations ..............................................................................103
9.3 Site Inspections ....................................................................................103
9.4 Administrative Structure .................................................................103
9.5 Publication of Data and Protection of Trade Secrets ...............................104
9.6 Protocol Amendments ........................................................................105

10. REFERENCES ..............................................................................................106
LIST OF TABLES

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP ........................................................ 27
Table 2  Guidelines for Management of Specific Adverse Events with Alectinib ...................................................................................... 70
Table 3  Crizotinib Dose Modification-Hematologic Toxicities (Except Lymphopenia) ............................................................................. 74
Table 4  Crizotinib Dose Modification-Non-Hematologic Toxicities ........... 75
Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE ......................................................... 79

LIST OF FIGURES

Figure 1  Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013) ......................... 26
Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ................................................................... 28
Figure 3  Best Percent Change in Size of Target Lesions from Baseline as Assessed by the Investigator in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ................................................................... 29
Figure 4  Summary of Study Design .................................................................................................................. 36

LIST OF APPENDICES

Appendix 1  Schedule of Assessments ....................................................................................................................... 111
Appendix 2  Schedule of Alectinib Pharmacokinetic Assessments ................................................................. 119
Appendix 3  List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters .................................................................................................................. 120
Appendix 4  Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication .................................................................................. 122
Appendix 5  Eastern Cooperative Oncology Group Performance Status Scale ................................................................................................................. 134
Appendix 6  EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires ............................................... 135
Appendix 7  Modification of Diet in Renal Disease (MDRD) Formula ........................................................ 143
Appendix 8  Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry .................................................. 144
Appendix 9  Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms ............................................................................................................................... 145
Appendix 10 Formulae for the Calculation of QTcF and RR .............................................................. 147
PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 5 (Canada)
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: 
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: 
SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

__________________________________________________________________________
Principal Investigator’s Name (print)

__________________________________________________________________________
Principal Investigator’s Signature Date

Please retain the signed original of this form for your study files. Please return a copy to your local study monitor.
PROTOCOL SYNOPSIS

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 5 (Canada)
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [redacted]
TEST PRODUCT: Alectinib (RO5424802)
PHASE: Phase III
INDICATION: Anaplastic lymphoma kinase–positive (ALK-positive) non–small cell lung cancer (NSCLC)
SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives

The primary efficacy objective for this study is as follows:
• To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as measured by investigator-assessed progression-free survival (PFS)

The secondary efficacy objectives for this study are as follows:
• To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of Independent Review Committee (IRC) review of radiographs by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  - To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  - To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  - To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the overall survival (OS)

Safety Objective

The safety objective for this study is as follows:
• To evaluate the safety and tolerability of alectinib compared to crizotinib
Pharmacokinetic Objective
The secondary pharmacokinetic (PK) objective for this study is as follows:
- To characterize the pharmacokinetics of alectinib and metabolite(s)

Patient-Reported Outcome Objectives
The secondary patient-reported outcome (PRO) objectives for this study are as follows:
- To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm and shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)
- To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

Exploratory Objectives
The exploratory objectives for this study are as follows:
- To evaluate and compare patient's health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement
- To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG]), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels in blood
- To evaluate and compare efficacy in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
- To evaluate and compare efficacy and safety in patients having treatment-naive ALK positive NSCLC as assessed by plasma ALK assays (polymerase chain reaction [PCR] and/or sequencing)
- To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)
- To investigate molecular mechanisms of resistance to ALK inhibitors
- To investigate detection of ALK mutations/fusions in plasma

Study Design
Description of Study
This is a randomized, active controlled, multicenter Phase III open-label study in patients with treatment-naive ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] testing). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide.

Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally twice daily (BID), taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first
dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), a local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

**Number of Patients**

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

**Target Population**

**Inclusion Criteria**

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age \( \geq 18 \) years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count \( \geq 100 \times 10^9/L \)
  - ANC \( \geq 1500 \) cells/\( \mu \)L
  - Hemoglobin \( \geq 9.0 \) g/dL
- Adequate renal function:
  - An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m\(^2\)
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- Measurable disease (by RECIST v1.1) prior to the administration of study treatment
Alectinib—F. Hoffmann-La Roche Ltd

Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.

For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.

For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinenc or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of < 1% per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate < 1% per year. Barrier methods must always be supplemented with the use of a spermicide.

For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).
- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection
- Liver disease characterized by:
  - ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  - Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  - Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
- National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication
- History of organ transplant

Alectinib—F. Hoffmann-La Roche Ltd
15/Protocol BO28984, Version 5 (Canada)
• Co-administration of anti-cancer therapies other than those administered in this study
• Patients with baseline QTc > 470 ms or symptomatic bradycardia
• Administration of strong/potent cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib
• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug for all patients and while on treatment through the end of the study for crizotinib-treated patients only (see protocol for details)
• History of hypersensitivity to any of the additives in the alectinib drug formulation (see protocol for details)
• History of hypersensitivity to any of the additives in the crizotinib drug formulation (see protocol for details)
• Pregnant or lactating women
• Known HIV positivity or AIDS-related illness
• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study
• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

Length of Study
The time from first patient screened to end of study, defined below, will be approximately 43 months.

End of Study
This study is event driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Outcome Measures
Efficacy Outcome Measures
The efficacy outcome measures for this study are as follows:
• PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.
• ORR, which is defined as the percentage of patients who attain complete response (CR) or partial response (PR); response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.
• Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months

• DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

Safety Outcome Measures
The secondary safety outcome measures for this study are as follows:
• Serious and non-serious adverse events
• Safety laboratory tests values
• Vital signs (blood pressure, heart rate), ECG
• Physical examination

Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:
• Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment

• Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%−15%, at least approximately \( n = 20 \))

• PK parameters will be determined as appropriate and where data allow:
  - The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  - Non-compartmental analysis may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

Patient-Reported Outcome Measures
The PRO measures for this study are as follows:
• EORTC QLQ-C30 and the EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue)

• The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib

Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:
• EQ-5D-3L to generate utility scores for use in economic models for the purpose of reimbursement

• Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH in blood to measure an onset of hypogonadism in adult men

Alectinib—F. Hoffmann-La Roche Ltd
17/Protocol BO28984, Version 5 (Canada)
• Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy in patients with treatment-naive NSCLC that is ALK-positive by FISH test
• ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
• Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
• ALK mutation status in plasma DNA to monitor efficacy and disease progression

Investigational Medicinal Products

Test Product
Alectinib comes in a capsule dosage form containing the following active ingredient:
[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate.
Alectinib capsules should be stored in accordance with the storage instructions on the label. Alectinib capsules should be administered orally BID with food in the morning and evening.

Comparator
Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID. For further details, see the local prescribing information for crizotinib (Xalkori®).

Non-Investigational Medicinal Products
Standard-of-care therapy administered to all patients in addition to test product or comparator.

Statistical Methods

Primary Analysis
PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.
Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.
The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.
The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.
The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:
H0: SDF (alectinib) = SDF (crizotinib)
versus
H1: SDF (alectinib) ≠ SDF (crizotinib)
where SDF denotes the survival distribution function of the parameter PFS.

Alectinib—F. Hoffmann-La Roche Ltd
18/Protocol BO28984, Version 5 (Canada)
Determination of Sample Size

The focus of this clinical trial is hypothesis testing, and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥ 2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed−platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib.

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.

In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

Interim Analyses

No interim analysis for efficacy or futility is planned.
## LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma kinase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration–time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C-DOR</td>
<td>CNS duration of response</td>
</tr>
<tr>
<td>C-ORR</td>
<td>CNS objective response rate</td>
</tr>
<tr>
<td>C-PR</td>
<td>CNS progression rate</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>DOT</td>
<td>duration of treatment</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>Eastern Cooperative Oncology Group Performance Status</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EML4</td>
<td>echinoderm microtubule-associated protein-like 4</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for the Research and Treatment of Cancer</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-3L</td>
<td>EuroQoL 5 Dimension</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FISH</td>
<td>fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>iDMC</td>
<td>independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (application)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRC</td>
<td>Independent Review Committee</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>IxRS</td>
<td>interactive voice or web-based response system</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>MET</td>
<td>mesenchymal-epithelial transition factor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NCA</td>
<td>non-compartmental analysis</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>not evaluable</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non−small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>patient-reported outcome</td>
</tr>
<tr>
<td>PS</td>
<td>Performance Status</td>
</tr>
<tr>
<td>QLQ-C30</td>
<td>Quality of Life Questionnaire−Core</td>
</tr>
<tr>
<td>QLQ-LC13</td>
<td>Quality of Life Questionnaire lung cancer module</td>
</tr>
<tr>
<td>QTcF</td>
<td>QT interval corrected using Fridericia's formula</td>
</tr>
<tr>
<td>RANO</td>
<td>Revised Assessment in Neuro Oncology</td>
</tr>
<tr>
<td>RCR</td>
<td>Roche Clinical Repository</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>RON</td>
<td>receuteur d'origine nantais</td>
</tr>
<tr>
<td>ROS1</td>
<td>c-ros oncogene 1</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Safety Analysis Population</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SDF</td>
<td>survival distribution function</td>
</tr>
<tr>
<td>SHBG</td>
<td>sex hormone-binding globulin</td>
</tr>
<tr>
<td>SLS</td>
<td>sodium lauryl sulfate</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TTD</td>
<td>time to deterioration</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine 5'-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
1. BACKGROUND

1.1 BACKGROUND ON ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON–SMALL CELL LUNG CANCER

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Lung cancer was estimated to cause 160,340 deaths in the United States in 2012, accounting for 28% of all cancer-related deaths according to the report from the American Lung Association (Lung Cancer Fact Sheet). There is an annual incidence of 310,000 cases of NSCLC in men in Europe with a mortality of 276,000 deaths (GLOBOCAN 2008). Among women in Europe, there is an annual incidence of 107,000 cases and a mortality of 91,000 deaths. In total, there are 417,000 cases of NSCLC and 367,000 deaths in Europe each year, which represents a major health problem. Survival rates for lung cancer tend to be much lower than other common cancers because of its late diagnosis and limited effective therapy in the advanced stage. The expected 5-year survival rate for all patients in whom lung cancer is diagnosed is 16.3% compared with 65.2% for colon cancer, 90.0% for breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012). Conventional anti-cancer therapies are far from satisfactory, and there is an unmet medical need for the development of new therapies for NSCLC.

Recent progress in the identification of genetic mutations or chromosomal rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other genes has provided new opportunities to use targeted therapeutic agents for the treatment of NSCLC, when the tumor is identified as having these mutations (Katayama et al. 2011; Doebele et al. 2012).

Approximately 5% of NSCLC cases have been shown to harbor the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; Ou et al. 2012). The formation of the resulting ALK fusion protein results in activation and dysregulation of the gene’s expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these genes. This is further supported by reports that the TFG and KIF5B genes can also serve as ALK fusion partners in some NSCLC patients. Expression of these ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced proliferation. ALK gene alterations are generally in a mutually exclusive relationship with mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism after treatment with crizotinib (Doebele et al. 2012). Inhibition of ALK activity in Ba/F3 cells transfected with the EML4-ALK fusion protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models harboring the EML4-ALK and
nucleophosmin-ALK fusion proteins, respectively. Hence, ALK appears to be a suitable therapeutic target for NSCLC with ALK gene rearrangements.

Wild-type ALK is expressed at very low levels in most normal human tissues, but is expressed at higher levels in a few limited types of tissue such as developing and mature nervous system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997). By contrast, an aberrant ALK with constitutively active kinase results from the formation of the EML4-ALK fusion gene by chromosomal translocation.

Currently, the only approved medicine for treatment-naive ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), recepteur d’origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

Crizotinib was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test in August 2011. The approval was based on two single-arm trials. The primary endpoint of both trials was objective response rate (ORR) as assessed by the investigator. In one study, the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks, and, in the other study, the ORR was 61% (95% CI: 52%, 70%) with a median response duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012). In November 2013, the FDA granted regular approval for crizotinib on the basis of demonstrating superior progression-free survival (PFS) and ORR for crizotinib compared with chemotherapy in patients with ALK-positive NSCLC whose disease progressed after platinum-based doublet chemotherapy (PROFILE 1007 study). An open-label active-controlled multinational randomized trial enrolled 347 patients with ALK-positive metastatic NSCLC. Patients were required to have disease progression following platinum-based chemotherapy. The trial demonstrated significantly prolonged PFS with crizotinib treatment compared with chemotherapy (hazard ratio [HR] = 0.49 [95% CI: 0.37, 0.64], p < 0.0001). Median PFS was 7.7 months for patients treated with crizotinib and 3.0 months for patients treated with chemotherapy. The ORR was significantly higher for patients treated with crizotinib (65% vs. 20%), with median response durations of 7.4 months for patients treated with crizotinib and 5.6 months for patients treated with chemotherapy. No difference in overall survival (OS) was noted between the two groups (HR = 1.02 [95% CI: 0.68%, 1.54%]) in a planned interim analysis (Shaw et al. 2013).

Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue (National Cancer Institute 2013). These results showed that an ALK inhibitor is effective in patients with NSCLC harboring ALK fusion genes. Crizotinib has subsequently been approved in other countries, such as Japan, Korea, Canada, and Switzerland. In the European Union, crizotinib was conditionally approved in October 2012 for the treatment of adults with previously treated ALK positive NSCLC.

Alectinib—F. Hoffmann-La Roche Ltd
24/Protocol BO28984, Version 5 (Canada)
Although substantial benefit has been observed with crizotinib therapy, relapse remains the norm. Studies with patients who had progression with crizotinib treatment revealed two main reasons for treatment failure: the development of resistance because of secondary (e.g., gatekeeper) mutations (predominantly in ALK or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease). The CNS is the primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC treated with crizotinib (Costa et al. 2011; Chun et al. 2012; Weickhardt et al. 2012). Significant morbidity is associated with brain metastases as a function of brain involvement, and because of treatment (corticosteroids, surgery, and radiation) required for disease control.

A new generation of ALK inhibitors will have the potential to overcome these two major limitations of crizotinib treatment and may offer patients a better chance of prolonged remission and minimize the development of CNS metastases and the attendant comorbidity.

1.2 BACKGROUND ON ALECTINIB

Alectinib (also RO5424802 or CH5424802) is a newly developed small molecule, highly selective, and potent oral next-generation ALK inhibitor with a benzo[b]carbazole scaffold. In enzyme inhibition assays performed in vitro, this compound has been shown to selectively inhibit ALK. The compound also shows high antitumor activity both in vitro and in vivo against tumor cell lines with some types of ALK gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an ALK translocation and a neuroblastoma line harboring amplified ALK gene.

Nonclinical pharmacology studies showed that alectinib is efficacious in a model of tumors expressing an ALK fusion bearing the L1196M mutation, which is associated with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC xenografts that are already maximally suppressed by crizotinib. Alectinib also prolongs survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth in an intracranial model monitored using bioluminescence.

The clinical development program for alectinib, to date, comprises three ongoing Phase I/II studies in patients with ALK-positive NSCLC. The ongoing Phase I/II studies are as follows: Study AF-001JP, which is being conducted in Japan; Study NP28761/AF-002JG, which is being conducted in United States and Canada; and Study NP28673, which is being conducted globally.

The first-in-human study AF-001JP is an open-label Phase I/II study being conducted in Japan. This study is assessing the pharmacokinetics, safety, and efficacy of alectinib in patients with ALK-positive NSCLC who are crizotinib-naive and have disease progression after at least one line of chemotherapy. This study has completed enrollment, but it is still ongoing. A total of 70 patients were included (24 patients in the...
Phase I portion and 46 patients in the Phase II portion of the study). In the Phase I portion of the study, at the data cutoff date of 31 July 2012, 24 patients were treated at doses of 20–300 mg twice daily (BID). No dose-limiting toxicities (DLTs) or adverse events of Grade 4 were noted up to the highest dose; thus, 300 mg BID was evaluated in the Phase II portion of the study without further escalating the dose. In the Phase II portion of the study, 46 patients were treated with the highest evaluated dose of 300 mg BID, of whom 43 achieved an objective response (93.5%; 95% CI: 82.1%, 98.6%) and 7 patients had a complete response (CR) on the basis of an independent radiological review in the 12-month follow-up analysis (data cutoff for response data: 18 April 2013). The median duration of treatment (DOT) in the study has not been achieved at that date because 86% of patients were still on treatment in the study, but the projected median DOT is more than 14 months as data mature.

Figure 1 shows the waterfall plot of the best change from baseline in the size of target lesions by an independent radiological review. Table 1 shows the ORR by time interval. The majority (86%) of patients had a time to response of within 6 weeks after administration of the first dose.

**Figure 1** Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013)
Two of 7 patients who were assessed as having a CR had lymph nodes as the target lesions. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), the percent change from baseline for patients with CR can be less than 100% when lymph nodes are identified as the target lesions. Therefore, they were assessed as having CR, although their tumor change from baseline was less than 100%.

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP

<table>
<thead>
<tr>
<th>Response (Data Cutoff Date: 18 April 2013)</th>
<th>IRC Assessment (N = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
</tr>
<tr>
<td>Partial response</td>
<td>36</td>
</tr>
<tr>
<td>Stable disease</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2</td>
</tr>
<tr>
<td>Total response</td>
<td>43</td>
</tr>
<tr>
<td>Overall response rate (95% CI)</td>
<td>93.5% (82.1%, 98.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to Response</th>
<th>IRC Assessment (N = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to ≤3 weeks</td>
<td>22 (51%)</td>
</tr>
<tr>
<td>&gt;3 to ≤6 weeks</td>
<td>15 (35%)</td>
</tr>
<tr>
<td>&gt;6 to ≤9 weeks</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>&gt;9 weeks</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>

IRC = Independent Review Committee.

In Study NP28761/AF-002JG (crizotinib-failed ALK-positive NSCLC patients), the Phase I portion has completed enrollment. Two ‘bridging’ cohorts of patients receiving alectinib using the 150-mg capsule at 600 and 900 mg BID were included in Study NP28761/AF-002JG to transition/facilitate the planned formulation for the Phase II trials. A total of 47 patients were enrolled in Phase I (Part 1). There does not appear to be any substantial difference in pharmacokinetics between the two formulations (20/40-mg capsule and the 150-mg capsule) at the 600-mg dose on the basis of available data.

The radiological imaging analysis performed in 44 evaluable patients who had a baseline scan and at least one follow-up scan (data cutoff date: 12 September 2013) has shown that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort have achieved a confirmed partial response (PR), as assessed by the investigator. Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort have achieved a PR, as assessed by the investigator, which is still to be confirmed. Three patients (all in the 600-mg BID dose on the basis of available data.

Alectinib—F. Hoffmann-La Roche Ltd
27/Protocol BO28984, Version 5 (Canada)
dosage cohort) were unevaluable. The ORR was 54.5% (i.e., ORR was reported for 24 of 44 evaluable patients who had a baseline scan and at least one post-treatment scan available to determine overall response, or who had a best overall response of progressive disease (PD) determined by the investigator, on the basis of symptomatic progression [3 patients]), including unconfirmed responses across all dose cohorts. Thirty-three of the 47 (70%) treated patients were still receiving study treatment. The durations of dosing by cohort are shown in Figure 2.

Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013)

The waterfall plot for the 42 patients, with a post-baseline radiological tumor assessment, is shown in Figure 3. On the basis of the data analyzed at that date, 27 patients experienced tumor shrinkage of >30%, of whom 23 patients were assessed as experiencing PR (9 of whom are still to be confirmed by a second tumor assessment).
Patients were enrolled in Study NP28673 starting on 20 June 2013 and no data are available to report at this time.

The benefit of alectinib on CNS activity has been described by the DOT (before progression) or ORR in patients with brain metastases at baseline in the two active studies: Study AF-001JP in Japan and Study NP28761/AF-002JG in the United States. In Phase II of Study AF-001JP, 14 of the 46 (30%) crizotinib-naive patients had documented CNS lesions before enrollment into the trial. Three of these 14 patients were asymptomatic and had not received prior CNS radiation. At the clinical cutoff date of 18 March 2013, 5 of the 14 patients were off-study because of systemic disease progression or an adverse event. Nine patients remain in the study with DOT ranging from 10 to 18 months (none of these patients presented signs or evidence of systemic disease or CNS progression).

Similarly, in Study NP28761/AF-002JG, among the 47 patients enrolled (data cutoff date: 12 September 2013), 21 patients (45%) were known to have brain metastases at baseline. Of these 21 patients, 11 (52%) achieved an ORR as determined by Independent Review Committee (IRC; data cutoff date: 12 September 2013) (Inoue et al. 2013). Moreover, of these 21 patients, 17 remained on active study treatment and 4 discontinued study treatment because of systemic PD (1 patient had...
both systemic disease and CNS progression). No patient discontinued because of CNS progression alone.

In addition, 2 patients with leptomeningeal carcinomatosis received benefit from alectinib treatment. One patient with leptomeningeal spread in Study NP28761/AF-002JG achieved PR after 6 weeks of treatment. Another patient with leptomeningeal carcinomatosis but without systemic lesions was treated under a single-patient Investigational New Drug (IND) application because of ineligibility to enter either of the two Phase II alectinib studies (because of the high intake of dexamethasone for symptom control). After 6 weeks of treatment, this patient achieved CR as demonstrated by complete disappearance of gadolinium enhancement on magnetic resonance imaging (MRI) and disappearance of positive CSF cytology. This patient has been able to reduce corticosteroids to physiological replacement dose only.

See the Alectinib Investigator's Brochure for additional details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Over the past 10 years, the treatment of NSCLC has become increasingly focused on guiding treatment based on the presence or absence of an actionable mutation. Numerous oncogenes have now been identified in NSCLC, including mutations in the genes coding for EGFR, KRAS, phosphoinositide-3-kinase (specifically, the catalytic α polypeptide), and EGFR 2 (Pao and Girard 2011). As described in previous sections, a translocation in the gene encoding the receptor tyrosine kinase ALK, leading to the expression of ALK fusion proteins, was identified as an oncogenic driver in a subset of patients with NSCLC (Soda et al. 2007). ALK rearrangements are found in approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012;).

Crizotinib is the first ALK inhibitor that has been approved and registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The previous clinical studies reported that the median PFS with crizotinib ranged from 7.7–9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013). The PROFILE 1014 study, a Phase III study of crizotinib compared to standard pemetrexed-platinum-based chemotherapy, was presented at the ASCO 2014 congress (Mok et al. 2014). The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p<0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively.
Although substantial benefit has been observed with crizotinib therapy, relapse eventually occurs. Two major reasons for this are the development of resistance because of secondary (e.g., gatekeeper) mutations, or CNS relapse (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). This could be due to the fact that crizotinib is a P-gp substrate and has a low penetration in the CNS. Thus, ALK-positive NSCLC treated with crizotinib has impaired control of brain metastases relative to other sites of systemic disease, with 46% of progressions in patients treated with crizotinib involving the CNS (Costa et al. 2011; Weickhardt et al. 2012). The CNS becomes a sanctuary site for ALK-positive NSCLC treated with crizotinib—a physiologic and anatomic mechanism of drug resistance.

Alectinib is a highly selective and potent oral next generation ALK inhibitor. Clinical data collection from the Phase II portion is still ongoing. Study AF-001JP, assessing alectinib in patients with ALK-positive NSCLC who are crizotinib-naive and have disease progression after at least one line of chemotherapy, reported that the median treatment duration in the study had not been achieved as 86% of patients were still active on the study, but the projected median DOT is estimated to be at least 14 months at the final point of data collection (Inoue et al. 2013).

Moreover, alectinib is a lipophilic drug and is not a P-glycoprotein (P-gp) substrate. Thus, it is able to penetrate the blood-brain barrier and has the potential to reach higher concentrations in the brain as compared to substrates of P-gp such as crizotinib. This has been shown in the nonclinical setting on the basis of the prolongation of survival in a mouse model with implanted CNS lesions and in a tissue distribution study with a single oral dose of $[^{14}C]$-alectinib at 1 mg/kg in albino rats (Ou et al. 2013). Preliminary clinical data from the Phase I/II studies show consistent therapeutic efficacy of alectinib in brain metastases.

The clinical efficacy data is compelling given the demonstrated activity for a longer progression-free interval with alectinib treatment and improved activity in the CNS. This progression-free interval delays the impact of CNS metastases on neurologic function along with the morbidities associated with treatment like brain radiation, surgery and corticosteroid use required for disease control. The currently available clinical safety data is supportive of an acceptable safety and tolerability profile with alectinib. Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for treatment-naive ALK-positive advanced NSCLC patients.

Alectinib was granted approval in Japan on 04 July 2014 for treatment of ALK fusion gene-positive, unresectable, recurrent or advanced NSCLC.

In this proposed Phase III study, treatment-naive patients with ALK-positive advanced NSCLC will be enrolled and will be randomized to receive either crizotinib or alectinib treatment. The results of this study will determine whether alectinib treatment has superior efficacy compared to crizotinib.
The first Phase I dose-escalation study of alectinib (Study AF001-JP, conducted only in Japan) with a dose schedule of 20, 40, 80, 160, 240, and 300 mg BID orally showed that alectinib was generally well tolerated without major toxicities. Of the 58 patients who received treatment with 300 mg BID alectinib in Study AF-001JP, 27 experienced Grade 3 adverse events and 9 experienced serious adverse events. No deaths were reported during this study and up to 28 days after treatment discontinuation. There were 5 adverse events leading to treatment discontinuation in Part 2 (brain edema, sclerosing cholangitis, interstitial lung disease [ILD], ALT increased, and tumor hemorrhage). Alectinib was well tolerated at all doses investigated in this study. Its adverse event profile was consistent with the one known to be associated with TKIs. In the Phase II Study NP28761/AF-002JG, alectinib was well tolerated with no DLTs or treatment-related dose modifications up to 600 mg BID. Two DLTs were reported at 900 mg BID. The recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best balance between clinical safety, efficacy, and pharmacokinetic (PK) data as observed in the Phase I/II studies (see Section 3.3.1).

On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks. Specifically:

- Available nonclinical and clinical data demonstrate that alectinib is active in NSCLC in crizotinib-naive patients as well as after progression on prior crizotinib therapy.
- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with ALK inhibitors.

Identified and potential risks associated with alectinib treatment will continue to be closely monitored throughout the clinical program. Patient safety during the alectinib program is ensured by targeting the most appropriate patient population, stringent safety monitoring by the Sponsor and independent Data Monitoring Committee (iDMC), and by protocol-specified study drug interruption criteria.

2. OBJECTIVES

2.1 EFFICACY OBJECTIVES

The primary efficacy objective for this study is:

- To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naive ALK-positive advanced NSCLC, as measured by investigator-assessed PFS

The secondary efficacy objectives for this study are:

- To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of IRC review of radiographs by RECIST v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence

• To evaluate and compare the PFS assessment by the IRC

• To evaluate and compare the OS

2.2 SAFETY OBJECTIVES

The secondary safety objective for this study is:

• To evaluate the safety and tolerability of alectinib compared to crizotinib

2.3 PHARMACOKINETIC OBJECTIVES

The secondary PK objective for this study is:

• To characterize the pharmacokinetics of alectinib and metabolite(s)

2.4 PATIENT-REPORTED OUTCOME OBJECTIVES

The secondary patient-reported outcome (PRO) objectives for this study are:

• To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm and shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)

• To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

2.5 EXPLORATORY OBJECTIVES

The exploratory objectives for this study are:

• To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement

• To evaluate and compare the onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG]), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels in blood
• To evaluate and compare efficacy in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott)

• To evaluate and compare efficacy and safety in patients having treatment-naive ALK positive NSCLC as assessed by plasma ALK assays (polymerase chain reaction [PCR] and/or sequencing)

• To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)

• To investigate molecular mechanisms of resistance to ALK inhibitors.

• To investigate detection of ALK mutations/fusions in plasma

3. STUDY DESIGN

3.1 DESCRIPTION OF STUDY

This is a randomized, active-controlled, multicenter Phase III open-label study in patients with treatment-naive ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide.

The primary endpoint of the study is investigator-assessed PFS.

Central randomization will be performed via an interactive voice or web-based response system (ixRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An ixRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by
continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from their respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Approximately 286 patients (143 per treatment arm) will be enrolled into the study over a planned competitive recruitment period of 24 months. Patients inappropriately randomized into the study will not be replaced. The final analysis evaluating the primary endpoint of investigator-assessed PFS will occur when approximately 170 patients have progressed or died, which is expected to occur approximately 33 months after the first patient has been enrolled. Data collection will continue for each patient until death or study closure, whichever occurs first.

An iDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised as outlined in Section 9.4.

A summary of the study design is shown in Figure 4.

A schedule of assessments is provided in Appendix 1.
3.2 END OF STUDY

This study is event-driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.
3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Alectinib Dosage

Selection of the alectinib dose for the study is based on the clinical safety, efficacy, and PK data observed in the Phase I/II studies, AF-001JP and NP28761/AF-002JG, and the supportive nonclinical data for alectinib.

The first-in-human study, AF-001JP evaluated escalating doses of alectinib in an accelerated titration scheme to rapidly identify the maximum tolerated dose (MTD). All doses, including the highest evaluated dose in the study, 300 mg BID, were well tolerated with no DLTs observed at any dose. The highest tested dose, 300 mg BID, was further evaluated in the Phase II portion of the study and demonstrated robust efficacy and good safety with an ORR by IRC of 93.5% (43/46 patients; 95% CI: 82.1%, 98.6%).

With no MTD determined in Study AF-001JP, dose escalation progressed in the North American Study NP28761/AF-002JG using a modified 3 + 3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation. The starting dose in Study NP28761/AF-002JG was the highest dosage evaluated in Study AF-001JP, 300 mg BID. Following multiple dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, median alectinib exposure (area under the concentration-time curve [AUC] from 0 to 10 hours) appeared to be approximately two-fold lower compared with that in patients from Study AF-001JP, which demonstrated robust efficacy and safety. Dose escalation progressed with evaluation of higher doses of alectinib up to 900 mg BID.

In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts up to dose-level of 900 mg BID. However, 2 patients in the subsequent 900 mg BID bridging cohort experienced a DLT; 1 patient had Grade 3 headache and 1 patient had Grade 3 neutropenia, and both patients continued study treatment at a reduced dosage of 600 mg BID. Overall, alectinib was well tolerated in the study population.

Importantly, administration of 600 mg BID provides systemic exposures that meet or exceed exposures achieved in patients receiving 300 mg BID in Study AF-001JP, demonstrating its robust efficacy and safety in crizotinib-naive patients. Furthermore, in Study NP28761/AF-002JG, the 600 mg BID regimen has demonstrated promising activity in crizotinib-resistant patients, including activity in patients with CNS metastases while being tolerated by patients. On the basis of available preclinical data, administration of alectinib 600 mg BID provides systemic exposures within the expected range (on the basis of regression of available data) for tumor regression observed in mouse xenograft models.

Thus, on the basis of nonclinical and clinical data, a dosing regimen of 600 mg BID of alectinib has been chosen as the optimal therapeutic dose level with the best balance between efficacy and safety.

Alectinib—F. Hoffmann-La Roche Ltd
37/Protocol BO28984, Version 5 (Canada)
Alectinib at 600 mg should be administered orally BID with food in the morning and evening.

3.3.2 **Rationale for Patient Population**

The study population will comprise patients with non-resectable, locally advanced and metastatic NSCLC who have been shown to be ALK-positive by the Ventana IHC test performed at central laboratories specially designated for the study. Patients should not have received any prior treatment for advanced NSCLC (treatment-naive).

Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted therapies. The clinical practice guidelines recommend targeted treatment for patients with metastatic, oncogene-driven disease as first-line systemic therapy (i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive NSCLC) (NCCN 2014).

To be eligible for the study, determination of ALK positivity will be performed centrally using the IHC assay (see Appendix 8) that is being developed by Ventana Medical Systems as a companion diagnostic to alectinib. IHC may replace fluorescence in situ hybridization (FISH)-based identification of ALK rearrangement as the standard companion diagnostic in the future. IHC is faster, easier to perform in local laboratories, and requires less equipment compared with the FISH assay. In addition, IHC has high concordance with FISH and a lower false-negative rate (Kim et al. 2011).

3.3.3 **Rationale for Control Group**

Targeted therapy (including ALK-targeted therapy) is likely to have a greater anti-tumor effect than standard chemotherapy, offering patients a higher response rate and longer durability of response with less toxicity compared with any potential chemotherapy options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013).

Crizotinib (Xalkori®) is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). It is the only first-generation ALK inhibitor that has been approved in multiple countries worldwide for the treatment of ALK-positive NSCLC.

In the United States, in November 2013, crizotinib was granted a regular approval for the ALK-positive NSCLC setting regardless of treatment line (XALKORI® U.S. Package Insert), whereas in Europe, crizotinib is currently only approved conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC).

The National Comprehensive Cancer Network (NCCN) guidelines recommend crizotinib as a first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014).

The randomized Phase III PROFILE 1014 study was conducted to assess the efficacy of crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or
carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC. The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p < 0.0001) for crizotinib and pemetrexed platinum-based chemotherapy, respectively (Mok et al. 2014). The authors concluded that these findings support crizotinib as the standard of care for patients with previously untreated advanced ALK-positive non-squamous NSCLC (Mok et al. 2014).

Crizotinib will be dosed as per standard dose recommendations from prescribing information; patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death. See Section 5.1.4 for criteria for dosing interruption and/or dose reduction for treatment with crizotinib.

3.3.4 Rationale for Open-Label Design
An open-label study design is more appropriate for patients enrolled in this particular trial for a number of reasons described below, and with the ultimate goal to ensure patient compliance as much as possible.

For a blinded study design, all enrolled patients would be required to take five large capsules twice per day. This high pill count results from the difference in capsule size between crizotinib (size 0) and alectinib (size 1). Each dose would comprise one 250-mg capsule of crizotinib or matching placebo and four 150-mg capsules of alectinib or matching placebo. In order to blind, crizotinib capsules must be over-encapsulated. That further increases the size of a capsule from size 0 to size 00. Size 00 is usually the largest capsule size used orally for humans. For some patients, size 00 capsules are too large to swallow. This high pill count of large capsules is considered to be a significant burden to patients and increases the risk of non-compliance.

Additionally, a blinded study would increase the complexity of standard dose reductions. Dose interruption or dose reduction may be required on the basis of individual safety and tolerability. The standard dose reductions for crizotinib would be 200 mg BID (different capsule, size 1), followed by 250 mg QD. Dose reductions for alectinib would occur in 150-mg steps. In a double-blind study, these multiple step dose reductions introduce a high level of complexity and potential for error.

In order to avoid a significant burden to patients with high pill count, increased risk of non-compliance, and complexity of standard dose reductions, adequate steps have been taken to ensure the validity of the data in an open-label study design. These include performing a supportive analysis of efficacy on the basis of determining progression by an IRC, performing sensitivity analyses to demonstrate the robustness of the primary endpoint, defining progression using established response evaluation criteria (RECIST v1.1), performing tumor assessment at the same frequency in both arms and adhering to protocol-defined schedules, and finalizing the strategy for the final analysis.
of the primary endpoint before trial start, including developing predefined methods for handling missing data and censoring rules. Efficacy analyses will only be performed at the pre-specified analysis timepoints in the protocol (final analysis once 170 PFS events have occurred and survival follow-up analysis at 143 events).

3.3.5 Rationale for Primary Endpoint Selection

The investigator-assessed PFS (which will be supported by IRC-assessed PFS analysis, one of the secondary endpoints of the study) is the primary endpoint for this trial.

PFS, as an endpoint, can reflect tumor growth and can be assessed before the determination of a survival benefit, and its determination is not generally confounded by subsequent therapies. Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit of the new treatment compared to available therapies (Guidance for Industry 2007; European Medicines Agency 2012). A PFS HR of 0.65 will be targeted, which constitutes a clinically meaningful benefit in this patient population as it will delay the use of platinum-based chemotherapy and will potentially reduce the frequency of CNS relapse and the morbidity associated with treating CNS metastases.

The assumed median PFS of patients in the alectinib treatment arm is 16.8 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 13 months. Patients with ALK-positive NSCLC treated with crizotinib in the second-line setting had a median PFS of 7.7 months and an interim median OS of 20.3 months (Shaw et al. 2013), which equated to a post-progression survival of 12.6 months. This lengthy post-progression survival provides an opportunity for subsequent treatment with other ALK inhibitors, several additional lines of chemotherapy, or participation in additional clinical trials.

Patients in both study arms who experience disease progression on study treatment will likely be treated with other subsequent treatment options, including ALK inhibitors. The availability of crizotinib on the market, as well as the likely availability of other next-generation ALK TKIs, and the availability of other investigational agents in clinical trials offer potential treatment options to patients in the study who will eventually have disease progression. Subsequent therapies frequently confound the detection of an OS benefit, particularly in a setting with a long post-progression survival, such as ALK-positive NSCLC. This has been observed in trials for EGFR TKIs, in which strong PFS benefits were observed without evidence of OS benefit (Rosell et al. 2009; Fukuoka et al. 2011).

The long post-progression survival and the confounding effects of subsequent lines of therapy indicate that it would be difficult to detect an OS benefit in this setting. Nevertheless, OS is one of the study’s secondary endpoints. The crossover from the crizotinib arm to alectinib will not be allowed in this study, with the aim of preserving the trial’s ability to potentially demonstrate some degree of treatment benefit of alectinib in
OS. However, the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.

To ensure the validity of the PFS as the primary endpoint, a number of measures have been implemented: full IRC assessment to support the analysis of the primary endpoint, a substantial target magnitude of benefit (target HR = 0.65) and study assessments that will allow a robust evaluation of risk-benefit (standard RECIST criteria to define progression with fixed assessment intervals that are identical in both treatment arms and a robust definition of PFS and prospectively defined methods to assess, quantify, and analyze PFS, including censoring methods and sensitivity analyses).

### 3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression

Lung cancer is the most common type of cancer to spread to the brain, with at least 40% of people with lung cancer developing brain metastases at some point during their disease. ALK-positive NSCLC has a propensity to metastasize to the brain, and crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease (Chun et al. 2012).

Delaying or preventing the development of CNS metastases would provide patients with clinically meaningful benefit by avoiding consequences of neurological deficits from brain metastasis or by delaying/preventing long-term side effects associated with steroid use and brain irradiation.

Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase I/II studies. See Section 1.2 and Alectinib Investigator’s Brochure for additional details.

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression is documented. The aim of the pre-specified analysis will be to evaluate whether alectinib significantly delays or prevents the development of CNS metastases.

Randomization of the Phase III study will be stratified by the presence or absence of CNS metastasis at baseline.

Imaging analysis by consistently used uniform image acquisition technique (MRI scans) will be performed routinely at baseline and at subsequent follow-up assessments along with every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical suspicion of CNS metastasis) in order to achieve an accurate determination of time to CNS progression. This ensures that early brain metastatic lesions are detected and that assessment bias between the two arms is avoided by having regularly scheduled scans.
An independent central radiological review will be performed for all patients and the analysis of time to CNS progression or response will be based on the data from the independent review. The review will be based on the standard RECIST v1.1 criteria to assess the CNS lesions, and a second independent review on the basis of the RANO criteria, which are typically used to assess brain tumors (Wen et al. 2010), will be performed. The assessment will be performed independently from the overall disease progression assessment.

3.3.7 **Rationale for PK Sample Collection Schedule**

To date, the pharmacokinetics of alectinib have been characterized in chemotherapy-failed, crizotinib-naive patients with NSCLC in Study AF-001JP and in patients who have failed chemotherapy and crizotinib treatment in Study NP28761/AF-002JG and Study NP28673. In order to better understand the pharmacokinetics of alectinib and to further support the development of a robust population PK model for alectinib in order to better understand, identify, and characterize variables which lead to changes in exposure, characterization of alectinib pharmacokinetics will be done in this study. This study will include PK assessment of alectinib in ALK inhibitor treatment-naive patients with ALK-positive advanced NSCLC by collecting trough samples from all patients receiving alectinib. Serial/intensive PK samples will be collected from a subset of patients (10%–15% [at least n=20] of patients receiving alectinib) to facilitate the PK assessment. The data that will be collected from this study will enable more robust understanding of alectinib pharmacokinetics in the global crizotinib-naive population including investigation and potential identification of sources of variability influencing alectinib pharmacokinetics and/or response to alectinib therapy. Results from PK data collection in this study and analyses of PK data could help support optimal use of alectinib therapy.

3.3.8 **Rationale for Biomarker Assessments**

Several molecular mechanisms of resistance to crizotinib have been reported in the literature: increased copy number of ALK gene, increased expression of ALK mRNA, secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased copy number, increased phosphorylation, or point mutations) in escape genes such as EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). In order to investigate molecular mechanisms of resistance to ALK inhibitors and ALK mutation status, tumor samples will be collected before treatment and at the time of disease progression with the goal of sequencing nucleic acids. Two types of approaches will be used: 1) targeted sequencing of a panel of genes known to be involved in cancer and 2) unbiased genomic sequencing.

Mutations in cancer genes appearing from drug resistance can be monitored in circulating nucleic acids in plasma (Forshew et al. 2012). Tumor nucleic acids are shed into circulation in amounts that allow direct amplification by PCR and sequencing. Plasma samples will be collected before treatment and at certain timepoints during
treatment to monitor mutations in ALK and other genes involved in resistance to ALK inhibitors. Information from mutated genes in the tumor will be correlated with mutations in plasma DNA.

Determination of ALK positivity will be initially performed by Ventana IHC (see Appendix 8). In addition, the Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. For exploratory purposes, other methods to determine ALK positivity (e.g., reverse transcription-PCR) may also be used. Currently, ALK positivity for fusions can only be determined in tissue samples using assays such as FISH, IHC or PCR. As tissue sampling is difficult and tissue biopsy sample sizes from lung cancer patients are very small, testing of several important biomarkers is challenging. Many NSCLC patients may not have enough tumor tissue available and therefore cannot be tested for some biomarkers such as ALK. Plasma ALK assays analyzing circulating tumor nucleic acids will enable more NSCLC patients to be tested for ALK fusions. Information from plasma ALK assays will be used to investigate the use of circulating tumor nucleic acids from plasma as a surrogate for tumor tissue for diagnostic purposes.

### 3.3.9 Rationale for PRO Assessments

In the treatment of lung cancer, it is important to both increase survival and palliate symptoms because disease symptoms have negative impacts on HRQoL (Hyde and Hyde 1974; Hopwood and Stephens 1995; Sarna et al. 2008). This is especially true for trials that use PFS as a primary endpoint, where it is important to translate the delay in disease progression into an endpoint that is meaningful to patients.

Pain (chest; arm and shoulder), dyspnea, cough, and fatigue have been regarded as the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC. The BR.21 study (erlotinib vs. chemotherapy in second- or third-line NSCLC) demonstrated that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ-C30 and QLQ-LC13 was consistent with superior PFS, OS, and quality-of-life benefits in the erlotinib arm as compared with the placebo arm (Aaronson et al. 1993; Bergman et al. 1994; Bezjak et al. 2006). Additionally, patients in the crizotinib PROFILE 1005 trial reported clinically significant improvements (by 10 points) in the pain, cough, dyspnea, and fatigue symptom scales seen as early as 2 weeks on treatment (Crinò et al. 2011).

The EORTC QLQ-C30 and QLQ-LC13 were used in the Phase III PROFILE 1007 study (second-line crizotinib vs. chemotherapy). The study reported significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than with chemotherapy (p < 0.001 for all comparisons, without adjustment for multiple testing). Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. There was also a significantly greater overall improvement from baseline in
the global quality of life among patients who received crizotinib treatment than among those who received chemotherapy ($p < 0.001$). In all domains measuring function, except for the domain measuring cognitive function, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Shaw et al. 2013).

Therefore, to assess the quality of life of patients in this trial, PRO data will be collected from patients enrolled in this study using the validated questionnaires EORTC QLQ-C30 and QLQ-LC13.

### 3.4 OUTCOME MEASURES

#### 3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

- **PFS**, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.

- **ORR**, which is defined as the percentage of patients who attain CR or PR; response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.

- **Time to CNS progression**, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.

- **DOR**, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

- **OS**, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

#### 3.4.2 Safety Outcome Measures

The safety outcome measures for this study are as follows:

- Serious and non-serious adverse events
- Safety laboratory tests values
3.4.3 **Pharmacokinetic Outcome Measures**

The PK outcome measures for this study are as follows:

- **Sparse (pre-dose) PK samples** for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment. See Appendix 1 and Appendix 2 for PK sampling times.

- **Serial/intensive PK sampling** will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n=20). See Appendix 1 and Appendix 2 for PK sampling times.

- **PK parameters** will be determined as appropriate and where data allow:
  - The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  - Non-compartmental analysis (NCA) may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

3.4.4 **Patient-Reported Outcome Measures**

The PRO measures included for this study are as follows and will be administered to patients every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months:

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post-treatment.

For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.

**Alectinib—F. Hoffmann-La Roche Ltd**

45/Protocol BO28984, Version 5 (Canada)
3.4.5 **Exploratory Outcome Measures**

The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for the purpose of reimbursement
- Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH in blood to measure the onset of hypogonadism in adult men
- Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy in patients with treatment-naive NSCLC that is ALK-positive by FISH test
- ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
- ALK mutation status in plasma DNA to monitor efficacy and disease progression

4. **MATERIALS AND METHODS**

4.1 **PATIENTS**

The target population is patients with treatment-naive, ALK-positive, non-resectable, locally advanced and metastatic NSCLC.

4.1.1 **Inclusion Criteria**

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIB not amenable to multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count ≥ 100 × 10⁹/L
  - ANC ≥ 1500 cells/µL
  - Hemoglobin ≥ 9.0 g/dL
• Adequate renal function:
  An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m²
• Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
• Measurable disease (by RECIST v1.1) prior to the administration of study treatment
• Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
• For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
• For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide.
• For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
• Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.
4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal [GI] cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).
- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection
- Liver disease characterized by:
  - ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  - Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  - Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
- National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication
- History of organ transplant
- Co-administration of anti-cancer therapies other than those administered in this study
- Patients with baseline QTc > 470 ms or symptomatic bradycardia
- Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3)
- Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug for all patients and while on treatment through the end of the study for crizotinib-treated patients only (see Section 4.4.2 for further details)
- History of hypersensitivity to any of the additives in the alectinib drug formulation (see Section 4.3.1.1 for further details)
- History of hypersensitivity to any of the additives in the crizotinib drug formulation (see Section 4.3.1.2 for further details)
- Pregnant or lactating women
- Known HIV positivity or AIDS-related illness
Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study

Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

This is an open-label trial, for which the rationale is described in Section 3.3.4.

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block-stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Central randomization and drug pack number allocations will be performed and managed by an IxRS. Further details will be provided in an IxRS manual.

The independent review of scans for the secondary endpoints of PFS and time to CNS progression on the basis of IRC will be performed in a blinded fashion.

4.3 STUDY TREATMENT

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Alectinib

Alectinib comes in a hard capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, sodium lauryl sulfate (SLS), and magnesium stearate as excipients.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food in the morning and evening.
The formulation contains SLS as an excipient. This excipient is known to be potentially associated with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

For further details, see the alectinib Investigator's Brochure.

**4.3.1.2 Crizotinib**

Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (XALKORI® U.S. Package Insert).

**4.3.2 Dosage, Administration, and Compliance**

**4.3.2.1 Alectinib**

Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food in the morning and evening.

If a patient misses a dose, it can be taken within 6 hours of the scheduled time. If the time is greater than 6 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

Guidelines for dosage modifications and treatment interruptions or discontinuation due to specified adverse events are provided in Section 5.1.3.

Any overdose or incorrect administration of study drug should be noted on the Study Drug Administration electronic Case Report Form (eCRF). Adverse events associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF.

**4.3.2.2 Crizotinib**

Crizotinib at 250 mg (one 250-mg capsule) should be administered orally BID with or without food (in the morning and evening).

If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose of crizotinib, the next dose should be taken as scheduled.

If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to
250 mg taken once daily. Guidelines for dosage modification and treatment interruption or discontinuation are provided in Section 5.1.4.

Any overdose or incorrect administration of crizotinib should be noted on the crizotinib Administration eCRF. Adverse events associated with an overdose or incorrect administration of crizotinib should be recorded on the Adverse Event eCRF.

4.3.3 Investigational Medicinal Product Accountability

All investigational medicinal products (IMPs) required for completion of this study (alectinib and crizotinib) will be provided by the Sponsor where required by local health authority regulations. The study site will acknowledge receipt of IMPs and confirm the shipment condition and content. Any damaged shipments will be replaced.

IMPs will either be disposed of at the study site according to the study site’s institutional standard operating procedure or returned to the Sponsor with the appropriate documentation. The site's method of IMP destruction must be agreed to by the Sponsor. The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.

Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the study site should be recorded on the Drug Inventory Log.

4.3.4 Post-Trial Access to Alectinib

The Sponsor will offer post-trial access to the study drug alectinib free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below.

A patient will be eligible to receive study drug after the end of the study if all of the following conditions are met:

- The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being
- There are no appropriate alternative treatments available to the patient
- The patient and his or her doctor comply with and satisfy any legal or regulatory requirements that apply to them

A patient will not be eligible to receive study drug after the end of the study if any of the following conditions are met:

- The study drug is commercially marketed in the patient's country and is reasonably accessible to the patient (e.g., is covered by the patient's insurance or would not otherwise create a financial hardship for the patient)
- The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for ALK-positive NSCLC
• The Sponsor has reasonable safety concerns regarding the study drug as treatment for ALK-positive NSCLC
• Provision of study drug is not permitted under the laws and regulations of the patient's country

The Roche Global Policy on Continued Access to Investigational Medicinal Product is available at the following Web site:

http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf

4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from screening to the study completion/discontinuation visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

All therapy and/or medication administered to manage adverse events should be recorded on the Adverse Event eCRF.

The medications and/or treatments below are permitted:

• Anticoagulants and antithrombotic agents (i.e., coumadin-derived anticoagulants, unfractionated heparin or low-molecular heparins, aspirin (≤325 mg/day), and clopidogrel)
• Acetaminophen up to 2 g/day
• Gastric pH elevating medications (such as proton pump inhibitors, H2 blockers, or antacids)
• Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients with isolated asymptomatic CNS progression (e.g., new CNS oligometastases).

Caution should be exercised when the following are co-administered with alectinib:

• For medications that are substrates of P-gp transporter or breast cancer resistance protein transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of these transporters. Substrates with a narrow therapeutic index (e.g., methotrexate, digoxin) should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

Caution should be exercised when the following are co-administered with crizotinib:

• Crizotinib has been shown to be a moderate inhibitor of CYP3A. Dose reduction may be needed for co-administered drugs that are predominantly metabolized by
CYP3A in patients receiving crizotinib. Concurrent use of CYP3A substrates with narrow therapeutic indices should be avoided (see Appendix 3).

- On the basis of an in vitro study, crizotinib is predicted to inhibit intestinal P-gp. Therefore, administration of crizotinib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their therapeutic effect and adverse reactions (see Appendix 3). Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.

- Bradycardia has been reported during clinical studies; therefore, avoid using crizotinib in combination with other agents known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) to the extent possible.

- In vitro studies in human hepatocytes indicated that crizotinib may induce pregnane X receptor and constitutive androstane receptor-regulated enzymes (e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1). However, there was no observed induction in vivo when crizotinib was coadministered with the CYP3A probe substrate midazolam. Caution should be exercised in administering crizotinib in combination with medicinal products that are predominantly metabolized by these enzymes. Of note, the effectiveness of concomitant administration of oral contraceptives may be altered.

- In vitro studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered drugs that are metabolized by CYP2B6 (e.g., bupropion, efavirenz).

### 4.4.2 Prohibited Therapy

Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) is prohibited during the study and for at least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless otherwise specified below. Exceptions to restrictions of the concomitant therapies listed below (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) may be made if the rationale is discussed and documented between the investigator and the Sponsor’s Clinical Pharmacologist.

- Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s wort [Hypericum perforatum]) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drugs (see Appendix 3).

- Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drug (see Appendix 3).

- Any concomitant medications known to affect QT interval duration, including but not limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone, and quinidine, within 2 weeks before the first dose of study drug treatment for all
patients and while on treatment through the end of the study for crizotinib-treated patients only

- Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents (other than study drug treatment), ergot derivatives, probenecid, and bile acid-binding resins while on study treatment.
- Systemic chemotherapy.
- Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions or for pain control. If palliative radiation is indicated for bone metastases, palliative radiation may start within 24 hours of the last dose of alectinib, unless, in the judgment of the investigator, patient safety will require a longer washout period prior to palliative therapy. Dosing of alectinib may resume with the resolution of any radiation toxicity to \( \leq \) Grade 1.
- Additional investigational drug (except for during the follow-up period)

The list of medications provided above is not necessarily comprehensive. Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication strongly inhibits or induces CYP3A. In addition, the investigator should contact the Medical Monitor if questions arise regarding medications not listed above.

http://medicine.iupui.edu/clinpharm/ddis/table.aspx (for P450 drug interactions)

4.4.3 Prohibited Food

Use of grapefruit or grapefruit juice should be avoided during the study and for at least 14 days prior to the initiation of study treatment (either alectinib or crizotinib) because it is a potent CYP3A inhibitor and may increase plasma concentration of either alectinib or crizotinib.

4.5 STUDY ASSESSMENTS

See Appendix 1 for the schedule of assessments performed during the study.

4.5.1 Informed Consent Forms and Screening Log

Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site.

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.
4.5.2 Medical History and Demographic Data

Medical history includes a record of clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 28 days prior to the screening visit.

Demographic data will include age, sex, and self-reported race/ethnicity.

4.5.3 Corticosteroid Use for CNS Metastases

For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake should be captured at all tumor assessment visits and compared to the corticosteroid intake at the time of the last disease assessment. The changes will be recorded as Increased, Unchanged, or Decreased. Increases and decreases in corticosteroid intake should be clinically justified. Increases in corticosteroid dose for reasons other than for CNS metastases control do not need to be taken into consideration when making this comparison.

4.5.4 Physical Examinations

A complete physical examination at screening and baseline should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems as well as height and weight. Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.

At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations should be performed. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant abnormalities should be recorded as adverse events on the Adverse Event eCRF.

Note: for patients with known CNS metastases, a neurological examination must be performed at each tumor assessment visit and compared to the neurological examination performed at the time of the last disease assessment. Definition of clear neurological worsening is difficult to describe because progression in the CNS can present in numerous ways. Accordingly, evaluation of neurological function at each disease assessment will be based purely on the investigator’s assessment of the patient’s neurological state compared to the neurological function at the time of the last disease assessment. Neurological status will be recorded as Improved, Stable, or Worsened.

4.5.5 Vital Signs

Vital signs will include measurements of respiratory rate, oxygen saturation, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

Alectinib—F. Hoffmann-La Roche Ltd
55/Protocol BO28984, Version 5 (Canada)
4.5.6 **ECOG Performance Status**

Performance Status (PS) will be measured using the ECOG PS Scale (see Appendix 5). It is recommended, where possible, that a patient’s PS be assessed by the same person throughout the study.

4.5.7 **Tumor and Response Evaluations**

Disease burden must be documented at screening and re-assessed at each subsequent tumor evaluation. Response will be assessed by the investigator on the basis of physical examinations. Clinical lesions will be documented by color photography (with caliper measurement for measurable lesions), computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4). For assessing response in patients with measurable disease, the preferred radiologic tumor response assessment is CT scan with intravenous contrast. If intravenous contrast is contraindicated, a non-contrast-enhanced chest CT scan will be acceptable for chest lesions, and MRI can be used for non-chest lesions. If contrast-enhanced MRI is contraindicated, then non-contrast-enhanced MRI will suffice. Positron emission tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesion as per RECIST v1.1 (see Appendix 4).

The same radiographic procedure used to define measurable disease sites at screening must be used throughout the study (e.g., the same contrast protocol for CT scans). Assessments should be performed by the same evaluator to ensure internal consistency across visits.

CT/MRI scans of chest and abdomen, and MRI scans of the brain should be performed for all patients as described in Schedule of Assessments (see Appendix 1) at screening, then every 8 weeks subsequently until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression and at the post-treatment visit (4 weeks after permanent treatment discontinuation). CT/MRI scans of the neck bone and pelvis should be included if clinically indicated. At the investigator’s discretion, CT/MRI scans may be repeated at any time if PD is suspected.

Note: Brain imaging should be performed using MRI with the following image acquisition requirements.

- Minimum sequences required:
  - Pre-contrast T1, T2/FLAIR
  - Post-contrast T1, with two orthogonal planes (or a volume acquisition) recommended

- Recommended slice thickness $\leq$ 5 mm with no gap

Patients with known or suspected bone metastases should undergo radionuclide bone scan at screening. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions and do not need to be repeated routinely.
but can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered measurable lesions of the soft tissue component and meet the definition of measurability and should be followed by cross-sectional imaging.

4.5.8 Laboratory, Biomarker, and Other Biological Sample

4.5.8.1 Laboratory Assessments

Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells])
- Coagulation (PT [or INR], and aPTT)
- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase [GGT]; calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone and free testosterone [either by direct measurement or by calculation using, albumin and SHBG], FSH, and LH [for male patients only])
- Urinalysis. Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein will be measured by dipstick test.
- Pregnancy test. All women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile will have a serum pregnancy test at screening, within 3 days of dosing. Urine pregnancy tests will be performed anytime during the course of the study, as per investigator’s discretion. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

4.5.8.2 Pre-Treatment Tumor Samples (Mandatory)

Mandatory pre-treatment tumor samples will be collected to centrally examine ALK status by Ventana IHC (eligibility criteria) and Vysis FISH. Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred source, but if blocks are not available, unstained slides (ten to fifteen 5-µm slides cut less than 3 months before screening) are also accepted. Remaining tumor blocks will be returned to the sites; slides will not be returned.

For fresh tumor biopsies (guided by ultrasound or CT scan), acceptable methods include core biopsies for lung and liver lesions and bronchoscopic biopsies for lung lesions. The minimum size for the biopsy needle recommended is 20G.
Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by Ventana IHC (Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott). Additionally, other ALK assays may be used for testing patient samples to establish performance characteristics of these assays for diagnostic development. Testing may be performed on all screened patients (screen- failed and enrolled). These additional testing data will have no impact on eligibility, and testing will be performed only after eligibility is established for each patient. In addition, local ALK test information, baseline demographic, and disease-related characteristic data for all screened patients may be collected in order to support potential registration of a companion diagnostic assay for alectinib.

The tumor sample may also be tested for the presence of EGFR mutations, if requested by the investigator.

Pre-treatment tumor samples may be used, after proper informed consent is obtained, for genomic sequencing.

For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual.

4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)

Pre-treatment tumor samples (preferably formalin-fixed blocks but if not available a minimum of 10-15 unstained 5 µm slides) for ALK testing is a mandatory requirement for this study. Optional additional pre-treatment tumor samples and fresh post-treatment tumor biopsy at disease progression or permanent treatment discontinuation (at the last treatment or post-progression visit) may be collected, with proper informed consent. These samples will be used to help to understand molecular mechanisms of resistance to ALK inhibitors by genomic sequencing. Remaining tumor blocks will be returned to the sites, slides will not be returned.

The remaining mandatory (Section 4.5.8.2) and optional specimens (Section 4.5.8.3) will be destroyed within 5 years after the date of final closure of the clinical database. Other residual tissue material (slides, extracts, etc.) will be destroyed within 5 years after the date of final closure of the clinical database.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of optional tumor biopsies with exploratory purposes may be stopped at any time if the data from the samples collected do not produce useful information.
4.5.8.4  Blood and Plasma Samples

Mandatory plasma samples will be obtained to determine:

- Mutation status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline, at the Visit 3 (Week 16) treatment, and subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for detailed information) until disease progression, and during post-progression on treatment in case of isolated, asymptomatic CNS progression. For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual. These samples will not be taken in countries where regulatory agency or Institutional Review Board (IRB) does not allow genetic testing.

- ALK rearrangement in plasma. This will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline.

Mandatory blood samples will be obtained to determine:

- All patients who are randomized in alectinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alectinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Section 4.5.8.4.1).

Optional blood samples will be collected to obtain:

- Plasma. Centrally ALK negative tested patients (by Ventana ALK IHC) who agree to donate 10 ml plasma will be assessed by plasma ALK assays (PCR and/or Sequencing) for the development of a plasma ALK diagnostic test.

- A source of healthy tissue for patients who agreed to participate in the optional genomic sequencing assessment. For patients in the crizotinib arm, a 3-mL blood sample will be drawn at baseline. For patients in the alectinib arm, a source of healthy tissue will be used as a portion of the sample for the pharmacogenomics research (see Section 4.5.8.4.1).

- A portion of this blood sample will also be used as a source of healthy tissue for the patients on alectinib treatment who agree to participate in the optional genomic sequencing research.

For biomarkers, a maximum of 43 mL of blood will be collected at baseline (20 mL of blood for plasma purification and determination of mutation status in ALK and other escape genes, 20 mL of blood for plasma purification and detection of ALK rearrangements, and 3 mL blood for pharmacogenomics research. Twenty mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 20 mL will be collected at disease progression (CNS and/or systemic disease progression) for plasma purification, for determination of mutation status in ALK and other escape genes.
Details of sample handling procedures, sample storage, and shipment will be described in a separate laboratory manual.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma with exploratory purposes may be stopped at any time if they are deemed not informative.

### 4.5.8.4.1 Samples for Pharmacogenomic Assessments

One sample (approximately 3 mL of whole blood) will be collected from all patients on alectinib treatment. Samples will be used for the evaluation of genetic polymorphisms of drug metabolic enzymes including but not limited to CYP2C9, CYP3A4/5, and UGT1A1, and transporters (e.g., organic anion transporter polypeptide 1B1) and for genetic variants that could contribute to potentially drug-related liver safety assessments (including but not limited to human leukocyte antigen, see Appendix 9 for more details).

For sample handling procedures, storage conditions, and shipment instructions, see the laboratory manual. Only in circumstances where there is concern for collection of this genetic material for above evaluations can this assessment be considered not mandatory as part of study assessments in this study. Results of any analyses from these samples will be reported outside the clinical study report.

### 4.5.8.5 Samples for Pharmacokinetic Assessments

PK samples will be collected in all patients on alectinib treatment, as indicated in Appendix 1 and Appendix 2 for the analysis of alectinib and its major metabolite(s) (RO5468924, RO5507197, and/or others, if applicable and if appropriate, and if assays are available). Residual samples following PK analysis may be used to evaluate profiling for alectinib metabolite(s).

All trough/pre-dose PK samples should be collected within 2 hours BEFORE the morning doses of study medications.

Serial/intensive samples will be collected in a subset of patients (10%–15% [at least approximately n = 20] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

Plasma concentrations for alectinib and its metabolite(s), if applicable, will be measured by specific and validated liquid chromatography tandem mass spectrometry methods.

For each sample, approximately 2 mL of venous blood will be collected for alectinib PK analysis at the timepoints specified in the PK schedule in Appendix 1 and Appendix 2.

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual.
These samples will be destroyed when the final Clinical Study Report is complete.

On the basis of continuous analysis of the data in this study and other studies, any sample type collection may be stopped at any time if the data from the samples collected do not produce useful information or at the discretion of the Sponsor.

4.5.9 Electrocardiograms
An ECG will be recorded at specified timepoints as outlined in the schedule of assessments (Appendix 1) at screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), and at the last treatment visit and as clinically indicated throughout the study. All ECG recordings must be performed using a standard high-quality, high-fidelity digital electrocardiograph machine equipped with computer-based interval measurements. All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug administration) as well as prior to meals. Circumstances that may induce changes in heart rate, including environmental distractions (e.g., television, radio, conversation), should be avoided during the pre-ECG resting period and during ECG recording.

Patients must have been in a supine or semi-supine position for at least 5 minutes prior to the recording being taken. The same recording position (supine or semi-supine) and the same equipment should be used for each patient throughout the study. The ECG printout must be (1) reviewed by a medically qualified member of the study team at the site, (2) annotated to indicate any clinical finding, and (3) dated and signed by this person and filed in the patient notes. ECG parameters will be entered on the ECG eCRF. The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula (QTcF). In the event that the ECG machine does not directly provide results for RR and/or QTcF, these parameters can be derived using the formulae provided in Appendix 10.

If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory.

4.5.10 Patient-Reported Outcomes
PROs (EORTC QLQ-C30, QLQ-L13, and EQ-5D) will be collected to more fully characterize the clinical profile of alectinib. The instruments will be translated as required in the local language. To ensure instrument validity and that data standards meet health authority requirements, the PROs scheduled for administration during a clinic visit (EORTC QLQ-C30, QLQ-L13, and EQ-5D) should be completed prior to the performance of non-PRO assessments and the administration of study treatment.
Patients will use an ePRO device to capture PRO data and maintain a diary of daily drug intake (crizotinib arm) or drug intake with food (alectinib arm). The ePRO device and instructions for completing the PRO questionnaires and diaries electronically will be provided by the investigator staff. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be accessed by appropriate study personnel securely via the Internet.

4.5.11 Samples for Roche Clinical Repository

4.5.11.1 Overview of the Roche Clinical Repository

The Roche Clinical Repository (RCR) is a centrally administered group of facilities used for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.

Specimens for the RCR will be collected from patients who give specific consent to participate in optional research. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

4.5.11.2 Approval by the Institutional Review Board or Ethics Committee

Collection and submission of biological samples to the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site’s IRB or Ethics Committee (EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol (Section 4.5.11) will not be applicable at that site.

4.5.11.3 Sample Collection

For RCR purposes, 10 mL of blood will be collected. Any remaining tissue samples from study-related or non-study-related procedures that are performed during the study may also be collected for RCR purposes. For all samples, date of consent should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.

Alectinib—F. Hoffmann-La Roche Ltd
62/Protocol BO28984, Version 5 (Canada)
RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be subject to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

4.5.11.4 Confidentiality
Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure database system. Access to the linking key is restricted to authorized individuals and is monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche's Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

4.5.11.5 Consent to Participate in the Roche Clinical Repository
The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the
objectives, methods, and potential hazards of participation in the RCR. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to provide optional RCR specimens. Patients who decline to participate will not provide a separate signature.

The investigator should document whether the patient has given consent to participate by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's specimens and data will continue to be used as part of the RCR research.

4.5.11.6 Withdrawal from the Roche Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their specimens from the RCR at any time for any reason. If a patient wishes to withdraw consent to the testing of his or her specimens, the investigator must inform the Medical Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research Sample Withdrawal of Informed Consent eCRF. The patient will be provided with instructions on how to withdraw consent after the trial is closed. A patient's withdrawal from Study BO28984 does not, by itself, constitute withdrawal of specimens from the RCR. Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from Study BO28984.

4.5.11.7 Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a quality-controlled, auditable, and appropriately validated laboratory information management system, to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the Informed Consent Form. Roche monitors and auditors will have direct access to appropriate parts of records relating to patient participation in the RCR for the purposes of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the RCR samples.

4.6 PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION

4.6.1 Patient Discontinuation
Patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the investigator has the right to withdraw a patient from the study at any time. Reasons for withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study

Alectinib—F. Hoffmann-La Roche Ltd
64/Protocol BO28984, Version 5 (Canada)
• Investigator or Sponsor determines it is in the best interest of the patient

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. Patients who withdraw consent for treatment should continue to be followed for tumor assessments until progression and for OS, provided they have not withdrawn consent for the study. However, patients will not be followed for any reason after consent for the study has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study Treatment Discontinuation

Patients must discontinue study treatment if they experience any of the following:

• Pregnancy
• Inability to tolerate study medication on the basis of the investigator judgment

See guidelines for managing adverse events and for comprehensive guidance on study drug discontinuation in Section 5.1.3.

Patients who discontinue study drug prematurely will be asked to return to the clinic for tumor assessments until progression as per study schedule (see Appendix 1).

The primary reason for premature study drug discontinuation should be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.3 Study and Site Discontinuation

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

• The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
• Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

• Excessively slow recruitment
• Poor protocol adherence
• Inaccurate or incomplete data recording
• Non-compliance with the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice
• No study activity (i.e., all patients have completed and all obligations have been fulfilled)
5. ASSESSMENT OF SAFETY

5.1 SAFETY PLAN

5.1.1 Adverse Events Collection

After informed consent has been obtained but prior to initiation of study treatment, only serious adverse events (SAEs) caused by a protocol-mandated intervention should be reported (e.g., SAEs related to invasive procedures such as biopsies). After the first dose of study treatment and up to the 4-week follow-up after the last dose of study treatment, all adverse events (AEs) regardless of seriousness, causality assessment, or actions taken reported by the investigator or designated medically qualified study site personnel will be collected as described below. At each visit, the investigator or designated medically qualified study site personnel will ask the patient if any untoward medical event occurred since the last visit. It is the investigator’s responsibility to record all AEs in the source patient’s medical records.

All SAEs and non-SAEs will be reported on the standard AE/SAE eCRF.

5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data

Events described in Section 5.1.2.1 through Section 5.1.2.10 will be closely monitored and represent selected AEs for this study.

A more detailed safety profile of alectinib is provided in the alectinib Investigator’s Brochure.

5.1.2.1 Interstitial Lung Disease

TKIs, including ALK inhibitor crizotinib, have been associated with the occurrence of treatment-related ILD (including fatalities).

See Section 5.1.3 for management and follow-up.

5.1.2.2 Hepatotoxicity

Hepatobiliary findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. The findings were at or close to clinically relevant exposures. Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT and liver weight, vacuolation/degeneration/necrosis of bile duct epithelium, inflammatory cell infiltration in Glisson’s sheath, enlargement/focal necrosis of hepatocytes, and enlargement of Kupffer cells.

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved. In patients with Grade 3–4 AST/ALT elevations, documented drug-induced liver injury by liver biopsy was reported with uncommon frequency in alectinib pivotal clinical trials.
Concurrent elevations in ALT or AST greater than or equal to three times the ULN and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred with uncommon frequency in patients treated in alectinib clinical trials.

In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and drug-induced hepatotoxicity, including cases with fatal outcome, have been reported.

See Section 5.1.3 for management and follow-up.

### 5.1.2.3 Anemia
Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. Findings were at or close to clinically relevant exposures. Hematologic adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have been observed with most TKIs, including ALK inhibitor crizotinib.

Cases of anemia have been reported in patients treated with alectinib; the majority of the events were Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

### 5.1.2.4 Gastrointestinal Disorders
*In pivotal clinical trials, one case of GI perforation (0.4%) occurred and had a fatal outcome. In the post-market setting, cases of GI perforation were also reported with alectinib.*

GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported with alectinib. Similar GI disorders have been observed with other TKIs, including ALK inhibitor crizotinib.

SLS (sodium lauryl sulfate, syn. sodium dodecyl sulfate) is a surfactant excipient in the clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical ingredient). This excipient is a known GI irritant and may be associated with GI AEs including nausea, vomiting, diarrhea, and abdominal pain. Of note, GI tract toxicity as the safety determinant of SLS is not because of systemic toxicity, but a consequence of local irritation to the GI tract. In general, when mixed with diet, higher levels of SLS—a known GI tract mucosal irritant—are tolerated versus gavage administrations.

See Section 5.1.3 for management and follow-up.

### 5.1.2.5 Skin Disorders
Results of an in vitro phototoxicity study indicated that alectinib may have phototoxic potential.
Skin rash has been reported with majority of TKIs including those targeting the ALK receptor (Hartmann et al. 2009).

Cases of skin rash and photosensitivity have been reported with alectinib and were generally Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.6 Vision Disorders

In the rat quantitative whole body autoradiography study, tissue radioactivity disappeared over time, following a time course comparable to that of plasma radioactivity, except for melanin-containing tissues such as uveal tract of eyes, which had much higher and more sustained exposure in pigmented rats. This is consistent with what is commonly observed for lipophilic basic drugs.

Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and vitreous floaters, have been reported with several TKIs, including ALK inhibitors (crizotinib) (Shaw et al. 2013).

Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and vision impaired, have been reported with alectinib and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.7 Edema

Most TKIs, including ALK inhibitor crizotinib, have been associated with edema. Events of edema have been reported with alectinib, mostly Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.8 Bradycardia

In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration $[C_{\text{max}}]$: 279 ng/mL).

In a preliminary non-Good Laboratory Practice telemetry study in conscious cynomolgus monkeys, a slight hypotensive effect (approximately 10 mmHg) was seen when alectinib was administered at 20 and 60 mg/kg orally with no effects on ECG or heart rate. The hypotensive effect of alectinib observed in monkeys was considered to likely be caused by vasodilatation induced by L-type Ca$^{2+}$ channel inhibition.

Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse
events, as well as decreases in heart rate based on ECG and pulse measurements, have also been reported (XALKORI® U.S. Package Insert; ZYKADIA® U.S. Package Insert).

In case of bradycardia, concomitant medications must be evaluated to identify those that are known to cause bradycardia, as well as anti-hypertensive medications; and discontinuation or dose reduction of these concomitant medications must be considered.

See Section 5.1.3 for management and follow-up.

5.1.2.9 Abnormal Renal Function
In the 2-week non-human primate study at 60 mg/kg, an increase in creatinine was observed but no changes were observed in histopathology. In all other non-human primate studies, no changes in creatinine were observed.

Serum creatinine increases have been reported with alectinib treatment and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.10 Severe Myalgia and CPK Elevations
Postmarketing experience with some TKIs includes reports of myopathy and rhabdomyolysis (Hohenegger 2012).

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment. Grade 3 myalgia and CPK elevations have been reported with alectinib treatment and were reversible upon dose reduction and interruption.

See Section 5.1.3 for management and follow-up and Table 2 for guidelines for managing AEs.
### 5.1.3 Management of Specific Adverse Events with Alectinib

#### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Interstitial lung disease    | • Patients should be monitored for pulmonary symptoms indicative of pneumonitis.  
                                 | • Study drug should be permanently discontinued in patients diagnosed with interstitial lung disease.                                                                                                                |
| Hepatotoxicity               | Liver test laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4 and Section 5.3.5.6.  
                                 | • If ALT or AST $>3 \times$ baseline, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry about symptoms. If upon repeat testing the transaminases remain $>3 \times$ baseline, but are not $>5 \times$ baseline or not accompanied with bilirubin increases or do not match any other rule for permanent discontinuation, then monitoring can continue as per investigator judgment, and dose modification is not necessary.  
                                 | • At any time during the study treatment, if symptoms compatible with liver injury are observed, liver enzymes should be measured as soon as possible.  
                                 | • Study drug treatment has to be permanently discontinued if any of the following occurs:  
                                 | First observation of ALT or AST $>8 \times$ ULN  
                                 | ALT or AST $>5 \times$ ULN for more than 2 weeks  
                                 | First observation of ALT or AST $>3 \times$ ULN and total bilirubin $>2 \times$ ULN  
                                 | First observation of ALT or AST $>3 \times$ ULN and the appearance of jaundice or signs of hepatic dysfunction or other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia [$>5\%$]).  
                                 | • Following study drug discontinuation, weekly monitoring of laboratory values should continue until the abnormal values have normalized to pre-treatment levels and/or an adequate explanation of the abnormal value is found.  
                                 | • Resumption of study drug is not allowed in patients discontinuing because of any of the above criteria.                                                                                                             |
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal perforation</td>
<td>In patients at risk for GI perforation (e.g., concomitant use of medications with a risk of GI perforation, history of diverticulitis, or metastases to the GI tract), alectinib should be used with caution. Patients should be informed of potential signs of GI perforations and seek medical advice rapidly in case of occurrence. Study drug should be permanently discontinued in patients who develop GI perforation.</td>
</tr>
<tr>
<td>Other gastrointestinal tract AEs (e.g., nausea, vomiting, diarrhea)</td>
<td>The events are expected to be minimized by taking the study drug with meal. In case GI events occur, appropriate measures should be taken in accordance with local clinical practice guidelines. If GI toxicities are observed and not tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower.</td>
</tr>
<tr>
<td>Skin disorder AEs (e.g., phototoxicity, rash)</td>
<td>Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 5 days after study drug discontinuation. Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least SPF 50 to help protect against potential sunburn</td>
</tr>
<tr>
<td>Vision disorders</td>
<td>Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice guidelines, if vision disorders persist or worsen in severity, and to advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder.</td>
</tr>
<tr>
<td>Edema</td>
<td>Physical examinations will be performed routinely in clinical trials. In case edema events occur, appropriate measures should be taken in accordance with local clinical practice guidelines</td>
</tr>
</tbody>
</table>

Alectinib—F. Hoffmann-La Roche Ltd
71/Protocol BO28984, Version 5 (Canada)

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984  Report Number 1078196  2026
<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Abnormal kidney function AEs | Kidney function laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
- If, at any time during the study treatment, eGFR decreases by >50% of the baseline visit value, the patient has to be carefully monitored. All of the underlying factors that may have acutely impacted serum creatinine levels need to be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.).  
- Any eGFR decrease by >50% of the baseline visit value requires repeat testing.  
  - If, at the repeat test, the eGFR decrease is still >50% of the baseline visit value, the treatment with alectinib should be interrupted.  
- Alectinib treatment may be resumed with caution if the eGFR value has increased to approximately the baseline visit value. |
| Severe myalgia and CPK elevations | CPK laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
- Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms.  
- At the first occurrence of any of asymptomatic CPK values (>10 × ULN, symptomatic CPK >5 × ULN, or in the presence of severe muscular symptoms with CPK > ULN but ≤5 × ULN) at any time during the study treatment, the patient requires monitoring of the CPK values until they are normalized to pre-treatment levels or a reasonable explanation for the CPK elevation and the symptoms is established. |
### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other AEs (including bradycardia, anemia, and CPK elevation) or laboratory abnormalities:</td>
<td></td>
</tr>
<tr>
<td>• Grade 3 or 4:</td>
<td>Temporarily interrupt alectinib for a maximum of 3 weeks. If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib. First episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by another 150 mg (1 capsule) BID (300 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 2 (except any symptoms and signs that can be corrected with supportive care):</td>
<td>Temporarily interrupt alectinib and resume if recovering to Grade ≤ 1 or baseline if clinically indicated. First episode: If improvement to Grade ≤ 1 or baseline within 10 days, continue same dose of alectinib. If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID when resuming treatment (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID or 300 mg BID if after first episode dose was reduced to 450 mg BID). If improvement occurs after 10 days, decrease the current dose of alectinib by 300 mg (2 capsules) when resuming treatment (300 mg BID or 150 mg BID if after first episode dose was reduced to 450 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 1: no action required</td>
<td></td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate.  
Note: Diarrhea, nausea, and vomiting should be handled with best supportive care first before considering dose modification. Preexisting pleural effusion will not be considered as an adverse event.

5.1.4 Safety of Crizotinib and Management of Adverse Events

Dosing interruption and/or dose reduction may be required on the basis of individual safety and tolerability. If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily on the basis of individual safety and tolerability (**XALKORI® U.S. Package Insert; Crizotinib SmPC**). Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Table 3 and Table 4.

Alectinib—F. Hoffmann-La Roche Ltd  
73/Protocol BO28984, Version 5 (Canada)
### Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia)

<table>
<thead>
<tr>
<th>CTCAE&lt;sup&gt;a&lt;/sup&gt; Grade</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events

<sup>b</sup> In case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of a third episode of Grade 4 hematologic toxicity.
### Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT or AST elevation &gt; 5 × ULN with total bilirubin ≤ 1.5 × ULN</td>
<td>Withhold until recovery to baseline or ≤ 3 × ULN, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
<tr>
<td>ALT or AST elevation &gt; 3 × ULN with concurrent total bilirubin elevation &gt; 1.5 × ULN (in the absence of cholestasis or hemolysis)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Any grade drug-related ILD/pneumonitis</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>QTc &gt; 500 ms on at least 2 separate ECGs</td>
<td>Withhold until recovery to baseline or &lt; 481 ms, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence (i.e., QTc &gt; 500 ms on at least 2 separate ECGs).</td>
</tr>
<tr>
<td>QTc &gt; 500 ms or ≥ 60 ms change from baseline with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt; 60 bpm, symptomatic, may be severe and medically significant, medical intervention indicated)</td>
<td>Withhold until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm. Evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If a contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume crizotinib at previous dose upon recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medication is identified but not discontinued or its dose was not modified, resume crizotinib at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm.</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt; 60 bpm, life-threatening consequences, urgent intervention indicated)</td>
<td>Permanently discontinue if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at 250 mg once daily upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
</tbody>
</table>

Gastrointestinal events were commonly reported with crizotinib in clinical trials. Nausea, diarrhea, vomiting, and constipation were the most commonly reported gastrointestinal events.
events and were primarily Grade 1 in severity. Supportive care for gastrointestinal events may include standard antiemetic and/or antidiarrheal or laxative medicinal products. In clinical studies with crizotinib, events of gastrointestinal perforations were reported (XALKORI® U.S. Package Insert; Crizotinib SmPC).

Blood counts and liver function tests including ALT, AST, and total bilirubin should be monitored as per local prescribing information for crizotinib.

See local prescribing information for further crizotinib safety information.

5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest, performing protocol-specified safety laboratory assessments, measuring protocol-specified vital signs, and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 5.4.

5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation where a patient is administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition).
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug
- AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor)

An SAE is any AE that meets any of the following criteria:

- Is fatal (i.e., the AE actually causes or leads to death)
- Is life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate risk of death)
  
  This does not include any AE that had it occurred in a more severe form or was allowed to continue might have caused death.
- Requires or prolongs inpatient hospitalization (see Section 5.3.5.10)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient’s ability to conduct normal life functions)
- Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- Is a significant medical event in the investigator’s judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the eCRF.

SAEs are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions).

5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)

Non-SAEs of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). AEs of special interest for this study are the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law (see Section 5.3.5.6)
• Suspected transmission of an infectious agent by the study drug, as defined below:

Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.

5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4–5.6. For each AE recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient’s medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting SAEs).

After initiation of study drug, all AEs will be reported until 4 weeks after the last dose of study drug. After this period, the investigator should report any SAEs that are believed to be related to study drug treatment (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all patient evaluation timepoints. Examples of non-directive questions include the following:

• "How have you felt since your last clinic visit?"
• "Have you had any new or changed health problems since you were last here?"

5.3.3 Assessment of Severity of Adverse Events

The AE severity grading scale for the NCI CTCAE (v4.0) will be used for assessing AE severity. Table 5 will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.
Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE

<table>
<thead>
<tr>
<th>Grade</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living(^a)</td>
</tr>
<tr>
<td>3</td>
<td>Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living(^b,c)</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences or urgent intervention indicated(^d)</td>
</tr>
<tr>
<td>5</td>
<td>Death related to adverse event(^d)</td>
</tr>
</tbody>
</table>

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.

Note: On the basis of the most recent version of NCI CTCAE (v4.0), which can be found at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

\(^a\) Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

\(^b\) Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one's self, using the toilet, and taking medications, as performed by patients who are not bedridden.

\(^c\) If an event is assessed as a "significant medical event," it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

\(^d\) Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

5.3.4  Assessment of Causality of Adverse Events

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly.

The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (as applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event
5.3.5 Procedures for Recording Adverse Events

Investigators should use correct medical terminology and concepts when recording AEs on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one AE term should be recorded in the event field on the Adverse Event eCRF.

5.3.5.1 Diagnosis Versus Signs and Symptoms

A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

5.3.5.2 Adverse Events that are Secondary to Other Events

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event on the Adverse Event eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

5.3.5.3 Persistent or Recurrent Adverse Events

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported. If a persistent AE becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes
A recurrent AE is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values

Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Is clinically significant in the investigator's judgment

Note: For oncology trials, certain abnormal values may not qualify as AEs.

It is the investigator's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., ALP and bilirubin 5 times the ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent AEs).
### 5.3.5.5 Abnormal Vital Sign Values

Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Is clinically significant in the investigator’s judgment

It is the investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded one on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent adverse events).

### 5.3.5.6 Abnormal Liver Function Tests

The finding of an elevated ALT or AST (>3×baseline value) in combination with either an elevated total bilirubin (>2×ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, investigators must report as an AE the occurrence of either of the following:

- Treatment-emergent ALT or AST >3×baseline value in combination with total bilirubin >2×ULN (of which ≥35% is direct bilirubin)
- Treatment-emergent ALT or AST >3×baseline value in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or a non-SAE of special interest (see Section 5.4.2).

### 5.3.5.7 Deaths

For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-specified AE reporting period (see Section 5.3.1) that are attributed by the investigator solely to progression of NSCLC should be recorded only on the Study Completion/Early Discontinuation eCRF. All other on-study deaths, regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and
immediately reported to the Sponsor (see Section 5.4.2). An independent monitoring committee will monitor the frequency of deaths from all causes.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. The term "sudden death" should be used only for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, "unexplained death" should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), "unexplained death" should be replaced by the established cause of death.

During survival follow-up, deaths attributed to progression of NSCLC should be recorded only on the Survival eCRF.

5.3.5.8 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not be recorded as AEs. These data will be captured as efficacy assessment data only. In most cases, the expected pattern of progression will be based on RECIST criteria v1.1 (Appendix 4). In rare cases, the determination of clinical progression will be based on symptomatic deterioration. However, every effort should be made to document progression using objective criteria. If there is any uncertainty as to whether an event is due to disease progression, it should be reported as an AE.

5.3.5.10 Hospitalization or Prolonged Hospitalization
Any AE that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 5.2.2), except as outlined below.
The following hospitalization scenarios are not considered to be AEs:

- Hospitalization for respite care
- Planned hospitalization required by the protocol
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:
  - The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease.
  - The patient has not experienced an AE.
- Hospitalization due solely to progression of the underlying cancer

5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration

An overdose is the accidental or intentional use of a drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE. All AEs associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF. If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

AE reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. However, if any PRO responses suggestive of a possible AE are identified during site review of the PRO data, the investigator will determine whether the criteria for an AE have been met and, if so, will report the event on the Adverse Event eCRF.

5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study

If an AE inadvertently occurs in an individual not enrolled in the study, the Adverse Event Form provided to investigators should be completed and submitted to Roche or its designee, either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- SAEs
• Non-SAEs of special interest
• Pregnancies

The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:
• New signs or symptoms or a change in the diagnosis
• Significant new diagnostic test results
• Change in causality based on new information
• Change in the event’s outcome, including recovery
• Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts

Medical Monitor (Roche Medical Responsible) Contact Information
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the Roche Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Roche Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk as well as Medical Monitor contact information will be distributed to all investigators.

This list can be generated using contact numbers found at the following link: http://gcpcenter.roche.com/synergy/portal/view/pdq-spi/gcpcenter/34-64711453.

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest

5.4.2.1 Events That Occur Prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4.2.2 Events That Occur After Study Drug Initiation
After initiation of study drug, SAEs and non-SAEs of special interest will be reported until 4 weeks after the last dose of study drug. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) system.
A report will be generated and sent to Roche Safety Risk Management by the EDC system.

In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

Instructions for reporting post-study AEs are provided in Section 5.6.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. A pregnancy report will automatically be generated and sent to Roche Safety Risk Management. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In the event that the EDC system is unavailable, the Clinical Trial Pregnancy Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3.2 Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the
Pregnancy Report eCRF with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

In the event that the EDC system is unavailable, follow reporting instructions provided in Section 5.4.3.1.

5.4.3.3 Abortions
Any abortion should be classified as an SAE (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study drug or the female partner of a male patient exposed to study drug should be classified as an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.5 FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS

5.5.1 Investigator Follow-Up
The investigator should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented on the Adverse Event eCRF and in the patient’s medical record to facilitate source data verification.

All pregnancies reported during the study should be followed until pregnancy outcome. If the EDC system is not available at the time of pregnancy outcome, follow reporting instructions provided in Section 5.4.3.1.

5.5.2 Sponsor Follow-Up
For SAEs, non-SAEs of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.
5.6 POST-STUDY ADVERSE EVENTS

The Sponsor should be notified if the investigator becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug), if the event is believed to be related to study drug treatment.

The investigator should report these events directly to Roche or its designee, either by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number or email address provided to investigators.

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all SAEs and non-SAEs of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single AE cases, the Sponsor will assess the expectedness of these events using the following reference documents:

- Alectinib Investigator's Brochure
- Local prescribing information for crizotinib

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis population for efficacy is the intent-to-treat (ITT) population defined as all randomized patients. Patients will be assigned to the treatment group to which they were randomized.

The primary analysis population for safety is the Safety Analysis Population (SAP) defined as all patients who received at least one dose of study medication. Patients will be assigned to treatment groups as treated, and all patients who received any dose of alectinib will be included in the alectinib treatment arm.

A secondary analysis population for efficacy is the FISH Positive Population (FPP). This is defined as all patients in the ITT population who were ALK-positive using the Vysis FISH assay. Patients will be assigned to the treatment group to which they were
randomized. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay.

An analysis of the primary endpoint of investigator-assessed PFS based on the FPP will be performed at the time of the primary analysis. A major discrepancy between the Ventana IHC assay and the Vysis FISH assay may necessitate a follow-up analysis of the primary endpoint based on 170 PFS events observed in the FPP to ensure 80% power of the log-rank test under the assumption of a hazard ratio of 0.65 in this secondary population.

The final analysis of the primary endpoint of PFS will occur when 170 PFS events have occurred, on the basis of the investigators’ assessments. On the basis of the assumptions outlined in Section 6.1, this is estimated to occur approximately 33 months after the first patient has been enrolled. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Hypothesis tests will be two-sided with a significance level of 5% unless otherwise indicated.

The baseline value of any variable will be defined as the last available value recorded prior to the first administration of alectinib or crizotinib.

Further details of all analyses will be provided in the Statistical Analysis Plan.

6.1 DETERMINATION OF SAMPLE SIZE

The focus of this clinical trial is hypothesis testing (Section 6.4.1), and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.
In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 24 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size (N=286), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude. At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 106 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.

6.2 SUMMARIES OF CONDUCT OF STUDY

Study enrollment, study treatment administration, reasons for discontinuation from study treatment, and reasons for study termination will be summarized by treatment arm for all randomized patients. Violations of inclusion and exclusion criteria, on the basis of information captured on the eCRF, will be reported and summarized by treatment arm.

6.3 SUMMARIES OF TREATMENT GROUP COMPARABILITY

Summaries of treatment group comparability will be based on the ITT population.

Demographic, baseline disease characteristics and lung cancer history will be summarized by treatment arm for all randomized patients, including the randomization...
stratification factors. Descriptive baseline summaries of continuous data will present the group mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequency and percentages.

Previous and concomitant cancer therapy will also be summarized, as well as anti-cancer subsequent therapy. Previous and concurrent diseases and medications will also be summarized.

6.4 EFFICACY ANALYSES

The primary population for all primary and secondary efficacy analyses will be the ITT population.

6.4.1 Primary Efficacy Endpoint

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as an HR (alectinib vs. crizotinib), as well as a 95% CI.
The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[ H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \]

versus

\[ H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)} \]

where SDF denotes the survival distribution function of the parameter PFS.

### 6.4.2 Secondary Efficacy Endpoints

If the primary endpoint of PFS is statistically significant at a two-sided 5% significance level, the following secondary endpoints will be tested in the following sequential order, each at a two-sided 5% significance level:

- PFS by IRC
- Time to CNS progression
- ORR
- OS

**PFS by IRC**

An analysis of PFS on the basis of the IRC assessments will be performed using the same methodology as specified for PFS on the basis of investigator assessment.

**Time to CNS Progression**

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression. An independent central radiological review will be performed for all patients, and the analysis of CNS progression or response will be on the basis of the data from the independent review. All patients will be included in the analysis regardless of their baseline status of CNS metastases. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of preexisting baseline CNS lesions. On the basis of RECIST v1.1, this is defined as a new post-baseline CNS/brain lesion(s) and/or an increase of \( \geq 20\% \) in the sum of longest diameters of the measurable baseline CNS lesions compared to nadir and/or unequivocal progression of non-measurable baseline CNS lesions.

In order to account for the competing risks inherent in such an analysis, HRs, including statistical inference on the basis of a two-sided log-rank test, to compare the risk of CNS progression between the alectinib and crizotinib treatment groups, will be computed on the basis of cause-specific hazard functions.

The probability of CNS progression, non-CNS progression, and death will each be estimated using cumulative incidence functions.
For descriptive purposes, estimates of the CNS progression rates over time with 95% CIs on the basis of cumulative incidence functions will be presented. A Gray’s test to compare the risk of CNS progression between alectinib and crizotinib will also be performed as a supportive analysis.

An exploratory analysis of CNS Time to Progression on the basis of RANO criteria will also be performed on the basis of the IRC assessments.

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. Similar analyses will be performed in the subgroup of patients with measurable and/or non-measurable CNS lesions at baseline. An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

**Objective Response Rate**

ORR, on the basis of investigator assessment, is defined as the percentage of patients who attain a CR or PR. Per RECIST v1.1, confirmation of objective response is not required for this secondary endpoint. Patients without a post-baseline tumor assessment will be considered non-responders, as will patients with a best overall response of stable disease (SD), PD, or NE (not evaluable).

An estimate of ORR and its two-sided 95% CI will be calculated using the Clopper-Pearson method for each treatment arm. Response rates in the treatment groups will be compared using a stratified Mantel-Haenszel test on the basis of the randomization stratification factors. The difference in ORR between the two treatment arms will be presented together with a two-sided 95% CI on the basis of a normal approximation to the binomial distribution.

**DOR**

For patients who have experienced an objective response (CR or PR) during the study as assessed by the investigator, DOR is defined as the duration from the first tumor assessment that supports the patient’s objective response (CR or PR, whichever is first recorded) to first documented disease progression or death due to any causes, whichever occurred first. Patients who have not progressed or died at the time of analysis will be censored at the last tumor assessment date. Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing will not be performed. DOR will be estimated using Kaplan-Meier methodology and an HR on the basis of a Cox proportional regression model will be calculated.
Overall Survival
OS is defined as the time from the date of randomization to the date of death due to any cause. Patients who are not reported as having died at the time of analysis will be censored at the date when they were last known to be alive. Patients who do not have post-baseline information will be censored at the date of randomization. OS will be analyzed using the same methodology as specified for the primary endpoint. A survival follow-up will be performed based on more mature data.

6.4.2.1 Sensitivity Analyses
The following sensitivity analyses will be performed on the primary endpoint of PFS:

- The effect of non-protocol-specified anti-cancer therapy prior to progression will be assessed by censoring patients at the last adequate tumor assessment prior to the start of non-protocol-specified anti-cancer therapy.
- The effect of missing tumor assessments will be assessed if the number of missing assessments in either arm is >5%. For patients with progression determined following one or more missing tumor assessments, the progression will be backdated to the first missing tumor assessment.
- The effect of loss to follow-up will be assessed depending on the number of patients who are lost to follow-up. If >5% of patients are lost to follow-up for PFS in either treatment arm, a “worst-case” analysis will be performed in which patients who are lost to follow-up will be considered to have progressed at the last date they were known to be progression-free.

6.4.2.2 Subgroup Analyses
Subgroup analyses of PFS will be performed for patients with baseline CNS metastases and for patients without baseline CNS metastases. In addition, a subgroup analysis of Time to CNS Progression will be performed, excluding patients who had pre-treatment radiation therapy for CNS lesions.

All other subgroup analyses will be specified in the SAP.

6.5 SAFETY ANALYSES
The primary population for all safety analyses will be the SAP as defined in Section 6.

All safety parameters will be summarized in tables to evaluate and compare the safety profile of patients treated with alectinib versus crizotinib in terms of:

- Adverse events including adverse events leading to dose modifications or interruptions, study drug withdrawal, and death
- Severe, serious, and selected adverse events
- Deaths
- Laboratory parameters and abnormalities
- Vital signs
• ECGs
• ECOG PS

Adverse events will be coded using MedDRA and summarized by mapped term and appropriate thesaurus level. All adverse events and routine laboratory parameters will be assessed according to the NCI CTCAE v4.0 grading system. For adverse events, the most extreme severity will be used for reporting. Adverse events will be described by individual listings and by body system, as well as by severity. In tables showing the overall incidence of adverse events, patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency.

Laboratory values will be summarized by treatment arm including summary tables for the shifts in grades from baseline to the worst grade observed during treatment. In order to evaluate and compare hypogonadism in the two treatment arms, testosterone levels in the blood will be summarized for males by treatment arm over time (for details, see Section 6.8).

Descriptive summary tables of change from baseline over time will be provided for vital signs and descriptive statistics will be tabulated for ECOG PS. ECG findings over time will be summarized.

Study drug administration will be summarized by duration and cumulative dose. In addition, treatment exposure will be summarized including the number of doses received, dose intensity, and the percentage of planned dose.

Subgroup analyses will be performed to evaluate the safety profile within the subgroups of patients including by sex, age (<65 vs. ≥65 years), and race (non-Asian vs. Asian).

An iDMC will review the safety data collected during the conduct of the study. Safety monitoring will be performed periodically. Further details will be outlined in the iDMC Charter.

6.6 PHARMACOKINETIC ANALYSES

Standard NCA may be conducted for PK data collected from patients participating in serial/-intensive PK collections for relevant analytes, as data allow, as appropriate, and if needed. PK parameters, including but not limited to AUC, C\text{max}, and time to maximum concentration (T\text{max}), will be calculated on the basis of the available data as appropriate and where data allow. Additional PK parameters may be calculated as deemed appropriate.

Individual and mean plasma concentrations at each sampling timepoint and/or PK parameters for alectinib and metabolite(s) will be listed, as appropriate.
Summary statistics (e.g., means, standard deviation, coefficient of variation %, geometric means, medians and ranges) for plasma concentrations and/or PK parameters for alectinib and metabolite(s) will be presented by treatment and nominal collection times (plasma concentrations only), as appropriate. Additional plots or summary statistics may be constructed or calculated, as appropriate.

Results of PK and/or any PK/pharmacodynamic analyses may be reported outside the clinical study report.

Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be used to analyze the sparse and/or serial/intensive plasma concentration-time data for alectinib. The PK data from this study may be pooled with data from other studies. Population and individual PK parameters will be estimated and the influence of various covariates (such as age, gender, and body weight) on these parameters will be investigated.

Exploratory analyses will be conducted to investigate the relationship between alectinib PK exposure and efficacy/safety parameters.

Details of the mixed-effects modeling and exploratory analyses will be reported in a document separate from the clinical study report.

6.7 PATIENT-REPORTED OUTCOME ANALYSES

The following PRO endpoints will be analyzed and PRO data will be presented separately from adverse event data.

6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms

TTD from baseline will be assessed at every study visit (Week 4, Week 8, and then after every 4 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at post-treatment Visit (4 weeks after permanent treatment discontinuation); and at subsequent 8-weekly survival follow-up visits for 6 months, for the following lung cancer symptoms: cough (Question 31 on the QLQ-LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale (Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), arm/shoulder pain (Question 41 on the QLQ-LC13) and fatigue multi-item subscale (Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm.

Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. TTD will be analyzed for the ITT population. If a baseline or post-baseline PRO evaluation is not available, TTD will be censored at the date of randomization. If they have not deteriorated, patients will be censored at the last time when they completed an assessment for cough, dyspnea (single item), dyspnea (subscale items), chest pain, arm/shoulder pain, and fatigue.
6.7.2 Additional Patient-Reported Outcomes

PROs of HRQoL, lung cancer–related symptoms, and health status will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13.

Summary statistics (mean, standard deviation, median, and range) of linear transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire, and the QLQ-LC13 according to the EORTC scoring manual guidelines. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. Only patients with a baseline assessment and at least one post-treatment assessment will be included in the analyses.

6.8 EXPLORATORY ANALYSES

The EQ-5D-3L is a generic PRO instrument that is used for across diseases and indications cost-effectiveness analyses. This instrument quantifies the QoL of various health outcomes and is applicable to a wide range of health states. Analyses of this outcome will be exploratory and will generate utility scores for use in economic models for reimbursement purposes only. The PRO will be administered every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months (see Appendix 1).

It has been reported that crizotinib therapy triggers rapid suppression of testosterone levels in men causing rapid-onset hypogonadism. It is unknown if reductions in testosterone reflect an effect of crizotinib on ALK or on some combination of the drug’s targets (i.e., c-MET) (Weickhardt et al. 2012; Weickhardt et al. 2013). Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG] calculator: http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m.

The Abbott Vysis FISH test will be used as an exploratory assay after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between Vysis FISH and Ventana IHC for the detection of ALK-positive NSCLC.

ALK plasma assays (PCR and/or sequencing) will be used as exploratory assays for ALK positive and consented ALK negative patients. Results from these analyses will be used to quantify the degree of correlation between ALK plasma tests and Ventana IHC and Vysis FISH for the detection of ALK positive NSCLC. The ALK plasma assay population may be used for exploratory efficacy and safety analysis. This analysis population will be used to support diagnostic development. Assays from this population

Alectinib—F. Hoffmann-La Roche Ltd
97/Protocol BO28984, Version 5 (Canada)
may be used for the registration of a plasma assay as a companion diagnostic. This analysis will be dependent on the successful technical development of a plasma ALK assay. Results of analyses related to those alternative diagnostic tests and exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure ALK rearrangements in circulating tumor cells will be communicated outside the main clinical study report.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

The Sponsor will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC using eCRFs. Sites will be responsible for data entry into the EDC system. In the event of discrepant data, the Sponsor will request data clarification from the sites, which the sites will resolve electronically in the EDC system.

The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. Central laboratory data or other electronic data will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle and process the electronic transfer of these data.

eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

ePRO data will be collected through use of an electronic device provided by an ePRO vendor. The device is designed for entry of data in a way that is attributable, secure, and accurate, in compliance with the FDA regulations for electronic records (21 CFR Part 11). The ePRO device data are available for view access only via secure access to a web server. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.
At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.

### 7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patients will use an ePRO device to capture PRO data. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be reviewed by site staff via secure access to a web server.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The investigator will receive patient data for the site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records as source data. Acknowledgement of receipt of the compact disc is required. In addition, the Sponsor will receive all patient data in a machine-readable format on a compact disc.

### 7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by applicable health authorities.

**Alectinib—F. Hoffmann-La Roche Ltd**

99/Protocol BO28984, Version 5 (Canada)
7.5 USE OF COMPUTERIZED SYSTEMS

When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS

Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a United States IND application will comply with FDA regulations and applicable local, state, and federal laws. Studies conducted in the European Union or European Economic Area will comply with the EU Clinical Trial Directive (2001/20/EC).

8.2 INFORMED CONSENT

The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child’s Assent or Caregiver’s Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor’s sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the "Consent Forms") before IRB/EC.
submissions. The final IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to allow any remaining specimens to be used for exploratory research. Patients who decline to participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient's legally authorized representative. All signed and dated Consent Forms must remain in each patient's study file or in the site file and must be available for verification by study monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.
8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site's study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which includes an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL DEVIATIONS
The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.

9.3 SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients’ medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE
Steering Committee is established to provide the study Sponsor with recommendations related to any aspect of the trial, specifically study design, data interpretation, exploratory analyses, or alternate changes to the trial that may assist in patient accrual, data collection, analysis, and interpretation of the study results. The Sponsor is ultimately responsible for all decisions regarding the study.

The test for the study inclusion criteria of ALK-positive NSCLC will be performed at Sponsor’s designated central laboratories and assessed by Ventana IHC test.

An iDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised. Details of the composition, roles, and responsibilities, and processes of the iDMC are documented in a separate iDMC charter. The iDMC will review safety data and can make recommendations to the Sponsor to stop or amend the study on the basis of safety findings. The frequency of these reviews as well as the data to be reviewed will be agreed with the iDMC and outlined in the separate iDMC charter. No stopping for early proof of efficacy will result from any of these regular safety reviews. iDMC review meetings will be held in a blinded manner to the Sponsor.
An IRC will review the tumor assessments to determine the secondary endpoints of the overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1. In addition to the secondary endpoint of time to CNS progression together with C-ORR, C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the tumor assessments on the basis of RANO criteria.

The independent review of MRI and CT scans will NOT determine either eligibility OR patient treatment. All treatment decisions will be made by the investigator using local assessments.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


The results of this study may be published or presented at scientific congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).
10. REFERENCES


Alectinib—F. Hoffmann-La Roche Ltd
110/Protocol BO28984, Version 5 (Canada)


Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.


## Appendix 1
### Schedule of Assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Days -28 to 0</td>
<td>Days -3 to 0</td>
<td>Visit 0 (Baseline)</td>
<td>Visit 1 (Week 4)</td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test b</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination c</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECG d</td>
<td>x</td>
<td>x e</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Hematology, Coagulation</td>
<td>x</td>
<td>x e</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x e</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x e</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Mandatory tumor sample for ALK testing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional plasma sample from centrally confirmed ALK negative patients (20 ml of blood)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional tumor sample</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

- Days -28 to 0
- Days -3 to 0
- Visit 0 (Baseline)
- Visit 1 (Week 4)
- Visit 2 (Week 8)
- PD: Progression Disease
- CNS: Central Nervous System
- PRO: Patient-Reported Outcome
- EORTC: European Organization for Research and Treatment of Cancer
- EQ-5D: EuroQol 5-Dimension
- ALK: Anaplastic Lymphoma Kinase
- NSCLC: Non-Small Cell Lung Cancer.
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma sample for ALK fusion detection in nucleic acids (20 mL of blood)</td>
<td></td>
<td></td>
<td>All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD^a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma for detection of ALK mutation status (20 mL of blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for pharmacogenomics research at pre-dose (3 mL of blood)^b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

^a Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)
### Appendix 1
**Schedule of Assessments (cont.)**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor assessment(^1) (x^m)</td>
<td>(x^m)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x^o)</td>
</tr>
<tr>
<td>MRI scan of the brain (x^m)</td>
<td>(x^m)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x^o)</td>
</tr>
<tr>
<td>PK samples (2 mL blood)(^2)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td></td>
</tr>
<tr>
<td>PRO (EORTC QLQ-C30/LC13); EQ-5D(^3)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x) (x^r)</td>
</tr>
<tr>
<td>Total testosterone, (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH(^4)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td></td>
</tr>
<tr>
<td>Adverse events (^1)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
</tr>
</tbody>
</table>
Appendix 1
Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsequent therapy for NSCLC</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Drug dispensing and accountability</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Blood Sample for Roche Clinical Repository (10 mL)</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x (accountability only)</td>
<td>x</td>
</tr>
</tbody>
</table>

ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire–Core; EQ-5D = EuroQoL 5 Dimension; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NSCLC = non–small cell lung cancer; PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal.

Notes: First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided–within ≤ 24 hours. Post-baseline assessments are to be performed within ± 1 week for the first two 4 weekly and subsequent 8 weekly assessments.

a For details on assessments when patient permanently discontinues from study treatment, see flowchart in Figure 1.

b Urine or serum, to be repeated as necessary.

c Including an ophthalmologic examination if clinically indicated.
Appendix 1
Schedule of Assessments (cont.)

d At screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), last treatment visit, and as clinically indicated throughout the study.

e Screening laboratory assessment done within 3 days can be counted as the baseline assessment.

f Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 10 to 15 unstained 5-µm slides are required. Tumor ALK status will be assessed by central laboratory before randomization.

g Optional tumor sample could be taken from the tumor block obtained at screening.

h At the time of disease progression from progressive lesions.

i Mandatory blood sample (20 mL) for detection of ALK rearrangements in nucleic acids in plasma collected at baseline only.

j Blood sample (20 mL) to obtain plasma for exploratory biomarkers will be collected at Visit 0 (baseline), during the study every second visit (i.e., every 16 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression.

k This sample is required in all patients in alectinib arm, and in those patients in the crizotinib arm who wish to participate in optional genomics sequencing.

l Tumor assessment consists at minimum of a CT/MRI scan of chest and abdomen (for imaging of liver and adrenal glands). Patients who are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP > 1.5 × ULN) of bone metastasis should undergo radionuclide bone scan. Clinical lesions should be assessed with caliper measurement and documented by color photography, including a ruler to estimate the size of the lesion. Post-baseline assessments are to be performed within ±1 week for the 8 weekly assessments. If there is suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be performed as soon as possible before the next scheduled evaluation.

m Screening tumor assessment done within 14 days will be counted as the baseline assessment.

n Tumor assessment can be performed whenever clinically indicated. Brain assessment scans should be performed at every systemic imaging tumor assessment. Tumor assessment should continue until disease progression if a patient discontinues treatment prior to PD, regardless of whether they subsequently receive non-study, anti-cancer therapy.

o If treatment was permanently discontinued due to disease progression.

p Pre-dose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit. The pre-dose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits. Remind the patient not to take a daily dose at home on the day of scheduled study visit. For a subset of patients on alectinib treatment (10%–15%, or at least approximately n = 20) participating in serial/intensive PK sample collection, additional PK will be collected on Visits 0 (baseline) and 1 (Week 4) at pre-dose (within 2 hours before intake of study medication), 1, 2, 4, 6, and 8 hours post-dose.
Appendix 1
Schedule of Assessments (cont.)

PRO questionnaires are to be completed every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow up visit (every 8 weeks) after post-treatment visit for 6 months. Further guidelines on PRO questionnaire administration will be provided in the study manual.

Performed every 8 weeks after post-treatment visit during the first 6 months and then every 12 weeks. The PRO assessments should be performed during the first 6 months. For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post treatment. For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.

Male patients only, using institutional standard assay. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m. Albumin and SHBG measurements are not required when a direct assessment of free testosterone is available. If free testosterone level cannot be directly assessed, it will be calculated from albumin and SHBG using a free testosterone calculator:

Graded according to NCI CTCAE (version 4.0). Serious adverse events collection must start from first study-specific procedure.

For details on drug dispensing and accountability, see Section 4.3.3.
Appendix 1
Schedule of Assessments (cont.)

Figure 1  Flowchart for Patients who Permanently Discontinue Study Treatment

Patient permanently discontinues from study treatment
due to or not due to Progressive Disease (PD)

If patient withdrawn due to PD
(At time of PD: PD blood samples, optional tumour samples should be collected)

Post Treatment Visit
(4 weeks after treatment discontinuation)
Tumour Assessments are required

Enters Survival-Follow up

Complete ‘Study Treatment Discontinuation’ eForm

Tumour Assessments,
CNS metastasis evaluation
(if CNS mets at BL) and ePRO collection continue as per original 8 weekly study schedule*

PD confirmed – Tumour assessments stop

Study Completion eform
If any of the discontinuation reasons listed occur

If patient withdrawn for reason other than PD

Post Treatment Visit
(4 weeks after treatment discontinuation) –
Tumour Assessments are NOT required

Subject decides to discontinue study assessments

Subject consents to Survival-Follow Up ICF

Follow-up on:
- AEs, Subsequent therapies, IMP accountability if required
- No labs, ECG, ECGD, etc. to be assessed.
- All related SAEs to be reported beyond end of study treatment

AEs = adverse events; ECOG = Eastern Cooperative Oncology Group; ePRO = electronic patient-reported outcome; ICF = Informed Consent Form; IMP = investigational medicinal product; PD = Progressive Disease.

Alectinib—F. Hoffmann-La Roche Ltd
118/Protocol BO28984, Version 5 (Canada)
## Appendix 2
### Schedule of Alectinib Pharmacokinetic Assessments

<table>
<thead>
<tr>
<th>Visit Description</th>
<th>Timepoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 0 (baseline)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>All subsequent visits (every 8 weeks) until PD or death/withdrawal from study prior to PD</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 0 (baseline) and Visit 1 (Week 4)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Pre-dose (within 2 hours before intake of alectinib), 1, 2, 4, 6, and 8 hours post-dose</td>
</tr>
</tbody>
</table>

PD = progressive disease; PK = Pharmacokinetic.

<sup>a</sup> For patients participating in the serial/intensive PK sample collection only.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters

This representative list is not intended to be an exhaustive list. Each patient’s concomitant medications should be carefully considered by the investigator with regard to the risk-benefit for the particular patient and appropriate monitoring, including any concomitant medication, dose adjustment, or therapeutic alternatives, which should be determined by the investigator caring for the patient.

<table>
<thead>
<tr>
<th>CYP3A Potent Inducers</th>
<th>CYP3A Potent Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>avasimibe, barbiturates, carbamazepine, efavirenz, ethosuximide, garlic supplements, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, primidone, rifabutin, rifampin, rifapentine, St. John’s wort, troglitazone</td>
<td>aprepitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, neffinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-gp Substrates</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>aliskiren, ambrisentan, colchicine, dabigatran, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, pravastatin, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan</td>
<td>avasimibe, carbamazepine, phenytoin, rifampin, St John’s wort, tipranavir</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dual UGT1A1/CYP3A Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>buprenorphine, raltegravir</td>
<td>atazanavir</td>
<td>rifampin</td>
</tr>
</tbody>
</table>


This information in this appendix is adapted from Levien and Baker 2003¹, Zhang 2010², and FDA Guidance on Drug-Drug Interactions.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters (cont.)

Also see:

- http://medicine.iupui.edu/clinpharm/ddis/table.aspx

Potent inhibitors of CYP3A are those considered to be “strong CYP3A inhibitors” previously shown to result in a ≥ 5-fold increase in the AUC of a concomitantly administered CYP3A substrate. These are based on the available published literature and, thus, are not considered exhaustive or inclusive. See FDA Guidance on Drug-Drug Interactions for further detail.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication

Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, are presented below, with slight modifications and the addition of explanatory text as needed for clarity.

MEASURABILITY OF TUMOR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as described below.

**Measurable tumor lesions**

**Tumor lesions**

Tumor lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size as follows:

- 10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than 5 mm)
- 10-mm caliper measurement by clinical examination (lesions that cannot be accurately measured with calipers should be recorded as non-measurable)
- 20 mm by chest X-ray

**Malignant lymph nodes**

To be considered pathologically enlarged and measurable, a lymph node must be ≥15 mm in the short axis when assessed by CT scan (CT scan slice thickness is recommended to be no greater than 5 mm). At baseline and follow-up, only the short axis will be measured and followed. See also notes below on “Baseline Documentation of Target and Non-Target Lesions” for information on lymph node measurement.

**Non-Measurable tumor lesions**

Non-measurable tumor lesions encompass small lesions (longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal mass/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques.

---

2 For consistency within this document, the section numbers and cross-references to other sections within the article have been deleted and minor formatting changes have been made.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Special considerations regarding lesion measurability

Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.

Bone lesions

Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.

Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques, such as CT or MRI, can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

Blastic bone lesions are non-measurable.

Cystic lesions

Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

Lesions with prior local treatment

Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.

TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS

Measurement of lesions

All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST)  
Version 1.1: Excerpt from Original Publication (cont.)

Method of assessment
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study. Imaging-based evaluation should always be the preferred option.

Clinical lesions
Clinical lesions will only be considered measurable when they are superficial and \( \geq 10 \) mm in diameter as assessed using calipers (e.g., skin nodules). For the case of clinical lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is required.

Chest X-Ray
Chest CT is preferred over chest X-Ray, particularly when progression is an important endpoint, because CT is more sensitive than X-Ray, particularly in identifying new lesions. However, lesions on chest X-Ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

CT, MRI
CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan on the basis of the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable.

If, prior to enrollment, it is known that a patient is unable to undergo CT scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the study should be guided by the tumor type under investigation and the anatomic location of the disease. For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible. Each case should be discussed with the radiologist to determine if the substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of target lesions on a different modality and interpretation of non-target disease or new lesions because the same lesion may appear to have a different size using a new modality.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement.

Endoscopy, laparoscopy, tumor markers, cytology, histology
The utilization of these techniques for objective tumor evaluation cannot generally be advised.

TUMOR RESPONSE EVALUATION
ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE
To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable lesion, as detailed above.

BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS
When more than one measurable lesion is present at baseline, all lesions, up to a maximum of five lesions total and a maximum of two lesions per organ, representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline. This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions (albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size is \(> 10\) mm by CT scan).

Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but, in addition, the lesions should lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.

Lymph nodes merit special mention since they are normal anatomical structures that may be visible by imaging even if not involved by tumor. As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of \(\geq 15\) mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT this is
almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥ 10 mm but < 15 mm) should be considered non-target lesions. Nodes that have a short axis of < 10 mm are considered non-pathological and should not be recorded or followed.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum of diameters. If lymph nodes are to be included in the sum, then, as noted above, only the short axis is added into the sum. The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions or sites of disease, including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression”.

In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).

RESPONSE CRITERIA

Evaluation of target lesions

This section provides the definitions of the criteria used to determine objective tumor response for target lesions.

- **CR**: Disappearance of all target lesions
  
  Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

- **PR**: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

- **PD**: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
  
  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

  The appearance of one or more new lesions is also considered progression.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

- SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

**Special notes on the assessment of target lesions**

**Lymph nodes**

Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to <10 mm on study. This means that when lymph nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of <10 mm.

**Target lesions that become too small to measure**

During the study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as target lesions at baseline become so faint on the CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being too small to measure. When this occurs, it is important that a value be recorded on the CRF, as follows:

If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.

If the lesion is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned and BML (below measurable limit) should be ticked. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned in this circumstance as well and BML should also be ticked).

To reiterate: If the radiologist is able to provide an actual measure, this measurement should be recorded, even if it is below 5 mm, and, in that case, BML should not be ticked.

**Lesions that split or coalesce on treatment**

When non-nodal lesions fragment, the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.

Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the group of non-target lesions. Whereas some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the timepoints specified in the protocol.

- **CR:** Disappearance of all non-target lesions
  
  All lymph nodes must be non-pathological in size (<10 mm short axis).

- **Non-CR/Non-PD:** Persistence of one or more non-target lesions

- **PD:** Unequivocal progression of existing non-target lesions
  
  The appearance of one or more new lesions is also considered progression.

**Special notes on assessment of progression of non-target disease**

**When the patient also has measurable disease**
In this setting, to achieve unequivocal progression on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease in a magnitude that, even in the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

**When the patient has only non-measurable disease**
This circumstance arises in some Phase III trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden on the basis of the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

disease from localized to widespread. Examples may be described in protocols as “sufficient to require a change in therapy”. If unequivocal progression is seen, the patient should be considered to have had overall PD at that point. Though it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore, the increase must be substantial.

New lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly important when the patient’s baseline lesions show PR or CR (e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not).

A lesion identified during the study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.

If a new lesion is equivocal (e.g., because of its small size) continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.

EVALUATION OF RESPONSE
Timepoint response (overall response)
It is assumed that at each protocol-specified timepoint, a response assessment occurs. Table 1 provides a summary of the overall response status calculation at each timepoint for patients who have measurable disease at baseline.

When patients have non-measurable (therefore non-target) disease only, Table 2 is to be used.
## Appendix 4
### Response Evaluation Criteria in Solid Tumors (RECIST)
#### Version 1.1: Excerpt from Original Publication (cont.)

### Table 1  Timepoint Response: Patients with Target Lesions (with or without Non-Target Lesions)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

### Table 2  Timepoint Response: Patients with Non-Target Lesions Only

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD a</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease.

a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can be measured is not advised.

### Missing assessments and not-evaluable designation

When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at that timepoint. If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response. This would be most likely...
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three measured lesions and during the study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution of the missing lesion).

If one or more target lesions were not assessed either because the scan was not done or because the scan could not be assessed due to poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable. Similarly, if one or more non-target lesions are not assessed, the response for non-target lesions should be “unable to assess”, except where there is clear progression. Overall response would be “unable to assess” if either the target response or the non-target response is “unable to assess”, except where this is clear evidence of progression, as this equates with the case being not evaluable at that timepoint.
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST)  
Version 1.1: Excerpt from Original Publication (cont.)

Table 3  Best Overall Response When Confirmation Is Required

<table>
<thead>
<tr>
<th>Overall Response at First Timepoint</th>
<th>Overall Response at Subsequent Timepoint</th>
<th>Best Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR a</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even disease meeting PR criteria relative to baseline, qualifies as PD at that point (since disease must have reappeared after CR). Best response would depend on whether the minimum duration for SD was met. However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint. Under these circumstances, the original CR should be changed to PR and the best response is PR.

Special notes on response assessment

When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (<10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document objective progression even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stopping study therapy. The objective response status of such patients is to be determined by evaluation of target and non-target disease as shown in Table 1 to Table 3.

For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non-target lesion, as appropriate. This is to avoid an incorrect assessment of complete response if the primary tumor is still present but not evaluated as a target or non-target lesion.
### Appendix 5

**Eastern Cooperative Oncology Group Performance Status Scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework or office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt; 50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to a bed or chair &gt; 50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires

EORTC QLQ-C30 (version 3)

We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will remain strictly confidential.

Please fill in your initials: [ ] [ ] [ ]
Your birthdate (Day, Month, Year): [ ] [ ] [ ] [ ] [ ] [ ]
Today's date (Day, Month, Year): 31 [ ] [ ] [ ] [ ] [ ] [ ]

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do you have any trouble doing strenuous activities,</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>like carrying a heavy shopping bag or a suitcase?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Do you have any trouble taking a long walk?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>3. Do you have any trouble taking a short walk outside of the house?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4. Do you need to stay in bed or a chair during the day?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5. Do you need help with eating, dressing, washing yourself or using the toilet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

During the past week:

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Were you limited in doing either your work or other daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7. Were you limited in pursuing your hobbies or other leisure time activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>8. Were you short of breath?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>9. Have you had pain?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>10. Did you need to rest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>11. Have you had trouble sleeping?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>12. Have you felt weak?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>13. Have you lacked appetite?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>14. Have you felt nauseated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>15. Have you vomited?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>16. Have you been constipated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Please go on to the next page
### Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

<table>
<thead>
<tr>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>During the past week:</td>
</tr>
<tr>
<td>17. Have you had diarrhea?</td>
</tr>
<tr>
<td>18. Were you tired?</td>
</tr>
<tr>
<td>19. Did pain interfere with your daily activities?</td>
</tr>
<tr>
<td>20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television?</td>
</tr>
<tr>
<td>21. Did you feel tense?</td>
</tr>
<tr>
<td>22. Did you worry?</td>
</tr>
<tr>
<td>23. Did you feel irritable?</td>
</tr>
<tr>
<td>24. Did you feel depressed?</td>
</tr>
<tr>
<td>25. Have you had difficulty remembering things?</td>
</tr>
<tr>
<td>26. Has your physical condition or medical treatment interfered with your family life?</td>
</tr>
<tr>
<td>27. Has your physical condition or medical treatment interfered with your social activities?</td>
</tr>
<tr>
<td>28. Has your physical condition or medical treatment caused you financial difficulties?</td>
</tr>
</tbody>
</table>

For the following questions please circle the number between 1 and 7 that best applies to you:

<table>
<thead>
<tr>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>29. How would you rate your overall health during the past week?</td>
</tr>
<tr>
<td>Very poor</td>
</tr>
<tr>
<td>30. How would you rate your overall quality of life during the past week?</td>
</tr>
<tr>
<td>Very poor</td>
</tr>
</tbody>
</table>

© Copyright 1999 EORTC Quality of Life Group. All rights reserved. Version 3.0
### EORTC QLQ - LC13

Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems during the past week. Please answer by circling the number that best applies to you.

<table>
<thead>
<tr>
<th>During the past week</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. How much did you cough?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>32. Did you cough up blood?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>33. Were you short of breath when you rested?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>34. Were you short of breath when you walked?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>35. Were you short of breath when you climbed stairs?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>36. Have you had a sore mouth or tongue?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>37. Have you had trouble swallowing?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>38. Have you had tingling hands or feet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>39. Have you had hair loss?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>40. Have you had pain in your chest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>41. Have you had pain in your arm or shoulder?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>42. Have you had pain in other parts of your body?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>If yes, where</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

43. Did you take any medicine for pain?

<table>
<thead>
<tr>
<th>1</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Yes</td>
</tr>
</tbody>
</table>

If yes, how much did it help?

| 1 | 2 | 3 | 4 |

© QLQ-C30-LC13 Copyright 1994 EORTC Quality of life Group. All rights reserved
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

Health Questionnaire

(English version for the US)

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

**Mobility**
- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

**Self-Care**
- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

**Usual Activities (e.g. work, study, housework, family or leisure activities)**
- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

**Pain/Discomfort**
- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

**Anxiety/Depression**
- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 7
Modification of Diet in Renal Disease (MDRD) Formula

The estimating glomerular filtration rate (eGFR) will be calculated on the basis of the following formula:

\[
eGFR \text{ [mL/min/1.73 m²]} = 175 \times SCRT -1.154 \times AGE -0.203 \times 0.742 \times \text{ if female} \times 1.212 \times \text{ if African American} \text{ (conventional units)}
\]

where SCRT = serum creatinine in conventional units, i.e. mg/dL. The following conversion factor should be used in case the serum creatinine value is provided by the lab in \( \mu \text{mol/L} \) units:

\[
\text{Serum creatinine [mg/dL]} = \text{Serum creatinine [\( \mu \text{mol/L} \)] } \times 0.0113
\]

References:
Appendix 8
Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry

Overview
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA anti-ALK [D5F3]) IHC assay will be used to determine anaplastic lymphoma kinase (ALK) IHC status and to select patients with positive ALK for enrollment in Study BO28984. The anti-ALK (D5F3) rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib. For Study BO28984, the VENTANA anti-ALK (D5F3) assay will be used for investigational purposes only.

VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with using a VENTANA automated slide stainer. It is indicated as an aid in identifying patients eligible for treatment with alectinib.

Device Description
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary antibody, the BenchMark® automated slide staining platform, OptiView DAB detection kit, OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA anti-ALK 2-in-1 cell line control slides or other appropriate system run control.

Scoring System
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern. Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish non-specific staining from specific ALK positivity. Samples must be assessed for morphological damage and the presence of viable tumor versus necrosis. Light, granular, cytoplasmic stippling in alveolar macrophages can occur on anti-ALK (D5F3) and/or NRC slides as an artifact of the detection system. This staining artifact should be noted on the Slide Evaluation Form comment field but should NOT be interpreted as ALK-positive staining. Some background staining has also been observed on normal mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also should not be interpreted as ALK-positive staining. Case slide sets failing to show specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be considered ALK-positive. Refer to VENTANA ALK Scoring Interpretation Guide for non-small cell lung carcinoma (NSCLC) for additional information.
### Appendix 9

**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms**

<table>
<thead>
<tr>
<th>Gene</th>
<th>CHST</th>
<th>CYP</th>
<th>HNMT</th>
<th>SLC22A</th>
<th>UGT1A</th>
<th>ADRB3</th>
<th>HSP90AA</th>
<th>STAT6</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>CHST13</td>
<td>CYP3A5</td>
<td>HNMT</td>
<td>SLC22A3</td>
<td>UGT1A4</td>
<td>ADRB3</td>
<td>HSP90AA</td>
<td>STAT6</td>
</tr>
<tr>
<td>ABCB11</td>
<td>CHST2</td>
<td>CYP3A7</td>
<td>MAOA</td>
<td>SLC22A4</td>
<td>UGT1A5</td>
<td>ALG10B</td>
<td>IGF1</td>
<td>TNF</td>
</tr>
<tr>
<td>ABCB4</td>
<td>CHST3</td>
<td>CYP4A1</td>
<td>MAOB</td>
<td>SLC22A5</td>
<td>UGT1A6</td>
<td>APOA1</td>
<td>IGF2</td>
<td>TNFRSF1B</td>
</tr>
<tr>
<td>ABCB7</td>
<td>CHST4</td>
<td>CYP4A11</td>
<td>MAT1A</td>
<td>SLC22A6</td>
<td>UGT1A7</td>
<td>APOC3</td>
<td>IL10</td>
<td>TXNIP</td>
</tr>
<tr>
<td>ABCC1</td>
<td>CHST5</td>
<td>CYP4B1</td>
<td>METTL1</td>
<td>SLC22A7</td>
<td>UGT1A8</td>
<td>ARHGAP24</td>
<td>IL22</td>
<td>UBC</td>
</tr>
<tr>
<td>ABCC2</td>
<td>CHST6</td>
<td>CYP4F11</td>
<td>NAT1</td>
<td>SLC22A8</td>
<td>UGT1A9</td>
<td>ATF3</td>
<td>IL4</td>
<td>UCP1</td>
</tr>
<tr>
<td>ABCC3</td>
<td>CHST7</td>
<td>CYP4F12</td>
<td>NAT2</td>
<td>SLC25A27</td>
<td>UGT2A1</td>
<td>ATIC</td>
<td>IL4R</td>
<td>VDR</td>
</tr>
<tr>
<td>ABCC4</td>
<td>CHST8</td>
<td>CYP4F2</td>
<td>NNMT</td>
<td>SLC28A1</td>
<td>UGT2B11</td>
<td>BIRC2</td>
<td>IL6</td>
<td></td>
</tr>
<tr>
<td>ABCC5</td>
<td>CHST9</td>
<td>CYP4F3</td>
<td>NQO1</td>
<td>SLC28A2</td>
<td>UGT2B15</td>
<td>BIRC3</td>
<td>IL8</td>
<td></td>
</tr>
<tr>
<td>ABCC6</td>
<td>COMT</td>
<td>CYP4F8</td>
<td>NR1I2</td>
<td>SLC28A3</td>
<td>UGT2B17</td>
<td>C3orf38</td>
<td>INSR</td>
<td></td>
</tr>
<tr>
<td>ABCC8</td>
<td>CROT</td>
<td>CYP4Z1</td>
<td>NR1I3</td>
<td>SLC29A1</td>
<td>UGT2B28</td>
<td>CALCA</td>
<td>IRS1</td>
<td></td>
</tr>
<tr>
<td>ABCC9</td>
<td>CYP11A1</td>
<td>CYP51A1</td>
<td>NR3C1</td>
<td>SLC29A2</td>
<td>UGT2B4</td>
<td>CASP9</td>
<td>IRS2</td>
<td></td>
</tr>
<tr>
<td>ABCG1</td>
<td>CYP11B1</td>
<td>CYP7A1</td>
<td>ORM1</td>
<td>SLC5A6</td>
<td>UGT2B7</td>
<td>CD33</td>
<td>IRS4</td>
<td></td>
</tr>
<tr>
<td>ABCG2</td>
<td>CYP11B2</td>
<td>CYP7B1</td>
<td>ORM2</td>
<td>SLC6A6</td>
<td>UGT8</td>
<td>CD36</td>
<td>ITPA</td>
<td></td>
</tr>
<tr>
<td>ABP1</td>
<td>CYP17A1</td>
<td>CYP8B1</td>
<td>PGAP3</td>
<td>SLC7A5</td>
<td>VKORC1</td>
<td>CD44</td>
<td>JAK1</td>
<td></td>
</tr>
<tr>
<td>ADH1A</td>
<td>CYP19A1</td>
<td>DCK</td>
<td>PNMT</td>
<td>SLC7A7</td>
<td>XDH</td>
<td>CDK4</td>
<td>JUN</td>
<td></td>
</tr>
<tr>
<td>ADH1B</td>
<td>CYP1A1</td>
<td>DPYD</td>
<td>PON1</td>
<td>SLC7A8</td>
<td></td>
<td>CDK6</td>
<td>KCNIP4</td>
<td></td>
</tr>
<tr>
<td>ADH1C</td>
<td>CYP1A2</td>
<td>EPHX1</td>
<td>PON2</td>
<td>SLCO1A2</td>
<td></td>
<td>CEBPB</td>
<td>KRT18</td>
<td></td>
</tr>
<tr>
<td>ADH4</td>
<td>CYP1B1</td>
<td>EPHX2</td>
<td>PON3</td>
<td>SLCO1B1</td>
<td></td>
<td>CEP44</td>
<td>KRT8</td>
<td></td>
</tr>
<tr>
<td>ADH5</td>
<td>CYP20A1</td>
<td>FAAH</td>
<td>POR</td>
<td>SLCO1B3</td>
<td></td>
<td>CES1</td>
<td>LEP</td>
<td></td>
</tr>
<tr>
<td>ADH6</td>
<td>CYP21A2</td>
<td>FMO1</td>
<td>PPARD</td>
<td>SLCO2B1</td>
<td></td>
<td>CTLA4</td>
<td>LEPR</td>
<td></td>
</tr>
<tr>
<td>ADH7</td>
<td>CYP24A1</td>
<td>FMO2</td>
<td>PPARG</td>
<td>SLCO3A1</td>
<td></td>
<td>CYP3A</td>
<td>LMX1A</td>
<td></td>
</tr>
<tr>
<td>AHR</td>
<td>CYP26A1</td>
<td>FMO3</td>
<td>PPP1R9A</td>
<td>SLCO4A1</td>
<td></td>
<td>EGFR</td>
<td>LPL</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 9
### Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms (cont.)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AKAP9</td>
<td>CYP26C1</td>
<td>FMO4</td>
<td>PRSS53</td>
<td>SLC05A1</td>
<td>ETNK2</td>
<td>MCTP2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALB</td>
<td>CYP27A1</td>
<td>FMO5</td>
<td>PTGIS</td>
<td>SPG7</td>
<td>FASLG</td>
<td>MT-CO2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>CYP27B1</td>
<td>FMO6</td>
<td>QPRT</td>
<td>SPN</td>
<td>FMOD</td>
<td>MTHFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH2</td>
<td>CYP2A13</td>
<td>G6PD</td>
<td>RALBP1</td>
<td>SULT1A1</td>
<td>FOS</td>
<td>NFE2L2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH3A1</td>
<td>CYP2A6</td>
<td>GSTA1</td>
<td>RPL13</td>
<td>SULT1A2</td>
<td>FPAGS</td>
<td>NOS2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>CYP2A7</td>
<td>GSTA2</td>
<td>RXRA</td>
<td>SULT1A3</td>
<td>GGH</td>
<td>NOS3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AOX1</td>
<td>CYP2B6</td>
<td>GSTA3</td>
<td>SERPINA7</td>
<td>SULT1B1</td>
<td>GPNMB</td>
<td>OR5H2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOA2</td>
<td>CYP2B7P1</td>
<td>GSTA4</td>
<td>SLC10A1</td>
<td>SULT1C2</td>
<td>GPT</td>
<td>PARD3B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARNT</td>
<td>CYP2C18</td>
<td>GSTA5</td>
<td>SLC10A2</td>
<td>SULT1C4</td>
<td>GPX1</td>
<td>PRKCI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARSA</td>
<td>CYP2C19</td>
<td>GSTM1</td>
<td>SLC13A1</td>
<td>SULT1E1</td>
<td>GPX3</td>
<td>RASGPR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATP7A</td>
<td>CYP2C8</td>
<td>GSTM2</td>
<td>SLC15A1</td>
<td>SULT2A1</td>
<td>GPX4</td>
<td>RB1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATP7B</td>
<td>CYP2C9</td>
<td>GSTM3</td>
<td>SLC15A2</td>
<td>SULT2B1</td>
<td>GYS1</td>
<td>RDH5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA5P</td>
<td>CYP2D6</td>
<td>GSTM4</td>
<td>SLC16A1</td>
<td>SULT4A1</td>
<td>GYS2</td>
<td>RIPK1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBR1</td>
<td>CYP2E1</td>
<td>GSTM5</td>
<td>SLC19A1</td>
<td>TBXAS1</td>
<td>HCP5</td>
<td>SOCS3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBR3</td>
<td>CYP2F1</td>
<td>GSTO1</td>
<td>SLC22A1</td>
<td>TPSMT</td>
<td>HGF</td>
<td>SOD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDA</td>
<td>CYP2J2</td>
<td>GSTP1</td>
<td>SLC22A11</td>
<td>TPSG1</td>
<td>HLA-A</td>
<td>SOD2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CES2</td>
<td>CYP2S1</td>
<td>GSTT1</td>
<td>SLC22A12</td>
<td>TYMS</td>
<td>HLA-B</td>
<td>SPP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHST1</td>
<td>CYP39A1</td>
<td>GSTT2</td>
<td>SLC22A13</td>
<td>UGT1A1</td>
<td>HLA-DQA1</td>
<td>SQSTM1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHST10</td>
<td>CYP3A4</td>
<td>GSTZ1</td>
<td>SLC22A14</td>
<td>UGT1A10</td>
<td>HLA-DQB1</td>
<td>ST6GAL1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHST11</td>
<td>CYP3A43</td>
<td>HMGCR</td>
<td>SLC22A2</td>
<td>UGT1A3</td>
<td>HLA-DRB1</td>
<td>STAT1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 10 Formulae for the Calculation of QTcF and RR

QTcF – Fridericia’s correction for QTc measurement (if not provided directly by the ECG machine):

\[
\text{QTcF (ms)} = \frac{\text{QT (ms)}}{\sqrt[6]{\text{RR (ms)/1000}}}
\]

RR Interval Formula (if not provided directly by the ECG machine):

\[
\text{RR (ms)} = \frac{60000}{\text{heart rate (bpm)}}
\]
PROTOCOL

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 4
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: 
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: 
SPONSOR: F. Hoffmann-La Roche Ltd
DATE FINAL: Version 1: 10 February 2014
DATE AMENDED: Version 2: 08 October 2014
Version 4: See electronic date stamp below.

PROTOCOL AMENDMENT APPROVAL

Approver's Name: Company Signatory
Title: Company Signatory
Date and Time (UTC): 15-Apr-2016 00:17:48

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
PROTOCOL AMENDMENT, VERSION 4:
RATIONALE

Protocol BO28984 has been amended to incorporate the latest safety and drug administration information. Changes include those to adverse events (AEs) relating to alectinib data and management of alectinib AEs guidelines, restrictions related to QT-prolonging concomitant medications for alectinib, and guideline for the management of missing doses of alectinib.

The major changes to the protocol are as follows:

Change of the risk of hepatobiliary laboratory tests elevations to hepatotoxicity for alectinib, on the basis of the following information: two patients with Grade 3-4 AST/ALT elevations had documented drug-induced liver injury by liver biopsy in alectinib pivotal Phase II clinical trials. Concurrent elevations in ALT or AST greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 1 patient treated in alectinib clinical trials (0.2%) (Section 5.1.2.2 and Section 5.1.3).

Change of the risk of muscular adverse events and CPK elevations to severe myalgia and CPK elevations for alectinib, on the basis of the following information: Grade 3 myalgia and CPK elevations have been reported with alectinib treatment and were reversible upon dose reduction and interruption (Section 5.1.2.10 and Section 5.1.3).

The list of adverse events relating to ALK inhibitors and/or tyrosine kinase inhibitor class and alectinib data has been updated accordingly. The list was updated to replace the “hematologic abnormalities” events with the “anemia” events. This is in line with the alectinib Investigator’s Brochure (IB) version 6. The guideline for management of specific adverse events related to hematological abnormalities in alectinib-treated patients has been removed accordingly. In case of the occurrence of events falling in the category of hematological abnormalities, appropriate management of the adverse events is already covered by the guideline “Other AEs or laboratory abnormalities”, also included in Table 2 (Section 5.1.2.3).

Restrictions related to concomitant medications known to prolong the QT interval have been modified. The restriction is no longer required for alectinib-treated patients on the basis of the detailed evaluation of the pooled ECG data from the two pivotal Studies NP28761 and NP28673 and ECG data from the supportive Study AF-001JP, which showed no evidence that alectinib caused any clinically relevant QTcF prolongation. Furthermore, there was no apparent correlation between the change in QTcF and alectinib plasma concentration. For crizotinib-treated patients, this restriction still applies. For the same reason, the guideline for management of specific adverse events related to QT prolongation in alectinib-treated patients has been removed from Table 2 (Section 4.1.2 and Section 4.4.2).
The guideline for management of specific adverse events related to skin disorder adverse events in alectinib-treated patients has been updated to advise patients to use a broad-spectrum sunscreen and lip balm of at least sun protection factor SPF 50 to help protect against potential photosensitivity (Section 5.1.3).

Guidelines for the management of missing doses of alectinib have been updated. Following oral administration of 600 mg twice daily (BID) under fed conditions in patients with ALK-positive non–small cell lung cancer (NSCLC), alectinib was rapidly absorbed reaching $T_{\text{max}}$ after approximately 4 to 6 hours (Studies NP28761 and NP28673). On the basis of the known $T_{\text{max}}$, if a dose of alectinib is missed, the dose should be made up unless the next dose is due within 6 hours. This is to ensure any missed dose is taken during the expected elimination phase (post-$T_{\text{max}}$) of the alectinib dosing interval. This approach is consistent with other molecules with similar PK characteristics ($T_{\text{max}}$ of 4 to 6 hours and an apparent $T_{1/2}$ of greater than 30 hours) and BID dosing interval (XALKORI® U.S. Package Insert, ZELBORAF® U.S. Package Insert) (Section 4.3.2.1).

The FISH Positive Population (FPP) was intended to be used for possible registration purposes in the event that the Ventana IHC companion diagnostic for Alectinib would not be registered. All analyses would, in that event, have been based on the FPP-population and the same pre-specified testing strategy of secondary endpoints would have been applied for the FPP. Following the FDA approval in June 2015 of the Ventana ALK IHC assay as companion diagnostic for crizotinib the fully powered analyses of the FPP have become redundant and are removed from the BO28984 study protocol. The ALK FISH positive secondary population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay (Section 6 and Section 6.8).

Appendix 3, List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters, has been updated to include only potent CYP3A4 Inducers.

Additional minor changes have been made to improve clarity and consistency. This amendment represents cumulative changes to the original protocol.
PROTOCOL AMENDMENT, VERSION 4:
SUMMARY OF CHANGES

PROTOCOL SYNOPSIS
The protocol synopsis has been updated to reflect the changes to the protocol, where applicable.

SECTION 1.3: STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT
On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks. Specifically:

- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with TKIs ALK inhibitors.

SECTION 2.5: EXPLORATORY OBJECTIVES
The exploratory objectives for this study are:

- To evaluate and compare efficacy and safety in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott)

SECTION 3.4.5: Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:

- Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by FISH test

SECTION 4.1.1: Inclusion Criteria
Patients must meet the following criteria for study entry:

- For women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide.

SECTION 4.1.2: Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:

- Patients with baseline QTc > 470 ms or symptomatic bradycardia

Alectinib—F. Hoffmann-La Roche Ltd
4/Protocol BO28984, Version 4
• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug for all patients and while on treatment through the end of the study for crizotinib-treated patients only (see Section 4.4.2 for further details)

• Pregnant or lactating women

SECTION 4.3.2.1: Alectinib
If a patient misses a dose, it can be taken within 4 6 hours of the scheduled time. If the time is greater than 4 6 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

SECTION 4.4.2: Prohibited Therapy
Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) is prohibited during the study and for at least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless otherwise specified below. Exceptions to restrictions of the concomitant therapies listed below (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) may be made if the rationale is discussed and documented between the investigator and the Sponsor’s Clinical Pharmacologist.

• Any concomitant medications known to affect QT interval duration, including but not limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone, and quinidine, within 2 weeks before the first dose of study drug treatment for all patients and while on treatment with study drugs and through the end of the study for crizotinib-treated patients only

SECTION 4.5.8.1: Laboratory Assessments
Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis of the following:

SECTION 4.5.8.2: Pre-Treatment Tumor Samples (Mandatory)
Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by Ventana IHC (Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) for possible companion diagnostic development.

SECTION 4.5.9: Electrocardiograms
If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5. Management of QT interval prolongation should be done according to guidance provided in Section 5.1.3.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory. Guidance for abnormal ECG results (QT prolongation) is provided in Table 2.
SECTION 5.1.2.2: Hepatobiliary Laboratory Test Elevations

**Hepatotoxicity**

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved. In patients with Grade 3–4 AST/ALT elevations, documented drug-induced liver injury by liver biopsy was reported with uncommon frequency in alectinib pivotal clinical trials. Concurrent elevations in ALT or AST greater than or equal to three times the ULN and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred with uncommon frequency in patients treated in alectinib clinical trials.

In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and fatal cases of hepatic failure, drug-induced hepatotoxicity, including cases with fatal outcome, have been reported.

SECTION 5.1.2.3: Hematologic Abnormalities

**Anemia**

Hematologic abnormalities of neutropenia, leukopenia, thrombocytopenia, and anemia have been reported with alectinib administration. Neutrophil counts generally decreased early and remained stable thereafter.

Cases of anemia have been reported in patients treated with alectinib; the majority of the events were Grade 1 or 2.

SECTION 5.1.2.8: Cardiovascular Effects

**Bradycardia**

QT interval prolongation appears to be an off-target class effect of some TKIs, including ALK inhibitor crizotinib (Shah et al. 2013; XALKORI® U.S. Package Insert). Many TKIs have been associated with bradycardia and hypertension.

In the in vitro study of the cardiovascular system, alectinib inhibited the hERG current ($IC_{20} = 58$ ng/mL; $IC_{50} = 217$ ng/mL). Because plasma protein binding by alectinib is $\geq 99\%$, the plasma concentration of alectinib required to induce the same inhibition in vivo would be 100 or more times greater than the concentration required in vitro. In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration $[C_{\text{max}}]$: 279 ng/mL).

Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse events, as well as decreases in heart rate based on ECG and pulse measurements, have also been reported (XALKORI® U.S. Package Insert; ZYKADIA™ U.S. Package Insert).
SECTION 5.1.2.10: Muscular Adverse Events

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment. *Grade 3 myalgia and CPK elevations have been reported with alectinib treatment and were reversible upon dose reduction and interruption.*

SECTION 6: STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

A secondary analysis population for efficacy and safety is the FISH Positive Population (FPP). For efficacy, this is defined as all patients in the ITT population who were ALK-positive using the Vysis FISH assay. Patients will be assigned to the treatment group to which they were randomized. For safety, this is defined as all patients in the SAP who were ALK positive using the Vysis FISH assay. Patients will be assigned to treatment groups as treated. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population and the same prespecified testing strategy of secondary endpoints defined in Section 6.4.2 will be applied.

An analysis of the primary endpoint of investigator-assessed PFS based on the FPP will be performed at the time of the primary analysis. A major discrepancy between the Ventana IHC assay and the Vysis FISH assay may necessitate a follow-up analysis of the primary endpoint based on 170 PFS events observed in the FPP to ensure 80% power of the log-rank test under the assumption of a hazard ratio of 0.65 in this secondary population.

SECTION 6.1: DETERMINATION OF SAMPLE SIZE

A follow-up analysis will be performed based on the FPP. This will occur once 170 PFS events have occurred in the FPP to ensure 80% power of the log-rank test assuming a hazard ratio of 0.65 in this subpopulation. Based on a potential discrepancy/technical failure rate of 10% between the Ventana IHC assay and the Vysis FISH assay, 257 patients would be eligible for the FPP analysis, which is estimated to occur approximately 35 months after the first patient has been enrolled (i.e., 2 months after the primary IHC analysis) based on the above assumptions.

SECTION 6.4.2: Secondary Efficacy Endpoints

Time to CNS Progression

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. Similar analyses will be performed in the subgroup of patients with measurable and/or non-measurable CNS lesions at baseline.
An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

SECTION 6.8: EXPLORATORY ANALYSES
The Abbott Vysis FISH test will be used as an exploratory assay after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between Vysis FISH and Ventana IHC for the detection of ALK-positive NSCLC. The FPP will be a secondary analysis population for efficacy and safety. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population.

...Results of analyses related to those alternative diagnostic tests and exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure ALK rearrangements in circulating tumor cells will be communicated outside the main clinical study report.

TABLE 2: Guidelines for Management of Specific Adverse Events with Alectinib
Table 2, Guidelines for Management of Specific Adverse Events with Alectinib, has been revised to reflect changes in the protocol.

TABLE 4: Crizotinib Dose Modification—Non-Hematologic Toxicities
Table 4, Crizotinib Dose Modification—Non-Hematologic Toxicities, has been modified to remove some typographical errors around the QTc interval, thus clarifying that the QTc interval should be >500 ms.

APPENDIX 1: Schedule of Assessments
Appendix 1, Schedule of Assessments, has been revised to add a flowchart detailing assessments needed when a patient permanently discontinues from study treatment.

APPENDIX 3: List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters
Appendix 3, List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters, has been updated to include only potent CYP3A4 Inducers.

APPENDIX 10: Formulae for the Calculation of QTcF and RR
Appendix 10, Formulae for the Calculation of QTcF and RR, has been corrected.

SAMPLE INFORMED CONSENT FORM
The sample Informed Consent Form has been revised to reflect the changes to the protocol.

Alectinib—F. Hoffmann-La Roche Ltd
8/Protocol BO28984, Version 4
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROTOCOL AMENDMENT ACCEPTANCE FORM</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>PROTOCOL SYNOPSIS</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>1. BACKGROUND</td>
<td></td>
<td>28</td>
</tr>
<tr>
<td>1.1</td>
<td>Background on Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</td>
<td>28</td>
</tr>
<tr>
<td>1.2</td>
<td>Background on Alectinib</td>
<td>30</td>
</tr>
<tr>
<td>1.3</td>
<td>Study Rationale and Benefit-Risk Assessment</td>
<td>35</td>
</tr>
<tr>
<td>2. OBJECTIVES</td>
<td></td>
<td>37</td>
</tr>
<tr>
<td>2.1</td>
<td>Efficacy Objectives</td>
<td>37</td>
</tr>
<tr>
<td>2.2</td>
<td>Safety Objectives</td>
<td>38</td>
</tr>
<tr>
<td>2.3</td>
<td>Pharmacokinetic Objectives</td>
<td>38</td>
</tr>
<tr>
<td>2.4</td>
<td>Patient-Reported Outcome Objectives</td>
<td>38</td>
</tr>
<tr>
<td>2.5</td>
<td>Exploratory Objectives</td>
<td>38</td>
</tr>
<tr>
<td>3. STUDY DESIGN</td>
<td></td>
<td>39</td>
</tr>
<tr>
<td>3.1</td>
<td>Description of Study</td>
<td>39</td>
</tr>
<tr>
<td>3.2</td>
<td>End of Study</td>
<td>41</td>
</tr>
<tr>
<td>3.3</td>
<td>Rationale for Study Design</td>
<td>42</td>
</tr>
<tr>
<td>3.3.1</td>
<td>Rationale for Alectinib Dosage</td>
<td>42</td>
</tr>
<tr>
<td>3.3.2</td>
<td>Rationale for Patient Population</td>
<td>43</td>
</tr>
<tr>
<td>3.3.3</td>
<td>Rationale for Control Group</td>
<td>43</td>
</tr>
<tr>
<td>3.3.4</td>
<td>Rationale for Open-Label Design</td>
<td>44</td>
</tr>
<tr>
<td>3.3.5</td>
<td>Rationale for Primary Endpoint Selection</td>
<td>45</td>
</tr>
<tr>
<td>3.3.6</td>
<td>Rationale for Secondary Endpoint of Time to CNS Progression</td>
<td>46</td>
</tr>
<tr>
<td>3.3.7</td>
<td>Rationale for PK Sample Collection Schedule</td>
<td>47</td>
</tr>
<tr>
<td>3.3.8</td>
<td>Rationale for Biomarker Assessments</td>
<td>47</td>
</tr>
<tr>
<td>3.3.9</td>
<td>Rationale for PRO Assessments</td>
<td>48</td>
</tr>
<tr>
<td>3.4</td>
<td>Outcome Measures</td>
<td>49</td>
</tr>
<tr>
<td>3.4.1</td>
<td>Efficacy Outcome Measures</td>
<td>49</td>
</tr>
<tr>
<td>3.4.2</td>
<td>Safety Outcome Measures</td>
<td>49</td>
</tr>
<tr>
<td>3.4.3</td>
<td>Pharmacokinetic Outcome Measures</td>
<td>50</td>
</tr>
</tbody>
</table>
3.4.4 Patient-Reported Outcome Measures ........................................ 50
3.4.5 Exploratory Outcome Measures ............................................. 51

4. MATERIALS AND METHODS ................................................................. 51
4.1 Patients ..................................................................................... 51
4.1.1 Inclusion Criteria ............................................................... 51
4.1.2 Exclusion Criteria .................................................................. 53
4.2 Method of Treatment Assignment and Blinding ......................... 54
4.3 Study Treatment ........................................................................ 54
4.3.1 Formulation, Packaging, and Handling .................................. 54
4.3.1.1 Alectinib ........................................................................ 54
4.3.1.2 Crizotinib ....................................................................... 55
4.3.2 Dosage, Administration, and Compliance ................................ 55
4.3.2.1 Alectinib ........................................................................ 55
4.3.2.2 Crizotinib ....................................................................... 55
4.3.3 Investigational Medicinal Product Accountability ..................... 56
4.3.4 Post-Trial Access to Alectinib ................................................ 56
4.4 Concomitant Therapy .............................................................. 57
4.4.1 Permitted Therapy ................................................................. 57
4.4.2 Prohibited Therapy ............................................................... 58
4.4.3 Prohibited Food ..................................................................... 59
4.5 Study Assessments .................................................................... 59
4.5.1 Informed Consent Forms and Screening Log ......................... 59
4.5.2 Medical History and Demographic Data .................................. 60
4.5.3 Corticosteroid Use for CNS Metastases .................................. 60
4.5.4 Physical Examinations .......................................................... 60
4.5.5 Vital Signs ............................................................................. 60
4.5.6 ECOG Performance Status .................................................. 61
4.5.7 Tumor and Response Evaluations .......................................... 61
4.5.8 Laboratory, Biomarker, and Other Biological Sample .............. 62
4.5.8.1 Laboratory Assessments .................................................. 62
4.5.8.2 Pre-Treatment Tumor Samples (Mandatory) ................. 62
4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional) .............................................................. 63
4.5.8.4 Blood and Plasma Samples .................................................. 64
4.5.8.5 Samples for Pharmacokinetic Assessments .......................... 65
4.5.9 Electrocardiograms ............................................................... 66
4.5.10 Patient-Reported Outcomes ................................................. 66
4.5.11 Samples for Roche Clinical Repository ................................ 67
4.5.11.1 Overview of the Roche Clinical Repository ................. 67
4.5.11.2 Approval by the Institutional Review Board or Ethics Committee .................................................. 67
4.5.11.3 Sample Collection ............................................................. 67
4.5.11.4 Confidentiality ................................................................. 68
4.5.11.5 Consent to Participate in the Roche Clinical Repository ............................................................. 68
4.5.11.6 Withdrawal from the Roche Clinical Repository ......... 69
4.5.11.7 Monitoring and Oversight .................................................. 69
4.6 Patient, Treatment, Study, and Site Discontinuation ............. 69
4.6.1 Patient Discontinuation .......................................................... 69
4.6.2 Study Treatment Discontinuation ......................................... 70
4.6.3 Study and Site Discontinuation .............................................. 70
5. ASSESSMENT OF SAFETY .................................................. 71
5.1 Safety Plan ............................................................................ 71
5.1.1 Adverse Events Collection .................................................. 71
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data ............................................................. 71
5.1.2.1 Interstitial Lung Disease .................................................. 71
5.1.2.2 Hepatotoxicity ................................................................. 71
5.1.2.3 Anemia ........................................................................... 72
5.1.2.4 Gastrointestinal Disorders .............................................. 72
5.1.2.5 Skin Disorders ............................................................... 72
5.1.2.6 Vision Disorders ............................................................. 73
5.1.2.7 Edema ............................................................................. 73
5.1.2.8 Bradycardia ........................................................................... 73
5.1.2.9 Abnormal Renal Function ...................................................... 74
5.1.2.10 Severe Myalgia and CPK Elevations ..................................... 74
5.1.3 Management of Specific Adverse Events with Alectinib ................................................................. 75
5.1.4 Safety of Crizotinib and Management of Adverse Events ........................................................................ 78
5.2 Safety Parameters and Definitions ............................................ 81
5.2.1 Adverse Events ..................................................................... 81
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor) ...................................................................... 82
5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor) .............................. 82
5.3 Methods and Timing for Capturing and Assessing Safety Parameters ................................................ 83
5.3.1 Adverse Event Reporting Period ........................................... 83
5.3.2 Eliciting Adverse Event Information ..................................... 83
5.3.3 Assessment of Severity of Adverse Events ........................... 83
5.3.4 Assessment of Causality of Adverse Events ......................... 84
5.3.5 Procedures for Recording Adverse Events ............................ 85
5.3.5.1 Diagnosis Versus Signs and Symptoms ................................ 85
5.3.5.2 Adverse Events that are Secondary to Other Events ........................................................................ 85
5.3.5.3 Persistent or Recurrent Adverse Events ................................. 85
5.3.5.4 Abnormal Laboratory Values ........................................... 86
5.3.5.5 Abnormal Vital Sign Values ............................................. 87
5.3.5.6 Abnormal Liver Function Tests ....................................... 87
5.3.5.7 Deaths .................................................................................... 87
5.3.5.8 Preexisting Medical Conditions ........................................ 88
5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer .................................................................. 88
5.3.5.10 Hospitalization or Prolonged Hospitalization ..................... 88
5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration .......................................... 89
5.3.5.12 Patient-Reported Outcome Data ........................................... 89
5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study .....................................................................................89
5.4 Immediate Reporting Requirements from Investigator to Sponsor........................................................................... 89
5.4.1 Emergency Medical Contacts ................................................................................................................................. 90
5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest ................................................................................................................................. 90
5.4.2.1 Events That Occur Prior to Study Drug Initiation ................. 90
5.4.2.2 Events That Occur After Study Drug Initiation ..................... 90
5.4.3 Reporting Requirements for Pregnancies.......................................................... 91
5.4.3.1 Pregnancies in Female Patients ........................................ 91
5.4.3.2 Pregnancies in Female Partners of Male Patients .............. 91
5.4.3.3 Abortions ............................................................................ 92
5.4.3.4 Congenital Anomalies/Birth Defects ................................ 92
5.5 Follow-Up of Patients after Adverse Events ........................................ 92
5.5.1 Investigator Follow-Up ................................................................................. 92
5.5.2 Sponsor Follow-Up .................................................................................. 92
5.6 Post-Study Adverse Events .................................................................................. 93
5.7 Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Ethics Committees ................................................................................................................................. 93

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN ......................................................................................... 93
6.1 Determination of Sample Size ................................................................................................................................. 94
6.2 Summaries of Conduct of Study ................................................................................................................................. 95
6.3 Summaries of Treatment Group Comparability ........................................................................................................... 95
6.4 Efficacy Analyses ................................................................................................................................. 96
6.4.1 Primary Efficacy Endpoint ................................................................................. 96
6.4.2 Secondary Efficacy Endpoints .................................................................................. 97
6.4.2.1 Sensitivity Analyses ............................................................................ 99
6.4.2.2 Subgroup Analyses ............................................................................. 99
6.5 Safety Analyses ................................................................................................................................. 99
6.6 Pharmacokinetic Analyses .................................................................................. 100
6.7 Patient-Reported Outcome Analyses ................................................................................................................................. 101
6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms ...............................................................101
6.7.2 Additional Patient-Reported Outcomes ...............................102
6.8 Exploratory Analyses ........................................................... 102

7. DATA COLLECTION AND MANAGEMENT .................................103
  7.1 Data Quality Assurance ..........................................................103
  7.2 Electronic Case Report Forms ............................................. 103
  7.3 Electronic Patient-Reported Outcome Data ..........................104
  7.4 Source Data Documentation ................................................104
  7.5 Use of Computerized Systems .............................................105
  7.6 Retention of Records ...........................................................105

8. ETHICAL CONSIDERATIONS .................................................. 105
  8.1 Compliance with Laws and Regulations ..............................105
  8.2 Informed Consent ...............................................................105
  8.3 Institutional Review Board or Ethics Committee ..................107
  8.4 Confidentiality .................................................................107
  8.5 Financial Disclosure ..........................................................107

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION ...................................................................................108
  9.1 Study Documentation ..........................................................108
  9.2 Protocol Deviations .............................................................108
  9.3 Site Inspections ...................................................................108
  9.4 Administrative Structure ....................................................108
  9.5 Publication of Data and Protection of Trade Secrets .................109
  9.6 Protocol Amendments ........................................................110

10. REFERENCES ......................................................................... 111
LIST OF TABLES

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP ........................................................ 32
Table 2  Guidelines for Management of Specific Adverse Events with Alectinib ...................................................................................... 75
Table 3  Crizotinib Dose Modification-Hematologic Toxicities (Except Lymphopenia) ........................................................................... 79
Table 4  Crizotinib Dose Modification-Non-Hematologic Toxicities ........... 80
Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE ....................................................... 84

LIST OF FIGURES

Figure 1  Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013) ......................... 31
Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ...................................................................33
Figure 3  Best Percent Change in Size of Target Lesions from Baseline as Assessed by the Investigator in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) .................................................................................. 34
Figure 4  Summary of Study Design ..........................................................................................................................41

LIST OF APPENDICES

Appendix 1  Schedule of Assessments .......................................................................................................................... 116
Appendix 2  Schedule of Alectinib Pharmacokinetic Assessments ...................................................................................... 124
Appendix 3  List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters ........................................................................... 125
Appendix 4  Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication ...................................................................... 127
Appendix 5  Eastern Cooperative Oncology Group Performance Status Scale ........................................................................................................................... 138
Appendix 6  EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires ........................................................................ 139
Appendix 7  Modification of Diet in Renal Disease (MDRD) Formula ............................................................................. 147
Appendix 8  Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry ............................................................................ 148
Appendix 9  Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms ............................................................................ 149
Appendix 10 Formulae for the Calculation of QTcF and RR ...................................................... 151
PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 4
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [REDACTED]
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [REDACTED]
SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

Principal Investigator’s Name  (print)

Principal Investigator’s Signature  Date

Please retain the signed original of this form for your study files. Please return a copy to your local study monitor.
PROTOCOL SYNOPSIS

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 4
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: 
TEST PRODUCT: Alectinib (RO5424802)
PHASE: Phase III
INDICATION: Anaplastic lymphoma kinase–positive (ALK-positive) non–small cell lung cancer (NSCLC)
SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives
The primary efficacy objective for this study is as follows:
• To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as measured by investigator-assessed progression-free survival (PFS)

The secondary efficacy objectives for this study are as follows:
• To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of Independent Review Committee (IRC) review of radiographs by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the overall survival (OS)

Safety Objective
The safety objective for this study is as follows:
• To evaluate the safety and tolerability of alectinib compared to crizotinib

Alectinib—F. Hoffmann-La Roche Ltd
17/Protocol BO28984, Version 4
Pharmacokinetic Objective
The secondary pharmacokinetic (PK) objective for this study is as follows:
• To characterize the pharmacokinetics of alectinib and metabolite(s)

Patient-Reported Outcome Objectives
The secondary patient-reported outcome (PRO) objectives for this study are as follows:
• To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm and shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)
• To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

Exploratory Objectives
The exploratory objectives for this study are as follows:
• To evaluate and compare patient's health status as assessed by the EuroQol 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement
• To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG]), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels in blood
• To evaluate and compare efficacy in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
• To evaluate and compare efficacy and safety in patients having treatment-naive ALK positive NSCLC as assessed by plasma ALK assays (polymerase chain reaction [PCR] and/or sequencing)
• To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)
• To investigate molecular mechanisms of resistance to ALK inhibitors
• To investigate detection of ALK mutations/fusions in plasma

Study Design
Description of Study
This is a randomized, active controlled, multicenter Phase III open-label study in patients with treatment-naive ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] testing). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide. The primary endpoint of the study is investigator-assessed PFS. Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally twice daily (BID), taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first
The dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), a local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

**Number of Patients**

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

**Target Population**

**Inclusion Criteria**

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count ≥ 100 x 10^9/L
  - ANC ≥ 1500 cells/µL
  - Hemoglobin ≥ 9.0 g/dL
- Adequate renal function:
  - An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m^2
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- Measurable disease (by RECIST v1.1) prior to the administration of study treatment.
- Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
- For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
- For women who are not postmenopausal ($\geq 12$ months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of $<1\%$ per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of $<1\%$ per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate $<1\%$ per year. Barrier methods must always be supplemented with the use of a spermicide.
- For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of $<1\%$ per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.

**Exclusion Criteria**

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).
- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection
- Liver disease characterized by:
  ALT or AST $>3 \times$ ULN ($\geq 5 \times$ ULN for patients with concurrent liver metastasis)
  confirmed on two consecutive measurements
  OR
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  OR
  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
- National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)
  Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication
- History of organ transplant
• Co-administration of anti-cancer therapies other than those administered in this study
• Patients with baseline QTc > 470 ms or symptomatic bradycardia
• Administration of strong/potent cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib
• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug for all patients and while on treatment through the end of the study for crizotinib-treated patients only (see protocol for details)
• History of hypersensitivity to any of the additives in the alectinib drug formulation (see protocol for details)
• History of hypersensitivity to any of the additives in the crizotinib drug formulation (see protocol for details)
• Pregnant or lactating women
• Known HIV positivity or AIDS-related illness
• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study
• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

Length of Study
The time from first patient screened to end of study, defined below, will be approximately 43 months.

End of Study
This study is event driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Outcome Measures
Efficacy Outcome Measures
The efficacy outcome measures for this study are as follows:
• PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.
• ORR, which is defined as the percentage of patients who attain complete response (CR) or partial response (PR); response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.
• Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.
• DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.
• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

**Safety Outcome Measures**
The secondary safety outcome measures for this study are as follows:
• Serious and non-serious adverse events
• Safety laboratory tests values
• Vital signs (blood pressure, heart rate), ECG
• Physical examination

**Pharmacokinetic Outcome Measures**
The PK outcome measures for this study are as follows:
• Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment
• Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%−15%, at least approximately n = 20)
• PK parameters will be determined as appropriate and where data allow:
  - The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  - Non-compartmental analysis may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

**Patient-Reported Outcome Measures**
The PRO measures for this study are as follows:
• EORTC QLQ-C30 and the EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue)
• The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib

**Exploratory Outcome Measures**
The exploratory outcome measures for this study are as follows:
• EQ-5D-3L to generate utility scores for use in economic models for the purpose of reimbursement
• Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH in blood to measure an onset of hypogonadism in adult men

**Alectinib—F. Hoffmann-La Roche Ltd**
22/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
- Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy in patients with treatment-naive NSCLC that is ALK-positive by FISH test
- ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
- ALK mutation status in plasma DNA to monitor efficacy and disease progression

**Investigational Medicinal Products**

**Test Product**

Alectinib comes in a capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate.

Alectinib capsules should be stored in accordance with the storage instructions on the label. Alectinib capsules should be administered orally BID with food in the morning and evening.

**Comparator**

Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (Xalkori®).

**Non-Investigational Medicinal Products**

Standard-of-care therapy administered to all patients in addition to test product or comparator.

**Statistical Methods**

**Primary Analysis**

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

H0: SDF (alectinib) = SDF (crizotinib) versus
H1: SDF (alectinib) ≠ SDF (crizotinib)

where SDF denotes the survival distribution function of the parameter PFS.

**Alectinib—F. Hoffmann-La Roche Ltd**

23/Protocol BO28984, Version 4
Determination of Sample Size

The focus of this clinical trial is hypothesis testing, and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed–platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib.

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.

In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

Interim Analyses

No interim analysis for efficacy or futility is planned.
## LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma kinase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration–time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C-DOR</td>
<td>CNS duration of response</td>
</tr>
<tr>
<td>C-ORR</td>
<td>CNS objective response rate</td>
</tr>
<tr>
<td>C-PR</td>
<td>CNS progression rate</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>DOT</td>
<td>duration of treatment</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>Eastern Cooperative Oncology Group Performance Status</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EML4</td>
<td>echinoderm microtubule-associated protein-like 4</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for the Research and Treatment of Cancer</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-3L</td>
<td>EuroQoL 5 Dimension</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FISH</td>
<td>fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>iDMC</td>
<td>independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (application)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRC</td>
<td>Independent Review Committee</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>IxRS</td>
<td>interactive voice or web-based response system</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>MET</td>
<td>mesenchymal-epithelial transition factor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NCA</td>
<td>non-compartmental analysis</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>not evaluable</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non–small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>patient-reported outcome</td>
</tr>
<tr>
<td>PS</td>
<td>Performance Status</td>
</tr>
<tr>
<td>QLQ-C30</td>
<td>Quality of Life Questionnaire–Core</td>
</tr>
<tr>
<td>QLQ-LC13</td>
<td>Quality of Life Questionnaire lung cancer module</td>
</tr>
<tr>
<td>QTcF</td>
<td>QT interval corrected using Fridericia’s formula</td>
</tr>
<tr>
<td>RANO</td>
<td>Revised Assessment in Neuro Oncology</td>
</tr>
<tr>
<td>RCR</td>
<td>Roche Clinical Repository</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>RON</td>
<td>recepteur d'origine nantais</td>
</tr>
<tr>
<td>ROS1</td>
<td>c-ros oncogene 1</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Safety Analysis Population</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SDF</td>
<td>survival distribution function</td>
</tr>
<tr>
<td>SHBG</td>
<td>sex hormone-binding globulin</td>
</tr>
<tr>
<td>SLS</td>
<td>sodium lauryl sulfate</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TTD</td>
<td>time to deterioration</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine 5'-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
1. BACKGROUND

1.1 BACKGROUND ON ANAPLASTIC LYMPHOMA KINASE–POSITIVE NON–SMALL CELL LUNG CANCER

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Lung cancer was estimated to cause 160,340 deaths in the United States in 2012, accounting for 28% of all cancer-related deaths according to the report from the American Lung Association (Lung Cancer Fact Sheet). There is an annual incidence of 310,000 cases of NSCLC in men in Europe with a mortality of 276,000 deaths (GLOBOCAN 2008). Among women in Europe, there is an annual incidence of 107,000 cases and a mortality of 91,000 deaths. In total, there are 417,000 cases of NSCLC and 367,000 deaths in Europe each year, which represents a major health problem. Survival rates for lung cancer tend to be much lower than other common cancers because of its late diagnosis and limited effective therapy in the advanced stage. The expected 5-year survival rate for all patients in whom lung cancer is diagnosed is 16.3% compared with 65.2% for colon cancer, 90.0% for breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012). Conventional anti-cancer therapies are far from satisfactory, and there is an unmet medical need for the development of new therapies for NSCLC.

Recent progress in the identification of genetic mutations or chromosomal rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other genes has provided new opportunities to use targeted therapeutic agents for the treatment of NSCLC, when the tumor is identified as having these mutations (Katayama et al. 2011; Doebele et al. 2012).

Approximately 5% of NSCLC cases have been shown to harbor the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; Ou et al. 2012). The formation of the resulting ALK fusion protein results in activation and dysregulation of the gene’s expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these genes. This is further supported by reports that the TFG and KIF5B genes can also serve as ALK fusion partners in some NSCLC patients. Expression of these ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced proliferation. ALK gene alterations are generally in a mutually exclusive relationship with mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism after treatment with crizotinib (Doebele et al. 2012). Inhibition of ALK activity in Ba/F3 cells transfected with the EML4-ALK fusion protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models harboring the EML4-ALK and...
nucleophosmin-ALK fusion proteins, respectively. Hence, ALK appears to be a suitable therapeutic target for NSCLC with ALK gene rearrangements.

Wild-type ALK is expressed at very low levels in most normal human tissues, but is expressed at higher levels in a few limited types of tissue such as developing and mature nervous system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997). By contrast, an aberrant ALK with constitutively active kinase results from the formation of the EML4-ALK fusion gene by chromosomal translocation.

Currently, the only approved medicine for treatment-naive ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), recepteur d’origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

Crizotinib was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test in August 2011. The approval was based on two single-arm trials. The primary endpoint of both trials was objective response rate (ORR) as assessed by the investigator. In one study, the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks, and, in the other study, the ORR was 61% (95% CI: 52%, 70%) with a median response duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012). In November 2013, the FDA granted regular approval for crizotinib on the basis of demonstrating superior progression-free survival (PFS) and ORR for crizotinib compared with chemotherapy in patients with ALK-positive NSCLC whose disease progressed after platinum-based doublet chemotherapy (PROFILE 1007 study). An open-label active-controlled multinational randomized trial enrolled 347 patients with ALK-positive metastatic NSCLC. Patients were required to have disease progression following platinum-based chemotherapy. The trial demonstrated significantly prolonged PFS with crizotinib treatment compared with chemotherapy (hazard ratio [HR] = 0.49 [95% CI: 0.37, 0.64], p < 0.0001). Median PFS was 7.7 months for patients treated with crizotinib and 3.0 months for patients treated with chemotherapy. The ORR was significantly higher for patients treated with crizotinib (65% vs. 20%), with median response durations of 7.4 months for patients treated with crizotinib and 5.6 months for patients treated with chemotherapy. No difference in overall survival (OS) was noted between the two groups (HR = 1.02 [95% CI: 0.68%, 1.54%]) in a planned interim analysis (Shaw et al. 2013). Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue (National Cancer Institute 2013). These results showed that an ALK inhibitor is effective in patients with NSCLC harboring ALK fusion genes. Crizotinib has subsequently been approved in other countries, such as Japan, Korea, Canada, and Switzerland. In the European Union, crizotinib was conditionally approved in October 2012 for the treatment of adults with previously treated ALK positive NSCLC.

Alectinib—F. Hoffmann-La Roche Ltd
29/Protocol BO28984, Version 4
Although substantial benefit has been observed with crizotinib therapy, relapse remains the norm. Studies with patients who had progression with crizotinib treatment revealed two main reasons for treatment failure: the development of resistance because of secondary (e.g., gatekeeper) mutations (predominantly in ALK or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease). The CNS is the primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC treated with crizotinib (Costa et al. 2011; Chun et al. 2012; Weickhardt et al. 2012). Significant morbidity is associated with brain metastases as a function of brain involvement, and because of treatment (corticosteroids, surgery, and radiation) required for disease control.

A new generation of ALK inhibitors will have the potential to overcome these two major limitations of crizotinib treatment and may offer patients a better chance of prolonged remission and minimize the development of CNS metastases and the attendant comorbidity.

1.2 BACKGROUND ON ALECTINIB

Alectinib (also RO5424802 or CH5424802) is a newly developed small molecule, highly selective, and potent oral next-generation ALK inhibitor with a benzo[b]carbazole scaffold. In enzyme inhibition assays performed in vitro, this compound has been shown to selectively inhibit ALK. The compound also shows high antitumor activity both in vitro and in vivo against tumor cell lines with some types of ALK gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an ALK translocation and a neuroblastoma line harboring amplified ALK gene.

Nonclinical pharmacology studies showed that alectinib is efficacious in a model of tumors expressing an ALK fusion bearing the L1196M mutation, which is associated with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC xenografts that are already maximally suppressed by crizotinib. Alectinib also prolongs survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth in an intracranial model monitored using bioluminescence.

The clinical development program for alectinib, to date, comprises three ongoing Phase I/II studies in patients with ALK-positive NSCLC. The ongoing Phase I/II studies are as follows: Study AF-001JP, which is being conducted in Japan; Study NP28761/AF-002JG, which is being conducted in United States and Canada; and Study NP28673, which is being conducted globally.

The first-in-human study AF-001JP is an open-label Phase I/II study being conducted in Japan. This study is assessing the pharmacokinetics, safety, and efficacy of alectinib in patients with ALK-positive NSCLC who are crizotinib-naive and have disease progression after at least one line of chemotherapy. This study has completed enrollment, but it is still ongoing. A total of 70 patients were included (24 patients in the
Phase I portion and 46 patients in the Phase II portion of the study). In the Phase I portion of the study, at the data cutoff date of 31 July 2012, 24 patients were treated at doses of 20–300 mg twice daily (BID). No dose-limiting toxicities (DLTs) or adverse events of Grade 4 were noted up to the highest dose; thus, 300 mg BID was evaluated in the Phase II portion of the study without further escalating the dose. In the Phase II portion of the study, 46 patients were treated with the highest evaluated dose of 300 mg BID, of whom 43 achieved an objective response (93.5%; 95% CI: 82.1%, 98.6%) and 7 patients had a complete response (CR) on the basis of an independent radiological review in the 12-month follow-up analysis (data cutoff for response data: 18 April 2013). The median duration of treatment (DOT) in the study has not been achieved at that date because 86% of patients were still on treatment in the study, but the projected median DOT is more than 14 months as data mature.

Figure 1 shows the waterfall plot of the best change from baseline in the size of target lesions by an independent radiological review. Table 1 shows the ORR by time interval. The majority (86%) of patients had a time to response of within 6 weeks after administration of the first dose.

**Figure 1** Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013)
Two of 7 patients who were assessed as having a CR had lymph nodes as the target lesions. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), the percent change from baseline for patients with CR can be less than 100% when lymph nodes are identified as the target lesions. Therefore, they were assessed as having CR, although their tumor change from baseline was less than 100%.

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP

<table>
<thead>
<tr>
<th>Response (Data Cutoff Date: 18 April 2013)</th>
<th>IRC Assessment (N = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
</tr>
<tr>
<td>Partial response</td>
<td>36</td>
</tr>
<tr>
<td>Stable disease</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2</td>
</tr>
<tr>
<td>Total response</td>
<td>43</td>
</tr>
<tr>
<td>Overall response rate (95% CI)</td>
<td>93.5% (82.1%, 98.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to Response</th>
<th>IRC Assessment (N = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to ≤3 weeks</td>
<td>22 (51%)</td>
</tr>
<tr>
<td>&gt;3 to ≤6 weeks</td>
<td>15 (35%)</td>
</tr>
<tr>
<td>&gt;6 to ≤9 weeks</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>&gt;9 weeks</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>

IRC = Independent Review Committee.

In Study NP28761/AF-002JG (crizotinib-failed ALK-positive NSCLC patients), the Phase I portion has completed enrollment. Two ‘bridging’ cohorts of patients receiving alectinib using the 150-mg capsule at 600 and 900 mg BID were included in Study NP28761/AF-002JG to transition/facilitate the planned formulation for the Phase II trials. A total of 47 patients were enrolled in Phase I (Part 1). There does not appear to be any substantial difference in pharmacokinetics between the two formulations (20/40-mg capsule and the 150-mg capsule) at the 600-mg dose on the basis of available data.

The radiological imaging analysis performed in 44 evaluable patients who had a baseline scan and at least one follow-up scan (data cutoff date: 12 September 2013) has shown that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort have achieved a confirmed partial response (PR), as assessed by the investigator. Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort have achieved a PR, as assessed by the investigator, which is still to be confirmed. Three patients (all in the 600-mg BID...
dosage cohort) were unevaluable. The ORR was 54.5% (i.e., ORR was reported for 24 of 44 evaluable patients who had a baseline scan and at least one post-treatment scan available to determine overall response, or who had a best overall response of progressive disease [PD] determined by the investigator, on the basis of symptomatic progression [3 patients]), including unconfirmed responses across all dose cohorts. Thirty-three of the 47 (70%) treated patients were still receiving study treatment. The durations of dosing by cohort are shown in Figure 2.

Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013)

The waterfall plot for the 42 patients, with a post-baseline radiological tumor assessment, is shown in Figure 3. On the basis of the data analyzed at that date, 27 patients experienced tumor shrinkage of >30%, of whom 23 patients were assessed as experiencing PR (9 of whom are still to be confirmed by a second tumor assessment).
Patients were enrolled in Study NP28673 starting on 20 June 2013 and no data are available to report at this time.

The benefit of alectinib on CNS activity has been described by the DOT (before progression) or ORR in patients with brain metastases at baseline in the two active studies: Study AF-001JP in Japan and Study NP28761/AF-002JG in the United States. In Phase II of Study AF-001JP, 14 of the 46 (30%) crizotinib-naïve patients had documented CNS lesions before enrollment into the trial. Three of these 14 patients were asymptomatic and had not received prior CNS radiation. At the clinical cutoff date of 18 March 2013, 5 of the 14 patients were off-study because of systemic disease progression or an adverse event. Nine patients remain in the study with DOT ranging from 10 to 18 months (none of these patients presented signs or evidence of systemic disease or CNS progression).

Similarly, in Study NP28761/AF-002JG, among the 47 patients enrolled (data cutoff date: 12 September 2013), 21 patients (45%) were known to have brain metastases at baseline. Of these 21 patients, 11 (52%) achieved an ORR as determined by Independent Review Committee (IRC; data cutoff date: 12 September 2013) (Inoue et al. 2013). Moreover, of these 21 patients, 17 remained on active study treatment and 4 discontinued study treatment because of systemic PD (1 patient had
both systemic disease and CNS progression). No patient discontinued because of CNS progression alone.

In addition, 2 patients with leptomeningeal carcinomatosis received benefit from alectinib treatment. One patient with leptomeningeal spread in Study NP28761/AF-002JG achieved PR after 6 weeks of treatment. Another patient with leptomeningeal carcinomatosis but without systemic lesions was treated under a single-patient Investigational New Drug (IND) application because of ineligibility to enter either of the two Phase II alectinib studies (because of the high intake of dexamethasone for symptom control). After 6 weeks of treatment, this patient achieved CR as demonstrated by complete disappearance of gadolinium enhancement on magnetic resonance imaging (MRI) and disappearance of positive CSF cytology. This patient has been able to reduce corticosteroids to physiological replacement dose only.

See the Alectinib Investigator’s Brochure for additional details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Over the past 10 years, the treatment of NSCLC has become increasingly focused on guiding treatment based on the presence or absence of an actionable mutation. Numerous oncogenes have now been identified in NSCLC, including mutations in the genes coding for EGFR, KRAS, phosphoinositide-3-kinase (specifically, the catalytic α polypeptide), and EGFR 2 (Pao and Girard 2011). As described in previous sections, a translocation in the gene encoding the receptor tyrosine kinase ALK, leading to the expression of ALK fusion proteins, was identified as an oncogenic driver in a subset of patients with NSCLC (Soda et al. 2007). ALK rearrangements are found in approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012;).

Crizotinib is the first ALK inhibitor that has been approved and registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The previous clinical studies reported that the median PFS with crizotinib ranged from 7.7–9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013). The PROFILE 1014 study, a Phase III study of crizotinib compared to standard pemetrexed-platinum-based chemotherapy, was presented at the ASCO 2014 congress (Mok et al. 2014). The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p < 0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively.
Although substantial benefit has been observed with crizotinib therapy, relapse eventually occurs. Two major reasons for this are the development of resistance because of secondary (e.g., gatekeeper) mutations, or CNS relapse (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). This could be due to the fact that crizotinib is a P-gp substrate and has a low penetration in the CNS. Thus, ALK-positive NSCLC treated with crizotinib has impaired control of brain metastases relative to other sites of systemic disease, with 46% of progressions in patients treated with crizotinib involving the CNS (Costa et al. 2011; Weickhardt et al. 2012). The CNS becomes a sanctuary site for ALK-positive NSCLC treated with crizotinib—a physiologic and anatomic mechanism of drug resistance.

Alectinib is a highly selective and potent oral next generation ALK inhibitor. Clinical data collection from the Phase II portion is still ongoing. Study AF-001JP, assessing alectinib in patients with ALK-positive NSCLC who are crizotinib-naive and have disease progression after at least one line of chemotherapy, reported that the median treatment duration in the study had not been achieved as 86% of patients were still active on the study, but the projected median DOT is estimated to be at least 14 months at the final point of data collection (Inoue et al. 2013).

Moreover, alectinib is a lipophilic drug and is not a P-glycoprotein (P-gp) substrate. Thus, it is able to penetrate the blood-brain barrier and has the potential to reach higher concentrations in the brain as compared to substrates of P-gp such as crizotinib. This has been shown in the nonclinical setting on the basis of the prolongation of survival in a mouse model with implanted CNS lesions and in a tissue distribution study with a single oral dose of 

\[ ^{14}C \] -alectinib at 1 mg/kg in albino rats (Ou et al. 2013). Preliminary clinical data from the Phase I/II studies show consistent therapeutic efficacy of alectinib in brain metastases.

The clinical efficacy data is compelling given the demonstrated activity for a longer progression-free interval with alectinib treatment and improved activity in the CNS. This progression-free interval delays the impact of CNS metastases on neurologic function along with the morbidities associated with treatment like brain radiation, surgery and corticosteroid use required for disease control. The currently available clinical safety data is supportive of an acceptable safety and tolerability profile with alectinib. Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for treatment-naive ALK-positive advanced NSCLC patients.

Alectinib was granted approval in Japan on 04 July 2014 for treatment of ALK fusion gene-positive, unresectable, recurrent or advanced NSCLC.

In this proposed Phase III study, treatment-naive patients with ALK-positive advanced NSCLC will be enrolled and will be randomized to receive either crizotinib or alectinib treatment. The results of this study will determine whether alectinib treatment has superior efficacy compared to crizotinib.
The first Phase I dose-escalation study of alectinib (Study AF001-JP, conducted only in Japan) with a dose schedule of 20, 40, 80, 160, 240, and 300 mg BID orally showed that alectinib was generally well tolerated without major toxicities. Of the 58 patients who received treatment with 300 mg BID alectinib in Study AF-001JP, 27 experienced Grade 3 adverse events and 9 experienced serious adverse events. No deaths were reported during this study and up to 28 days after treatment discontinuation. There were 5 adverse events leading to treatment discontinuation in Part 2 (brain edema, sclerosing cholangitis, interstitial lung disease [ILD], ALT increased, and tumor hemorrhage). Alectinib was well tolerated at all doses investigated in this study. Its adverse event profile was consistent with the one known to be associated with TKIs. In the Phase II Study NP28761/AF-002JG, alectinib was well tolerated with no DLTs or treatment-related dose modifications up to 600 mg BID. Two DLTs were reported at 900 mg BID. The recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best balance between clinical safety, efficacy, and pharmacokinetic (PK) data as observed in the Phase I/II studies (see Section 3.3.1).

On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks. Specifically:

- Available nonclinical and clinical data demonstrate that alectinib is active in NSCLC in crizotinib-naive patients as well as after progression on prior crizotinib therapy.
- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with ALK inhibitors.

Identified and potential risks associated with alectinib treatment will continue to be closely monitored throughout the clinical program. Patient safety during the alectinib program is ensured by targeting the most appropriate patient population, stringent safety monitoring by the Sponsor and independent Data Monitoring Committee (iDMC), and by protocol-specified study drug interruption criteria.

2. OBJECTIVES

2.1 EFFICACY OBJECTIVES

The primary efficacy objective for this study is:

- To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naive ALK-positive advanced NSCLC, as measured by investigator-assessed PFS

The secondary efficacy objectives for this study are:

- To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of IRC review of radiographs by RECIST v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the OS

2.2 SAFETY OBJECTIVES
The secondary safety objective for this study is:
• To evaluate the safety and tolerability of alectinib compared to crizotinib

2.3 PHARMACOKINETIC OBJECTIVES
The secondary PK objective for this study is:
• To characterize the pharmacokinetics of alectinib and metabolite(s)

2.4 PATIENT-REPORTED OUTCOME OBJECTIVES
The secondary patient-reported outcome (PRO) objectives for this study are:
• To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm and shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)
• To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

2.5 EXPLORATORY OBJECTIVES
The exploratory objectives for this study are:
• To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement
• To evaluate and compare the onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG]), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels in blood
• To evaluate and compare efficacy in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott)
• To evaluate and compare efficacy and safety in patients having treatment-naive ALK positive NSCLC as assessed by plasma ALK assays (polymerase chain reaction [PCR] and/or sequencing)
• To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)
• To investigate molecular mechanisms of resistance to ALK inhibitors.
• To investigate detection of ALK mutations/fusions in plasma

3. STUDY DESIGN

3.1 DESCRIPTION OF STUDY

This is a randomized, active-controlled, multicenter Phase III open-label study in patients with treatment-naive ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide.

The primary endpoint of the study is investigator-assessed PFS.

Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by
continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from their respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Approximately 286 patients (143 per treatment arm) will be enrolled into the study over a planned competitive recruitment period of 24 months. Patients inappropriately randomized into the study will not be replaced. The final analysis evaluating the primary endpoint of investigator-assessed PFS will occur when approximately 170 patients have progressed or died, which is expected to occur approximately 33 months after the first patient has been enrolled. Data collection will continue for each patient until death or study closure, whichever occurs first.

An iDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised as outlined in Section 9.4.

A summary of the study design is shown in Figure 4.

A schedule of assessments is provided in Appendix 1.
3.2 END OF STUDY

This study is event-driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.
3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Alectinib Dosage

Selection of the alectinib dose for the study is based on the clinical safety, efficacy, and PK data observed in the Phase I/II studies, AF-001JP and NP28761/AF-002JG, and the supportive nonclinical data for alectinib.

The first-in-human study, AF-001JP evaluated escalating doses of alectinib in an accelerated titration scheme to rapidly identify the maximum tolerated dose (MTD). All doses, including the highest evaluated dose in the study, 300 mg BID, were well tolerated with no DLTs observed at any dose. The highest tested dose, 300 mg BID, was further evaluated in the Phase II portion of the study and demonstrated robust efficacy and good safety with an ORR by IRC of 93.5% (43/46 patients; 95% CI: 82.1%, 98.6%).

With no MTD determined in Study AF-001JP, dose escalation progressed in the North American Study NP28761/AF-002JG using a modified 3+3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation. The starting dose in Study NP28761/AF-002JG was the highest dosage evaluated in Study AF-001JP, 300 mg BID. Following multiple dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, median alectinib exposure (area under the concentration-time curve [AUC] from 0 to 10 hours) appeared to be approximately two-fold lower compared with that in patients from Study AF-001JP, which demonstrated robust efficacy and safety. Dose escalation progressed with evaluation of higher doses of alectinib up to 900 mg BID.

In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts up to dose-level of 900 mg BID. However, 2 patients in the subsequent 900 mg BID bridging cohort experienced a DLT; 1 patient had Grade 3 headache and 1 patient had Grade 3 neutropenia, and both patients continued study treatment at a reduced dosage of 600 mg BID. Overall, alectinib was well tolerated in the study population.

Importantly, administration of 600 mg BID provides systemic exposures that meet or exceed exposures achieved in patients receiving 300 mg BID in Study AF-001JP, demonstrating its robust efficacy and safety in crizotinib-naive patients. Furthermore, in Study NP28761/AF-002JG, the 600 mg BID regimen has demonstrated promising activity in crizotinib-resistant patients, including activity in patients with CNS metastases while being tolerated by patients. On the basis of available preclinical data, administration of alectinib 600 mg BID provides systemic exposures within the expected range (on the basis of regression of available data) for tumor regression observed in mouse xenograft models.

Thus, on the basis of nonclinical and clinical data, a dosing regimen of 600 mg BID of alectinib has been chosen as the optimal therapeutic dose level with the best balance between efficacy and safety.

Alectinib—F. Hoffmann-La Roche Ltd 
42/Protocol BO28984, Version 4
Alectinib at 600 mg should be administered orally BID with food in the morning and evening.

### 3.3.2 Rationale for Patient Population

The study population will comprise patients with non-resectable, locally advanced and metastatic NSCLC who have been shown to be ALK-positive by the Ventana IHC test performed at central laboratories specially designated for the study. Patients should not have received any prior treatment for advanced NSCLC (treatment-naive).

Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted therapies. The clinical practice guidelines recommend targeted treatment for patients with metastatic, oncogene-driven disease as first-line systemic therapy (i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive NSCLC) (NCCN 2014).

To be eligible for the study, determination of ALK positivity will be performed centrally using the IHC assay (see Appendix 8) that is being developed by Ventana Medical Systems as a companion diagnostic to alectinib. IHC may replace fluorescence in situ hybridization (FISH)-based identification of ALK rearrangement as the standard companion diagnostic in the future. IHC is faster, easier to perform in local laboratories, and requires less equipment compared with the FISH assay. In addition, IHC has high concordance with FISH and a lower false-negative rate (Kim et al. 2011).

### 3.3.3 Rationale for Control Group

Targeted therapy (including ALK-targeted therapy) is likely to have a greater anti-tumor effect than standard chemotherapy, offering patients a higher response rate and longer durability of response with less toxicity compared with any potential chemotherapy options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013).

Crizotinib (Xalkori®) is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). It is the only first-generation ALK inhibitor that has been approved in multiple countries worldwide for the treatment of ALK-positive NSCLC.

In the United States, in November 2013, crizotinib was granted a regular approval for the ALK-positive NSCLC setting regardless of treatment line (XALKORI® U.S. Package Insert), whereas in Europe, crizotinib is currently only approved conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC).

The National Comprehensive Cancer Network (NCCN) guidelines recommend crizotinib as a first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014).

The randomized Phase III PROFILE 1014 study was conducted to assess the efficacy of crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or
carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC. The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p < 0.0001) for crizotinib and pemetrexed platinum-based chemotherapy, respectively (Mok et al. 2014). The authors concluded that these findings support crizotinib as the standard of care for patients with previously untreated advanced ALK-positive non-squamous NSCLC (Mok et al. 2014).

Crizotinib will be dosed as per standard dose recommendations from prescribing information; patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death. See Section 5.1.4 for criteria for dosing interruption and/or dose reduction for treatment with crizotinib.

3.3.4 Rationale for Open-Label Design
An open-label study design is more appropriate for patients enrolled in this particular trial for a number of reasons described below, and with the ultimate goal to ensure patient compliance as much as possible.

For a blinded study design, all enrolled patients would be required to take five large capsules twice per day. This high pill count results from the difference in capsule size between crizotinib (size 0) and alectinib (size 1). Each dose would comprise one 250-mg capsule of crizotinib or matching placebo and four 150-mg capsules of alectinib or matching placebo. In order to blind, crizotinib capsules must be over-encapsulated. That further increases the size of a capsule from size 0 to size 00. Size 00 is usually the largest capsule size used orally for humans. For some patients, size 00 capsules are too large to swallow. This high pill count of large capsules is considered to be a significant burden to patients and increases the risk of non-compliance.

Additionally, a blinded study would increase the complexity of standard dose reductions. Dose interruption or dose reduction may be required on the basis of individual safety and tolerability. The standard dose reductions for crizotinib would be 200 mg BID (different capsule, size 1), followed by 250 mg QD. Dose reductions for alectinib would occur in 150-mg steps. In a double-blind study, these multiple step dose reductions introduce a high level of complexity and potential for error.

In order to avoid a significant burden to patients with high pill count, increased risk of non-compliance, and complexity of standard dose reductions, adequate steps have been taken to ensure the validity of the data in an open-label study design. These include performing a supportive analysis of efficacy on the basis of determining progression by an IRC, performing sensitivity analyses to demonstrate the robustness of the primary endpoint, defining progression using established response evaluation criteria (RECIST v1.1), performing tumor assessment at the same frequency in both arms and adhering to protocol-defined schedules, and finalizing the strategy for the final analysis.
of the primary endpoint before trial start, including developing predefined methods for handling missing data and censoring rules. Efficacy analyses will only be performed at the pre-specified analysis timepoints in the protocol (final analysis once 170 PFS events have occurred and survival follow-up analysis at 143 events).

3.3.5 Rationale for Primary Endpoint Selection

The investigator-assessed PFS (which will be supported by IRC-assessed PFS analysis, one of the secondary endpoints of the study) is the primary endpoint for this trial.

PFS, as an endpoint, can reflect tumor growth and can be assessed before the determination of a survival benefit, and its determination is not generally confounded by subsequent therapies. Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit of the new treatment compared to available therapies (Guidance for Industry 2007; European Medicines Agency 2012). A PFS HR of 0.65 will be targeted, which constitutes a clinically meaningful benefit in this patient population as it will delay the use of platinum-based chemotherapy and will potentially reduce the frequency of CNS relapse and the morbidity associated with treating CNS metastases.

The assumed median PFS of patients in the alectinib treatment arm is 16.8 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 13 months. Patients with ALK-positive NSCLC treated with crizotinib in the second-line setting had a median PFS of 7.7 months and an interim median OS of 20.3 months (Shaw et al. 2013), which equated to a post-progression survival of 12.6 months. This lengthy post-progression survival provides an opportunity for subsequent treatment with other ALK inhibitors, several additional lines of chemotherapy, or participation in additional clinical trials.

Patients in both study arms who experience disease progression on study treatment will likely be treated with other subsequent treatment options, including ALK inhibitors. The availability of crizotinib on the market, as well as the likely availability of other next-generation ALK TKIs, and the availability of other investigational agents in clinical trials offer potential treatment options to patients in the study who will eventually have disease progression. Subsequent therapies frequently confound the detection of an OS benefit, particularly in a setting with a long post-progression survival, such as ALK-positive NSCLC. This has been observed in trials for EGFR TKIs, in which strong PFS benefits were observed without evidence of OS benefit (Rosell et al. 2009; Fukuoka et al. 2011).

The long post-progression survival and the confounding effects of subsequent lines of therapy indicate that it would be difficult to detect an OS benefit in this setting. Nevertheless, OS is one of the study’s secondary endpoints. The crossover from the crizotinib arm to alectinib will not be allowed in this study, with the aim of preserving the trial’s ability to potentially demonstrate some degree of treatment benefit of alectinib in
OS. However, the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.

To ensure the validity of the PFS as the primary endpoint, a number of measures have been implemented: full IRC assessment to support the analysis of the primary endpoint, a substantial target magnitude of benefit (target HR = 0.65) and study assessments that will allow a robust evaluation of risk-benefit (standard RECIST criteria to define progression with fixed assessment intervals that are identical in both treatment arms and a robust definition of PFS and prospectively defined methods to assess, quantify, and analyze PFS, including censoring methods and sensitivity analyses).

3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression

Lung cancer is the most common type of cancer to spread to the brain, with at least 40% of people with lung cancer developing brain metastases at some point during their disease. ALK-positive NSCLC has a propensity to metastasize to the brain, and crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease (Chun et al. 2012).

Delaying or preventing the development of CNS metastases would provide patients with clinically meaningful benefit by avoiding consequences of neurological deficits from brain metastasis or by delaying/preventing long-term side effects associated with steroid use and brain irradiation.

Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase I/II studies. See Section 1.2 and Alectinib Investigator’s Brochure for additional details.

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression is documented. The aim of the pre-specified analysis will be to evaluate whether alectinib significantly delays or prevents the development of CNS metastases.

Randomization of the Phase III study will be stratified by the presence or absence of CNS metastasis at baseline.

Imaging analysis by consistently used uniform image acquisition technique (MRI scans) will be performed routinely at baseline and at subsequent follow-up assessments along with every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical suspicion of CNS metastasis) in order to achieve an accurate determination of time to CNS progression. This ensures that early brain metastatic lesions are detected and that assessment bias between the two arms is avoided by having regularly scheduled scans.
An independent central radiological review will be performed for all patients and the analysis of time to CNS progression or response will be based on the data from the independent review. The review will be based on the standard RECIST v1.1 criteria to assess the CNS lesions, and a second independent review on the basis of the RANO criteria, which are typically used to assess brain tumors (Wen et al. 2010), will be performed. The assessment will be performed independently from the overall disease progression assessment.

3.3.7 Rationale for PK Sample Collection Schedule
To date, the pharmacokinetics of alectinib have been characterized in chemotherapy-failed, crizotinib-naive patients with NSCLC in Study AF-001JP and in patients who have failed chemotherapy and crizotinib treatment in Study NP28761/AF-002JG and Study NP28673. In order to better understand the pharmacokinetics of alectinib and to further support the development of a robust population PK model for alectinib in order to better understand, identify, and characterize variables which lead to changes in exposure, characterization of alectinib pharmacokinetics will be done in this study. This study will include PK assessment of alectinib in ALK inhibitor treatment-naive patients with ALK-positive advanced NSCLC by collecting trough samples from all patients receiving alectinib. Serial/intensive PK samples will be collected from a subset of patients (10%–15% [at least n=20] of patients receiving alectinib) to facilitate the PK assessment. The data that will be collected from this study will enable more robust understanding of alectinib pharmacokinetics in the global crizotinib-naive population including investigation and potential identification of sources of variability influencing alectinib pharmacokinetics and/or response to alectinib therapy. Results from PK data collection in this study and analyses of PK data could help support optimal use of alectinib therapy.

3.3.8 Rationale for Biomarker Assessments
Several molecular mechanisms of resistance to crizotinib have been reported in the literature: increased copy number of ALK gene, increased expression of ALK mRNA, secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased copy number, increased phosphorylation, or point mutations) in escape genes such as EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). In order to investigate molecular mechanisms of resistance to ALK inhibitors and ALK mutation status, tumor samples will be collected before treatment and at the time of disease progression with the goal of sequencing nucleic acids. Two types of approaches will be used: 1) targeted sequencing of a panel of genes known to be involved in cancer and 2) unbiased genomic sequencing. Mutations in cancer genes appearing from drug resistance can be monitored in circulating nucleic acids in plasma (Forshew et al. 2012). Tumor nucleic acids are shed into circulation in amounts that allow direct amplification by PCR and sequencing. Plasma samples will be collected before treatment and at certain timepoints during
treatment to monitor mutations in ALK and other genes involved in resistance to ALK inhibitors. Information from mutated genes in the tumor will be correlated with mutations in plasma DNA.

Determination of ALK positivity will be initially performed by Ventana IHC (see Appendix 8). In addition, the Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. For exploratory purposes, other methods to determine ALK positivity (e.g., reverse transcription-PCR) may also be used. Currently, ALK positivity for fusions can only be determined in tissue samples using assays such as FISH, IHC or PCR. As tissue sampling is difficult and tissue biopsy sample sizes from lung cancer patients are very small, testing of several important biomarkers is challenging. Many NSCLC patients may not have enough tumor tissue available and therefore cannot be tested for some biomarkers such as ALK. Plasma ALK assays analyzing circulating tumor nucleic acids will enable more NSCLC patients to be tested for ALK fusions. Information from plasma ALK assays will be used to investigate the use of circulating tumor nucleic acids from plasma as a surrogate for tumor tissue for diagnostic purposes.

3.3.9 Rationale for PRO Assessments

In the treatment of lung cancer, it is important to both increase survival and palliate symptoms because disease symptoms have negative impacts on HRQoL (Hyde and Hyde 1974; Hopwood and Stephens 1995; Sarna et al. 2008). This is especially true for trials that use PFS as a primary endpoint, where it is important to translate the delay in disease progression into an endpoint that is meaningful to patients.

Pain (chest; arm and shoulder), dyspnea, cough, and fatigue have been regarded as the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC. The BR.21 study (erlotinib vs. chemotherapy in second- or third-line NSCLC) demonstrated that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ-C30 and QLQ-LC13 was consistent with superior PFS, OS, and quality-of-life benefits in the erlotinib arm as compared with the placebo arm (Aaronson et al. 1993; Bergman et al. 1994; Bezjak et al. 2006). Additionally, patients in the crizotinib PROFILE 1005 trial reported clinically significant improvements (by 10 points) in the pain, cough, dyspnea, and fatigue symptom scales seen as early as 2 weeks on treatment (Crinò et al. 2011).

The EORTC QLQ-C30 and QLQ-LC13 were used in the Phase III PROFILE 1007 study (second-line crizotinib vs. chemotherapy). The study reported significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than with chemotherapy (p<0.001 for all comparisons, without adjustment for multiple testing). Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. There was also a significantly greater overall improvement from baseline in

**Alectinib—F. Hoffmann-La Roche Ltd**

48/Protocol BO28984, Version 4
the global quality of life among patients who received crizotinib treatment than among those who received chemotherapy (p < 0.001). In all domains measuring function, except for the domain measuring cognitive function, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Shaw et al. 2013).

Therefore, to assess the quality of life of patients in this trial, PRO data will be collected from patients enrolled in this study using the validated questionnaires EORTC QLQ-C30 and QLQ-LC13.

3.4 OUTCOME MEASURES

3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

- **PFS**, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.

- **ORR**, which is defined as the percentage of patients who attain CR or PR; response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.

- **Time to CNS progression**, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.

- **DOR**, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

- **OS**, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

3.4.2 Safety Outcome Measures

The safety outcome measures for this study are as follows:

- Serious and non-serious adverse events
- Safety laboratory tests values
• Vital signs (blood pressure, heart rate), ECG
• Physical examination

3.4.3 Pharmacokinetic Outcome Measures

The PK outcome measures for this study are as follows:

• Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment. See Appendix 1 and Appendix 2 for PK sampling times.

• Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n=20). See Appendix 1 and Appendix 2 for PK sampling times.

• PK parameters will be determined as appropriate and where data allow:
  The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.

  Non-compartmental analysis (NCA) may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

3.4.4 Patient-Reported Outcome Measures

The PRO measures included for this study are as follows and will be administered to patients every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months:

• The EORTC QLQ-C30 and EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).

• The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post-treatment.

For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.
3.4.5 Exploratory Outcome Measures

The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for the purpose of reimbursement
- Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH in blood to measure the onset of hypogonadism in adult men
- Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy in patients with treatment-naive NSCLC that is ALK-positive by FISH test
- ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
- ALK mutation status in plasma DNA to monitor efficacy and disease progression

4. MATERIALS AND METHODS

4.1 PATIENTS

The target population is patients with treatment-naive, ALK-positive, non-resectable, locally advanced and metastatic NSCLC.

4.1.1 Inclusion Criteria

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIB not amenable to multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count ≥ 100 × 10^9/L
  - ANC ≥ 1500 cells/μL
  - Hemoglobin ≥ 9.0 g/dL
Adequate renal function:

An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m$^2$

Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.

Measurable disease (by RECIST v1.1) prior to the administration of study treatment

Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.

For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.

For women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide.

For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.
4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal [GI] cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection

- Liver disease characterized by:
  
  ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements

  OR

  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices

  OR

  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

- National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication

- History of organ transplant

- Co-administration of anti-cancer therapies other than those administered in this study

- Patients with baseline QTc > 470 ms or symptomatic bradycardia

- Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3)

- Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug for all patients and while on treatment through the end of the study for crizotinib-treated patients only (see Section 4.4.2 for further details)

- History of hypersensitivity to any of the additives in the alectinib drug formulation (see Section 4.3.1.1 for further details)

- History of hypersensitivity to any of the additives in the crizotinib drug formulation (see Section 4.3.1.2 for further details)

- Pregnant or lactating women

- Known HIV positivity or AIDS-related illness
• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study

• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

This is an open-label trial, for which the rationale is described in Section 3.3.4.

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block-stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Central randomization and drug pack number allocations will be performed and managed by an IxRS. Further details will be provided in an IxRS manual.

The independent review of scans for the secondary endpoints of PFS and time to CNS progression on the basis of IRC will be performed in a blinded fashion.

4.3 STUDY TREATMENT

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Alectinib

Alectinib comes in a hard capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, sodium lauryl sulfate (SLS), and magnesium stearate as excipients.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food in the morning and evening.

Alectinib—F. Hoffmann-La Roche Ltd
54/Protocol BO28984, Version 4
The formulation contains SLS as an excipient. This excipient is known to be potentially associated with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

For further details, see the alectinib Investigator's Brochure.

4.3.1.2 Crizotinib

Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (XALKORI® U.S. Package Insert).

4.3.2 Dosage, Administration, and Compliance

4.3.2.1 Alectinib

Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food in the morning and evening.

If a patient misses a dose, it can be taken within 6 hours of the scheduled time. If the time is greater than 6 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

Guidelines for dosage modifications and treatment interruptions or discontinuation due to specified adverse events are provided in Section 5.1.3.

Any overdose or incorrect administration of study drug should be noted on the Study Drug Administration electronic Case Report Form (eCRF). Adverse events associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF.

4.3.2.2 Crizotinib

Crizotinib at 250 mg (one 250-mg capsule) should be administered orally BID with or without food (in the morning and evening).

If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose of crizotinib, the next dose should be taken as scheduled.

If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to
250 mg taken once daily. Guidelines for dosage modification and treatment interruption or discontinuation are provided in Section 5.1.4.

Any overdose or incorrect administration of crizotinib should be noted on the crizotinib Administration eCRF. Adverse events associated with an overdose or incorrect administration of crizotinib should be recorded on the Adverse Event eCRF.

4.3.3 Investigational Medicinal Product Accountability
All investigational medicinal products (IMPs) required for completion of this study (alectinib and crizotinib) will be provided by the Sponsor where required by local health authority regulations. The study site will acknowledge receipt of IMPs and confirm the shipment condition and content. Any damaged shipments will be replaced.

IMPs will either be disposed of at the study site according to the study site’s institutional standard operating procedure or returned to the Sponsor with the appropriate documentation. The site’s method of IMP destruction must be agreed to by the Sponsor. The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.

Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the study site should be recorded on the Drug Inventory Log.

4.3.4 Post-Trial Access to Alectinib
The Sponsor will offer post-trial access to the study drug alectinib free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below.

A patient will be eligible to receive study drug after the end of the study if all of the following conditions are met:

- The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being
- There are no appropriate alternative treatments available to the patient
- The patient and his or her doctor comply with and satisfy any legal or regulatory requirements that apply to them

A patient will not be eligible to receive study drug after the end of the study if any of the following conditions are met:

- The study drug is commercially marketed in the patient's country and is reasonably accessible to the patient (e.g., is covered by the patient's insurance or would not otherwise create a financial hardship for the patient)
- The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for ALK-positive NSCLC
• The Sponsor has reasonable safety concerns regarding the study drug as treatment for ALK-positive NSCLC
• Provision of study drug is not permitted under the laws and regulations of the patient's country

The Roche Global Policy on Continued Access to Investigational Medicinal Product is available at the following Web site:

http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf

4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from screening to the study completion/discontinuation visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

All therapy and/or medication administered to manage adverse events should be recorded on the Adverse Event eCRF.

The medications and/or treatments below are permitted:

• Anticoagulants and antithrombotic agents (i.e., coumadin-derived anticoagulants, unfractionated heparin or low-molecular heparins, aspirin (≤325 mg/day), and clopidogrel)
• Acetaminophen up to 2 g/day
• Gastric pH elevating medications (such as proton pump inhibitors, H2 blockers, or antacids)
• Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients with isolated asymptomatic CNS progression (e.g., new CNS oligometastases).

Caution should be exercised when the following are co-administered with alectinib:

• For medications that are substrates of P-gp transporter or breast cancer resistance protein transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of these transporters. Substrates with a narrow therapeutic index (e.g., methotrexate, digoxin) should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

Caution should be exercised when the following are co-administered with crizotinib:

• Crizotinib has been shown to be a moderate inhibitor of CYP3A. Dose reduction may be needed for co-administered drugs that are predominantly metabolized by
CYP3A in patients receiving crizotinib. Concurrent use of CYP3A substrates with narrow therapeutic indices should be avoided (see Appendix 3).

- On the basis of an in vitro study, crizotinib is predicted to inhibit intestinal P-gp. Therefore, administration of crizotinib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their therapeutic effect and adverse reactions (see Appendix 3). Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.

- Bradycardia has been reported during clinical studies; therefore, avoid using crizotinib in combination with other agents known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) to the extent possible.

- In vitro studies in human hepatocytes indicated that crizotinib may induce pregnane X receptor and constitutive androstane receptor-regulated enzymes (e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1). However, there was no observed induction in vivo when crizotinib was coadministered with the CYP3A probe substrate midazolam. Caution should be exercised in administering crizotinib in combination with medicinal products that are predominantly metabolized by these enzymes. Of note, the effectiveness of concomitant administration of oral contraceptives may be altered.

- In vitro studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered drugs that are metabolized by CYP2B6 (e.g., bupropion, efavirenz).

### 4.4.2 Prohibited Therapy

Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) is prohibited during the study and for at least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless otherwise specified below. Exceptions to restrictions of the concomitant therapies listed below (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) may be made if the rationale is discussed and documented between the investigator and the Sponsor’s Clinical Pharmacologist.

- Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s wort [Hypericum perforatum]) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drugs (see Appendix 3).

- Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drug (see Appendix 3).

- Any concomitant medications known to affect QT interval duration, including but not limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone, and quinidine, within 2 weeks before the first dose of study drug treatment for all
patients and while on treatment through the end of the study for crizotinib-treated patients only

- Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents (other than study drug treatment), ergot derivatives, probenecid, and bile acid-binding resins while on study treatment.
- Systemic chemotherapy.
- Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions or for pain control. If palliative radiation is indicated for bone metastases, palliative radiation may start within 24 hours of the last dose of alectinib, unless, in the judgment of the investigator, patient safety will require a longer washout period prior to palliative therapy. Dosing of alectinib may resume with the resolution of any radiation toxicity to ≤ Grade 1.
- Additional investigational drug (except for during the follow-up period)

The list of medications provided above is not necessarily comprehensive. Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication strongly inhibits or induces CYP3A. In addition, the investigator should contact the Medical Monitor if questions arise regarding medications not listed above.

http://medicine.iupui.edu/clinpharm/ddis/table.aspx (for P450 drug interactions)

4.4.3 Prohibited Food

Use of grapefruit or grapefruit juice should be avoided during the study and for at least 14 days prior to the initiation of study treatment (either alectinib or crizotinib) because it is a potent CYP3A inhibitor and may increase plasma concentration of either alectinib or crizotinib.

4.5 STUDY ASSESSMENTS

See Appendix 1 for the schedule of assessments performed during the study.

4.5.1 Informed Consent Forms and Screening Log

Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site.

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.
4.5.2 Medical History and Demographic Data
Medical history includes a record of clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 28 days prior to the screening visit.

Demographic data will include age, sex, and self-reported race/ethnicity.

4.5.3 Corticosteroid Use for CNS Metastases
For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake should be captured at all tumor assessment visits and compared to the corticosteroid intake at the time of the last disease assessment. The changes will be recorded as Increased, Unchanged, or Decreased. Increases and decreases in corticosteroid intake should be clinically justified. Increases in corticosteroid dose for reasons other than for CNS metastases control do not need to be taken into consideration when making this comparison.

4.5.4 Physical Examinations
A complete physical examination at screening and baseline should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems as well as height and weight. Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.

At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations should be performed. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant abnormalities should be recorded as adverse events on the Adverse Event eCRF.

Note: for patients with known CNS metastases, a neurological examination must be performed at each tumor assessment visit and compared to the neurological examination performed at the time of the last disease assessment. Definition of clear neurological worsening is difficult to describe because progression in the CNS can present in numerous ways. Accordingly, evaluation of neurological function at each disease assessment will be based purely on the investigator’s assessment of the patient’s neurological state compared to the neurological function at the time of the last disease assessment. Neurological status will be recorded as Improved, Stable, or Worsened.

4.5.5 Vital Signs
Vital signs will include measurements of respiratory rate, oxygen saturation, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

Alectinib—F. Hoffmann-La Roche Ltd
60/Protocol BO28984, Version 4
4.5.6 ECOG Performance Status

Performance Status (PS) will be measured using the ECOG PS Scale (see Appendix 5). It is recommended, where possible, that a patient’s PS be assessed by the same person throughout the study.

4.5.7 Tumor and Response Evaluations

Disease burden must be documented at screening and re-assessed at each subsequent tumor evaluation. Response will be assessed by the investigator on the basis of physical examinations. Clinical lesions will be documented by color photography (with caliper measurement for measurable lesions), computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4). For assessing response in patients with measurable disease, the preferred radiologic tumor response assessment is CT scan with intravenous contrast. If intravenous contrast is contraindicated, a non-contrast-enhanced chest CT scan will be acceptable for chest lesions, and MRI can be used for non-chest lesions. If contrast-enhanced MRI is contraindicated, then non-contrast-enhanced MRI will suffice. Positron emission tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesion as per RECIST v1.1 (see Appendix 4).

The same radiographic procedure used to define measurable disease sites at screening must be used throughout the study (e.g., the same contrast protocol for CT scans). Assessments should be performed by the same evaluator to ensure internal consistency across visits.

CT/MRI scans of chest and abdomen, and MRI scans of the brain should be performed for all patients as described in Schedule of Assessments (see Appendix 1) at screening, then every 8 weeks subsequently until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression and at the post-treatment visit (4 weeks after permanent treatment discontinuation). CT/MRI scans of the neck bone and pelvis should be included if clinically indicated. At the investigator's discretion, CT/MRI scans may be repeated at any time if PD is suspected.

Note: Brain imaging should be performed using MRI with the following image acquisition requirements.

- Minimum sequences required:
  - Pre-contrast T1, T2/FLAIR
  - Post-contrast T1, with two orthogonal planes (or a volume acquisition) recommended

- Recommended slice thickness $\leq 5$ mm with no gap

Patients with known or suspected bone metastases should undergo radionuclide bone scan at screening. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions and do not need to be repeated routinely.

Alectinib—F. Hoffmann-La Roche Ltd

61/Protocol BO28984, Version 4
but can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered measurable lesions of the soft tissue component and meet the definition of measurability and should be followed by cross-sectional imaging.

4.5.8 Laboratory, Biomarker, and Other Biological Sample

4.5.8.1 Laboratory Assessments

Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells])
- Coagulation (PT [or INR], and aPTT)
- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase [GGT]; calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone and free testosterone [either by direct measurement or by calculation using, albumin and SHBG], FSH, and LH [for male patients only])

- Urinalysis. Urine samples will be collected according to the schedule of assessments (Appendix 1)(first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein will be measured by dipstick test.

- Pregnancy test. All women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile will have a serum pregnancy test at screening, within 3 days of dosing. Urine pregnancy tests will be performed anytime during the course of the study, as per investigator’s discretion. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

4.5.8.2 Pre-Treatment Tumor Samples (Mandatory)

Mandatory pre-treatment tumor samples will be collected to centrally examine ALK status by Ventana IHC (eligibility criteria) and Vysis FISH. Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred source, but if blocks are not available, unstained slides (ten to fifteen 5-µm slides cut less than 3 months before screening) are also accepted. Remaining tumor blocks will be returned to the sites; slides will not be returned.

For fresh tumor biopsies (guided by ultrasound or CT scan), acceptable methods include core biopsies for lung and liver lesions and bronchosscopic biopsies for lung lesions. The minimum size for the biopsy needle recommended is 20G.
Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by Ventana IHC (Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott). Additionally, other ALK assays may be used for testing patient samples to establish performance characteristics of these assays for diagnostic development. Testing may be performed on all screened patients (screen- failed and enrolled). These additional testing data will have no impact on eligibility, and testing will be performed only after eligibility is established for each patient. In addition, local ALK test information, baseline demographic, and disease-related characteristic data for all screened patients may be collected in order to support potential registration of a companion diagnostic assay for alectinib.

The tumor sample may also be tested for the presence of EGFR mutations, if requested by the investigator.

Pre-treatment tumor samples may be used, after proper informed consent is obtained, for genomic sequencing.

For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual.

4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)

Pre-treatment tumor samples (preferably formalin-fixed blocks but if not available a minimum of 10-15 unstained 5 µm slides) for ALK testing is a mandatory requirement for this study. Optional additional pre-treatment tumor samples and fresh post-treatment tumor biopsy at disease progression or permanent treatment discontinuation (at the last treatment or post-progression visit) may be collected, with proper informed consent. These samples will be used to help to understand molecular mechanisms of resistance to ALK inhibitors by genomic sequencing. Remaining tumor blocks will be returned to the sites, slides will not be returned.

The remaining mandatory (Section 4.5.8.2) and optional specimens (Section 4.5.8.3) will be destroyed within 5 years after the date of final closure of the clinical database. Other residual tissue material (slides, extracts, etc.) will be destroyed within 5 years after the date of final closure of the clinical database.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of optional tumor biopsies with exploratory purposes may be stopped at any time if the data from the samples collected do not produce useful information.
4.5.8.4 Blood and Plasma Samples

Mandatory plasma samples will be obtained to determine:

- Mutation status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline, at the Visit 3 (Week 16) treatment, and subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for detailed information) until disease progression, and during post-progression on treatment in case of isolated, asymptomatic CNS progression. For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual. These samples will not be taken in countries where regulatory agency or Institutional Review Board (IRB) does not allow genetic testing.

- ALK rearrangement in plasma. This will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline.

Mandatory blood samples will be obtained to determine:

- All patients who are randomized in alecrtinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alecrtinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Section 4.5.8.4.1).

Optional blood samples will be collected to obtain:

- Plasma. Centrally ALK negative tested patients (by Ventana ALK IHC) who agree to donate 10 ml plasma will be assessed by plasma ALK assays (PCR and/or Sequencing) for the development of a plasma ALK diagnostic test

- A source of healthy tissue for patients who agreed to participate in the optional genomic sequencing assessment. For patients in the crizotinib arm, a 3-mL blood sample will be drawn at baseline. For patients in the alecrtinib arm, a source of healthy tissue will be used as a portion of the sample for the pharmacogenomics research (see Section 4.5.8.4.1)

- A portion of this blood sample will also be used as a source of healthy tissue for the patients on alecrtinib treatment who agree to participate in the optional genomic sequencing research.

For biomarkers, a maximum of 43 mL of blood will be collected at baseline (20 mL of blood for plasma purification and determination of mutation status in ALK and other escape genes, 20 mL of blood for plasma purification and detection of ALK rearrangements, and 3 mL blood for pharmacogenomics research. Twenty mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 20 mL will be collected at disease progression (CNS and/or systemic disease progression) for plasma purification, for determination of mutation status in ALK and other escape genes.
Details of sample handling procedures, sample storage, and shipment will be described in a separate laboratory manual.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma with exploratory purposes may be stopped at any time if they are deemed not informative.

4.5.8.4.1 Samples for Pharmacogenomic Assessments

One sample (approximately 3 mL of whole blood) will be collected from all patients on alectinib treatment. Samples will be used for the evaluation of genetic polymorphisms of drug metabolic enzymes including but not limited to CYP2C9, CYP3A4/5, and UGT1A1, and transporters (e.g., organic anion transporter polypeptide 1B1) and for genetic variants that could contribute to potentially drug-related liver safety assessments (including but not limited to human leukocyte antigen, see Appendix 9 for more details).

For sample handling procedures, storage conditions, and shipment instructions, see the laboratory manual. Only in circumstances where there is concern for collection of this genetic material for above evaluations can this assessment be considered not mandatory as part of study assessments in this study. Results of any analyses from these samples will be reported outside the clinical study report.

4.5.8.5 Samples for Pharmacokinetic Assessments

PK samples will be collected in all patients on alectinib treatment, as indicated in Appendix 1 and Appendix 2 for the analysis of alectinib and its major metabolite(s) (RO5468924, RO5507197, and/or others, if applicable and if appropriate, and if assays are available). Residual samples following PK analysis may be used to evaluate profiling for alectinib metabolite(s).

All trough/pre-dose PK samples should be collected within 2 hours BEFORE the morning doses of study medications.

Serial/intensive samples will be collected in a subset of patients (10%–15% [at least approximately n = 20] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

Plasma concentrations for alectinib and its metabolite(s), if applicable, will be measured by specific and validated liquid chromatography tandem mass spectrometry methods.

For each sample, approximately 2 mL of venous blood will be collected for alectinib PK analysis at the timepoints specified in the PK schedule in Appendix 1 and Appendix 2.

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual.
These samples will be destroyed when the final Clinical Study Report is complete.

On the basis of continuous analysis of the data in this study and other studies, any sample type collection may be stopped at any time if the data from the samples collected do not produce useful information or at the discretion of the Sponsor.

4.5.9 Electrocardiograms

An ECG will be recorded at specified timepoints as outlined in the schedule of assessments (Appendix 1) at screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), and at the last treatment visit and as clinically indicated throughout the study. All ECG recordings must be performed using a standard high-quality, high-fidelity digital electrocardiograph machine equipped with computer-based interval measurements. All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug administration) as well as prior to meals. Circumstances that may induce changes in heart rate, including environmental distractions (e.g., television, radio, conversation), should be avoided during the pre-ECG resting period and during ECG recording.

Patients must have been in a supine or semi-supine position for at least 5 minutes prior to the recording being taken. The same recording position (supine or semi-supine) and the same equipment should be used for each patient throughout the study. The ECG printout must be (1) reviewed by a medically qualified member of the study team at the site, (2) annotated to indicate any clinical finding, and (3) dated and signed by this person and filed in the patient notes. ECG parameters will be entered on the ECG eCRF. The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula (QTcF). In the event that the ECG machine does not directly provide results for RR and/or QTcF, these parameters can be derived using the formulae provided in Appendix 10.

If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory.

4.5.10 Patient-Reported Outcomes

PROs (EORTC QLQ-C30, QLQ-L13, and EQ-5D) will be collected to more fully characterize the clinical profile of alectinib. The instruments will be translated as required in the local language. To ensure instrument validity and that data standards meet health authority requirements, the PROs scheduled for administration during a clinic visit (EORTC QLQ-C30, QLQ-L13, and EQ-5D) should be completed prior to the performance of non-PRO assessments and the administration of study treatment.
Patients will use an ePRO device to capture PRO data and maintain a diary of daily drug intake (crizotinib arm) or drug intake with food (alectinib arm). The ePRO device and instructions for completing the PRO questionnaires and diaries electronically will be provided by the investigator staff. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be accessed by appropriate study personnel securely via the Internet.

4.5.11  **Samples for Roche Clinical Repository**

4.5.11.1  **Overview of the Roche Clinical Repository**

The Roche Clinical Repository (RCR) is a centrally administered group of facilities used for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.

Specimens for the RCR will be collected from patients who give specific consent to participate in optional research. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

4.5.11.2  **Approval by the Institutional Review Board or Ethics Committee**

Collection and submission of biological samples to the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site’s IRB or Ethics Committee (EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol (Section 4.5.11) will not be applicable at that site.

4.5.11.3  **Sample Collection**

For RCR purposes, 10 mL of blood will be collected. Any remaining tissue samples from study-related or non-study related procedures that are performed during the study may also be collected for RCR purposes. For all samples, date of consent should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.
RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be subject to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

4.5.11.4 Confidentiality

Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure database system. Access to the linking key is restricted to authorized individuals and is monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche’s Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

4.5.11.5 Consent to Participate in the Roche Clinical Repository

The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the
objectives, methods, and potential hazards of participation in the RCR. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to provide optional RCR specimens. Patients who decline to participate will not provide a separate signature.

The investigator should document whether the patient has given consent to participate by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's specimens and data will continue to be used as part of the RCR research.

4.5.11.6 Withdrawal from the Roche Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their specimens from the RCR at any time for any reason. If a patient wishes to withdraw consent to the testing of his or her specimens, the investigator must inform the Medical Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research Sample Withdrawal of Informed Consent eCRF. The patient will be provided with instructions on how to withdraw consent after the trial is closed. A patient's withdrawal from Study BO28984 does not, by itself, constitute withdrawal of specimens from the RCR. Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from Study BO28984.

4.5.11.7 Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a quality-controlled, auditable, and appropriately validated laboratory information management system, to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the Informed Consent Form. Roche monitors and auditors will have direct access to appropriate parts of records relating to patient participation in the RCR for the purposes of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the RCR samples.

4.6 PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION
4.6.1 Patient Discontinuation
Patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the investigator has the right to withdraw a patient from the study at any time. Reasons for withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study

Alectinib—F. Hoffmann-La Roche Ltd
69/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

2171
• Investigator or Sponsor determines it is in the best interest of the patient

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. Patients who withdraw consent for treatment should continue to be followed for tumor assessments until progression and for OS, provided they have not withdrawn consent for the study. However, patients will not be followed for any reason after consent for the study has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study Treatment Discontinuation

Patients must discontinue study treatment if they experience any of the following:

• Pregnancy
• Inability to tolerate study medication on the basis of the investigator judgment

See guidelines for managing adverse events and for comprehensive guidance on study drug discontinuation in Section 5.1.3.

Patients who discontinue study drug prematurely will be asked to return to the clinic for tumor assessments until progression as per study schedule (see Appendix 1).

The primary reason for premature study drug discontinuation should be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.3 Study and Site Discontinuation

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

• The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
• Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

• Excessively slow recruitment
• Poor protocol adherence
• Inaccurate or incomplete data recording
• Non-compliance with the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice
• No study activity (i.e., all patients have completed and all obligations have been fulfilled)
5. ASSESSMENT OF SAFETY

5.1 SAFETY PLAN

5.1.1 Adverse Events Collection

After informed consent has been obtained but prior to initiation of study treatment, only serious adverse events (SAEs) caused by a protocol-mandated intervention should be reported (e.g., SAEs related to invasive procedures such as biopsies). After the first dose of study treatment and up to the 4-week follow-up after the last dose of study treatment, all adverse events (AEs) regardless of seriousness, causality assessment, or actions taken reported by the investigator or designated medically qualified study site personnel will be collected as described below. At each visit, the investigator or designated medically qualified study site personnel will ask the patient if any untoward medical event occurred since the last visit. It is the investigator’s responsibility to record all AEs in the source patient’s medical records.

All SAEs and non-SAEs will be reported on the standard AE/SAE eCRF.

5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data

Events described in Section 5.1.2.1 through Section 5.1.2.10 will be closely monitored and represent selected AEs for this study.

A more detailed safety profile of alectinib is provided in the alectinib Investigator’s Brochure.

5.1.2.1 Interstitial Lung Disease

TKIs, including ALK inhibitor crizotinib, have been associated with the occurrence of treatment-related ILD (including fatalities).

See Section 5.1.3 for management and follow-up.

5.1.2.2 Hepatotoxicity

Hepatobiliary findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. The findings were at or close to clinically relevant exposures. Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT and liver weight, vacuolation/degeneration/necrosis of bile duct epithelium, inflammatory cell infiltration in Glisson’s sheath, enlargement/focal necrosis of hepatocytes, and enlargement of Kupffer cells.

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved. In patients with Grade 3–4 AST/ALT elevations, documented drug-induced liver injury by liver biopsy was reported with uncommon frequency in alectinib pivotal clinical
Concurrent elevations in ALT or AST greater than or equal to three times the ULN and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred with uncommon frequency in patients treated in alectinib clinical trials.

In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and drug-induced hepatotoxicity, including cases with fatal outcome, have been reported.

See Section 5.1.3 for management and follow-up.

5.1.2.3 Anemia
Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. Findings were at or close to clinically relevant exposures. Hematologic adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have been observed with most TKIs, including ALK inhibitor crizotinib.

Cases of anemia have been reported in patients treated with alectinib; the majority of the events were Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.4 Gastrointestinal Disorders
GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported with alectinib. Similar GI disorders have been observed with other TKIs, including ALK inhibitor crizotinib.

SLS (sodium lauryl sulfate, syn. sodium dodecyl sulfate) is a surfactant excipient in the clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical ingredient). This excipient is a known GI irritant and may be associated with GI AEs including nausea, vomiting, diarrhea, and abdominal pain. Of note, GI tract toxicity as the safety determinant of SLS is not because of systemic toxicity, but a consequence of local irritation to the GI tract. In general, when mixed with diet, higher levels of SLS—a known GI tract mucosal irritant—are tolerated versus gavage administrations.

See Section 5.1.3 for management and follow-up.

5.1.2.5 Skin Disorders
Results of an in vitro phototoxicity study indicated that alectinib may have phototoxic potential.

Skin rash has been reported with majority of TKIs including those targeting the ALK receptor (Hartmann et al. 2009).
Cases of skin rash and photosensitivity have been reported with alectinib and were generally Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

**5.1.2.6 Vision Disorders**
In the rat quantitative whole body autoradiography study, tissue radioactivity disappeared over time, following a time course comparable to that of plasma radioactivity, except for melanin-containing tissues such as uveal tract of eyes, which had much higher and more sustained exposure in pigmented rats. This is consistent with what is commonly observed for lipophilic basic drugs.

Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and vitreous floaters, have been reported with several TKIs, including ALK inhibitors (crizotinib) (Shaw et al. 2013).

Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and vision impaired, have been reported with alectinib and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

**5.1.2.7 Edema**
Most TKIs, including ALK inhibitor crizotinib, have been associated with edema. Events of edema have been reported with alectinib, mostly Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

**5.1.2.8 Bradycardia**
In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration \(C_{\text{max}}\): 279 ng/mL).

In a preliminary non-Good Laboratory Practice telemetry study in conscious cynomolgus monkeys, a slight hypotensive effect (approximately 10 mmHg) was seen when alectinib was administered at 20 and 60 mg/kg orally with no effects on ECG or heart rate. The hypotensive effect of alectinib observed in monkeys was considered to likely be caused by vasodilatation induced by L-type Ca\(^{2+}\) channel inhibition.

Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse events, as well as decreases in heart rate based on ECG and pulse measurements, have also been reported (*XALKORI*® U.S. Package Insert; ZYKADIA™ U.S. Package Insert).
In case of bradycardia, concomitant medications must be evaluated to identify those that are known to cause bradycardia, as well as anti-hypertensive medications; and discontinuation or dose reduction of these concomitant medications must be considered.

See Section 5.1.3 for management and follow-up.

5.1.2.9 Abnormal Renal Function
In the 2-week non-human primate study at 60 mg/kg, an increase in creatinine was observed but no changes were observed in histopathology. In all other non-human primate studies, no changes in creatinine were observed.

Serum creatinine increases have been reported with alectinib treatment and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.10 Severe Myalgia and CPK Elevations
Postmarketing experience with some TKIs includes reports of myopathy and rhabdomyolysis (Hohenegger 2012).

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment. Grade 3 myalgia and CPK elevations have been reported with alectinib treatment and were reversible upon dose reduction and interruption.

See Section 5.1.3 for management and follow-up and Table 2 for guidelines for managing AEs.
### 5.1.3 Management of Specific Adverse Events with Alectinib

#### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Interstitial lung disease | - Patients should be monitored for pulmonary symptoms indicative of pneumonitis.  
- Study drug should be permanently discontinued in patients diagnosed with interstitial lung disease.                                                                                                                                                                                                                                    |
| **Hepatotoxicity**       | Liver test laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4 and Section 5.3.5.6.  
- If ALT or AST $> 3 \times$ baseline, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry about symptoms. If upon repeat testing the transaminases remain $> 3 \times$ baseline, but are not $> 5 \times$ baseline or not accompanied with bilirubin increases or do not match any other rule for permanent discontinuation, then monitoring can continue as per investigator judgment, and dose modification is not necessary.  
- At any time during the study treatment, if symptoms compatible with liver injury are observed, liver enzymes should be measured as soon as possible.  
- Study drug treatment has to be permanently discontinued if any of the following occurs:  
  - First observation of ALT or AST $> 8 \times$ ULN  
  - ALT or AST $> 5 \times$ ULN for more than 2 weeks  
  - First observation of ALT or AST $> 3 \times$ ULN and total bilirubin $> 2 \times$ ULN  
  - First observation of ALT or AST $> 3 \times$ ULN and the appearance of jaundice or signs of hepatic dysfunction or other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia [$> 5\%$]).  
  - Following study drug discontinuation, weekly monitoring of laboratory values should continue until the abnormal values have normalized to pre-treatment levels and/or an adequate explanation of the abnormal value is found.  
  - Resumption of study drug is not allowed in patients discontinuing because of any of the above criteria. |
<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal tract AEs (e.g., nausea, vomiting, diarrhea)</td>
<td>The events are expected to be minimized by taking the study drug with meal. In case GI events occur, appropriate measures should be taken in accordance with local clinical practice guidelines. If GI toxicities are observed and not tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower.</td>
</tr>
<tr>
<td>Skin disorder AEs (e.g., phototoxicity, rash)</td>
<td>Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 5 days after study drug discontinuation. Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least SPF 50 to help protect against potential sunburn.</td>
</tr>
<tr>
<td>Vision disorders</td>
<td>Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice guidelines, if vision disorders persist or worsen in severity, and to advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder.</td>
</tr>
<tr>
<td>Edema</td>
<td>Physical examinations will be performed routinely in clinical trials. In case edema events occur, appropriate measures should be taken in accordance with local clinical practice guidelines.</td>
</tr>
</tbody>
</table>
Table 2 Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Abnormal kidney function AEs | Kidney function laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
  • If, at any time during the study treatment, eGFR decreases by >50% of the baseline visit value, the patient has to be carefully monitored. All of the underlying factors that may have acutely impacted serum creatinine levels need to be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.).  
  • Any eGFR decrease by >50% of the baseline visit value requires repeat testing. If, at the repeat test, the eGFR decrease is still >50% of the baseline visit value, the treatment with alectinib should be interrupted.  
  • Alectinib treatment may be resumed with caution if the eGFR value has increased to approximately the baseline visit value. |
| Severe myalgia and CPK elevations | CPK laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
  • Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms.  
  • At the first occurrence of any of asymptomatic CPK values (>10 × ULN, symptomatic CPK >5 × ULN, or in the presence of severe muscular symptoms with CPK > ULN but ≤5 × ULN) at any time during the study treatment, the patient requires monitoring of the CPK values until they are normalized to pre-treatment levels or a reasonable explanation for the CPK elevation and the symptoms is established. |
### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other AEs (including bradycardia, anemia, and CPK elevation) or laboratory abnormalities:</td>
<td></td>
</tr>
<tr>
<td>• Grade 3 or 4:</td>
<td>Temporarily interrupt alectinib for a maximum of 3 weeks. If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib. First episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by another 150 mg (1 capsule) BID (300 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 2 (except any symptoms and signs that can be corrected with supportive care):</td>
<td>Temporarily interrupt alectinib and resume if recovering to Grade ≤ 1 or baseline if clinically indicated. First episode: If improvement to Grade ≤ 1 or baseline within 10 days, continue same dose of alectinib. If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID when resuming treatment (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID or 300 mg BID if after first episode dose was reduced to 450 mg BID). If improvement occurs after 10 days, decrease the current dose of alectinib by 300 mg (2 capsules) when resuming treatment (300 mg BID or 150 mg BID if after first episode dose was reduced to 450 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 1: no action required</td>
<td></td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate.

Note: Diarrhea, nausea, and vomiting should be handled with best supportive care first before considering dose modification. Preexisting pleural effusion will not be considered as an adverse event.

### 5.1.4 Safety of Crizotinib and Management of Adverse Events

Dosing interruption and/or dose reduction may be required on the basis of individual safety and tolerability. If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily on the basis of individual safety and tolerability (XALKORI® U.S. Package Insert; Crizotinib SmPC). Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Table 3 and Table 4.

Alectinib—F. Hoffmann-La Roche Ltd
78/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196 2180
### Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia)

<table>
<thead>
<tr>
<th>CTCAE&lt;sup&gt;a&lt;/sup&gt; Grade</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events

<sup>b</sup> In case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of a third episode of Grade 4 hematologic toxicity.
### Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT or AST elevation $&gt; 5 \times ULN$ with total bilirubin $\leq 1.5 \times ULN$</td>
<td>Withhold until recovery to baseline or $\leq 3 \times ULN$, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
<tr>
<td>ALT or AST elevation $&gt; 3 \times ULN$ with concurrent total bilirubin elevation $&gt; 1.5 \times ULN$ (in the absence of cholestasis or hemolysis)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Any grade drug-related ILD/pneumonitis</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>QTc $&gt; 500$ ms on at least 2 separate ECGs</td>
<td>Withhold until recovery to baseline or $&lt; 481$ ms, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence (i.e., QTc $&gt; 500$ ms on at least 2 separate ECGs).</td>
</tr>
<tr>
<td>QTc $&gt; 500$ ms or $\geq 60$ ms change from baseline with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Bradycardia (heart rate $&lt; 60$ bpm, symptomatic, may be severe and medically significant, medical intervention indicated)</td>
<td>Withhold until recovery to asymptomatic bradycardia or to a heart rate $\geq 60$ bpm. Evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If a contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume crizotinib at previous dose upon recovery to asymptomatic bradycardia or to a heart rate $\geq 60$ bpm. If no contributing concomitant medication is identified, or if contributing concomitant medication is identified but not discontinued or its dose was not modified, resume crizotinib at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of $\geq 60$ bpm.</td>
</tr>
<tr>
<td>Bradycardia (heart rate $&lt; 60$ bpm, life-threatening consequences, urgent intervention indicated)</td>
<td>Permanently discontinue if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at 250 mg once daily upon recovery to asymptomatic bradycardia or to a heart rate of $\geq 60$ bpm, with frequent monitoring. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
</tbody>
</table>

Gastrointestinal events were commonly reported with crizotinib in clinical trials. Nausea, diarrhea, vomiting, and constipation were the most commonly reported gastrointestinal events.
events and were primarily Grade 1 in severity. Supportive care for gastrointestinal events may include standard antiemetic and/or antidiarrheal or laxative medicinal products. In clinical studies with crizotinib, events of gastrointestinal perforations were reported (XALKORI® U.S. Package Insert; Crizotinib SmPC).

Blood counts and liver function tests including ALT, AST, and total bilirubin should be monitored as per local prescribing information for crizotinib.

See local prescribing information for further crizotinib safety information.

5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest, performing protocol-specified safety laboratory assessments, measuring protocol-specified vital signs, and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 5.4.

5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation where a patient is administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition).
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug
- AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor)

An SAE is any AE that meets any of the following criteria:

- Is fatal (i.e., the AE actually causes or leads to death)
- Is life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate risk of death)

  This does not include any AE that had it occurred in a more severe form or was allowed to continue might have caused death.

- Requires or prolongs inpatient hospitalization (see Section 5.3.5.10)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient’s ability to conduct normal life functions)
- Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- Is a significant medical event in the investigator’s judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the eCRF.

SAEs are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions).

5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)

Non-SAEs of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). AEs of special interest for this study are the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law (see Section 5.3.5.6)
• Suspected transmission of an infectious agent by the study drug, as defined below:
  Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.

5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4–5.6. For each AE recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient’s medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting SAEs).

After initiation of study drug, all AEs will be reported until 4 weeks after the last dose of study drug. After this period, the investigator should report any SAEs that are believed to be related to study drug treatment (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all patient evaluation timepoints. Examples of non-directive questions include the following:

• "How have you felt since your last clinic visit?"
• "Have you had any new or changed health problems since you were last here?"

5.3.3 Assessment of Severity of Adverse Events

The AE severity grading scale for the NCI CTCAE (v4.0) will be used for assessing AE severity. Table 5 will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.
### Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE

<table>
<thead>
<tr>
<th>Grade</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living&lt;sup&gt;b,c&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences or urgent intervention indicated&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>Death related to adverse event&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.  
Note: On the basis of the most recent version of NCI CTCAE (v4.0), which can be found at:  
<sup>a</sup> Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.  
<sup>b</sup> Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one's self, using the toilet, and taking medications, as performed by patients who are not bedridden.  
<sup>c</sup> If an event is assessed as a "significant medical event," it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.  
<sup>d</sup> Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

### 5.3.4 Assessment of Causality of Adverse Events

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (as applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event
5.3.5  Procedures for Recording Adverse Events

Investigators should use correct medical terminology and concepts when recording AEs on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one AE term should be recorded in the event field on the Adverse Event eCRF.

5.3.5.1  Diagnosis Versus Signs and Symptoms

A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

5.3.5.2  Adverse Events that are Secondary to Other Events

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event on the Adverse Event eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

5.3.5.3  Persistent or Recurrent Adverse Events

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported. If a persistent AE becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes
serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event eCRF should be updated by changing the event from "non-serious" to "serious," providing the date that the event became serious, and completing all data fields related to SAEs.

A recurrent AE is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values

Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Is clinically significant in the investigator's judgment

Note: For oncology trials, certain abnormal values may not qualify as AEs.

It is the investigator's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., ALP and bilirubin 5 times the ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent AEs).
5.3.5.5 Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Is clinically significant in the investigator’s judgment

It is the investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded one on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent adverse events).

5.3.5.6 Abnormal Liver Function Tests
The finding of an elevated ALT or AST (>3 × baseline value) in combination with either an elevated total bilirubin (>2 × ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, investigators must report as an AE the occurrence of either of the following:

- Treatment-emergent ALT or AST >3 × baseline value in combination with total bilirubin >2 × ULN (of which ≥35% is direct bilirubin)
- Treatment-emergent ALT or AST >3 × baseline value in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or a non-SAE of special interest (see Section 5.4.2).

5.3.5.7 Deaths
For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-specified AE reporting period (see Section 5.3.1) that are attributed by the investigator solely to progression of NSCLC should be recorded only on the Study Completion/Early Discontinuation eCRF. All other on-study deaths, regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and
immediately reported to the Sponsor (see Section 5.4.2). An independent monitoring committee will monitor the frequency of deaths from all causes.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. The term "sudden death" should be used only for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, "unexplained death" should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), "unexplained death" should be replaced by the established cause of death.

During survival follow-up, deaths attributed to progression of NSCLC should be recorded only on the Survival eCRF.

5.3.5.8 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not be recorded as AEs. These data will be captured as efficacy assessment data only. In most cases, the expected pattern of progression will be based on RECIST criteria v1.1 (Appendix 4). In rare cases, the determination of clinical progression will be based on symptomatic deterioration. However, every effort should be made to document progression using objective criteria. If there is any uncertainty as to whether an event is due to disease progression, it should be reported as an AE.

5.3.5.10 Hospitalization or Prolonged Hospitalization
Any AE that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 5.2.2), except as outlined below.
The following hospitalization scenarios are not considered to be AEs:

- Hospitalization for respite care
- Planned hospitalization required by the protocol
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:
  - The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease.
  - The patient has not experienced an AE.
- Hospitalization due solely to progression of the underlying cancer

5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration

An overdose is the accidental or intentional use of a drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE. All AEs associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF. If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

AE reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. However, if any PRO responses suggestive of a possible AE are identified during site review of the PRO data, the investigator will determine whether the criteria for an AE have been met and, if so, will report the event on the Adverse Event eCRF.

5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study

If an AE inadvertently occurs in an individual not enrolled in the study, the Adverse Event Form provided to investigators should be completed and submitted to Roche or its designee, either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- SAEs
• Non-SAEs of special interest
• Pregnancies

The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:
• New signs or symptoms or a change in the diagnosis
• Significant new diagnostic test results
• Change in causality based on new information
• Change in the event’s outcome, including recovery
• Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts
Medical Monitor (Roche Medical Responsible) Contact Information
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the Roche Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Roche Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk as well as Medical Monitor contact information will be distributed to all investigators.

This list can be generated using contact numbers found at the following link: http://gcpcenter.roche.com/synergy/portal/view/pdq-spi/gcpcenter/34-64711453.

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest
5.4.2.1 Events That Occur Prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4.2.2 Events That Occur After Study Drug Initiation
After initiation of study drug, SAEs and non-SAEs of special interest will be reported until 4 weeks after the last dose of study drug. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) system.
A report will be generated and sent to Roche Safety Risk Management by the EDC system.

In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

Instructions for reporting post-study AEs are provided in Section 5.6.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnanies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. A pregnancy report will automatically be generated and sent to Roche Safety Risk Management. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In the event that the EDC system is unavailable, the Clinical Trial Pregnancy Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3.2 Pregnanies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

2193
Pregnancy Report eCRF with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

In the event that the EDC system is unavailable, follow reporting instructions provided in Section 5.4.3.1.

5.4.3.3 Abortions
Any abortion should be classified as an SAE (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study drug or the female partner of a male patient exposed to study drug should be classified as an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.5 FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS

5.5.1 Investigator Follow-Up
The investigator should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented on the Adverse Event eCRF and in the patient’s medical record to facilitate source data verification.

All pregnancies reported during the study should be followed until pregnancy outcome. If the EDC system is not available at the time of pregnancy outcome, follow reporting instructions provided in Section 5.4.3.1.

5.5.2 Sponsor Follow-Up
For SAEs, non-SAEs of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.
5.6 POST-STUDY ADVERSE EVENTS

The Sponsor should be notified if the investigator becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug), if the event is believed to be related to study drug treatment.

The investigator should report these events directly to Roche or its designee, either by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number or email address provided to investigators.

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all SAEs and non-SAEs of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single AE cases, the Sponsor will assess the expectedness of these events using the following reference documents:

- Alectinib Investigator's Brochure
- Local prescribing information for crizotinib

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis population for efficacy is the intent-to-treat (ITT) population defined as all randomized patients. Patients will be assigned to the treatment group to which they were randomized.

The primary analysis population for safety is the Safety Analysis Population (SAP) defined as all patients who received at least one dose of study medication. Patients will be assigned to treatment groups as treated, and all patients who received any dose of alectinib will be included in the alectinib treatment arm.

A secondary analysis population for efficacy is the FISH Positive Population (FPP). This is defined as all patients in the ITT population who were ALK-positive using the Vysis FISH assay. Patients will be assigned to the treatment group to which they were
randomized. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay.

An analysis of the primary endpoint of investigator-assessed PFS based on the FPP will be performed at the time of the primary analysis. A major discrepancy between the Ventana IHC assay and the Vysis FISH assay may necessitate a follow-up analysis of the primary endpoint based on 170 PFS events observed in the FPP to ensure 80% power of the log-rank test under the assumption of a hazard ratio of 0.65 in this secondary population.

The final analysis of the primary endpoint of PFS will occur when 170 PFS events have occurred, on the basis of the investigators’ assessments. On the basis of the assumptions outlined in Section 6.1, this is estimated to occur approximately 33 months after the first patient has been enrolled. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Hypothesis tests will be two-sided with a significance level of 5% unless otherwise indicated.

The baseline value of any variable will be defined as the last available value recorded prior to the first administration of alectinib or crizotinib.

Further details of all analyses will be provided in the Statistical Analysis Plan.

6.1 DETERMINATION OF SAMPLE SIZE

The focus of this clinical trial is hypothesis testing (Section 6.4.1), and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.

Alectinib—F. Hoffmann-La Roche Ltd
94/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984  Report Number 1078196  2196
In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 24 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size ($N=286$), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude. At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 106 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.

### 6.2 SUMMARIES OF CONDUCT OF STUDY

Study enrollment, study treatment administration, reasons for discontinuation from study treatment, and reasons for study termination will be summarized by treatment arm for all randomized patients. Violations of inclusion and exclusion criteria, on the basis of information captured on the eCRF, will be reported and summarized by treatment arm.

### 6.3 SUMMARIES OF TREATMENT GROUP COMPARABILITY

Summaries of treatment group comparability will be based on the ITT population.

Demographic, baseline disease characteristics and lung cancer history will be summarized by treatment arm for all randomized patients, including the randomization
stratification factors. Descriptive baseline summaries of continuous data will present the group mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequency and percentages.

Previous and concomitant cancer therapy will also be summarized, as well as anti-cancer subsequent therapy. Previous and concurrent diseases and medications will also be summarized.

6.4 EFFICACY ANALYSES

The primary population for all primary and secondary efficacy analyses will be the ITT population.

6.4.1 Primary Efficacy Endpoint

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as an HR (alectinib vs. crizotinib), as well as a 95% CI.
The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[ H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \]

versus

\[ H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)} \]

where SDF denotes the survival distribution function of the parameter PFS.

### 6.4.2 Secondary Efficacy Endpoints

If the primary endpoint of PFS is statistically significant at a two-sided 5% significance level, the following secondary endpoints will be tested in the following sequential order, each at a two-sided 5% significance level:

- PFS by IRC
- Time to CNS progression
- ORR
- OS

**PFS by IRC**

An analysis of PFS on the basis of the IRC assessments will be performed using the same methodology as specified for PFS on the basis of investigator assessment.

**Time to CNS Progression**

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression. An independent central radiological review will be performed for all patients, and the analysis of CNS progression or response will be on the basis of the data from the independent review. All patients will be included in the analysis regardless of their baseline status of CNS metastases. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of preexisting baseline CNS lesions. On the basis of RECIST v1.1, this is defined as a new post-baseline CNS/brain lesion(s) and/or an increase of \( \geq 20\% \) in the sum of longest diameters of the measurable baseline CNS lesions compared to nadir and/or unequivocal progression of non-measurable baseline CNS lesions.

In order to account for the competing risks inherent in such an analysis, HRs, including statistical inference on the basis of a two-sided log-rank test, to compare the risk of CNS progression between the alectinib and crizotinib treatment groups, will be computed on the basis of cause-specific hazard functions.

The probability of CNS progression, non-CNS progression, and death will each be estimated using cumulative incidence functions.
For descriptive purposes, estimates of the CNS progression rates over time with 95% CIs on the basis of cumulative incidence functions will be presented. A Gray’s test to compare the risk of CNS progression between alectinib and crizotinib will also be performed as a supportive analysis.

An exploratory analysis of CNS Time to Progression on the basis of RANO criteria will also be performed on the basis of the IRC assessments.

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. Similar analyses will be performed in the subgroup of patients with measurable and/or non-measurable CNS lesions at baseline. An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

**Objective Response Rate**

ORR, on the basis of investigator assessment, is defined as the percentage of patients who attain a CR or PR. Per RECIST v1.1, confirmation of objective response is not required for this secondary endpoint. Patients without a post-baseline tumor assessment will be considered non-responders, as will patients with a best overall response of stable disease (SD), PD, or NE (not evaluable).

An estimate of ORR and its two-sided 95% CI will be calculated using the Clopper-Pearson method for each treatment arm. Response rates in the treatment groups will be compared using a stratified Mantel-Haenszel test on the basis of the randomization stratification factors. The difference in ORR between the two treatment arms will be presented together with a two-sided 95% CI on the basis of a normal approximation to the binomial distribution.

**DOR**

For patients who have experienced an objective response (CR or PR) during the study as assessed by the investigator, DOR is defined as the duration from the first tumor assessment that supports the patient’s objective response (CR or PR, whichever is first recorded) to first documented disease progression or death due to any causes, whichever occurred first. Patients who have not progressed or died at the time of analysis will be censored at the last tumor assessment date. Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing will not be performed. DOR will be estimated using Kaplan-Meier methodology and an HR on the basis of a Cox proportional regression model will be calculated.
Overall Survival
OS is defined as the time from the date of randomization to the date of death due to any cause. Patients who are not reported as having died at the time of analysis will be censored at the date when they were last known to be alive. Patients who do not have post-baseline information will be censored at the date of randomization. OS will be analyzed using the same methodology as specified for the primary endpoint. A survival follow-up will be performed based on more mature data.

6.4.2.1 Sensitivity Analyses
The following sensitivity analyses will be performed on the primary endpoint of PFS:

- The effect of non-protocol-specified anti-cancer therapy prior to progression will be assessed by censoring patients at the last adequate tumor assessment prior to the start of non-protocol-specified anti-cancer therapy.
- The effect of missing tumor assessments will be assessed if the number of missing assessments in either arm is >5%. For patients with progression determined following one or more missing tumor assessments, the progression will be backdated to the first missing tumor assessment.
- The effect of loss to follow-up will be assessed depending on the number of patients who are lost to follow-up. If >5% of patients are lost to follow-up for PFS in either treatment arm, a “worst-case” analysis will be performed in which patients who are lost to follow-up will be considered to have progressed at the last date they were known to be progression-free.

6.4.2.2 Subgroup Analyses
Subgroup analyses of PFS will be performed for patients with baseline CNS metastases and for patients without baseline CNS metastases. In addition, a subgroup analysis of Time to CNS Progression will be performed, excluding patients who had pre-treatment radiation therapy for CNS lesions.

All other subgroup analyses will be specified in the SAP.

6.5 SAFETY ANALYSES
The primary population for all safety analyses will be the SAP as defined in Section 6.

All safety parameters will be summarized in tables to evaluate and compare the safety profile of patients treated with alectinib versus crizotinib in terms of:

- Adverse events including adverse events leading to dose modifications or interruptions, study drug withdrawal, and death
- Severe, serious, and selected adverse events
- Deaths
- Laboratory parameters and abnormalities
- Vital signs
- ECGs
- ECOG PS

Adverse events will be coded using MedDRA and summarized by mapped term and appropriate thesaurus level. All adverse events and routine laboratory parameters will be assessed according to the NCI CTCAE v4.0 grading system. For adverse events, the most extreme severity will be used for reporting. Adverse events will be described by individual listings and by body system, as well as by severity. In tables showing the overall incidence of adverse events, patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency.

Laboratory values will be summarized by treatment arm including summary tables for the shifts in grades from baseline to the worst grade observed during treatment. In order to evaluate and compare hypogonadism in the two treatment arms, testosterone levels in the blood will be summarized for males by treatment arm over time (for details, see Section 6.8).

Descriptive summary tables of change from baseline over time will be provided for vital signs and descriptive statistics will be tabulated for ECOG PS. ECG findings over time will be summarized.

Study drug administration will be summarized by duration and cumulative dose. In addition, treatment exposure will be summarized including the number of doses received, dose intensity, and the percentage of planned dose.

Subgroup analyses will be performed to evaluate the safety profile within the subgroups of patients including by sex, age (<65 vs. ≥65 years), and race (non-Asian vs. Asian).

An iDMC will review the safety data collected during the conduct of the study. Safety monitoring will be performed periodically. Further details will be outlined in the iDMC Charter.

6.6 PHARMACOKINETIC ANALYSES

Standard NCA may be conducted for PK data collected from patients participating in serial/intensive PK collections for relevant analytes, as data allow, as appropriate, and if needed. PK parameters, including but not limited to AUC, $C_{\text{max}}$, and time to maximum concentration ($T_{\text{max}}$), will be calculated on the basis of the available data as appropriate and where data allow. Additional PK parameters may be calculated as deemed appropriate.

Individual and mean plasma concentrations at each sampling timepoint and/or PK parameters for alectinib and metabolite(s) will be listed, as appropriate.
Summary statistics (e.g., means, standard deviation, coefficient of variation %, geometric means, medians and ranges) for plasma concentrations and/or PK parameters for alectinib and metabolite(s) will be presented by treatment and nominal collection times (plasma concentrations only), as appropriate. Additional plots or summary statistics may be constructed or calculated, as appropriate.

Results of PK and/or any PK/pharmacodynamic analyses may be reported outside the clinical study report.

Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be used to analyze the sparse and/or serial/intensive plasma concentration-time data for alectinib. The PK data from this study may be pooled with data from other studies. Population and individual PK parameters will be estimated and the influence of various covariates (such as age, gender, and body weight) on these parameters will be investigated.

Exploratory analyses will be conducted to investigate the relationship between alectinib PK exposure and efficacy/safety parameters.

Details of the mixed-effects modeling and exploratory analyses will be reported in a document separate from the clinical study report.

6.7 PATIENT-REPORTED OUTCOME ANALYSES

The following PRO endpoints will be analyzed and PRO data will be presented separately from adverse event data.

6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms

TTD from baseline will be assessed at every study visit (Week 4, Week 8, and then after every 4 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at post-treatment Visit (4 weeks after permanent treatment discontinuation); and at subsequent 8-weekly survival follow-up visits for 6 months, for the following lung cancer symptoms: cough (Question 31 on the QLQ-LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale (Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), arm/shoulder pain (Question 41 on the QLQ-LC13) and fatigue multi-item subscale (Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. TTD will be analyzed for the ITT population. If a baseline or post-baseline PRO evaluation is not available, TTD will be censored at the date of randomization. If they have not deteriorated, patients will be censored at the last time when they completed an assessment for cough, dyspnea (single item), dyspnea (subscale items), chest pain, arm/shoulder pain, and fatigue.
6.7.2 Additional Patient-Reported Outcomes

PROs of HRQoL, lung cancer–related symptoms, and health status will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13.

Summary statistics (mean, standard deviation, median, and range) of linear transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire, and the QLQ-LC13 according to the EORTC scoring manual guidelines. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. Only patients with a baseline assessment and at least one post-treatment assessment will be included in the analyses.

6.8 EXPLORATORY ANALYSES

The EQ-5D-3L is a generic PRO instrument that is used for across diseases and indications cost-effectiveness analyses. This instrument quantifies the QoL of various health outcomes and is applicable to a wide range of health states. Analyses of this outcome will be exploratory and will generate utility scores for use in economic models for reimbursement purposes only. The PRO will be administered every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months (see Appendix 1).

It has been reported that crizotinib therapy triggers rapid suppression of testosterone levels in men causing rapid-onset hypogonadism. It is unknown if reductions in testosterone reflect an effect of crizotinib on ALK or on some combination of the drug’s targets (i.e., c-MET) (Weickhardt et al. 2012; Weickhardt et al. 2013). Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and sex hormone-binding globulin [SHBG] calculator: http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m.

The Abbott Vysis FISH test will be used as an exploratory assay after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between Vysis FISH and Ventana IHC for the detection of ALK-positive NSCLC.

ALK plasma assays (PCR and/or sequencing) will be used as exploratory assays for ALK positive and consented ALK negative patients. Results from these analyses will be used to quantify the degree of correlation between ALK plasma tests and Ventana IHC and Vysis FISH for the detection of ALK positive NSCLC. The ALK plasma assay population may be used for exploratory efficacy and safety analysis. This analysis population will be used to support diagnostic development. Assays from this population
may be used for the registration of a plasma assay as a companion diagnostic. This analysis will be dependent on the successful technical development of a plasma ALK assay. Results of analyses related to those alternative diagnostic tests and exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure ALK rearrangements in circulating tumor cells will be communicated outside the main clinical study report.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

The Sponsor will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC using eCRFs. Sites will be responsible for data entry into the EDC system. In the event of discrepant data, the Sponsor will request data clarification from the sites, which the sites will resolve electronically in the EDC system.

The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. Central laboratory data or other electronic data will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle and process the electronic transfer of these data.

eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

ePRO data will be collected through use of an electronic device provided by an ePRO vendor. The device is designed for entry of data in a way that is attributable, secure, and accurate, in compliance with the FDA regulations for electronic records (21 CFR Part 11). The ePRO device data are available for view access only via secure access to a web server. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.
At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.

7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patients will use an ePRO device to capture PRO data. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be reviewed by site staff via secure access to a web server.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The investigator will receive patient data for the site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records as source data. Acknowledgement of receipt of the compact disc is required. In addition, the Sponsor will receive all patient data in a machine-readable format on a compact disc.

7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by applicable health authorities.
7.5 USE OF COMPUTERIZED SYSTEMS

When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS

Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a United States IND application will comply with FDA regulations and applicable local, state, and federal laws. Studies conducted in the European Union or European Economic Area will comply with the EU Clinical Trial Directive (2001/20/EC).

8.2 INFORMED CONSENT

The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child’s Assent or Caregiver’s Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor’s sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the "Consent Forms") before IRB/EC.
submission. The final IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to allow any remaining specimens to be used for exploratory research. Patients who decline to participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient’s legally authorized representative. All signed and dated Consent Forms must remain in each patient’s study file or in the site file and must be available for verification by study monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.
8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site's study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which includes an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL DEVIATIONS

The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.

9.3 SITE INSPECTIONS

Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients’ medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE

Steering Committee is established to provide the study Sponsor with recommendations related to any aspect of the trial, specifically study design, data interpretation, exploratory analyses, or alternate changes to the trial that may assist in patient accrual, data collection, analysis, and interpretation of the study results. The Sponsor is ultimately responsible for all decisions regarding the study.

The test for the study inclusion criteria of ALK-positive NSCLC will be performed at Sponsor’s designated central laboratories and assessed by Ventana IHC test.

An iDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised. Details of the composition, roles, and responsibilities, and processes of the iDMC are documented in a separate iDMC charter. The iDMC will review safety data and can make recommendations to the Sponsor to stop or amend the study on the basis of safety findings. The frequency of these reviews as well as the data to be reviewed will be agreed with the iDMC and outlined in the separate iDMC charter. No stopping for early proof of efficacy will result from any of these regular safety reviews. iDMC review meetings will be held in a blinded manner to the Sponsor.

Alectinib—F. Hoffmann-La Roche Ltd
108/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196 2210
An IRC will review the tumor assessments to determine the secondary endpoints of the overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1. In addition to the secondary endpoint of time to CNS progression together with C-ORR, C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the tumor assessments on the basis of RANO criteria.

The independent review of MRI and CT scans will NOT determine either eligibility OR patient treatment. All treatment decisions will be made by the investigator using local assessments.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


The results of this study may be published or presented at scientific congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).
10. REFERENCES


Alectinib—F. Hoffmann-La Roche Ltd
113/Protocol BO28984, Version 4

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196


Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.


## Appendix 1

### Schedule of Assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Days -28 to 0</td>
<td>Days -3 to 0</td>
<td>Visit 0 (Baseline)</td>
<td>Visit 1 (Week 4)</td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test (^b)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination (^c)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECG (^d)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Hematology, Coagulation</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

\(^a\) To be repeated as necessary

\(^b\) Informed consent, Demographics, Medical history, Pregnancy test

\(^c\) Physical examination, Vital signs, ECOG PS

\(^d\) ECG

\(^e\) To be repeated as necessary
### Appendix 1
**Schedule of Assessments (cont.)**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Mandatory tumor sample for ALK testing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional plasma sample from centrally confirmed ALK negative patients (20 ml of blood)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional tumor sample</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

---

*Abbreviations: ALK = Anaplastic Lymphoma Kinase; CNS = Central Nervous System; NSCLC = Non-Small Cell Lung Cancer; PRO = Patient-Reported Outcomes; PD = Progression of Disease; EORTC = European Organisation for Research and Treatment of Cancer; QLQ-C30 = Core 30-item Cancer Specific Module; EQ-5D = EuroQol 5D.*
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma sample for ALK fusion detection in nucleic acids (20 mL of blood)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Plasma for detection of ALK mutation status (20 mL of blood)</td>
<td>x</td>
<td>x,i</td>
<td>x,i</td>
<td></td>
</tr>
<tr>
<td>Blood sample for pharmacogenomics research at pre-dose (3 mL of blood)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- Days -28 to 0
- Days -3 to 0
- Visit 0 (Baseline)
- Visit 1 (Week 4)
- Visit 2 (Week 8)
- All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD
- Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)
- Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression</th>
<th>Post-Treatment</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor assessment¹</td>
<td>x⁻²</td>
<td>x⁻²</td>
<td>x⁻¹</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>MRI scan of the brain</td>
<td>x⁻²</td>
<td>x⁻²</td>
<td>x⁻¹</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>PK samples (2 mL blood)²</td>
<td>x⁻³</td>
<td>x⁻³</td>
<td>x⁻¹</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>PRO (EORTC QLQ-C30/LC13); EQ-5D³</td>
<td>x⁻³</td>
<td>x⁻³</td>
<td>x⁻¹</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Total testosterone, (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH⁴</td>
<td>x⁻³</td>
<td>x⁻³</td>
<td>x⁻¹</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Adverse events¹</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
### Appendix 1

**Schedule of Assessments (cont.)**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsequent therapy for NSCLC</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Drug dispensing and accountability</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Blood Sample for Roche Clinical Repository (10 mL)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided—within ≤ 24 hours.
- Post-baseline assessments are to be performed within ± 1 week for the first two 4 weekly and subsequent 8 weekly assessments.
- For details on assessments when patient permanently discontinues from study treatment, see flowchart in Figure 1.
- Urine or serum, to be repeated as necessary.
- Including an ophthalmologic examination if clinically indicated.

**Abbreviations:**
- ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire–Core; EQ-5D = EuroQoL 5 Dimension; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NSCLC = non–small cell lung cancer; PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal.
Appendix 1
Schedule of Assessments (cont.)

d At screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), last treatment visit, and as clinically indicated throughout the study.

e Screening laboratory assessment done within 3 days can be counted as the baseline assessment.

f Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 10 to 15 unstained 5-µm slides are required. Tumor ALK status will be assessed by central laboratory before randomization.

g Optional tumor sample could be taken from the tumor block obtained at screening.

h At the time of disease progression from progressive lesions.

i Mandatory blood sample (20 mL) for detection of ALK rearrangements in nucleic acids in plasma collected at baseline only.

j Blood sample (20 mL) to obtain plasma for exploratory biomarkers will be collected at Visit 0 (baseline), during the study every second visit (i.e., every 16 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression.

k This sample is required in all patients in alectinib arm, and in those patients in the crizotinib arm who wish to participate in optional genomics sequencing.

l Tumor assessment consists at minimum of a CT/MRI scan of chest and abdomen (for imaging of liver and adrenal glands). Patients who are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP >1.5 × ULN) of bone metastasis should undergo radionuclide bone scan. Clinical lesions should be assessed with caliper measurement and documented by color photography, including a ruler to estimate the size of the lesion. Post-baseline assessments are to be performed within ±1 week for the 8 weekly assessments. If there is suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be performed as soon as possible before the next scheduled evaluation.

m Screening tumor assessment done within 14 days will be counted as the baseline assessment.

n Tumor assessment can be performed whenever clinically indicated. Brain assessment scans should be performed at every systemic imaging tumor assessment. Tumor assessment should continue until disease progression if a patient discontinues treatment prior to PD, regardless of whether they subsequently receive non-study, anti-cancer therapy.

o If treatment was permanently discontinued due to disease progression.

p Pre-dose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit. The pre-dose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits. Remind the patient not to take a daily dose at home on the day of scheduled study visit. For a subset of patients on alectinib treatment (10%–15%, or at least approximately n = 20) participating in serial/intensive PK sample collection, additional PK will be collected on Visits 0 (baseline) and 1 (Week 4) at pre-dose (within 2 hours before intake of study medication), 1, 2, 4, 6, and 8 hours post-dose.
Appendix 1  
Schedule of Assessments (cont.)

PRO questionnaires are to be completed every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow up visit (every 8 weeks) after post-treatment visit for 6 months. Further guidelines on PRO questionnaire administration will be provided in the study manual.

Performed every 8 weeks after post-treatment visit during the first 6 months and then every 12 weeks. The PRO assessments should be performed during the first 6 months. For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post treatment. For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.

Male patients only, using institutional standard assay. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m. Albumin and SHBG measurements are not required when a direct assessment of free testosterone is available. If free testosterone level cannot be directly assessed, it will be calculated from albumin and SHBG using a free testosterone calculator: http://www.issam.ch/freetesto.htm.

Graded according to NCI CTCAE (version 4.0). Serious adverse events collection must start from first study-specific procedure.

For details on drug dispensing and accountability, see Section 4.3.3.
Appendix 1
Schedule of Assessments (cont.)

Figure 1  Flowchart for Patients who Permanently Discontinue Study Treatment

Patient permanently discontinues from study treatment
due to or not due to Progressive Disease (PD)

If patient withdrawn due to PD
(At time of PD: PD blood samples, optional tumour samples should be collected)

Complete ‘Study Treatment Discontinuation’ eForm

If patient withdrawn for reason other than PD

Post Treatment Visit
(4 weeks after treatment discontinuation)
Tumour Assessments are required

Tumour Assessments, CNS metastasis evaluation
(if CNS mets at BL) and ePRO collection continue as per original 8 weekly study schedule*

PD confirmed — Tumour assessments stop

Post Treatment Visit
(4 weeks after treatment discontinuation) — Tumour Assessments are NOT required

WBC entered under original Visits
(Not applicable eforms will be inactivated by CRA)

Subject decides to discontinue study assessments

Subject consents to Survival Follow Up ICF

Enters Survival Follow up

Study Completion eform
If any of the discontinuation reasons listed occur

*Follow up on:
- AEs: Subsequent therapies, IMP accountability if required
- No labs, ECG, ECOG, etc. to be assessed
- All related SAEs to be reported beyond end of study treatment

AEs = adverse events; ECOG = Eastern Cooperative Oncology Group; ePRO = electronic patient reported outcome; ICF = Informed Consent Form; IMP = investigational medicinal product; PD = Progressive Disease.

Alectinib—F. Hoffmann-La Roche Ltd
123/Protocol BO28984, Version 4
## Appendix 2
### Schedule of Alectinib Pharmacokinetic Assessments

<table>
<thead>
<tr>
<th>Visit</th>
<th>Timepoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 0 (baseline)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>All subsequent visits (every 8 weeks) until PD or death/withdrawal from study prior to PD</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 0 (baseline) and Visit 1 (Week 4) (^a)</td>
<td>Pre-dose (within 2 hours before intake of alectinib), 1, 2, 4, 6, and 8 hours post-dose</td>
</tr>
</tbody>
</table>

PD = progressive disease; PK = Pharmacokinetic.

\(^a\) For patients participating in the serial/intensive PK sample collection only.
## Appendix 3
### List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters

This representative list is not intended to be an exhaustive list. Each patient’s concomitant medications should be carefully considered by the investigator with regard to the risk-benefit for the particular patient and appropriate monitoring, including any concomitant medication, dose adjustment, or therapeutic alternatives, which should be determined by the investigator caring for the patient.

<table>
<thead>
<tr>
<th>CYP3A Potent Inducers</th>
<th>CYP3A Potent Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>avasimibe, barbiturates, carbamazepine, efavirenz, ethosuximide, garlic supplements, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, primidone, rifabutin, rifampin, rifapentine, St. John’s wort, troglitazone</td>
<td>aprepitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice, indinavir, irtraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-gp Substrates</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>aliskiren, ambrisentan, colchicine, dabigatran, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, pravastatin, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan</td>
<td>avasimibe, carbamazepine, phenytoin, rifampin, St John’s wort, tipranavir</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dual UGT1A1/CYP3A Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>buprenorphine, raltegravir</td>
<td>atazanavir</td>
<td>rifampin</td>
</tr>
</tbody>
</table>


This information in this appendix is adapted from Levien and Baker 2003, Zhang 2010, and FDA Guidance on Drug-Drug Interactions.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters (cont.)

Also see:

- http://medicine.iupui.edu/clinpharm/ddis/table.aspx

Potent inhibitors of CYP3A are those considered to be “strong CYP3A inhibitors” previously shown to result in a ≥ 5-fold increase in the AUC of a concomitantly administered CYP3A substrate. These are based on the available published literature and, thus, are not considered exhaustive or inclusive. See FDA Guidance on Drug-Drug Interactions for further detail.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST),
Version 1.1: Excerpt from Original Publication

Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST),
Version 1.1,1 are presented below, with slight modifications and the addition of
explanatory text as needed for clarity.2

MEASURABILITY OF TUMOR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized as measurable or
non-measurable as described below.

**Measurable tumor lesions**

**Tumor lesions**
Tumor lesions must be accurately measured in at least one dimension (longest diameter
in the plane of measurement is to be recorded) with a minimum size as follows:

- 10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than
  5 mm)
- 10-mm caliper measurement by clinical examination (lesions that cannot be
  accurately measured with calipers should be recorded as non-measurable)
- 20 mm by chest X-ray

**Malignant lymph nodes**
To be considered pathologically enlarged and measurable, a lymph node must be
≥ 15 mm in the short axis when assessed by CT scan (CT scan slice thickness is
recommended to be no greater than 5 mm). At baseline and follow-up, only the short
axis will be measured and followed. See also notes below on “Baseline Documentation
of Target and Non-Target Lesions” for information on lymph node measurement.

**Non-Measurable tumor lesions**
Non-measurable tumor lesions encompass small lesions (longest diameter <10 mm or
pathological lymph nodes with ≥ 10 to <15 mm short axis) as well as truly
non-measurable lesions. Lesions considered truly non-measurable include
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal
mass/abdominal organomegaly identified by physical examination that is not measurable
by reproducible imaging techniques.

---

1 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid
2 For consistency within this document, the section numbers and cross-references to other
sections within the article have been deleted and minor formatting changes have been made.

Alectinib—F. Hoffmann-La Roche Ltd
127/Protocol BO28984, Version 4
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Special considerations regarding lesion measurability
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.

Bone lesions
Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.

Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques, such as CT or MRI, can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

Blastic bone lesions are non-measurable.

Cystic lesions
Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

Lesions with prior local treatment
Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.

TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS

Measurement of lesions
All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.

Method of assessment
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study. Imaging-based evaluation should always be the preferred option.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Clinical lesions
Clinical lesions will only be considered measurable when they are superficial and \( \geq 10 \text{ mm} \) in diameter as assessed using calipers (e.g., skin nodules). For the case of clinical lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is required.

Chest X-Ray
Chest CT is preferred over chest X-Ray, particularly when progression is an important endpoint, because CT is more sensitive than X-Ray, particularly in identifying new lesions. However, lesions on chest X-Ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

CT, MRI
CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan on the basis of the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable.

If, prior to enrollment, it is known that a patient is unable to undergo CT scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the study should be guided by the tumor type under investigation and the anatomic location of the disease. For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible. Each case should be discussed with the radiologist to determine if the substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of target lesions on a different modality and interpretation of non-target disease or new lesions because the same lesion may appear to have a different size using a new modality.

Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement.

Endoscopy, laparoscopy, tumor markers, cytology, histology
The utilization of these techniques for objective tumor evaluation cannot generally be advised.

Alectinib—F. Hoffmann-La Roche Ltd
129/Protocol BO28984, Version 4
TUMOR RESPONSE EVALUATION

ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE

To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable lesion, as detailed above.

BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS

When more than one measurable lesion is present at baseline, all lesions, up to a maximum of five lesions total and a maximum of two lesions per organ, representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline. This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions (albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size is >10 mm by CT scan).

Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but, in addition, the lesions should lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.

Lymph nodes merit special mention since they are normal anatomical structures that may be visible by imaging even if not involved by tumor. As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥10 mm but <15 mm) should be considered non-target lesions. Nodes that have a short axis of <10 mm are considered non-pathological and should not be recorded or followed.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum of diameters. If lymph nodes are to be included in the sum, then, as noted above, only the short axis is added.

Alectinib—F. Hoffmann-La Roche Ltd
130/Protocol BO28984, Version 4
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

into the sum. The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions or sites of disease, including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases "unequivocal progression”.

In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).

RESPONSE CRITERIA
Evaluation of target lesions
This section provides the definitions of the criteria used to determine objective tumor response for target lesions.

• CR: Disappearance of all target lesions
  Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to $< 10$ mm.

• PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

• PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
  The appearance of one or more new lesions is also considered progression.

• SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Special notes on the assessment of target lesions
Lymph nodes
Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to $< 10$ mm on study. This means that when lymph nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of $< 10$ mm.

Target lesions that become too small to measure
During the study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as
target lesions at baseline become so faint on the CT scan that the radiologist may not
feel comfortable assigning an exact measure and may report them as being too small to
measure. When this occurs, it is important that a value be recorded on the CRF, as
follows:

If it is the opinion of the radiologist that the lesion has likely disappeared, the
measurement should be recorded as 0 mm.

If the lesion is believed to be present and is faintly seen but is too small to measure, a
default value of 5 mm should be assigned and BML (below measurable limit) should be
ticked. (Note: It is less likely that this rule will be used for lymph nodes since they
usually have a definable size when normal and are frequently surrounded by fat such as
in the retroperitoneum; however, if a lymph node is believed to be present and is faintly
seen but is too small to measure, a default value of 5 mm should be assigned in this
circumstance as well and BML should also be ticked).

To reiterate: If the radiologist is able to provide an actual measure, this
measurement should be recorded, even if it is below 5 mm, and, in that case, BML
should not be ticked.

Lesions that split or coalesce on treatment
When non-nodal lesions fragment, the longest diameters of the fragmented portions
should be added together to calculate the target lesion sum. Similarly, as lesions
coalesce, a plane between them may be maintained that would aid in obtaining maximal
diameter measurements of each individual lesion. If the lesions have truly coalesced
such that they are no longer separable, the vector of the longest diameter in this
instance should be the maximum longest diameter for the coalesced lesion.

Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response
for the group of non-target lesions. Whereas some non-target lesions may actually be
measurable, they need not be measured and instead should be assessed only
qualitatively at the timepoints specified in the protocol.

- CR: Disappearance of all non-target lesions
  All lymph nodes must be non-pathological in size (<10 mm short axis).
- Non-CR/Non-PD: Persistence of one or more non-target lesions
- PD: Unequivocal progression of existing non-target lesions
  The appearance of one or more new lesions is also considered progression.
Special notes on assessment of progression of non-target disease

When the patient also has measurable disease

In this setting, to achieve unequivocal progression on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease in a magnitude that, even in the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

When the patient has only non-measurable disease

This circumstance arises in some Phase III trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden on the basis of the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic disease from localized to widespread. Examples may be described in protocols as “sufficient to require a change in therapy”. If unequivocal progression is seen, the patient should be considered to have had overall PD at that point. Though it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore, the increase must be substantial.

New lesions

The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly important when the patient’s baseline lesions show PR or CR (e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not).

A lesion identified during the study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.

Alectinib—F. Hoffmann-La Roche Ltd
133/Protocol BO28984, Version 4
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

If a new lesion is equivocal (e.g., because of its small size) continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.

EVALUATION OF RESPONSE

Timepoint response (overall response)

It is assumed that at each protocol-specified timepoint, a response assessment occurs. Table 1 provides a summary of the overall response status calculation at each timepoint for patients who have measurable disease at baseline.

When patients have non-measurable (therefore non-target) disease only, Table 2 is to be used.

Table 1  Timepoint Response: Patients with Target Lesions (with or without Non-Target Lesions)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Table 2  Timepoint Response: Patients with Non-Target Lesions Only

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease.

a  “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can be measured is not advised.

Missing assessments and not-evaluable designation

When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at that timepoint. If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response. This would be most likely to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three measured lesions and during the study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution of the missing lesion).

If one or more target lesions were not assessed either because the scan was not done or because the scan could not be assessed due to poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable. Similarly, if one or more non-target lesions are not assessed, the response for non-target lesions should be “unable to assess”, except where there is clear progression. Overall response would be “unable to assess” if either the target response or the non-target response is “unable to assess”, except where this is clear evidence of progression, as this equates with the case being not evaluable at that timepoint.
### Table 3  Best Overall Response When Confirmation Is Required

<table>
<thead>
<tr>
<th>Overall Response at First Timepoint</th>
<th>Overall Response at Subsequent Timepoint</th>
<th>Best Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR a</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even disease meeting PR criteria relative to baseline, qualifies as PD at that point (since disease must have reappeared after CR). Best response would depend on whether the minimum duration for SD was met. However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint. Under these circumstances, the original CR should be changed to PR and the best response is PR.

**Special notes on response assessment**

When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (<10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document objective...
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST)  
Version 1.1: Excerpt from Original Publication (cont.)

progression even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stopping study therapy. The objective response status of such patients is to be determined by evaluation of target and non-target disease as shown in Table 1 to Table 3.

For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non-target lesion, as appropriate. This is to avoid an incorrect assessment of complete response if the primary tumor is still present but not evaluated as a target or non-target lesion.
### Appendix 5
**Eastern Cooperative Oncology Group Performance Status Scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework or office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to a bed or chair &gt;50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>

**Alectinib—F. Hoffmann-La Roche Ltd**

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd

Protocol BO28984 Report Number 1078196
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires

**EORTC QLQ-C30 (version 3)**

We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no “right” or “wrong” answers. The information that you provide will remain strictly confidential.

Please fill in your initials:  
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year): 31

<table>
<thead>
<tr>
<th></th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

During the past week:

<table>
<thead>
<tr>
<th></th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please go on to the next page
## Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

### During the past week:

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>17. Have you had diarrhea?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>18. Were you tired?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>19. Did pain interfere with your daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>21. Did you feel tense?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>22. Did you worry?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>23. Did you feel irritable?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>24. Did you feel depressed?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>25. Have you had difficulty remembering things?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>26. Has your physical condition or medical treatment interfered with your family life?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>27. Has your physical condition or medical treatment interfered with your social activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>28. Has your physical condition or medical treatment caused you financial difficulties?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

For the following questions please circle the number between 1 and 7 that best applies to you:

29. How would you rate your overall health during the past week?
    - 1 = Very poor
    - 2
    - 3
    - 4
    - 5
    - 6
    - 7 = Excellent

30. How would you rate your overall quality of life during the past week?
    - 1 = Very poor
    - 2
    - 3
    - 4
    - 5
    - 6
    - 7 = Excellent

© Copyright 1999 EORTC. Quality of Life Group. All rights reserved. Version 3.0
# Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

## EORTC QLQ - LC13

Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems during the past week. Please answer by circling the number that best applies to you.

<table>
<thead>
<tr>
<th>During the past week</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. How much did you cough?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>32. Did you cough up blood?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>33. Were you short of breath when you rested?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>34. Were you short of breath when you walked?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>35. Were you short of breath when you climbed stairs?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>36. Have you had a sore mouth or tongue?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>37. Have you had trouble swallowing?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>38. Have you had tingling hands or feet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>39. Have you had hair loss?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>40. Have you had pain in your chest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>41. Have you had pain in your arm or shoulder?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>42. Have you had pain in other parts of your body?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

If yes, where

43. Did you take any medicine for pain?
   1. No
   2. Yes

If yes, how much did it help?
   1 | 2 | 3 | 4
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

Health Questionnaire

(English version for the US)

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed

Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself

Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities

Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort

Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group

Alectinib—F. Hoffmann-La Roche Ltd
144/Protocol BO28984, Version 4
Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196 2246
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.
Appendix 7
Modification of Diet in Renal Disease (MDRD) Formula

The estimating glomerular filtration rate (eGFR) will be calculated on the basis of the following formula:

$$
eGFR \text{ [mL/min/1.73 m²]} = 175 \times \text{SCRT} - 1.154 \times \text{AGE} - 0.203 [\times 0.742 \text{ if female}] [\times 1.212 \text{ if African American}] \text{ (conventional units)}$$

where SCRT = serum creatinine in conventional units, i.e. mg/dL. The following conversion factor should be used in case the serum creatinine value is provided by the lab in μmol/L units:

$$\text{Serum creatinine [mg/dL] = Serum creatinine [μmol/L] \times 0.0113}$$

References:
Appendix 8
Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry

Overview
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA anti-ALK [D5F3]) IHC assay will be used to determine anaplastic lymphoma kinase (ALK) IHC status and to select patients with positive ALK for enrollment in Study BO28984. The anti-ALK (D5F3) rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib. For Study BO28984, the VENTANA anti-ALK (D5F3) assay will be used for investigational purposes only.

VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with using a VENTANA automated slide stainer. It is indicated as an aid in identifying patients eligible for treatment with alectinib.

Device Description
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary antibody, the BenchMark® automated slide staining platform, OptiView DAB detection kit, OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA anti-ALK 2-in-1 cell line control slides or other appropriate system run control.

Scoring System
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern. Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish non-specific staining from specific ALK positivity. Samples must be assessed for morphological damage and the presence of viable tumor versus necrosis. Light, granular, cytoplasmic stippling in alveolar macrophages can occur on anti-ALK (D5F3) and/or NRC slides as an artifact of the detection system. This staining artifact should be noted on the Slide Evaluation Form comment field but should NOT be interpreted as ALK-positive staining. Some background staining has also been observed on normal mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also should not be interpreted as ALK-positive staining. Case slide sets failing to show specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be considered ALK-positive. Refer to VENTANA ALK Scoring Interpretation Guide for non-small cell lung carcinoma (NSCLC) for additional information.
Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

Appendix 9
Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms

2251

ABCB1

CHST13

CYP3A5

HNMT

SLC22A3

UGT1A4

ADRB3

HSP90AA1

STAT6

ABCB11

CHST2

CYP3A7

MAOA

SLC22A4

UGT1A5

ALG10B

IGF1

TNF

ABCB4

CHST3

CYP46A1

MAOB

SLC22A5

UGT1A6

APOA1

IGF2

TNFRSF1B

ABCB7

CHST4

CYP4A11

MAT1A

SLC22A6

UGT1A7

APOC3

IL10

TXNIP

ABCC1

CHST5

CYP4B1

METTL1

SLC22A7

UGT1A8

ARHGAP24

IL22

UBC

ABCC2

CHST6

CYP4F11

NAT1

SLC22A8

UGT1A9

ATF3

IL4

UCP1

ABCC3

CHST7

CYP4F12

NAT2

SLC25A27

UGT2A1

ATIC

IL4R

VDR

ABCC4

CHST8

CYP4F2

NNMT

SLC28A1

UGT2B11

BIRC2

IL6

ABCC5

CHST9

CYP4F3

NQO1

SLC28A2

UGT2B15

BIRC3

IL8

ABCC6

COMT

CYP4F8

NR1I2

SLC28A3

UGT2B17

C3orf38

INSR

ABCC8

CROT

CYP4Z1

NR1I3

SLC29A1

UGT2B28

CALCA

IRS1

ABCC9

CYP11A1

CYP51A1

NR3C1

SLC29A2

UGT2B4

CASP9

IRS2

ABCG1

CYP11B1

CYP7A1

ORM1

SLC5A6

UGT2B7

CD33

IRS4

ABCG2

CYP11B2

CYP7B1

ORM2

SLC6A6

UGT8

CD36

ITPA

ABP1

CYP17A1

CYP8B1

PGAP3

SLC7A5

VKORC1

CD44

JAK1

ADH1A

CYP19A1

DCK

PNMT

SLC7A7

XDH

CDK4

JUN

ADH1B

CYP1A1

DPYD

PON1

SLC7A8

CDK6

KCNIP4

ADH1C

CYP1A2

EPHX1

PON2

SLCO1A2

CEBPB

KRT18

ADH4

CYP1B1

EPHX2

PON3

SLCO1B1

CEP44

KRT8

ADH5

CYP20A1

FAAH

POR

SLCO1B3

CES1

LEP

ADH6

CYP21A2

FMO1

PPARD

SLCO2B1

CTLA4

LEPR

ADH7

CYP24A1

FMO2

PPARG

SLCO3A1

CYP3A

LMX1A

AHR

CYP26A1

FMO3

PPP1R9A

SLCO4A1

EGFR

LPL

Alectinib—F. Hoffmann-La Roche Ltd
149/Protocol BO28984, Version 4


### Appendix 9

Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms (cont.)

<table>
<thead>
<tr>
<th>Gene 1</th>
<th>Gene 2</th>
<th>Gene 3</th>
<th>Gene 4</th>
<th>Gene 5</th>
<th>Gene 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKAP9</td>
<td>CYP26C1</td>
<td>FMO4</td>
<td>PRSS53</td>
<td>SLC05A1</td>
<td>ETNK2</td>
</tr>
<tr>
<td>ALB</td>
<td>CYP27A1</td>
<td>FMO5</td>
<td>PTGIS</td>
<td>SPG7</td>
<td>FASLG</td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>CYP27B1</td>
<td>FMO6</td>
<td>QPRT</td>
<td>SPN</td>
<td>FASLG</td>
</tr>
<tr>
<td>ALDH2</td>
<td>CYP2A13</td>
<td>G6PD</td>
<td>RALBP1</td>
<td>SULT1A1</td>
<td>FOS</td>
</tr>
<tr>
<td>ALDH3A1</td>
<td>CYP2A6</td>
<td>GSTA1</td>
<td>RPL13</td>
<td>SULT1A2</td>
<td>FPGS</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>CYP2A7</td>
<td>GSTA2</td>
<td>RXRA</td>
<td>SULT1A3</td>
<td>GGH</td>
</tr>
<tr>
<td>AOX1</td>
<td>CYP2B6</td>
<td>GSTA3</td>
<td>SERPINA7</td>
<td>SULT1B1</td>
<td>GPNMB</td>
</tr>
<tr>
<td>APOA2</td>
<td>CYP2B7P1</td>
<td>GSTA4</td>
<td>SLC10A1</td>
<td>SULT1C2</td>
<td>GPT</td>
</tr>
<tr>
<td>ARNT</td>
<td>CYP2C18</td>
<td>GSTA5</td>
<td>SLC10A2</td>
<td>SULT1C4</td>
<td>GPX1</td>
</tr>
<tr>
<td>ARSA</td>
<td>CYP2C19</td>
<td>GSTM1</td>
<td>SLC13A1</td>
<td>SULT1E1</td>
<td>GPX3</td>
</tr>
<tr>
<td>AT7A</td>
<td>CYP2C8</td>
<td>GSTM2</td>
<td>SLC15A1</td>
<td>SULT2A1</td>
<td>GPX4</td>
</tr>
<tr>
<td>ATP7B</td>
<td>CYP2C9</td>
<td>GSTM3</td>
<td>SLC15A2</td>
<td>SULT2B1</td>
<td>GYS1</td>
</tr>
<tr>
<td>CA5P</td>
<td>CYP2D6</td>
<td>GSTM4</td>
<td>SLC16A1</td>
<td>SULT4A1</td>
<td>GYS2</td>
</tr>
<tr>
<td>CBR1</td>
<td>CYP2E1</td>
<td>GSTM5</td>
<td>SLC19A1</td>
<td>TBXAS1</td>
<td>HCP5</td>
</tr>
<tr>
<td>CBR3</td>
<td>CYP2F1</td>
<td>GSTO1</td>
<td>SLC22A1</td>
<td>TPMT</td>
<td>HGF</td>
</tr>
<tr>
<td>CDA</td>
<td>CYP2J2</td>
<td>GSTP1</td>
<td>SLC22A11</td>
<td>TPSG1</td>
<td>HLA-A</td>
</tr>
<tr>
<td>CES2</td>
<td>CYP2S1</td>
<td>GSTT1</td>
<td>SLC22A12</td>
<td>TYMS</td>
<td>HLA-B</td>
</tr>
<tr>
<td>CHST1</td>
<td>CYP39A1</td>
<td>GSTT2</td>
<td>SLC22A13</td>
<td>UGT1A1</td>
<td>HLA-DQA1</td>
</tr>
<tr>
<td>CHST10</td>
<td>CYP3A4</td>
<td>GSTZ1</td>
<td>SLC22A14</td>
<td>UGT1A10</td>
<td>HLA-DQB1</td>
</tr>
<tr>
<td>CHST11</td>
<td>CYP3A43</td>
<td>HMGCR</td>
<td>SLC22A2</td>
<td>UGT1A3</td>
<td>HLA-DRB1</td>
</tr>
</tbody>
</table>

**Alectinib—F. Hoffmann-La Roche Ltd**
150/Protocol BO28984, Version 4
Appendix 10 Formulae for the Calculation of QTcF and RR

QTcF – Fridericia’s correction for QTc measurement (if not provided directly by the ECG machine):

\[ QTcF (ms) = \frac{QT (ms)}{\sqrt[6]{RR (ms)/1000}} \]

RR Interval Formula (if not provided directly by the ECG machine):

RR (ms) = 60000/heart rate (bpm)
PROTOCOL

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 3
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [redacted]
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [redacted]
SPONSOR: F. Hoffmann-La Roche Ltd
DATE FINAL: Version 1: 10 February 2014
DATE AMENDED: Version 2: 08 October 2014
Version 3: See electronic date stamp below

PROTOCOL AMENDMENT APPROVAL

Approver's Name: Company Signatory
Title: Company Signatory
Date and Time (UTC): 14-May-2015 20:45:15

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

2254
PROTOCOL AMENDMENT, VERSION 3: RATIONALE

Protocol BO28984 has been amended to incorporate the latest pre-clinical and safety information. Changes include those to the specific timing of dose administration, pharmacokinetic objectives, concomitant therapy, and exploratory objectives.

The major changes to the protocol are as follows:

Both observed clinical PK data and simulations from models support the rationale for removal of timing of dose administration with respect to meal timing. Physiologically based PK (PBPK) model simulations were conducted to evaluate the impact of variations in dose administration relative to meal timing. Results from the PBPK modeling support the clinical observation that drug levels seen following dosing after meal administration are not sensitive to slight variations in dosing times. Notably, simulated steady state concentrations of alectinib following administration at approximately 2 hours after a meal compared to those following administration immediately after a meal were within 20% of each other. These PBPK simulations are further supported by results from the Japanese BE Study JP28927 showing that steady state alectinib plasma concentrations following a 300-mg dose in Japanese patients with ALK positive NSCLC were not substantially different when alectinib was administered within 30 minutes after a meal compared with administration after fasting 2 hours before and 1 hour after alectinib intake. The results of the simulations along with the clinical PK data support administration of alectinib under fed conditions but not specifically linked to the timing of meals.

This study includes PK sample collection to fulfill the PK objective of characterizing alectinib and its major active metabolite(s) in the crizotinib naive patient population. The scheduled PK sampling times have been amended to facilitate optional participation in the intensive PK sampling. Specifically, PK samples scheduled at the 10 and 12 hr timepoints from the intensive/serial sample timepoint will be removed as these latest timepoints are considered a limiting factor for the patients’ participation in the intensive PK sampling. On the basis of available PK data derived from previous studies (AF001JP, NP28761 and NP28673), removing the 10 and 12 hr timepoints will still enable adequate characterization of the pharmacokinetics of alectinib and its major metabolite(s) and will still enable the PK objectives of the study to be met. Thus, this amendment will remove the 10 and 12 hr samples from the intensive PK sampling.

Recommendations for CYP3A, CYP2C8 and P-gp substrates have been modified to reflect updated data, as follows:

- In in-vitro experiments, alectinib and its major active metabolite (M4) showed weak time-dependent inhibition of CYP3A and a small CYP3A induction. On the basis of these findings, a clinical drug-drug interaction study (Study NP28763) has been recently conducted to evaluate the effect of alectinib on the pharmacokinetics of midazolam, a probe CYP3A substrate. Results from this study demonstrated that
alectinib and M4 have no influence on midazolam exposure, with a geometric mean ratio (midazolam+alectinib versus midazolam alone) of 0.971 (90% Confidence Interval [CI]: 0.717–1.315) for AUC_{inf} and 0.919 (90% CI: 0.648–1.305) for C_{max} of midazolam. Similarly, the pharmacokinetics of alpha-hydroxymidazolam and the metabolic ratio were not affected by multiple doses of alectinib. Thus, because this substudy demonstrated no effect of alectinib on CYP3A metabolism, CYP3A substrates may be allowed as concomitant treatments for patients enrolled in the study.

- In in-vitro experiments alectinib, but not M4, showed competitive inhibition of CYP2C8 (K_I=1.98 μM). A physiologically based PBPK model was used to predict possible interaction of alectinib with repaglinide, an in vivo probe CYP2C8 substrate. Results from the PBPK model indicate that multiple doses of alectinib would have no effect on the pharmacokinetics of repaglinide. Therefore, at clinically relevant concentrations, alectinib does not have the potential to increase plasma concentrations of co-administered substrates of CYP2C8. Thus, CYP2C8 substrates may be allowed as concomitant treatments for patients enrolled in the study.

- Based on in vitro data, alectinib is not a substrate of P-gp, but M4 is a P-gp substrate. Because alectinib inhibits P-gp, it is not expected that co-medication with P-gp inhibitors will have an effect on M4 exposure. Thus, P-gp inhibitors may be allowed as concomitant treatments for patients enrolled in the study.

Exploratory objectives have been amended to reflect the following:

- Blood sampling for the collection of Circulating Tumor Cells (CTCs) will be discontinued. CTCs are cells shed by the tumor to the blood stream. Because they originate in tumors, they have the potential to be considered as a surrogate for a tumor biopsy. Published studies have shown promising results demonstrating that ALK rearrangement can be detected accurately in CTCs. Therefore, we decided to investigate the value of CTCs for use in a diagnostic test of ALK rearrangement. However, after preliminary analyses of a subset of patients in ALEX, we failed to demonstrate an accurate correlation between the ALK fusion status in tissue and the ALK fusion status in CTCs.

- Information from plasma ALK assays will be used to investigate the use of circulating tumor nucleic acids from plasma as a surrogate of tumor tissue for diagnostic purposes. Currently, ALK positivity for fusions can only be determined in tissue samples using assays such as FISH, IHC or PCR. As tissue sampling from lung cancer patients may be difficult and lung cancer tissue biopsy samples are in general very small, testing of several important biomarkers from tumor tissue is challenging. In the last few years, various molecular markers with predictive and prognostic significance in lung cancer have evolved and molecular subtyping of lung cancer have become important. Many NSCLC patients may not have enough tumor tissue available and can therefore not be tested for all relevant biomarkers, especially low prevalence markers such as ALK and others. A plasma ALK assay analyzing circulating tumor nucleic acids will enable more NSCLC patients to be tested for ALK fusions.
Additional, minor changes have been made to improve clarity and consistency. This amendment represents cumulative changes to the original protocol.
PROTOCOL AMENDMENT, VERSION 3:
SUMMARY OF CHANGES

PROTOCOL SYNOPSIS
The protocol synopsis has been updated to reflect the changes to the protocol, where applicable.

SECTION 2.5: EXPLORATORY OBJECTIVES
- To evaluate and calculate free testosterone and compare the onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin (SHBG) follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood
- To evaluate and compare efficacy and safety in patients having treatment-naive ALK positive NSCLC as assessed by plasma ALK assays (PCR and/or sequencing)
- To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)
- To investigate detection of ALK mutations/fusions in plasma and circulating tumor cells.

SECTION 3.3.1: Rationale for Alectinib Dosage
With no MTD determined in Study AF-001JP, dose escalation progressed in the United States North American Study NP28761/AF-002JG using a modified 3+3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation.

Alectinib at 600 mg should be administered orally BID with food (within 30 minutes after a meal in the morning and evening.

SECTION 3.3.6: Rationale for Secondary Endpoint of Time to CNS Progression
Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase I/II studies.

SECTION 3.3.8: Rationale for Biomarker Assessments
ALK rearrangements can be monitored in circulating tumor cells in blood (Ilie et al. 2012; Pailler et al. 2013). Intact tumor cells are released into the circulation; hence, using specific surface markers, it is possible to selectively separate them from the remaining cells in the blood. This allows downstream analysis like IHC or FISH, and in rare occasions, there is enough material to perform reverse transcription polymerase chain reaction or sequencing to detect mutant mRNA. The presence of ALK rearrangements will be investigated in circulating tumor cells before treatment and at the end of study. This information will be used to investigate the use of blood as a surrogate of tumor for
diagnostic purposes and to monitor the presence of ALK rearrangements in circulating tumor cells in the blood before and after treatment.

Currently, ALK positivity for fusions can only be determined in tissue samples using assays such as FISH, IHC or PCR. As tissue sampling is difficult and tissue biopsy sample sizes from lung cancer patients are very small, testing of several important biomarkers is challenging. Many NSCLC patients may not have enough tumor tissue available and therefore cannot be tested for some biomarkers such as ALK. Plasma ALK assays analyzing circulating tumor nucleic acids will enable more NSCLC patients to be tested for ALK fusions. Information from plasma ALK assays will be used to investigate the use of circulating tumor nucleic acids from plasma as a surrogate for tumor tissue for diagnostic purposes.

SECTION 3.4.4: Patient-Reported Outcome Measures
For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post treatment.

For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.

SECTION 3.4.5: Exploratory Outcome Measures
- Total testosterone to calculate free testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH, in blood to measure the onset of hypogonadism in adult men
- ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naïve NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
- ALK fusion status in circulating tumor cells in blood.

SECTION 4.1.2: Exclusion Criteria
- Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3) except for oral corticosteroids up to 20 mg of prednisolone equivalent per day.
- History of hypersensitivity to any of the additives in the alectinib drug formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulfate [SLS], magnesium stearate). (see Section 4.3.1.1 for further details)
- History of hypersensitivity to any of the additives in the crizotinib drug formulation (silica, colloidal anhydrous cellulose, microcrystalline calcium hydrogen phosphate,
anhydrous sodium starch glycolate, magnesium stearate). (see Section 4.3.1.2 for further details)

SECTION 4.2: METHOD OF TREATMENT ASSIGNMENT AND BLINDING
The independent review of scans for the secondary endpoints of PFS on the basis of IRC and time to CNS progression on the basis of IRC will be performed in a blinded fashion.

SECTION 4.3.1: Formulation, Packaging, and Handling
SECTION 4.3.1.1: Alectinib
Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal), in the morning and evening.

SECTION 4.3.2: Dosage, Administration, and Compliance
SECTION 4.3.2.1: Alectinib
Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food (within 30 minutes after a meal), in the morning and evening.

SECTION 4.4.1: Permitted Therapy
• Systemic corticosteroid should be no more than oral 20 mg prednisone equivalent daily. Inhalation corticosteroid is allowed. Steroid equivalence converter could be found at: http://www.medcalc.com/steroid.html
• For medications that are inhibitors of P-gp transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. The major metabolite of alectinib, M4, has been shown to be a substrate of this transporter. Strong inhibitors of P-gp should be avoided, if possible (see Appendix 3).
• For medications that are metabolized by CYP3A and CYP2C8, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of CYP3A and CYP2C8, including potential time-dependent inhibition. Sensitive CYP3A and CYP2C8 substrates should be avoided. If coadministration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

SECTION 4.4.2: Prohibited Therapy
Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication is metabolized by or strongly inhibits or induces CYP3A.

SECTION 4.5.3: Corticosteroid Use for CNS Metastase
As per Section 4.4.1 of the protocol, systemic corticosteroid use cannot exceed oral 20 mg of prednisone equivalent daily.

SECTION 4.5.7: Tumor and Response Evaluations
Response will be assessed by the investigator on the basis of physical examinations. Clinical lesions will be documented by color photography (with caliper measurement for...
measurable lesions), computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4).

SECTION 4.5.8.1: Laboratory Assessments

- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase (GGT); calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone and free testosterone (either by direct measurement or by calculation using, albumin and SHBG) to calculate free testosterone, FSH, and LH [for male patients only])
- Urinalysis. Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein will be measured by dipstick test in order to assess micro- and macroproteinuria.

SECTION 4.5.8.3: Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)

The remaining mandatory (Section 4.5.8.2) and optional specimens (Section 4.5.8.3) will be destroyed within 5 years after the date of final closure of the clinical database.

SECTION 4.5.8.4: Blood and Plasma Samples

Mandatory plasma samples will be obtained to determine:

- Mutation status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline, at the Visit 3 (Week 16) treatment, and subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for detailed information) until disease progression, and during post-progression on treatment in case of isolated, asymptomatic CNS progression.
- ALK rearrangement in plasma. This will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline.

Mandatory blood (plasma) samples will be obtained to determine:

- ALK mutations assessment in circulating tumor cells nucleic acids. It will require 20 mL of blood sample to be collected (2 tubes of 10 mL each) at baseline for plasma preparation and at disease progression (at the last treatment or post-progression visit). It should match in time to tumor progression (CNS and/or systemic disease progression).

Optional blood samples will be collected to obtain:

- Plasma. Centrally ALK negative tested patients (by Ventana ALK IHC) who agree to donate 10 ml plasma will be assessed by plasma ALK assays (PCR and/or Sequencing) for the development of a plasma ALK diagnostic test.
For biomarkers, a maximum of 43 mL of blood will be collected at baseline (20 mL of blood for plasma purification and determination of mutation status in ALK and other escape genes, 20 mL of blood for plasma purification and detection of ALK rearrangements, and 3 mL blood for pharmacogenomics research) for ALK fusion detection in circulating tumor cells, and 3 mL for pharmacogenomics research). Twenty mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 3220 mL will be collected at disease progression (CNS and/or systemic disease progression) (20 mL for plasma purification, for determination of mutation status in ALK and other escape genes and 20 mL for ALK fusion detection in circulating tumor cells).

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma and circulating tumor cell samples with exploratory purposes may be stopped at any time if they are deemed not informative.

**SECTION 4.5.8.5: Samples for Pharmacokinetic Assessments**
Serial/intensive samples will be collected in a subset of patients (10%–15% [at least approximately n=20] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

**SECTION 4.5.9: Electrocardiograms**
The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula (QTcF). In the event that the ECG machine does not directly provide results for RR and/or QTcF, these parameters can be derived using the formulae provided in Appendix 10.

**SECTION 4.5.10: Patient-Reported Outcomes**
Patients will use an ePRO device to capture PRO data and maintain a diary of daily drug intake (crizotinib arm) / drug intake with food (alectinib arm). The ePRO device and instructions for completing the PRO questionnaires and diaries electronically will be provided by the investigator staff.

**SECTION 4.5.11.3: Sample Collection**
For all samples, date of consent should be recorded on the associated RCR page of the eCRF.

**SECTION 5.1.1: Adverse Events Collection**
All serious SAEs and non-SAEs will be reported on the standard AE/SAE eCRF.

**SECTION 6: STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN**
Hypothesis tests will be two-sided with a significance level of 5% unless otherwise indicated.
SECTION 6.8: EXPLORATORY ANALYSES
Total testosterone to calculate free testosterone, and free testosterone levels (either by direct measurement or by calculation using albumin, and sex hormone-binding globulin (SHBG) calculator: (http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism.

ALK plasma assays (PCR and/or sequencing) will be used as exploratory assays for ALK positive and consented ALK negative patients. Results from these analyses will be used to quantify the degree of correlation between ALK plasma tests and Ventana IHC and Vysis FISH for the detection of ALK positive NSCLC. The ALK plasma assay population may be used for exploratory efficacy and safety analysis. This analysis population will be used to support diagnostic development. Assays from this population may be used for the registration of a plasma assay as a companion diagnostic. This analysis will be dependent on the successful technical development of a plasma ALK assay.

SECTION 9.5: PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS
For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


APPENDIX 1: Schedule of Assessments
The Schedule of Assessments has been revised to reflect the changes to the protocol.

APPENDIX 3: List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters
Appendix 3 has been revised to reflect the changes to the protocol.

APPENDIX 4: Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication
Appendix 4 has been revised to improve clarity.

APPENDIX 10: Formulae for the Calculation of QTCF and RR
Appendix 10 has been added.

SAMPLE INFORMED CONSENT FORMS
The sample Informed Consent Forms have been revised to reflect the changes to the protocol.
# TABLE OF CONTENTS

PROTOCOL AMENDMENT ACCEPTANCE FORM ................................................. 18

PROTOCOL SYNOPSIS .................................................................................... 19

1. BACKGROUND .......................................................................................... 30
   1.1 Background on Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer ...................... 30
   1.2 Background on Alectinib ........................................................................ 32
   1.3 Study Rationale and Benefit-Risk Assessment .......................................... 37

2. OBJECTIVES ............................................................................................ 39
   2.1 Efficacy Objectives ................................................................................. 39
   2.2 Safety Objectives .................................................................................... 40
   2.3 Pharmacokinetic Objectives ................................................................. 40
   2.4 Patient-Reported Outcome Objectives .................................................... 40
   2.5 Exploratory Objectives ........................................................................... 40

3. STUDY DESIGN .......................................................................................... 41
   3.1 Description of Study ................................................................................. 41
   3.2 End of Study ............................................................................................ 43
   3.3 Rationale for Study Design ....................................................................... 43
      3.3.1 Rationale for Alectinib Dosage ............................................................. 43
      3.3.2 Rationale for Patient Population .......................................................... 45
      3.3.3 Rationale for Control Group ................................................................. 45
      3.3.4 Rationale for Open-Label Design ......................................................... 46
      3.3.5 Rationale for Primary Endpoint Selection ............................................ 47
      3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression .......... 48
      3.3.7 Rationale for PK Sample Collection Schedule ..................................... 49
      3.3.8 Rationale for Biomarker Assessments ............................................... 49
      3.3.9 Rationale for PRO Assessments ......................................................... 50
   3.4 Outcome Measures ................................................................................... 51
      3.4.1 Efficacy Outcome Measures ............................................................... 51
      3.4.2 Safety Outcome Measures ................................................................... 51
      3.4.3 Pharmacokinetic Outcome Measures ................................................ 52
3.4.4 Patient-Reported Outcome Measures ........................................ 52
3.4.5 Exploratory Outcome Measures ............................................. 53

4. MATERIALS AND METHODS ................................................................. 53
4.1 Patients .................................................................................................. 53
4.1.1 Inclusion Criteria ............................................................................. 53
4.1.2 Exclusion Criteria .......................................................................... 55
4.2 Method of Treatment Assignment and Blinding ................................ 56
4.3 Study Treatment ................................................................................ 56
4.3.1 Formulation, Packaging, and Handling ......................................... 56
4.3.1.1 Alectinib .................................................................................... 56
4.3.1.2 Crizotinib .................................................................................. 57
4.3.2 Dosage, Administration, and Compliance ..................................... 57
4.3.2.1 Alectinib .................................................................................... 57
4.3.2.2 Crizotinib .................................................................................. 57
4.3.3 Investigational Medicinal Product Accountability ....................... 58
4.3.4 Post-Trial Access to Alectinib ........................................................ 58
4.4 Concomitant Therapy .......................................................................... 59
4.4.1 Permitted Therapy ........................................................................... 59
4.4.2 Prohibited Therapy ......................................................................... 60
4.4.3 Prohibited Food ............................................................................. 61
4.5 Study Assessments .............................................................................. 61
4.5.1 Informed Consent Forms and Screening Log .............................. 61
4.5.2 Medical History and Demographic Data ....................................... 62
4.5.3 Corticosteroid Use for CNS Metastases ....................................... 62
4.5.4 Physical Examinations ..................................................................... 62
4.5.5 Vital Signs ........................................................................................ 62
4.5.6 ECOG Performance Status ............................................................ 63
4.5.7 Tumor and Response Evaluations ................................................. 63
4.5.8 Laboratory, Biomarker, and Other Biological Sample .................. 64
4.5.8.1 Laboratory Assessments .............................................................. 64
4.5.8.2 Pre-Treatment Tumor Samples (Mandatory) ............................. 64
4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional) .......................................................... 65
4.5.8.4 Blood and Plasma Samples ........................................................................................................ 66
4.5.8.5 Samples for Pharmacokinetic Assessments .............................................................................. 67
4.5.9 Electrocardiograms ......................................................................................................................... 68
4.5.10 Patient-Reported Outcomes .......................................................................................................... 68
4.5.11 Samples for Roche Clinical Repository ......................................................................................... 69
4.5.11.1 Overview of the Roche Clinical Repository ............................................................................. 69
4.5.11.2 Approval by the Institutional Review Board or Ethics Committee ........................................... 69
4.5.11.3 Sample Collection .................................................................................................................... 69
4.5.11.4 Confidentiality ......................................................................................................................... 70
4.5.11.5 Consent to Participate in the Roche Clinical Repository ........................................................... 70
4.5.11.6 Withdrawal from the Roche Clinical Repository ...................................................................... 71
4.5.11.7 Monitoring and Oversight ........................................................................................................ 71
4.6 Patient, Treatment, Study, and Site Discontinuation ........................................................................ 71
4.6.1 Patient Discontinuation ................................................................................................................ 71
4.6.2 Study Treatment Discontinuation ................................................................................................ 72
4.6.3 Study and Site Discontinuation ..................................................................................................... 72
5. ASSESSMENT OF SAFETY .............................................................................................................. 73
5.1 Safety Plan ..................................................................................................................................... 73
5.1.1 Adverse Events Collection ........................................................................................................... 73
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data .................................................................................................................. 73
5.1.2.1 Interstitial Lung Disease ............................................................................................................ 73
5.1.2.2 Hepatobiliary Laboratory Test Elevations ............................................................................... 73
5.1.2.3 Hematologic Abnormalities .................................................................................................... 74
5.1.2.4 Gastrointestinal Disorders ..................................................................................................... 74
5.1.2.5 Skin Disorders ........................................................................................................................ 74
5.1.2.6 Vision Disorders ...................................................................................................................... 75
5.1.2.7 Edema ...................................................................................................................................... 75
5.1.2.8 Cardiovascular Effects........................................................... 75
5.1.2.9 Abnormal Renal Function ..................................................... 76
5.1.2.10 Muscular Adverse Events and CPK Elevations ..................... 76
5.1.3 Management of Specific Adverse Events with Alectinib.......................... 77
5.1.4 Safety of Crizotinib and Management of Adverse Events.......................... 81
5.2 Safety Parameters and Definitions ............................................. 84
5.2.1 Adverse Events ....................................................................... 84
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor) ............ 85
5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor) ............................... 85
5.3 Methods and Timing for Capturing and Assessing Safety Parameters............... 86
5.3.1 Adverse Event Reporting Period ........................................... 86
5.3.2 Eliciting Adverse Event Information ..................................... 86
5.3.3 Assessment of Severity of Adverse Events ............................. 86
5.3.4 Assessment of Causality of Adverse Events .............................. 87
5.3.5 Procedures for Recording Adverse Events ............................... 88
5.3.5.1 Diagnosis Versus Signs and Symptoms.................................. 88
5.3.5.2 Adverse Events that are Secondary to Other Events....................... 88
5.3.5.3 Persistent or Recurrent Adverse Events .................................. 88
5.3.5.4 Abnormal Laboratory Values ............................................. 89
5.3.5.5 Abnormal Vital Sign Values ............................................... 90
5.3.5.6 Abnormal Liver Function Tests .......................................... 90
5.3.5.7 Deaths .................................................................................. 90
5.3.5.8 Preexisting Medical Conditions.......................................... 91
5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer ................................................................. 91
5.3.5.10 Hospitalization or Prolonged Hospitalization .......................... 91
5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration ................................................................. 92
5.3.5.12 Patient-Reported Outcome Data ......................................... 92
5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study ......................................................... 92
5.4 Immediate Reporting Requirements from Investigator to Sponsor .................................................. 92
5.4.1 Emergency Medical Contacts .................................................. 93
5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest ........................................................................ 93
5.4.2.1 Events That Occur Prior to Study Drug Initiation .................................................. 93
5.4.2.2 Events That Occur After Study Drug Initiation .................................................. 93
5.4.3 Reporting Requirements for Pregnancies ........................................................................ 94
5.4.3.1 Pregnancies in Female Patients ........................................................................ 94
5.4.3.2 Pregnancies in Female Partners of Male Patients .................................................. 94
5.4.3.3 Abortions ........................................................................ 95
5.4.3.4 Congenital Anomalies/Birth Defects ........................................................................ 95
5.5 Follow-Up of Patients after Adverse Events .................................................. 95
5.5.1 Investigator Follow-Up ........................................................................ 95
5.5.2 Sponsor Follow-Up ........................................................................ 95
5.6 Post-study Adverse Events ........................................................................ 96
5.7 Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Ethics Committees ........................................................................ 96

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN .................................................. 96
6.1 Determination of Sample Size ........................................................................ 97
6.2 Summaries of Conduct of Study ........................................................................ 98
6.3 Summaries of Treatment Group Comparability ........................................................................ 99
6.4 Efficacy Analyses ........................................................................ 99
6.4.1 Primary Efficacy Endpoint ........................................................................ 99
6.4.2 Secondary Efficacy Endpoints ........................................................................ 100
6.4.2.1 Sensitivity Analyses ........................................................................ 102
6.4.2.2 Subgroup Analyses ........................................................................ 102
6.5 Safety Analyses ........................................................................ 102
6.6 Pharmacokinetic Analyses ........................................................................ 103
6.7 Patient-Reported Outcome Analyses ........................................................................ 104
6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms ...............................................................104
6.7.2 Additional Patient-Reported Outcomes .................................................105
6.8 Exploratory Analyses ...........................................................................105

7. DATA COLLECTION AND MANAGEMENT .............................................. 106
7.1 Data Quality Assurance ....................................................................106
7.2 Electronic Case Report Forms ...........................................................107
7.3 Electronic Patient-Reported Outcome Data .....................................107
7.4 Source Data Documentation ................................................................107
7.5 Use of Computerized Systems .........................................................107
7.6 Retention of Records .........................................................................108

8. ETHICAL CONSIDERATIONS ................................................................ 108
8.1 Compliance with Laws and Regulations ..........................................108
8.2 Informed Consent .............................................................................109
8.3 Institutional Review Board or Ethics Committee ................................110
8.4 Confidentiality ................................................................................110
8.5 Financial Disclosure .........................................................................111

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION .................................................................111
9.1 Study Documentation ..........................................................................111
9.2 Protocol deviations ...........................................................................111
9.3 Site Inspections ................................................................................111
9.4 Administrative Structure ..................................................................111
9.5 Publication of Data and Protection of Trade Secrets ..........................112
9.6 Protocol Amendments .......................................................................113

10. REFERENCES ......................................................................................114
LIST OF TABLES

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP ........................................................ 34
Table 2  Guidelines for Management of Specific Adverse Events with Alectinib ......................................................................................77
Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia) ................................................................. 82
Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities........ 83
Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE ......................................................... 87

LIST OF FIGURES

Figure 1  Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013) ............... 33
Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) .......................................................... 35
Figure 3  Best Percent Change in Size of Target Lesions from Baseline as Assessed by the Investigator in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ......................................................... 36
Figure 4  Summary of Study Design .......................................................... 43

LIST OF APPENDICES

Appendix 1  Schedule of Assessments ......................................................... 119
Appendix 2  Schedule of Alectinib Pharmacokinetic Assessments .............. 127
Appendix 3  List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters ............................................. 128
Appendix 4  Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication ......................... 130
Appendix 5  Eastern Cooperative Oncology Group Performance Status Scale ......................................................................................... 141
Appendix 6  EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires ......... 142
Appendix 7  Modification of Diet in Renal Disease (MDRD) Formula ......... 150
Appendix 8  Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry.... 151
Appendix 9  Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms ......................................................... 152
Appendix 10 Formule for the Calculation of QTcF and RR ........................ 154
PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 3
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [Redacted]
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [Redacted]
SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

________________________________________
Principal Investigator’s Name (print)

________________________________________
Principal Investigator’s Signature Date

Please return a copy of the form to your local study monitor. Please retain the original for your study files.
PROTOCOL SYNOPSIS

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 3
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [redacted]
TEST PRODUCT: Alectinib (RO5424802)
PHASE: Phase III
INDICATION: Anaplastic lymphoma kinase–positive (ALK-positive) non–small cell lung cancer (NSCLC)

SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives
The primary efficacy objective for this study is as follows:

• To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced non–small cell lung cancer (NSCLC), as measured by investigator-assessed progression-free survival (PFS)

The secondary efficacy objectives for this study are as follows:

• To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)

• To evaluate and compare the time to progression in the CNS on the basis of Independent Review Committee (IRC) review of radiographs by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  - To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  - To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  - To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence

• To evaluate and compare the PFS assessment by the IRC

• To evaluate and compare the overall survival (OS)

Safety Objective
The safety objective for this study is as follows:

• To evaluate the safety and tolerability of alectinib compared to crizotinib
Pharmacokinetic Objective
The secondary pharmacokinetic (PK) objective for this study is as follows:

- To characterize the pharmacokinetics of alectinib and metabolite(s)

Patient-Reported Outcome Objectives
The secondary patient-reported outcome (PRO) objectives for this study are as follows:

- To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm/shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)
- To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

Exploratory Objectives
The exploratory objectives for this study are as follows:

- To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement
- To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin (SHBG)), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood
- To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
- To investigate molecular mechanisms of resistance to ALK inhibitors
- To investigate detection of ALK mutations/fusions in plasma

Study Design
Description of Study
This is a randomized, active controlled, multicenter Phase III open-label study in patients with treatment-naive ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (using Ventana immunohistochemistry [IHC] testing). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide. Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally twice daily (BID), taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.
In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases) a local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Number of Patients
Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Target Population
Inclusion Criteria
Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- Patients with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count ≥ 100 × 10^9/L
  - ANC ≥ 1500 cells/μL
  - Hemoglobin ≥ 9.0 g/dL
- Adequate renal function:
  - An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m²
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- Measurable disease (by RECIST v1.1) prior to the administration of study treatment
- Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
- For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
• For women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate <1% per year. Barrier methods must always be supplemented with the use of a spermicide.

• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• Able and willing to provide written informed consent prior to performing any study related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome device.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

• Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

• Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection

• Liver disease characterized by:
  ALT or AST > 3 × ULN (≥5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  OR
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  OR
  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

• National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication

• History of organ transplant

• Co-administration of anti-cancer therapies other than those administered in this study

• Patients with baseline QTc > 470 ms or symptomatic bradycardia

• Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib

• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment

• History of hypersensitivity to any of the additives in the alectinib drug formulation (see Section 4.3.1.1 for details)
• History of hypersensitivity to any of the additives in the crizotinib drug formulation (see Section 4.3.1.2 for details)

• Pregnancy or lactation

• Known HIV positivity or AIDS-related illness

• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study

• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

Length of Study

The time from first patient screened to end of study, defined below, will be approximately 43 months.

End of Study

This study is event driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Outcome Measures

Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

• PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.

• ORR, which is defined as the percentage of patients who attain complete response (CR) or partial response (PR); response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders

• Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months

• DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.
Safety Outcome Measures
The secondary safety outcome measures for this study are as follows:
- Serious and non-serious adverse events
- Safety laboratory tests values
- Vital signs (blood pressure, heart rate), ECG
- Results from Physical examination

Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:
- Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment
- Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%−15%, at least approximately n=20)
- PK parameters will be determined as appropriate and where data allow:
  The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  Non-compartmental analysis may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

Patient-Reported Outcome Measures
The PRO measures for this study are as follows:
- EORTC QLQ-C30 and the EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue)
- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib

Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:
- EQ-5D-3L to generate utility scores for use in economic models for reimbursement
- Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH, in blood to measure an onset of hypogonadism in adult men
- The FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naïve NSCLC that is ALK-positive by FISH test
- Post progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
- ALK mutation status in plasma DNA to monitor efficacy and disease progression
- ALK fusion status in plasma

Investigational Medicinal Products
Test Product
Alectinib comes in a capsule dosage form containing the following active ingredient:
[Chemical name] 9-Ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate. Alectinib capsules should be stored in accordance with the storage instructions on the label. Alectinib capsules should be administered orally BID with food in the morning and evening.

**Comparator**

Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (Xalkori®).

**Non-Investigational Medicinal Products**

Standard-of-care therapy administered to all patients in addition to test product or comparator.

**Statistical Methods**

**Primary Analysis**

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of PFS of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[
H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \\
\text{versus} \\
H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)}
\]

where SDF denotes the survival distribution function of the parameter PFS.

**Determination of Sample Size**

The focus of this clinical trial is hypothesis testing, and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first line setting in ALK-positive patients. The median PFS for crizotinib administered as second line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥ 1 line of chemotherapy (with 85% patients having received ≥ 2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. A HR of
0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted. In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

**Interim Analyses**

No interim analysis for efficacy or futility is planned.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma kinase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration–time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>$C_{\text{max}}$</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C-DOR</td>
<td>CNS duration of response</td>
</tr>
<tr>
<td>C-ORR</td>
<td>CNS objective response rate</td>
</tr>
<tr>
<td>C-PR</td>
<td>CNS progression rate</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>DOT</td>
<td>duration of treatment</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>Eastern Cooperative Oncology Group Performance Status</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EML4</td>
<td>echinoderm microtubule-associated protein-like 4</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for the Research and Treatment of Cancer</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-3L</td>
<td>EuroQoL 5 Dimension</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FISH</td>
<td>fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FPP</td>
<td>FISH Positive Population</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (application)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRC</td>
<td>Independent Review Committee</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>IxRS</td>
<td>interactive voice or web-based response system</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>MET</td>
<td>mesenchymal-epithelial transition factor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NCA</td>
<td>non-compartmental analysis</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>not evaluable</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non-small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PBPK</td>
<td>physiologically based pharmacokinetic</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>patient-reported outcome</td>
</tr>
<tr>
<td>QLQ-C30</td>
<td>Quality of Life Questionnaire–Core</td>
</tr>
<tr>
<td>QLQ-LC13</td>
<td>Quality of Life Questionnaire lung cancer module</td>
</tr>
<tr>
<td>QTcF</td>
<td>QT interval corrected according using Fridericia’s formula</td>
</tr>
<tr>
<td>RANO</td>
<td>Revised Assessment in Neuro Oncology</td>
</tr>
<tr>
<td>RCR</td>
<td>Roche Clinical Repository</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>ROS1</td>
<td>c-ros oncogene 1</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Safety Analysis Population</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SDF</td>
<td>survival distribution function</td>
</tr>
<tr>
<td>SLS</td>
<td>sodium lauryl sulfate</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TTD</td>
<td>time to deterioration</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine 5'-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
1. BACKGROUND

1.1 BACKGROUND ON ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON–SMALL CELL LUNG CANCER

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Lung cancer was estimated to cause 160,340 deaths in the United States in 2012, accounting for 28% of all cancer-related deaths according to the report from the American Lung Association (Lung Cancer Fact Sheet). There is an annual incidence of 310,000 cases of NSCLC in men in the Europe with a mortality of 276,000 deaths (GLOBOCAN 2008). Among women in the Europe, there is an annual incidence of 107,000 cases and a mortality of 91,000 deaths. In total, there are 417,000 cases of NSCLC and 367,000 deaths in Europe each year, which represents a major health problem. Survival rates for lung cancer tend to be much lower than other common cancers because of its late diagnosis and limited effective therapy in the advanced stage. The expected 5-year survival rate for all patients in whom lung cancer is diagnosed is 16.3% compared with 65.2% for colon cancer, 90.0% for breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012). Conventional anti-cancer therapies are far from satisfactory, and there is an unmet medical need for the development of new therapies for NSCLC.

Recent progress in the identification of genetic mutations or chromosomal rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other genes has provided new opportunities to use targeted therapeutic agents for the treatment of NSCLC, when the tumor is identified as having these mutations (Katayama et al. 2011; Doebele et al. 2012).

Approximately 5% of NSCLC cases have been shown to harbor the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; Ou et al. 2012). The formation of the resulting ALK fusion protein results in activation and dysregulation of the gene’s expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these genes. This is further supported by reports that the TFG and KIF5B genes can also serve as ALK fusion partners in some NSCLC patients. Expression of these ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced proliferation. ALK gene alterations are generally in a mutually exclusive relationship with mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism after treatment with crizotinib (Doebele et al. 2012). Inhibition of ALK activity in Ba/F3 cells transfected with the EML4-ALK fusion protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models harboring the EML4-ALK and

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3
nucleophosmin-ALK fusion proteins, respectively. Hence, ALK appears to be a suitable therapeutic target for NSCLC with ALK gene rearrangements.

Wild-type ALK is expressed at very low levels in most normal human tissues, but is expressed at higher levels in a few limited types of tissue such as developing and mature nervous system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997). By contrast, an aberrant ALK with constitutively active kinase results from the formation of the EML4-ALK fusion gene by chromosomal translocation.

Currently, the only approved medicine for treatment-naïve ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), receputeur d’origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

Crizotinib was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test in August 2011. The approval was based on two single-arm trials. The primary endpoint of both trials was ORR as assessed by the investigator. In one study, the ORR was 50\% (95% CI: 42\%, 59\%) with a median response duration of 42 weeks, and, in the other study, the ORR was 61\% (95% CI: 52\%, 70\%) with a median response duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012). In November 2013, the FDA granted regular approval for crizotinib on the basis of demonstrating superior PFS and ORR for crizotinib compared with chemotherapy in patients with ALK-positive NSCLC whose disease progressed after platinum-based doublet chemotherapy (PROFILE 1007 study). An open-label active-controlled multinational randomized trial enrolled 347 patients with ALK-positive metastatic NSCLC. Patients were required to have disease progression following platinum-based chemotherapy. The trial demonstrated significantly prolonged PFS with crizotinib treatment compared with chemotherapy (HR = 0.49 [95% CI: 0.37, 0.64], p < 0.0001). Median PFS was 7.7 months for patients treated with crizotinib and 3.0 months for patients treated with chemotherapy. The ORR was significantly higher for patients treated with crizotinib (65\% vs. 20\%), with median response durations of 7.4 months for patients treated with crizotinib and 5.6 months for patients treated with chemotherapy. No difference in overall survival (OS) was noted between the two groups (HR = 1.02 [95% CI: 0.68\%, 1.54\%]) in a planned interim analysis (Shaw et al. 2013).

Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25\% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue (National Cancer Institute 2013). These results showed that an ALK inhibitor is effective in patients with NSCLC harboring ALK fusion genes. Crizotinib has subsequently been approved in other countries, such as Japan, Korea, Canada, and Switzerland. In the European Union, crizotinib was conditionally approved in October 2012 for the treatment of adults with previously treated ALK positive NSCLC.
Although substantial benefit has been observed with crizotinib therapy, relapse remains the norm. Studies with patients who had progression with crizotinib treatment revealed two main reasons for treatment failure: the development of resistance because of secondary (e.g., gatekeeper) mutations (predominantly in ALK or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease). The CNS is the primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC treated with crizotinib (Costa et al. 2011; Chun et al. 2012; Weickhardt et al. 2012). Significant morbidity is associated with brain metastases as a function of brain involvement, and because of treatment (corticosteroids, surgery, and radiation) required for disease control.

A new generation of ALK inhibitors will have the potential to overcome these two major limitations of crizotinib treatment and may offer patients a better chance of prolonged remission and minimize the development of CNS metastases and the attendant comorbidity.

1.2 BACKGROUND ON ALECTINIB

Alectinib (also RO5424802 or CH5424802) is a newly developed small molecule, highly selective, and potent oral next-generation ALK inhibitor with a benzo[b]carbazole scaffold. In enzyme inhibition assays performed in vitro, this compound has been shown to selectively inhibit ALK. The compound also shows high antitumor activity both in vitro and in vivo against tumor cell lines with some types of ALK gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an ALK translocation and a neuroblastoma line harboring amplified ALK gene.

Nonclinical pharmacology studies showed that alectinib is efficacious in a model of tumors expressing an ALK fusion bearing the L1196M mutation, which is associated with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC xenografts that are already maximally suppressed by crizotinib. Alectinib also prolongs survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth in an intracranial model monitored using bioluminescence.

The clinical development program for alectinib, to date, comprises three ongoing Phase I/II studies in patients with ALK-positive NSCLC. The ongoing Phase I/II studies are as follows: Study AF-001JP, which is being conducted in Japan; Study NP28761/AF-002JG, which is being conducted in US and Canada; and Study NP28673, which is being conducted globally.

The first-in-human study AF-001JP is an open-label Phase I/II study being conducted in Japan. This study is assessing the pharmacokinetics, safety, and efficacy of alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy. This study has completed enrollment, but it is still ongoing. A total of 70 patients were included (24 patients in the
Phase I portion and 46 patients in the Phase II portion of the study). In the Phase I portion of the study, at the data cutoff date of 31 July 2012, 24 patients were treated at doses of 20–300 mg twice daily (BID). No dose-limiting toxicities (DLTs) or adverse events of Grade 4 were noted up to the highest dose; thus, 300 mg BID was evaluated in the Phase II portion of the study without further escalating the dose. In the Phase II portion of the study, 46 patients were treated with the highest evaluated dose of 300 mg BID, of whom 43 achieved an objective response (93.5%; 95% CI: 82.1%, 98.6%) and 7 patients had a complete response (CR) on the basis of an independent radiological review in the 12-month follow-up analysis (data cutoff for response data: 18 April 2013). The median duration of treatment (DOT) in the study has not been achieved at that date because 86% of patients were still on treatment in the study, but the projected median DOT is more than 14 months as data mature.

Figure 1 shows the waterfall plot of the best change from baseline in the size of target lesions by an independent radiological review. Table 1 shows the objective response rate (ORR) by time interval. The majority (86%) of patients had a time to response of within 6 weeks after administration of the first dose.

Figure 1 Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013)
Two of 7 patients who were assessed as having a CR had lymph nodes as the target lesions. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), the percent change from baseline for patients with CR can be less than 100% when lymph nodes are identified as the target lesions. Therefore, they were assessed as having CR, although their tumor change from baseline was less than 100%.

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP

<table>
<thead>
<tr>
<th>Response (Data Cutoff Date: 18 April 2013)</th>
<th>IRC Assessment (N = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
</tr>
<tr>
<td>Partial response</td>
<td>36</td>
</tr>
<tr>
<td>Stable disease</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2</td>
</tr>
<tr>
<td>Total response</td>
<td>43</td>
</tr>
<tr>
<td>Overall response rate (95% CI)</td>
<td>93.5% (82.1%, 98.6%)</td>
</tr>
</tbody>
</table>

Time to Response  IRC Assessment (N = 43)

<table>
<thead>
<tr>
<th>Time to Response</th>
<th>IRC Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to ≤3 weeks</td>
<td>22 (51%)</td>
</tr>
<tr>
<td>&gt;3 to ≤6 weeks</td>
<td>15 (35%)</td>
</tr>
<tr>
<td>&gt;6 to ≤9 weeks</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>&gt;9 weeks</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>

IRC = Independent Review Committee.

In Study NP28761/AF-002JG (crizotinib-failed ALK-positive NSCLC patients), the Phase I portion has completed enrollment. Two ‘bridging’ cohorts of patients receiving alectinib using the 150-mg capsule at 600 and 900 mg BID were included in Study NP28761/AF-002JG to transition/facilitate the planned formulation for the Phase II trials. A total of 47 patients were enrolled in Phase I (Part 1). There does not appear to be any substantial difference in pharmacokinetics between the two formulations (20/40-mg capsule and the 150-mg capsule) at the 600-mg dose on the basis of available data.

The radiological imaging analysis performed in 44 evaluable patients who had a baseline scan and at least one follow-up scan (data cutoff date: 12 September 2013) has shown that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort have achieved a confirmed partial response (PR), as assessed by the investigator. Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort have achieved a PR, as assessed by the investigator, which is still to be confirmed. Three patients (all in the 600-mg BID
dosage cohort) were unevaluable. The ORR was 54.5% (i.e., ORR was reported for 24 of 44 evaluable patients who had a baseline scan and at least one post-treatment scan available to determine overall response, or who had a best overall response of progressive disease (PD) determined by the investigator, on the basis of symptomatic progression [3 patients]), including unconfirmed responses across all dose cohorts. Thirty-three of the 47 (70%) treated patients were still receiving study treatment. The durations of dosing by cohort are shown in Figure 2.

Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013)

The waterfall plot for the 42 patients, with a post-baseline radiological tumor assessment, is shown in Figure 3. On the basis of the data analyzed at that date, 27 patients experienced tumor shrinkage of >30%, of whom 23 patients were assessed as experiencing PR (9 of whom are still to be confirmed by a second tumor assessment).
Patients were enrolled in Study NP28673 starting on 20 June 2013 and no data are available to report at this time.

The benefit of alectinib on CNS activity has been described by the DOT (before progression) or ORR in patients with brain metastases at baseline in the two active studies: Study AF-001JP in Japan and Study NP28761/AF-002JG in the United States. In Phase II of Study AF-001JP, 14 of the 46 (30%) crizotinib-naive patients had documented CNS lesions before enrollment into the trial. Three of these 14 patients were asymptomatic and had not received prior CNS radiation. At the clinical cutoff date of 18 March 2013, 5 of the 14 patients were off-study because of systemic disease progression or an adverse event. Nine patients remain in the study with DOT ranging from 10 to 18 months (none of these patients presented signs or evidence of systemic disease or CNS progression).

Similarly, in Study NP28761/AF-002JG, among the 47 patients enrolled (data cutoff date: 12 September 2013), 21 patients (45%) were known to have brain metastases at baseline. Of these 21 patients, 11 (52%) achieved an ORR as determined by Independent Review Committee (IRC; data cutoff date: 12 September 2013) (Inoue et al. 2013). Moreover, of these 21 patients, 17 remained on active study treatment and 4 discontinued study treatment because of systemic PD (1 patient had
both systemic disease and CNS progression). No patient discontinued because of CNS progression alone.

In addition, 2 patients with leptomeningeal carcinomatosis received benefit from alectinib treatment. One patient with leptomeningeal spread in Study NP28761/AF-002JG achieved PR after 6 weeks of treatment. Another patient with leptomeningeal carcinomatosis but without systemic lesions was treated under a single-patient Investigational New Drug (IND) application because of ineligibility to enter either of the two Phase II alectinib studies (because of the high intake of dexamethasone for symptom control). After 6 weeks of treatment, this patient achieved CR as demonstrated by complete disappearance of gadolinium enhancement on magnetic resonance imaging (MRI) and disappearance of positive CSF cytology. This patient has been able to reduce corticosteroids to physiological replacement dose only.

See the Alectinib Investigator's Brochure for additional details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Over the past 10 years, the treatment of NSCLC has become increasingly focused on guiding treatment based on the presence or absence of an actionable mutation. Numerous oncogenes have now been identified in NSCLC, including mutations in the genes coding for EGFR, KRAS, phosphoinositide-3-kinase (specifically, the catalytic α polypeptide), and EGFR 2 (Pao and Girard 2011). As described in previous sections, a translocation in the gene encoding the receptor tyrosine kinase ALK, leading to the expression of ALK fusion proteins, was identified as an oncogenic driver in a subset of patients with NSCLC (Soda et al. 2007). ALK rearrangements are found in approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012;).

Crizotinib is the first ALK inhibitor that has been approved and registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The previous clinical studies reported that the median PFS with crizotinib ranged from 7.7–9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013). The PROFILE 1014 study, a Phase III study of crizotinib compared to standard pemetrexed-platinum-based chemotherapy, was presented at the ASCO 2014 congress (Mok et al. 2014). The study met its primary objective of prolonging progression-free survival in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p<0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively.
Although substantial benefit has been observed with crizotinib therapy, relapse eventually occurs. Two major reasons for this are the development of resistance because of secondary (e.g., gatekeeper) mutations, or CNS relapse (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). This could be due to the fact that crizotinib is a P-gp substrate and has a low penetration in the CNS. Thus, ALK-positive NSCLC treated with crizotinib has impaired control of brain metastases relative to other sites of systemic disease, with 46% of progressions in patients treated with crizotinib involving the CNS (Costa et al. 2011; Weickhardt et al. 2012). The CNS becomes a sanctuary site for ALK-positive NSCLC treated with crizotinib—a physiologic and anatomic mechanism of drug resistance.

Alectinib is a highly selective and potent oral next generation ALK inhibitor. Clinical data collection from the Phase II portion is still ongoing. Study AF-001JP, assessing alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy, reported that the median treatment duration in the study had not been achieved as 86% of patients were still active on the study, but the projected median DOT is estimated to be at least 14 months at the final point of data collection (Inoue et al. 2013).

Moreover, alectinib is a lipophilic drug and is not a P-glycoprotein (P-gp) substrate. Thus, it is able to penetrate the blood-brain barrier and has the potential to reach higher concentrations in the brain as compared to substrates of P-gp such as crizotinib. This has been shown in the nonclinical setting on the basis of the prolongation of survival in a mouse model with implanted CNS lesions and in a tissue distribution study with a single oral dose of $[^{14}C]$-alectinib at 1 mg/kg in albino rats (Ou et al. 2013). Preliminary clinical data from the Phase I/II studies show consistent therapeutic efficacy of alectinib in brain metastases.

The clinical efficacy data is compelling given the demonstrated activity for a longer progression-free interval with alectinib treatment and improved activity in the CNS. This progression-free interval delays the impact of CNS metastases on neurologic function along with the morbidities associated with treatment like brain radiation, surgery and corticosteroid use required for disease control. The currently available clinical safety data is supportive of an acceptable safety and tolerability profile with alectinib. Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for treatment-naïve ALK-positive advanced NSCLC patients.

Alectinib was granted approval in Japan on 04 July 2014 for treatment of ALK fusion gene-positive, unresectable, recurrent or advanced NSCLC.

In this proposed Phase III study, treatment-naïve patients with ALK-positive advanced NSCLC will be enrolled and will be randomized to receive either crizotinib or alectinib treatment. The results of this study will determine whether alectinib treatment has superior efficacy compared to crizotinib.
The first Phase I dose-escalation study of alectinib (Study AF001-JP, conducted only in Japan) with a dose schedule of 20, 40, 80, 160, 240, and 300 mg BID orally, showed that alectinib was generally well tolerated without major toxicities. Of the 58 patients who received treatment with 300 mg BID alectinib in Study AF-001JP, 27 experienced Grade 3 adverse events and 9 experienced serious adverse events. No deaths were reported during this study and up to 28 days after treatment discontinuation. There were 5 adverse events leading to treatment discontinuation in Part 2 (brain edema, sclerosing cholangitis, interstitial lung disease [ILD], ALT increased, and tumor hemorrhage). Alectinib was well tolerated at all doses investigated in this study. Its adverse event profile was consistent with the one known to be associated with TKIs. In the Phase II Study NP28761/AF-002JG, alectinib was well tolerated with no DLTs or treatment-related dose modifications up to 600 mg BID. Two DLTs were reported at 900 mg BID. The recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best balance between clinical safety, efficacy, and pharmacokinetic (PK) data as observed in the Phase I/II studies (see Section 3.3.1).

On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks. Specifically:

- Available nonclinical and clinical data demonstrate that alectinib is active in NSCLC in crizotinib-naïve patients as well as after progression on prior crizotinib therapy.
- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with TKIs.

Identified and potential risks associated with alectinib treatment will continue to be closely monitored throughout the clinical program. Patient safety during the alectinib program is ensured by targeting the most appropriate patient population, stringent safety monitoring by the Sponsor and Independent Data Monitoring Committee (IDMC), and by protocol-specified study drug interruption criteria.

2. OBJECTIVES

2.1 EFFICACY OBJECTIVES

The primary efficacy objective for this study is:

- To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naïve ALK-positive advanced NSCLC, as measured by investigator-assessed PFS

The secondary efficacy objectives for this study are:

- To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
- To evaluate and compare the time to progression in the CNS on the basis of IRC review of radiographs by RECIST v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
to evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
to assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
to assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence

- To evaluate and compare the PFS assessment by the IRC
- To evaluate and compare the OS

2.2 SAFETY OBJECTIVES

The secondary safety objective for this study is:

- To evaluate the safety and tolerability of alectinib compared to crizotinib

2.3 PHARMACOKINETIC OBJECTIVES

The secondary PK objective for this study is:

- To characterize the pharmacokinetics of alectinib and metabolite(s)

2.4 PATIENT-REPORTED OUTCOME OBJECTIVES

The secondary patient-reported outcome (PRO) objectives for this study are:

- To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm and shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain)
- To evaluate and compare PROs of (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13

2.5 EXPLORATORY OBJECTIVES

The exploratory objectives for this study are:

- To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement
- To evaluate and compare the onset of hypogonadism in adult men by measuring total testosterone and free testosterone (either by direct measurement or by calculation using albumin and sex hormone-binding globulin (SHBG, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood
- To evaluate and compare efficacy and safety in patients with treatment-naive ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott)
• To evaluate and compare efficacy and safety in patients having treatment-naïve ALK positive NSCLC as assessed by plasma ALK assays (PCR and/or sequencing)

• To determine the correlation between ALK status as assessed by plasma ALK PCR and/or plasma ALK sequencing tests, with ALK status obtained using the Ventana ALK IHC and FISH Vysis ALK Break Apart FISH Probe Kit (Abbott)

• To investigate molecular mechanisms of resistance to ALK inhibitors.

• To investigate detection of ALK mutations/fusions in plasma

3. STUDY DESIGN

3.1 DESCRIPTION OF STUDY

This is a randomized, active-controlled, multicenter Phase III open-label study in patients with treatment-naïve ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide.

The primary endpoint of the study is investigator-assessed PFS.

Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the
investigator’s discretion for patients who can continue to benefit from their respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Approximately 286 patients (143 per treatment arm) will be enrolled into the study over a planned competitive recruitment period of 24 months. Patients inappropriately randomized into the study will not be replaced. The final analysis evaluating the primary endpoint of investigator-assessed PFS will occur when approximately 170 patients have progressed or died which is expected to occur approximately 33 months after the first patient has been enrolled. Data collection will continue for each patient until death or study closure, whichever occurs first.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised as outlined in Section 9.4.

A summary of the study design is shown in Figure 4.

A schedule of assessments is provided in Appendix 1.
3.2 END OF STUDY

This study is event-driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Alectinib Dosage

Selection of the alectinib dose for the study is based on the clinical safety, efficacy, and PK data observed in the Phase I/II studies, AF-001JP and NP28761/AF-002JG, and the supportive nonclinical data for alectinib.
The first-in-human study, AF-001JP evaluated escalating doses of alectinib in an accelerated titration scheme to rapidly identify the maximum tolerated dose (MTD). All doses, including the highest evaluated dose in the study, 300 mg BID, were well tolerated with no DLTs observed at any dose. The highest tested dose, 300 mg BID, was further evaluated in the Phase II portion of the study and demonstrated robust efficacy and good safety with an ORR by IRC of 93.5% (43/46 patients; 95% CI: 82.1%, 98.6%).

With no MTD determined in Study AF-001JP, dose escalation progressed in the North American Study NP28761/AF-002JG using a modified 3+3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation. The starting dose in Study NP28761/AF-002JG was the highest dosage evaluated in Study AF-001JP, 300 mg BID. Following multiple dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, median alectinib exposure (area under the concentration time curve [AUC] from 0 to 10 hours) appeared to be approximately two-fold lower compared with that in patients from Study AF-001JP, which demonstrated robust efficacy and safety. Dose escalation progressed with evaluation of higher doses of alectinib up to 900 mg BID.

In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts up to dose-level of 900 mg BID. However, 2 patients in the subsequent 900 mg BID bridging cohort experienced a DLT; 1 patient had Grade 3 headache and 1 patient had Grade 3 neutropenia, and both patients continued study treatment at a reduced dosage of 600 mg BID. Overall, alectinib was well tolerated in the study population.

Importantly, administration of 600 mg BID provides systemic exposures that meet or exceed exposures achieved in patients receiving 300 mg BID in Study AF-001JP, demonstrating its robust efficacy and safety in crizotinib-naïve patients. Furthermore, in Study NP28761/AF-002JG, the 600 mg BID regimen has demonstrated promising activity in crizotinib-resistant patients, including activity in patients with CNS metastases while being tolerated by patients. On the basis of available preclinical data, administration of alectinib 600 mg BID provides systemic exposures within the expected range (on the basis of regression of available data) for tumor regression observed in mouse xenograft models.

Thus, on the basis of nonclinical and clinical data, a dosing regimen of 600 mg BID of alectinib has been chosen as the optimal therapeutic dose level with the best balance between efficacy and safety.

Alectinib at 600 mg should be administered orally BID with food in the morning and evening.
3.3.2 Rationale for Patient Population

The study population will comprise patients with non-resectable, locally advanced and metastatic NSCLC who have been shown to be ALK-positive by the Ventana IHC test performed at central laboratories specially designated for the study. Patients should not have received any prior treatment for advanced NSCLC (treatment-naïve).

Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted therapies. The clinical practice guidelines recommend targeted treatment for patients with metastatic, oncogene-driven disease as first-line systemic therapy (i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive NSCLC) (NCCN 2014).

To be eligible for the study, determination of ALK positivity will be performed centrally using the IHC assay (see Appendix 8) that is being developed by Ventana Medical Systems as a companion diagnostic to alectinib. IHC may replace fluorescence in situ hybridization (FISH)-based identification of ALK rearrangement as the standard companion diagnostic in the future. IHC is faster, easier to perform in local laboratories, and requires less equipment compared with the FISH assay. In addition, IHC has high concordance with FISH and a lower false-negative rate (Kim et al. 2011).

3.3.3 Rationale for Control Group

Targeted therapy (including ALK-targeted therapy) is likely to have a greater anti-tumor effect than standard chemotherapy, offering patients a higher response rate and longer durability of response with less toxicity compared with any potential chemotherapy options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013).

Crizotinib (Xalkori) is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). It is the only first-generation ALK inhibitor that has been approved in multiple countries worldwide for the treatment of ALK-positive NSCLC.

In the United States, in November 2013, crizotinib was granted a regular approval for the ALK-positive NSCLC setting regardless of treatment line (XALKORI® U.S. Package Insert), whereas in Europe, crizotinib is currently only approved conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC).

The NCCN guidelines recommend crizotinib as a first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014).

The randomized Phase III PROFILE 1014 study was conducted to assess the efficacy of crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC. The study met its primary objective of prolonging progression-free survival in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of...
10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p < 0.0001) for crizotinib and pemetrexed platinum-based chemotherapy, respectively (Mok et al. 2014). The authors concluded that these findings support crizotinib as the standard of care for patients with previously untreated advanced ALK-positive non-squamous NSCLC (Mok et al. 2014).

Crizotinib will be dosed as per standard dose recommendations from prescribing information; patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death. See Section 5.1.4 for criteria for dosing interruption and/or dose reduction for treatment with crizotinib.

3.3.4 Rationale for Open-Label Design
An open-label study design is more appropriate for patients enrolled in this particular trial for a number of reasons described below, and with the ultimate goal to ensure patient compliance as much as possible.

For a blinded study design, all enrolled patients would be required to take five large capsules twice per day. This high pill count results from the difference in capsule size between crizotinib (size 0) and alectinib (size 1). Each dose would comprise one 250-mg capsule of crizotinib or matching placebo and four 150-mg capsules of alectinib or matching placebo. In order to blind, crizotinib capsules must be over-encapsulated. That further increases the size of a capsule from size 0 to size 00. Size 00 is usually the largest capsule size used orally for humans. For some patients, size 00 capsules are too large to swallow. This high pill count of large capsules is considered to be a significant burden to patients and increases the risk of non-compliance.

Additionally, a blinded study would increase the complexity of standard dose reductions. Dose interruption or dose reduction may be required on the basis of individual safety and tolerability. The standard dose reductions for crizotinib would be 200 mg BID (different capsule, size 1), followed by 250 mg QD. Dose reductions for alectinib would occur in 150-mg steps. In a double blind study, these multiple step dose reductions introduce a high level of complexity and potential for error.

In order to avoid a significant burden to patients with high pill count, increased risk of non-compliance, and complexity of standard dose reductions, adequate steps have been taken to ensure the validity of the data in an open-label study design. These include performing a supportive analysis of efficacy on the basis of determining progression by an IRC, performing sensitivity analyses to demonstrate the robustness of the primary endpoint, defining progression using established response evaluation criteria (RECIST v1.1), performing tumor assessment at the same frequency in both arms and adhering to protocol-defined schedules, and finalizing the strategy for the final analysis of the primary endpoint before trial start, including developing predefined methods for handling missing data and censoring rules. Efficacy analyses will only be performed at
the pre-specified analysis timepoints in the protocol (final analysis once 170 PFS events have occurred and survival follow-up analysis at 143 events).

### 3.3.5 Rationale for Primary Endpoint Selection

The investigator-assessed PFS (which will be supported by IRC-assessed PFS analysis, one of the secondary endpoints of the study) is the primary endpoint for this trial.

PFS, as an endpoint, can reflect tumor growth and can be assessed before the determination of a survival benefit, and its determination is not generally confounded by subsequent therapies. Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit of the new treatment compared to available therapies (Guidance for Industry 2007; European Medicines Agency 2012). A PFS HR of 0.65 will be targeted, which constitutes a clinically meaningful benefit in this patient population as it will delay the use of platinum-based chemotherapy and will potentially reduce the frequency of CNS relapse and the morbidity associated with treating CNS metastases.

The assumed median PFS of patients in the alectinib treatment arm is 16.8 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 13 months. Patients with ALK-positive NSCLC treated with crizotinib in the second-line setting had a median PFS of 7.7 months and an interim median OS of 20.3 months (Shaw et al. 2013), which equated to a post-progression survival of 12.6 months. This lengthy post-progression survival provides an opportunity for subsequent treatment with other ALK inhibitors, several additional lines of chemotherapy, or participation in additional clinical trials.

Patients in both study arms who experience disease progression on study treatment will likely be treated with other subsequent treatment options, including ALK inhibitors. The availability of crizotinib on the market, as well as the likely availability of other next-generation ALK TKIs, and the availability of other investigational agents in clinical trials offer potential treatment options to patients in the study who will eventually have disease progression. Subsequent therapies frequently confound the detection of an OS benefit, particularly in a setting with a long post-progression survival, such as ALK-positive NSCLC. This has been observed in trials for EGFR TKIs, in which strong PFS benefits were observed without evidence of OS benefit (Rosell et al. 2009; Fukuoka et al. 2011).

The long post-progression survival and the confounding effects of subsequent lines of therapy indicate that it would be difficult to detect an OS benefit in this setting. Nevertheless, OS is one of the study’s secondary endpoints. The crossover from the crizotinib arm to alectinib will not be allowed in this study, with the aim of preserving the trial’s ability to potentially demonstrate some degree of treatment benefit of alectinib in OS. However, the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.

**Alectinib—F. Hoffmann-La Roche Ltd**  
Protocol BO28984, Version 3
To ensure the validity of the PFS as the primary endpoint, a number of measures have been implemented: full IRC assessment to support the analysis of the primary endpoint, a substantial target magnitude of benefit (target HR = 0.65) and study assessments that will allow a robust evaluation of risk-benefit (standard RECIST criteria to define progression with fixed assessment intervals that are identical in both treatment arms and a robust definition of PFS and prospectively defined methods to assess, quantify, and analyze PFS, including censoring methods and sensitivity analyses).

3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression

Lung cancer is the most common type of cancer to spread to the brain, with at least 40% of people with lung cancer developing brain metastases at some point during their disease. ALK-positive NSCLC has a propensity to metastasize to the brain, and crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease (Chun et al. 2012).

Delaying or preventing the development of CNS metastases would provide patients with clinically meaningful benefit by avoiding consequences of neurological deficits from brain metastasis or by delaying/preventing long-term side effects associated with steroid use and brain irradiation.

Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase I/II studies. See Section 1.2 and Alectinib Investigator’s Brochure for additional details.

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression is documented. The aim of the pre-specified analysis will be to evaluate whether alectinib significantly delays or prevents the development of CNS metastases.

Randomization of the Phase III study will be stratified by the presence or absence of CNS metastasis at baseline.

Imaging analysis by consistently used uniform image acquisition technique (MRI scans) will be performed routinely at baseline and at subsequent follow-up assessments along with every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical suspicion of CNS metastasis) in order to achieve an accurate determination of time to CNS progression. This ensures that early brain metastatic lesions are detected and that assessment bias between the two arms is avoided by having regularly scheduled scans.

An independent central radiological review will be performed for all patients and the analysis of time to CNS progression, or response will be based on the data from the independent review. The review will be based on the standard RECIST v1.1 criteria to assess the CNS lesions, and a second independent review on the basis of the RANO criteria.
criteria, which are typically used to assess brain tumors (Wen et al. 2010), will be performed. The assessment will be performed independently from the overall disease progression assessment.

3.3.7 Rationale for PK Sample Collection Schedule
To date, the pharmacokinetics of alectinib have been characterized in chemotherapy-failed, crizotinib-naive patients with NSCLC in Study AF-001JP and in patients who have failed chemotherapy and crizotinib treatment in Study NP28761/AF-002JG and Study NP28673. In order to better understand the pharmacokinetics of alectinib and to further support the development of a robust population PK model for alectinib in order to better understand, identify, and characterize variables which lead to changes in exposure, characterization of alectinib pharmacokinetics will be done in this study. This study will include PK assessment of alectinib in ALK inhibitor treatment-naive patients with ALK-positive advanced NSCLC by collecting trough samples from all patients receiving alectinib. Serial/intensive PK samples will be collected from a subset of patients (10%–15% [at least n = 20] of patients receiving alectinib) to facilitate the PK assessment. The data that will be collected from this study will enable more robust understanding of alectinib pharmacokinetics in the global crizotinib-naive population including investigation and potential identification of sources of variability influencing alectinib pharmacokinetics and/or response to alectinib therapy. Results from PK data collection in this study and analyses of PK data could help support optimal use of alectinib therapy.

3.3.8 Rationale for Biomarker Assessments
Several molecular mechanisms of resistance to crizotinib have been reported in the literature: increased copy number of ALK gene, increased expression of ALK mRNA, secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased copy number, increased phosphorylation, or point mutations) in escape genes such as EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). In order to investigate molecular mechanisms of resistance to ALK inhibitors and ALK mutation status, tumor samples will be collected before treatment and at the time of disease progression with the goal of sequencing nucleic acids. Two types of approaches will be used: 1) targeted sequencing of a panel of genes known to be involved in cancer and 2) unbiased genomic sequencing.

Mutations in cancer genes appearing from drug resistance can be monitored in circulating nucleic acids in plasma (Forshew et al. 2012). Tumor nucleic acids are shed into circulation in amounts that allow direct amplification by polymerase chain reaction and sequencing. Plasma samples will be collected before treatment and at certain timepoints during treatment, to monitor mutations in ALK and other genes involved in resistance to ALK inhibitors. Information from mutated genes in the tumor will be correlated with mutations in plasma DNA.
Determination of ALK positivity will be initially performed by Ventana IHC (see Appendix 8). In addition, the Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. For exploratory purposes, other methods to determine ALK positivity (e.g., reverse transcription-polymerase chain reaction) may also be used. Currently, ALK positivity for fusions can only be determined in tissue samples using assays such as FISH, IHC or PCR. As tissue sampling is difficult and tissue biopsy sample sizes from lung cancer patients are very small, testing of several important biomarkers is challenging. Many NSCLC patients may not have enough tumor tissue available and therefore cannot be tested for some biomarkers such as ALK. Plasma ALK assays analyzing circulating tumor nucleic acids will enable more NSCLC patients to be tested for ALK fusions. Information from plasma ALK assays will be used to investigate the use of circulating tumor nucleic acids from plasma as a surrogate for tumor tissue for diagnostic purposes.

3.3.9 Rationale for PRO Assessments

In the treatment of lung cancer, it is important to both increase survival and palliate symptoms because disease symptoms have negative impacts on HRQoL (Hyde and Hyde 1974; Hopwood and Stephens 1995; Sarna et al. 2008). This is especially true for trials that use PFS as a primary endpoint, where it is important to translate the delay in disease progression into an endpoint that is meaningful to patients.

Pain (chest; arm and shoulder), dyspnea, cough, and fatigue have been regarded as the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC. The BR.21 study (erlotinib vs. chemotherapy in second- or third-line NSCLC) demonstrated that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ-C30 and QLQ-LC13 was consistent with superior PFS, OS, and quality-of-life benefits in the erlotinib arm as compared with the placebo arm (Aaronson et al. 1993; Bergman et al. 1994; Bezjak et al. 2006). Additionally, patients in the crizotinib PROFILE 1005 trial reported clinically significant improvements (by 10 points) in the pain, cough, dyspnea, and fatigue symptom scales seen as early as 2 weeks on treatment (Crinò et al. 2011).

The EORTC QLQ-C30 and QLQ-LC13 were used in the Phase III PROFILE 1007 study (second-line crizotinib vs. chemotherapy). The study reported significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than with chemotherapy ($p<0.001$ for all comparisons, without adjustment for multiple testing). Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. There was also a significantly greater overall improvement from baseline in the global quality of life among patients who received crizotinib treatment than among those who received chemotherapy ($p<0.001$). In all domains measuring function,
except for the domain measuring cognitive function, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Shaw et al. 2013).

Therefore, to assess the quality of life of patients in this trial, PRO data will be collected from patients enrolled in this study using the validated questionnaires EORTC QLQ-C30 and QLQ-LC13.

3.4 OUTCOME MEASURES

3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

- **PFS**, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.

- **ORR**, which is defined as the percentage of patients who attain CR or PR; response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.

- **Time to CNS progression**, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.

- **DOR**, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

- **OS**, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

3.4.2 Safety Outcome Measures

The safety outcome measures for this study are as follows:

- Serious and non-serious adverse events
- Safety laboratory tests values
- Vital signs (blood pressure, heart rate), ECG
- Physical examination
3.4.3 Pharmacokinetic Outcome Measures

The PK outcome measures for this study are as follows:

- Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment. See Appendix 1 and Appendix 2 for PK sampling times.

- Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n=20). See Appendix 1 and Appendix 2 for PK sampling times.

- PK parameters will be determined as appropriate and where data allow:
  The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.

  Non-compartmental analysis (NCA) may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

3.4.4 Patient-Reported Outcome Measures

The PRO measures included for this study are as follows and will be administered to patients every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months:

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post treatment.

For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.
3.4.5 Exploratory Outcome Measures

The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for the purpose of reimbursement
- Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin and SHBG, FSH, and LH, in blood to measure the onset of hypogonadism in adult men
- Results from the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by FISH test
- ALK fusion status in circulating tumor nucleic acids from plasma to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by plasma ALK tests (PCR and/or sequencing) for diagnostic purposes
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors
- ALK mutation status in plasma DNA to monitor efficacy and disease progression

4. MATERIALS AND METHODS

4.1 PATIENTS

The target population is patients with treatment-naive, ALK-positive, non-resectable, locally advanced and metastatic NSCLC.

4.1.1 Inclusion Criteria

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old
- Life expectancy of at least 12 weeks
- ECOG PS of 0–2
- No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIIB not amenable to multimodality treatment) or metastatic (Stage IV) NSCLC
- Adequate hematologic function:
  - Platelet count ≥ 100 × 10^9/L
  - ANC ≥ 1500 cells/μL
  - Hemoglobin ≥ 9.0 g/dL
- Adequate renal function:
  An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m²
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- Measurable disease (by RECIST v1.1) prior to the administration of study treatment
- Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
- For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
- For women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year include tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as condom and cervical cap use) may be combined to achieve a failure rate of < 1% per year. Barrier methods must always be supplemented with the use of a spermicide.
- For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.
4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection

- Liver disease characterized by:
  
  ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  
  OR
  
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  
  OR
  
  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

- National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication

- History of organ transplant

- Co-administration of anti-cancer therapies other than those administered in this study

- Patients with baseline QTc > 470 ms or symptomatic

- Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3)

- Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment. See Section 4.4.2 for further details

- History of hypersensitivity to any of the additives in the alectinib drug formulation (see Section 4.3.1.1 for further details)

- History of hypersensitivity to any of the additives in the crizotinib drug formulation (see Section 4.3.1.2 for further details)

- Pregnant or lactating

- Known HIV positivity or AIDS-related illness
• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study

• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

This is an open-label trial, for which the rationale is described in Section 3.3.4.

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block-stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Central randomization and drug pack number allocations will be performed and managed by an IxRS. Further details will be provided in an IxRS manual.

The independent review of scans for the secondary endpoints of PFS and time to CNS progression on the basis of IRC will be performed in a blinded fashion.

4.3 STUDY TREATMENT

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Alectinib

Alectinib comes in a hard capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, sodium lauryl sulfate (SLS), and magnesium stearate as excipients.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food in the morning and evening.
The formulation contains SLS as an excipient. This excipient is known to be potentially associated with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

For further details, see the alectinib Investigator’s Brochure.

4.3.1.2 Crizotinib
Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (XALKORI® U.S. Package Insert).

4.3.2 Dosage, Administration, and Compliance
4.3.2.1 Alectinib
Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food in the morning and evening.

If a patient misses a dose, it can be taken within 4 hours of the scheduled time. If the time is greater than 4 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

Guidelines for dosage modifications and treatment interruptions or discontinuation due to specified adverse events are provided in Section 5.1.3.

Any overdose or incorrect administration of study drug should be noted on the Study Drug Administration electronic Case Report Form (eCRF). Adverse events associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF.

4.3.2.2 Crizotinib
Crizotinib at 250 mg (one 250-mg capsule) should be administered orally BID with or without food (in the morning and evening).

If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose of crizotinib, the next dose should be taken as scheduled.

If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to
250 mg taken once daily. Guidelines for dosage modification and treatment interruption or discontinuation are provided in Section 5.1.4.

Any overdose or incorrect administration of crizotinib should be noted on the crizotinib Administration eCRF. Adverse events associated with an overdose or incorrect administration of crizotinib should be recorded on the Adverse Event eCRF.

4.3.3 Investigational Medicinal Product Accountability
All investigational medicinal products (IMPs) required for completion of this study (alectinib and crizotinib) will be provided by the Sponsor where required by local health authority regulations. The study site will acknowledge receipt of IMPs and confirm the shipment condition and content. Any damaged shipments will be replaced.

IMPs will either be disposed of at the study site according to the study site’s institutional standard operating procedure or returned to the Sponsor with the appropriate documentation. The site's method of IMP destruction must be agreed to by the Sponsor. The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.

Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the study site should be recorded on the Drug Inventory Log.

4.3.4 Post-Trial Access to Alectinib
The Sponsor will offer post-trial access to the study drug alectinib free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below.

A patient will be eligible to receive study drug after the end of the study if all of the following conditions are met:
- The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being
- There are no appropriate alternative treatments available to the patient
- The patient and his or her doctor comply with and satisfy any legal or regulatory requirements that apply to them

A patient will not be eligible to receive study drug after the end of the study if any of the following conditions are met:
- The study drug is commercially marketed in the patient's country and is reasonably accessible to the patient (e.g., is covered by the patient's insurance or would not otherwise create a financial hardship for the patient)
- The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for ALK-positive NSCLC
4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from screening to the study completion/discontinuation visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

All therapy and/or medication administered to manage adverse events should be recorded on the Adverse Event eCRF.

The medications and/or treatments below are permitted:

- Anticoagulants and antithrombotic agents (i.e., coumadin-derived anticoagulants, unfractionated heparin or low-molecular heparins, aspirin (≤325 mg/day), and clopidogrel.
- Acetaminophen up to 2 g/day
- Gastric pH elevating medications (such as proton pump inhibitors, H2 blockers, or antacids)
- Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients with isolated asymptomatic CNS progression (e.g., new CNS oligometastases).

Caution should be exercised when the following are co-administered with alectinib:

- For medications that are substrates of P-gp transporter or breast cancer resistance protein transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of these transporters. Substrates with a narrow therapeutic index (e.g., methotrexate, digoxin) should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

Caution should be exercised when the following are co-administered with crizotinib:

- Crizotinib has been shown to be a moderate inhibitor of CYP3A. Dose reduction may be needed for co-administered drugs that are predominantly metabolized by
Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3

4.4.2 Prohibited Therapy

Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) is prohibited during the study and for at least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless otherwise specified below. Exceptions to restrictions of the concomitant therapies listed below (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) may be made if the rationale is discussed and documented between the investigator and the Sponsor’s Clinical Pharmacologist.

- Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s wort [Hypericum perforatum]) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drugs (see Appendix 3).

- Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drug (see Appendix 3).

- Any concomitant medications known to affect QT interval duration, including but not limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone, and quinidine, within 2 weeks before the first dose of study drug treatment and while on treatment with study drugs and through the end of the study.
- Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents (other than study drug treatment), ergot derivatives, probenecid, and bile acid-binding resins while on study treatment.

- Systemic chemotherapy.

- Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions or for pain control. If palliative radiation is indicated for bone metastases, palliative radiation may start within 24 hours of the last dose of alectinib, unless, in the judgment of the investigator, patient safety will require a longer washout period prior to palliative therapy. Dosing of alectinib may resume with the resolution of any radiation toxicity to ≤ Grade 1.

- Additional investigational drug (except for during the follow-up period).

The list of medications provided above is not necessarily comprehensive. Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication strongly inhibits or induces CYP3A. In addition, the investigator should contact the Medical Monitor if questions arise regarding medications not listed above.

http://medicine.iupui.edu/clinpharm/ddis/table.aspx (for P450 drug interactions)

4.4.3 Prohibited Food

Use of grapefruit or grapefruit juice should be avoided during the study and for at least 14 days prior to the initiation of study treatment (either alectinib or crizotinib) because it is a potent CYP3A inhibitor and may increase plasma concentration of either alectinib or crizotinib.

4.5 STUDY ASSESSMENTS

See Appendix 1 for the schedule of assessments performed during the study.

4.5.1 Informed Consent Forms and Screening Log

Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site.

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.
4.5.2 Medical History and Demographic Data

Medical history includes a record of clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 28 days prior to the screening visit.

Demographic data will include age, sex, and self-reported race/ethnicity.

4.5.3 Corticosteroid Use for CNS Metastases

For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake should be captured at all tumor assessment visits and compared to the corticosteroid intake at the time of the last disease assessment. The changes will be recorded as Increased, Unchanged, or Decreased. Increases and decreases in corticosteroid intake should be clinically justified. Increases in corticosteroid dose for reasons other than for CNS metastases control do not need to be taken into consideration when making this comparison.

4.5.4 Physical Examinations

A complete physical examination at screening and baseline should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems as well as height and weight. Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.

At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations should be performed. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant abnormalities should be recorded as adverse events on the Adverse Event eCRF.

Note: for patients with known CNS metastases, a neurological examination must be performed at each tumor assessment visit and compared to the neurological examination performed at the time of the last disease assessment. Definition of clear neurological worsening is difficult to describe because progression in the CNS can present in numerous ways. Accordingly, evaluation of neurological function at each disease assessment will be based purely on the investigator’s assessment of the patient’s neurological state compared to the neurological function at the time of the last disease assessment. Neurological status will be recorded as Improved, Stable, or Worsened.

4.5.5 Vital Signs

Vital signs will include measurements of respiratory rate, oxygen saturation, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated position, and temperature.
4.5.6  **ECOG Performance Status**

PS will be measured using the ECOG Performance Status Scale (see Appendix 5). It is recommended, where possible, that a patient’s PS be assessed by the same person throughout the study.

4.5.7  **Tumor and Response Evaluations**

Disease burden must be documented at screening and re-assessed at each subsequent tumor evaluation. Response will be assessed by the investigator on the basis of physical examinations. Clinical lesions will be documented by color photography (with caliper measurement for measurable lesions), computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4). For assessing response in patients with measurable disease, the preferred radiologic tumor response assessment is CT scan with intravenous contrast. If intravenous contrast is contraindicated, a non-contrast-enhanced chest CT scan will be acceptable for chest lesions, and MRI can be used for non-chest lesions. If contrast-enhanced MRI is contraindicated, then non-contrast-enhanced MRI will suffice. Positron emission tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesion as per RECIST v1.1 (see Appendix 4).

The same radiographic procedure used to define measurable disease sites at screening must be used throughout the study (e.g., the same contrast protocol for CT scans). Assessments should be performed by the same evaluator to ensure internal consistency across visits.

CT/MRI scans of chest and abdomen, and MRI scans of the brain should be performed for all patients as described in Schedule of Assessments (see Appendix 1) at screening, then every 8 weeks subsequently until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression and at the post-treatment visit (4 weeks after permanent treatment discontinuation). CT/MRI scans of the neck bone and pelvis should be included if clinically indicated. At the investigator’s discretion, CT/MRI scans may be repeated at any time if PD is suspected.

Note: Brain imaging should be performed using MRI with the following image acquisition requirements.

- Minimum sequences required:
  - Pre-contrast T1, T2/FLAIR
  - Post-contrast T1, with two orthogonal planes (or a volume acquisition) recommended

Patients with known or suspected bone metastases should undergo radionuclide bone scan at screening. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions and do not need to be repeated routinely.
but can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered measurable lesions of the soft tissue component and meet the definition of measurability and should be followed by cross-sectional imaging.

4.5.8 **Laboratory, Biomarker, and Other Biological Sample**

4.5.8.1 **Laboratory Assessments**

Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis of the following:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells])
- Coagulation (PT [or INR], and aPTT)
- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase (GGT); calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone and free testosterone (either by direct measurement or by calculation using albumin and SHBG), FSH, and LH [for male patients only])
- Urinalysis. Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein will be measured by dipstick test.
- Pregnancy test. All women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile will have a serum pregnancy test at screening, within 3 days of dosing. Urine pregnancy tests will be performed anytime during the course of the study, as per investigator’s discretion. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

4.5.8.2 **Pre-Treatment Tumor Samples (Mandatory)**

Mandatory pre-treatment tumor samples will be collected to centrally examine ALK status by Ventana IHC (eligibility criteria) and Vysis FISH. Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred source, but if blocks are not available, unstained slides (ten to fifteen 5-µm slides cut less than 3 months before screening) are also accepted. Remaining tumor blocks will be returned to the sites; slides will not be returned.

For fresh tumor biopsies (guided by ultrasound or CT scan), acceptable methods include core biopsies for lung and liver lesions and bronchoscopic biopsies for lung lesions. The minimum size for the biopsy needle recommended is 20G.
Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by Ventana IHC (Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) for possible companion diagnostic development. Additionally, other ALK assays may be used for testing patient samples to establish performance characteristics of these assays for diagnostic development. Testing may be performed on all screened patients (screen-failed and enrolled). These additional testing data will have no impact on eligibility, and testing will be performed only after eligibility is established for each patient. In addition, local ALK test information, baseline demographic, and disease-related characteristic data for all screened patients may be collected in order to support potential registration of a companion diagnostic assay for alectinib.

The tumor sample may also be tested for the presence of EGFR mutations, if requested by the investigator.

Pre-treatment tumor samples may be used, after proper informed consent is obtained, for genomic sequencing.

For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual.

**4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)**

Pre-treatment tumor samples (preferably formalin-fixed blocks but if not available a minimum of 10-15 unstained 5 µm slides) for ALK testing is a mandatory requirement for this study. Optional additional pre-treatment tumor samples and fresh post-treatment tumor biopsy at disease progression or permanent treatment discontinuation (at the last treatment or post-progression visit) may be collected, with proper informed consent. These samples will be used to help to understand molecular mechanisms of resistance to ALK inhibitors by genomic sequencing. Remaining tumor blocks will be returned to the sites, slides will not be returned.

The remaining mandatory (Section 4.5.8.2) and optional specimens (Section 4.5.8.3) will be destroyed within 5 years after the date of final closure of the clinical database. Other residual tissue material (slides, extracts, etc.) will be destroyed within 5 years after the date of final closure of the clinical database.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of optional tumor biopsies with exploratory purposes may be stopped at any time if the data from the samples collected do not produce useful information.
4.5.8.4 Blood and Plasma Samples

Mandatory plasma samples will be obtained to determine:

- Mutation status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline, at the Visit 3 (Week 16) treatment, and subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for detailed information) until disease progression, and during post-progression on treatment in case of isolated, asymptomatic CNS progression. For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual. These samples will not be taken in countries where regulatory agency or Institutional Review Board (IRB) does not allow genetic testing.

- ALK rearrangement in plasma. This will require 20 mL of blood (2 tubes of 10 mL each) to be collected at baseline.

Mandatory blood samples will be obtained to determine:

- All patients who are randomized in alectinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alectinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Section 4.5.8.4.1).

Optional blood samples will be collected to obtain:

- Plasma. Centrally ALK negative tested patients (by Ventana ALK IHC) who agree to donate 10 mL plasma will be assessed by plasma ALK assays (PCR and/or Sequencing) for the development of a plasma ALK diagnostic test

- A source of healthy tissue for patients who agreed to participate in the optional genomic sequencing assessment. For patients in the crizotinib arm, a 3-mL blood sample will be drawn at baseline. For patients in the alectinib arm, a source of healthy tissue will be used as a portion of the sample for the pharmacogenomics research (see Section 4.5.8.4.1)

- A portion of this blood sample will also be used as a source of healthy tissue for the patients on alectinib treatment who agree to participate in the optional genomic sequencing research.

For biomarkers, a maximum of 43 mL of blood will be collected at baseline (20 mL of blood for plasma purification and determination of mutation status in ALK and other escape genes, 20 mL of blood for plasma purification and detection of ALK rearrangements, and 3 mL blood for pharmacogenomics research. Twenty mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 20 mL will be collected at disease progression (CNS and/or systemic disease progression) for plasma purification, for determination of mutation status in ALK and other escape genes.
Details of sample handling procedures, sample storage and shipment will be described in a separate laboratory manual.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma with exploratory purposes may be stopped at any time if they are deemed not informative.

4.5.8.4.1 Samples for Pharmacogenomic Assessments

One sample (approximately 3 mL of whole blood) will be collected from all patients on alectinib treatment. Samples will be used for the evaluation of genetic polymorphisms of drug metabolic enzymes including, but not limited to, CYP2C9, CYP3A4/5, and UGT1A1, and transporters (e.g., organic anion transporter polypeptide 1B1) and for genetic variants that could contribute to potentially drug-related liver safety assessments (including but not limited to human leukocyte antigen, see Appendix 9 for more details).

For sample handling procedures, storage conditions, and shipment instructions, see the laboratory manual. Only in circumstances where there is concern for collection of this genetic material for above evaluations can this assessment be considered not mandatory as part of study assessments in this study. Results of any analyses from these samples will be reported outside the clinical study report.

4.5.8.5 Samples for Pharmacokinetic Assessments

PK samples will be collected in all patients on alectinib treatment, as indicated in Appendix 1 and Appendix 2 for the analysis of alectinib and its major metabolite(s) (RO5468924, RO5507197, and/or others, if applicable and if appropriate, and if assays are available). Residual samples following PK analysis may be used to evaluate profiling for alectinib metabolite(s).

All trough/pre-dose PK samples should be collected within 2 hours BEFORE the morning doses of study medications.

Serial/intensive samples will be collected in a subset of patients (10%–15% [at least approximately n=20] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

Plasma concentrations for alectinib and its metabolite(s), if applicable, will be measured by specific and validated liquid chromatography tandem mass spectrometry methods.

For each sample, approximately 2 mL of venous blood will be collected for alectinib PK analysis at the timepoints specified in the PK schedule in Appendix 1 and Appendix 2.

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual.
These samples will be destroyed when the final Clinical Study Report is complete.

On the basis of continuous analysis of the data in this study and other studies, any sample type collection may be stopped at any time if the data from the samples collected do not produce useful information or at the discretion of the Sponsor.

4.5.9 Electrocardiograms

An ECG will be recorded at specified timepoints as outlined in the schedule of assessments (Appendix 1) at screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), and at the last treatment visit and as clinically indicated throughout the study. All ECG recordings must be performed using a standard high-quality, high-fidelity digital electrocardiograph machine equipped with computer-based interval measurements. All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug administration) as well as prior to meals. Circumstances that may induce changes in heart rate, including environmental distractions (e.g., television, radio, conversation), should be avoided during the pre-ECG resting period and during ECG recording.

Patients must have been in a supine or semi-supine position for at least 5 minutes prior to the recording being taken. The same recording position (supine or semi-supine) and the same equipment should be used for each patient throughout the study. The ECG printout must be (1) reviewed by a medically qualified member of the study team at the site, (2) annotated to indicate any clinical finding, and (3) dated and signed by this person and filed in the patient notes. ECG parameters will be entered on the ECG eCRF. The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula (QTcF). In the event that the ECG machine does not directly provide results for RR and/or QTcF, these parameters can be derived using the formulae provided in Appendix 10.

If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5. Management of QT interval prolongation should be done according to guidance provided in Section 5.1.3.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory. Guidance for abnormal ECG results (QT prolongation) is provided in Table 2.

4.5.10 Patient-Reported Outcomes

PROs (EORTC QLQ-C30, QLQ-L13, and EQ-5D) will be collected to more fully characterize the clinical profile of alectinib. The instruments will be translated as required in the local language. To ensure instrument validity and that data standards meet health authority requirements, the PROs scheduled for administration during a clinic visit (EORTC QLQ-C30, QLQ-L13, and EQ-5D) should be completed prior to the performance of non-PRO assessments and the administration of study treatment.
Patients will use an ePRO device to capture PRO data and maintain a diary of daily drug intake (crizotinib arm) / drug intake with food (alectinib arm). The ePRO device and instructions for completing the PRO questionnaires and diaries electronically will be provided by the investigator staff. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be accessed by appropriate study personnel securely via the Internet.

4.5.11 Samples for Roche Clinical Repository

4.5.11.1 Overview of the Roche Clinical Repository

The Roche Clinical Repository (RCR) is a centrally administered group of facilities used for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.

Specimens for the RCR will be collected from patients who give specific consent to participate in optional research. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

4.5.11.2 Approval by the Institutional Review Board or Ethics Committee

Collection and submission of biological samples to the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site’s IRB or Ethics Committee (EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol (Section 4.5.11) will not be applicable at that site.

4.5.11.3 Sample Collection

For RCR purposes, 10 mL of blood will be collected. Any remaining tissue samples from study-related or non-study related procedures that are performed during the study may also be collected for RCR purposes. For all samples, date of consent should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.
RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be subject to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

4.5.11.4 Confidentiality

Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure database system. Access to the linking key is restricted to authorized individuals and is monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche’s Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

4.5.11.5 Consent to Participate in the Roche Clinical Repository

The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the
objectives, methods, and potential hazards of participation in the RCR. Patients will be
told that they are free to refuse to participate and may withdraw their specimens at any
time and for any reason during the storage period. A separate, specific signature will be
required to document a patient's agreement to provide optional RCR specimens.
Patients who decline to participate will not provide a separate signature.

The investigator should document whether the patient has given consent to participate
by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's
specimens and data will continue to be used as part of the RCR research.

4.5.11.6 Withdrawal from the Roche Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their
specimens from the RCR at any time for any reason. If a patient wishes to withdraw
consent to the testing of his or her specimens, the investigator must inform the Medical
Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal
Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research
Sample Withdrawal of Informed Consent eCRF. The patient will be provided with
instructions on how to withdraw consent after the trial is closed. A patient's withdrawal
from Study BO28984 does not, by itself, constitute withdrawal of specimens from the
RCR. Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from
Study BO28984.

4.5.11.7 Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a
quality-controlled, auditable, and appropriately validated laboratory information
management system, to ensure compliance with data confidentiality as well as
adherence to authorized use of specimens as specified in this protocol and in the
Informed Consent Form. Roche monitors and auditors will have direct access to
appropriate parts of records relating to patient participation in the RCR for the purposes
of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC
review, and health authority inspections by providing direct access to source data and
documents related to the RCR samples.

4.6 PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION
4.6.1 Patient Discontinuation
Patients have the right to voluntarily withdraw from the study at any time for any reason.
In addition, the investigator has the right to withdraw a patient from the study at any time.
Reasons for withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize
  the patient's safety if he or she continues in the study
• Investigator or Sponsor determines it is in the best interest of the patient

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. Patients who withdraw consent for treatment should continue to be followed for tumor assessments until progression and for OS, provided they have not withdrawn consent for the study. However, patients will not be followed for any reason after consent for the study has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study Treatment Discontinuation

Patients must discontinue study treatment if they experience any of the following:

• Pregnancy
• Inability to tolerate study medication on the basis of the investigator judgment

See guidelines for managing adverse events and for comprehensive guidance on study drug discontinuation in Section 5.1.3.

Patients who discontinue study drug prematurely will be asked to return to the clinic for tumor assessments until progression as per study schedule (see Appendix 1).

The primary reason for premature study drug discontinuation should be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.3 Study and Site Discontinuation

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

• The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
• Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

• Excessively slow recruitment
• Poor protocol adherence
• Inaccurate or incomplete data recording
• Non-compliance with the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice
• No study activity (i.e., all patients have completed and all obligations have been fulfilled)
5. ASSESSMENT OF SAFETY

5.1 SAFETY PLAN

5.1.1 Adverse Events Collection

After informed consent has been obtained but prior to initiation of study treatment, only serious adverse events (SAEs) caused by a protocol-mandated intervention should be reported (e.g., SAEs related to invasive procedures such as biopsies). After the first dose of study treatment and up to the 4-week follow-up after the last dose of study treatment, all adverse events (AEs) regardless of seriousness, causality assessment, or actions taken reported by the investigator or designated medically qualified study site personnel will be collected as described below. At each visit, the investigator or designated medically qualified study site personnel will ask the patient if any untoward medical event occurred since the last visit. It is the investigator’s responsibility to record all AEs in the source patient’s medical records.

All SAEs and non-SAEs will be reported on the standard AE/SAE eCRF.

5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data

Events described in Section 5.1.2.1 through Section 5.1.2.10 will be closely monitored and represent selected AEs for this study.

A more detailed safety profile of alectinib is provided in the alectinib Investigator’s Brochure.

5.1.2.1 Interstitial Lung Disease

TKIs, including ALK inhibitor crizotinib, have been associated with the occurrence of treatment-related ILD (including fatalities). See Section 5.1.3 for management and follow-up.

5.1.2.2 Hepatobiliary Laboratory Test Elevations

Hepatobiliary findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. The findings were at or close to clinically relevant exposures. Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT and liver weight, vacuolation/degeneration/necrosis of bile duct epithelium, inflammatory cell infiltration in Glisson’s sheath, enlargement/focal necrosis of hepatocytes, and enlargement of Kupffer cells.

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved.
In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and fatal cases of hepatic failure have been reported.

See Section 5.1.3 for management and follow-up.

5.1.2.3 Hematologic Abnormalities
Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. Findings were at or close to clinically relevant exposures. Hematologic adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have been observed with most TKIs, including ALK inhibitor crizotinib.

Hematologic abnormalities of neutropenia, leukopenia, thrombocytopenia, and anemia have been reported with alectinib administration. Neutrophil counts generally decreased early and remained stable thereafter.

See Section 5.1.3 for management and follow-up.

5.1.2.4 Gastrointestinal Disorders
GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported with alectinib. Similar GI disorders have been observed with other TKIs, including ALK inhibitor crizotinib.

SLS (sodium lauryl sulfate, syn. sodium dodecyl sulfate) is a surfactant excipient in the clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical ingredient). This excipient is a known GI irritant and may be associated with GI AEs including nausea, vomiting, diarrhea, and abdominal pain. Of note, GI tract toxicity as the safety determinant of SLS is not because of systemic toxicity, but a consequence of local irritation to the GI tract. In general, when mixed with diet, higher levels of SLS—a known GI tract mucosal irritant—are tolerated versus gavage administrations.

See Section 5.1.3 for management and follow-up.

5.1.2.5 Skin Disorders
Results of an in vitro phototoxicity study indicated that alectinib may have phototoxic potential.

Skin rash has been reported with majority of TKIs including those targeting the ALK receptor (Hartmann et al. 2009).

Cases of skin rash and photosensitivity have been reported with alectinib and were generally Grade 1 or 2.

See Section 5.1.3 for management and follow-up.
5.1.2.6 Vision Disorders

In the rat quantitative whole body autoradiography study, tissue radioactivity disappeared over time, following a time course comparable to that of plasma radioactivity, except for melanin-containing tissues such as uveal tract of eyes, which had much higher and more sustained exposure in pigmented rats. This is consistent with what is commonly observed for lipophilic basic drugs.

Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and vitreous floaters, have been reported with several TKIs, including ALK inhibitors (crizotinib) (Shaw et al. 2013).

Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and vision impaired, have been reported with alectinib and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.7 Edema

Most TKIs, including ALK inhibitor crizotinib, have been associated with edema. Events of edema have been reported with alectinib, mostly Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.8 Cardiovascular Effects

QT interval prolongation appears to be an off-target class effect of some TKIs, including ALK inhibitor crizotinib (Shah et al. 2013; XALKORI® U.S. Package Insert). Many TKIs have been associated with bradycardia and hypertension.

In the in vitro study of the cardiovascular system, alectinib inhibited the hERG current (IC\text{20}: 58 ng/mL; IC\text{50}: 217 ng/mL). Because plasma protein binding by alectinib is $\geq$ 99%, the plasma concentration of alectinib required to induce the same inhibition in vivo would be 100 or more times greater than the concentration required in vitro. In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration [C\text{max}]: 279 ng/mL).

In a preliminary non- Good Laboratory Practice telemetry study in conscious cynomolgus monkeys, a slight hypotensive effect (approximately 10 mmHg) was seen when alectinib was administered at 20 and 60 mg/kg orally with no effects on ECG or heart rate. The hypotensive effect of alectinib observed in monkeys was considered to likely be caused by vasodilatation induced by L-type Ca\text{2+} channel inhibition.

Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse
events, as well as decreases in heart rate based on ECG and pulse measurements, have also been reported.

In case of bradycardia, concomitant medications must be evaluated to identify those that are known to cause bradycardia, as well as anti-hypertensive medications; and discontinuation or dose reduction of these concomitant medications must be considered.

See Section 5.1.3 for management and follow-up.

5.1.2.9 Abnormal Renal Function
In the 2-week non-human primate study at 60 mg/kg, an increase in creatinine was observed but no changes were observed in histopathology. In all other non-human primate studies, no changes in creatinine were observed.

Serum creatinine increases have been reported with alectinib treatment and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.10 Muscular Adverse Events and CPK Elevations
Postmarketing experience with some TKIs includes reports of myopathy and rhabdomyolysis (Hohenegger 2012).

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment.

See Section 5.1.3 for management and follow-up and Table 2 for guidelines for managing AEs.
### 5.1.3 Management of Specific Adverse Events with Alectinib

#### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Interstitial lung disease            | - Patients should be monitored for pulmonary symptoms indicative of pneumonitis.  
                                         - Study drug should be permanently discontinued in patients diagnosed with interstitial lung disease.                                                                                               |
| Hepatobiliary AE and laboratory test elevations | Liver test laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4 and Section 5.3.5.6.  
                                         - If ALT or AST $>3 \times$ baseline, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry about symptoms. If upon repeat testing the transaminases remain $>3 \times$ baseline, but are not $>5 \times$ baseline or not accompanied with bilirubin increases or do not match any other rule for permanent discontinuation, then monitoring can continue as per investigator judgment, and dose modification is not necessary.  
                                         - At any time during the study treatment, if symptoms compatible with liver injury are observed, liver enzymes should be measured as soon as possible.  
                                         - Study drug treatment has to be permanently discontinued if any of the following occurs:  
                                           First observation of ALT or AST $>8 \times$ ULN  
                                           ALT or AST $>5 \times$ ULN for more than 2 weeks  
                                           First observation of ALT or AST $>3 \times$ ULN and total bilirubin $>2 \times$ ULN  
                                           First observation of ALT or AST $>3 \times$ ULN and the appearance of jaundice or signs of hepatic dysfunction or other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia [$>5\%$]).  
                                         - Following study drug discontinuation, weekly monitoring of laboratory values should continue until the abnormal values have normalized to pre-treatment levels and/or an adequate explanation of the abnormal value is found.  
                                         - Resumption of study drug is not allowed in patients discontinuing because of any of the above criteria. |
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Hematologic abnormalities     | Hematologic laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
- In case of hematologic toxicity: Grade 4 (neutropenia, thrombocytopenia):  
  Give supportive treatment per treating physician.  
  First episode: Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL. Upon resumption, reduce alectinib dose by 150 mg (1 capsule) BID (450 mg BID).  
  Second episode: Reduce dose by another 150 mg (1 capsule) BID (300 mg BID).  
  Third episode: Permanently discontinue alectinib.  
- In case of hematologic toxicity: Grade 3 (neutropenia, thrombocytopenia):  
  Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL.  
  Give supportive treatment per treating physician.  
  If improvement to Grade ≤ 2 does not occur within 3 weeks, permanently discontinue alectinib.  
- In case of hematologic toxicity: Grade 1 or 2 (neutropenia, thrombocytopenia):  
  No action is required.                                                                                                                                                                                                                                                                    |
| Gastrointestinal tract AEs    | The events are expected to be minimized by taking the study drug with meal. In case GI events occur, appropriate measures should be taken in accordance with local clinical practice guidelines. If GI toxicities are observed and not tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower.                                                                                      |
| (e.g., nausea, vomiting, diarrhea) |                                                                                                                                                                                                                                                                                                                                                      |
| Skin disorder AEs            | Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 5 days after study drug discontinuation. Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least SPF > 30 to help protect against potential sunburn |
| (e.g., phototoxicity, rash)  |                                                                                                                                                                                                                                                                                                                                                      |
| Vision disorders             | Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice guidelines, if vision disorders persist or worsen in severity, and to advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder.                                                                 |
| Edema                        | Physical examinations will be performed routinely in clinical trials. In case edema events occur, appropriate measures should be taken in accordance with local clinical practice guidelines                                                                                                         |
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>QT prolongation</td>
<td><strong>Grade 1 (450–480 ms):</strong> no action required</td>
</tr>
<tr>
<td></td>
<td><strong>Grade 2 (481–500 ms):</strong></td>
</tr>
<tr>
<td></td>
<td>First and second episodes: Continue study medication and monitoring</td>
</tr>
<tr>
<td></td>
<td>Third episode: Decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID)</td>
</tr>
<tr>
<td></td>
<td><strong>Grade 3 (≥501 ms on at least two separate ECGs):</strong></td>
</tr>
<tr>
<td></td>
<td>Temporarily interrupt alectinib and refer patient to a cardiologist</td>
</tr>
<tr>
<td></td>
<td>First episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (450 mg BID)</td>
</tr>
<tr>
<td></td>
<td>Second episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (300 mg BID)</td>
</tr>
<tr>
<td></td>
<td>Third episode: Permanently discontinue alectinib</td>
</tr>
<tr>
<td></td>
<td><strong>Grade 4 (≥501 ms or &gt;60 ms change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia):</strong></td>
</tr>
<tr>
<td></td>
<td>Discontinue alectinib permanently and admit patient into the hospital for monitoring</td>
</tr>
<tr>
<td>Abnormal kidney function AEs</td>
<td>Kidney function laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</td>
</tr>
<tr>
<td></td>
<td>• If, at any time during the study treatment, eGFR decreases by &gt;50% of the baseline visit value, the patient has to be carefully monitored. All of the underlying factors that may have acutely impacted serum creatinine levels need to be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.).</td>
</tr>
<tr>
<td></td>
<td>• Any eGFR decrease by &gt;50% of the baseline visit value requires repeat testing.</td>
</tr>
<tr>
<td></td>
<td>If, at the repeat test, the eGFR decrease is still &gt;50% of the baseline visit value, the treatment with alectinib should be interrupted.</td>
</tr>
<tr>
<td></td>
<td>• Alectinib treatment may be resumed with caution if the eGFR value has increased to approximately the baseline visit value.</td>
</tr>
</tbody>
</table>
### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscular AEs and/or CPK elevations</td>
<td>CPK laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</td>
</tr>
<tr>
<td></td>
<td>• Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms.</td>
</tr>
<tr>
<td></td>
<td>• At the first occurrence of any of asymptomatic CPK values (&gt;10 × ULN, symptomatic CPK &gt; 5 × ULN, or in the presence of severe muscular symptoms with CPK &gt; ULN but ≤ 5 × ULN) at any time during the study treatment, the patient requires monitoring of the CPK values until they are normalized to pre-treatment levels or a reasonable explanation for the CPK elevation and the symptoms is established.</td>
</tr>
</tbody>
</table>
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other AEs (including bradycardia) or laboratory abnormalities:</td>
<td></td>
</tr>
<tr>
<td>• Grade 3 or 4:</td>
<td>Temporarily interrupt alectinib for a maximum of 3 weeks. If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib. First episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by another 150 mg (1 capsule) BID (300 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 2 (except any symptoms and signs that can be corrected with supportive care):</td>
<td>Temporarily interrupt alectinib and resume if recovering to Grade ≤ 1 or baseline if clinically indicated. First episode: If improvement to Grade ≤ 1 or baseline within 10 days, continue same dose of alectinib. If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID when resuming treatment (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID or 300 mg BID if after first episode dose was reduced to 450 mg BID). If improvement occurs after 10 days, decrease the current dose of alectinib by 300 mg (2 capsules) when resuming treatment (300 mg BID or 150 mg BID if after first episode dose was reduced to 450 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 1: no action required</td>
<td></td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate.

Note: Diarrhea, nausea, and vomiting should be handled with best supportive care first before considering dose modification. Preexisting pleural effusion will not be considered as an adverse event.

### 5.1.4 Safety of Crizotinib and Management of Adverse Events

Dosing interruption and/or dose reduction may be required on the basis of individual safety and tolerability. If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily on the basis of individual safety and tolerability (XALKORI® U.S. Package Insert; Crizotinib SmPC). Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Table 3 and Table 4.

**Alectinib—F. Hoffmann-La Roche Ltd**

Protocol BO28984, Version 3
<table>
<thead>
<tr>
<th>CTCAE&lt;sup&gt;a&lt;/sup&gt; Grade</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events

<sup>b</sup> In case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of a third episode of Grade 4 hematologic toxicity.
### Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT or AST elevation &gt; 5 × ULN with total bilirubin ≤ 1.5 × ULN</td>
<td>Withhold until recovery to baseline or ≤ 3 × ULN, then resume at reduced dose.</td>
</tr>
<tr>
<td>Crizotinib must be permanently discontinued in case of recurrence.</td>
<td></td>
</tr>
<tr>
<td>ALT or AST elevation &gt; 3 × ULN with concurrent total bilirubin elevation &gt; 1.5 × ULN (in the absence of cholestasis or hemolysis)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Any grade drug-related ILD/pneumonitis</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>QTc 5 &gt; 500 ms on at least 2 separate ECGs</td>
<td>Withhold until recovery to baseline or &lt; 481 ms, then resume at reduced dose.</td>
</tr>
<tr>
<td>Crizotinib must be permanently discontinued in case of recurrence (i.e., QTc &gt; 5.5 500 ms on at least 2 separate ECGs).</td>
<td></td>
</tr>
<tr>
<td>QTc &gt; 500 ms or ≥ 60 ms change from baseline with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt; 60 bpm, symptomatic, may be severe and medically significant, medical intervention indicated)</td>
<td>Withhold until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm. Evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If a contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume crizotinib at previous dose upon recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medication is identified but not discontinued or its dose was not modified, resume crizotinib at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm. Permanently discontinue if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at 250 mg once daily upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
</tbody>
</table>
Gastrointestinal events were commonly reported with crizotinib in clinical trials. Nausea, diarrhea, vomiting, and constipation were the most commonly reported gastrointestinal events and were primarily Grade 1 in severity. Supportive care for gastrointestinal events may include standard antiemetic and/or antidiarrheal or laxative medicinal products. In clinical studies with crizotinib, events of gastrointestinal perforations were reported (XALKORI® U.S. Package Insert; Crizotinib SmPC).

Blood counts and liver function tests including ALT, AST, and total bilirubin should be monitored as per local prescribing information for crizotinib.

See local prescribing information for further crizotinib safety information.

### 5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest, performing protocol-specified safety laboratory assessments, measuring protocol-specified vital signs, and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 5.4.

#### 5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation where a patient is administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition).
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug
- AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor)

An SAE is any AE that meets any of the following criteria:

- Is fatal (i.e., the AE actually causes or leads to death)
- Is life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate risk of death)
  
  This does not include any AE that had it occurred in a more severe form or was allowed to continue might have caused death.
- Requires or prolongs inpatient hospitalization (see Section 5.3.5.9)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient’s ability to conduct normal life functions)
- Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- Is a significant medical event in the investigator’s judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the eCRF.

SAEs are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions).

5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)

Non-SAEs of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). AEs of special interest for this study are the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law (see Section 5.3.5.6)
5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4 - 5.6. For each AE recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient’s medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting SAEs).

After initiation of study drug, all AEs will be reported until 4 weeks after the last dose of study drug. After this period, the investigator should report any SAEs that are believed to be related to study drug treatment (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all patient evaluation timepoints. Examples of non-directive questions include the following:

- "How have you felt since your last clinic visit?"
- "Have you had any new or changed health problems since you were last here?"

5.3.3 Assessment of Severity of Adverse Events

The AE severity grading scale for the NCI CTCAE (v4.0) will be used for assessing AE severity. Table 5 will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.
Table 5  Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE

<table>
<thead>
<tr>
<th>Grade</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living(^a)</td>
</tr>
<tr>
<td>3</td>
<td>Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living(^b,c)</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences or urgent intervention indicated(^d)</td>
</tr>
<tr>
<td>5</td>
<td>Death related to adverse event(^d)</td>
</tr>
</tbody>
</table>

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.

Note: On the basis of the most recent version of NCI CTCAE (v4.0), which can be found at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

\(^a\) Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

\(^b\) Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one's self, using the toilet, and taking medications, as performed by patients who are not bedridden.

\(^c\) If an event is assessed as a "significant medical event," it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

\(^d\) Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

5.3.4  Assessment of Causality of Adverse Events

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (as applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event
5.3.5  **Procedures for Recording Adverse Events**

Investigators should use correct medical terminology and concepts when recording AEs on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one AE term should be recorded in the event field on the Adverse Event eCRF.

**5.3.5.1  Diagnosis Versus Signs and Symptoms**

A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

**5.3.5.2  Adverse Events that are Secondary to Other Events**

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event on the eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

**5.3.5.3  Persistent or Recurrent Adverse Events**

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported. If a persistent AE becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes
serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event eCRF should be updated by changing the event from "non-serious" to "serious," providing the date that the event became serious, and completing all data fields related to SAEs.

A recurrent AE is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Is clinically significant in the investigator’s judgment

Note: For oncology trials, certain abnormal values may not qualify as AEs.

It is the investigator's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., ALP and bilirubin 5 times the ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent AEs).
5.3.5.5 Abnormal Vital Sign Values

Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

• Is accompanied by clinical symptoms
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
• Results in a medical intervention or a change in concomitant therapy
• Is clinically significant in the investigator’s judgment

It is the investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded one on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent adverse events).

5.3.5.6 Abnormal Liver Function Tests

The finding of an elevated ALT or AST (>3 × baseline value) in combination with either an elevated total bilirubin (>2 × ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, investigators must report as an AE the occurrence of either of the following:

• Treatment-emergent ALT or AST >3 × baseline value in combination with total bilirubin >2 × ULN (of which ≥35% is direct bilirubin)
• Treatment-emergent ALT or AST >3 × baseline value in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or a non-SAE of special interest (see Section 5.4.2).

5.3.5.7 Deaths

For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-specified AE reporting period (see Section 5.3.1) that are attributed by the investigator solely to progression of NSCLC should be recorded only on the Study Completion/Early Discontinuation eCRF. All other on-study deaths, regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and
immediately reported to the Sponsor (see Section 5.4.2). An independent monitoring committee will monitor the frequency of deaths from all causes.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. The term "sudden death" should be used only for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, "unexplained death" should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), "unexplained death" should be replaced by the established cause of death.

During survival follow-up, deaths attributed to progression of NSCLC should be recorded only on the Survival eCRF.

5.3.5.8 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not be recorded as AEs. These data will be captured as efficacy assessment data only. In most cases, the expected pattern of progression will be based on RECIST criteria v1.1 (Appendix 4). In rare cases, the determination of clinical progression will be based on symptomatic deterioration. However, every effort should be made to document progression using objective criteria. If there is any uncertainty as to whether an event is due to disease progression, it should be reported as an AE.

5.3.5.10 Hospitalization or Prolonged Hospitalization
Any AE that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 5.2.2), except as outlined below.
The following hospitalization scenarios are not considered to be AEs:

- Hospitalization for respite care
- Planned hospitalization required by the protocol
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:
  
  The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease.
  
  The patient has not experienced an AE.
- Hospitalization due solely to progression of the underlying cancer

5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration

An overdose is the accidental or intentional use of a drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE. All AEs associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF. If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

AE reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. However, if any PRO responses suggestive of a possible AE are identified during site review of the PRO data, the investigator will determine whether the criteria for an AE have been met and, if so, will report the event on the Adverse Event eCRF.

5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study

If an AE inadvertently occurs in an individual not enrolled in the study, the Adverse Event Form provided to investigators should be completed and submitted to Roche or its designee, either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- SAEs
• Non-SAEs of special interest
• Pregnancies

The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:
• New signs or symptoms or a change in the diagnosis
• Significant new diagnostic test results
• Change in causality based on new information
• Change in the event’s outcome, including recovery
• Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts

Medical Monitor (Roche Medical Responsible) Contact Information

To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the Roche Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Roche Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk as well as Medical Monitor contact information will be distributed to all investigators.

This list can be generated using contact numbers found at the following link:

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest

5.4.2.1 Events That Occur Prior to Study Drug Initiation

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4.2.2 Events That Occur After Study Drug Initiation

After initiation of study drug, SAEs and non-SAEs of special interest will be reported until 4 weeks after the last dose of study drug. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) system.
A report will be generated and sent to Roche Safety Risk Management by the EDC system.

In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

Instructions for reporting post-study AEs are provided in Section 5.6.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. A pregnancy report will automatically be generated and sent to Roche Safety Risk Management. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In the event that the EDC system is unavailable, the Clinical Trial Pregnancy Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3.2 Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the...
Pregnancy Report eCRF with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

In the event that the EDC system is unavailable, follow reporting instructions provided in Section 5.4.3.1.

5.4.3.3 Abortions
Any abortion should be classified as an SAE (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study drug or the female partner of a male patient exposed to study drug should be classified as an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.5 FOLLOW-UP OF PATIENTS AFTER Adverse EVENTS
5.5.1 Investigator Follow-Up
The investigator should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented on the Adverse Event eCRF and in the patient’s medical record to facilitate source data verification.

All pregnancies reported during the study should be followed until pregnancy outcome. If the EDC system is not available at the time of pregnancy outcome, follow reporting instructions provided in Section 5.4.3.1.

5.5.2 Sponsor Follow-Up
For SAEs, non-SAEs of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.
5.6 POST-STUDY ADVERSE EVENTS

The Sponsor should be notified if the investigator becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug), if the event is believed to be related to study drug treatment.

The investigator should report these events directly to Roche or its designee, either by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number or email address provided to investigators.

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all SAEs and non-SAEs of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single AE cases, the Sponsor will assess the expectedness of these events using the following reference documents:

- Alectinib Investigator's Brochure
- Local prescribing information for crizotinib

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis population for efficacy is the intent-to-treat (ITT) population defined as all randomized patients. Patients will be assigned to the treatment group to which they were randomized.

The primary analysis population for safety is the Safety Analysis Population (SAP) defined as all patients who received at least one dose of study medication. Patients will be assigned to treatment groups as treated, and all patients who received any dose of alectinib will be included in the alectinib treatment arm.

A secondary analysis population for efficacy and safety is the FISH Positive Population (FPP). For efficacy, this is defined as all patients in the ITT population who were ALK-positive using the Vysis FISH assay. Patients will be assigned to the treatment group to which they were randomized. For safety, this is defined as all patients in the
SAP who were ALK-positive using the Vysis FISH assay. Patients will be assigned to treatment groups as treated. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population and the same prespecified testing strategy of secondary endpoints defined in Section 6.4.2 will be applied.

The final analysis of the primary endpoint of PFS will occur when 170 PFS events have occurred, on the basis of the investigators’ assessments. On the basis of the assumptions outlined in Section 6.1, this is estimated to occur approximately 33 months after the first patient has been enrolled. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Hypothesis tests will be two-sided with a significance level of 5% unless otherwise indicated.

The baseline value of any variable will be defined as the last available value recorded prior to the first administration of alectinib or crizotinib.

Further details of all analyses will be provided in the Statistical Analysis Plan.

6.1 DETERMINATION OF SAMPLE SIZE

The focus of this clinical trial is hypothesis testing (Section 6.4.1), and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. A HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.
In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 24 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size (N=286), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude. At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 106 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.

A follow-up analysis will be performed based on the FPP. This will occur once 170 PFS events have occurred in the FPP to ensure 80% power of the log-rank test assuming a hazard ratio of 0.65 in this sub-population. Based on a potential discrepancy/technical failure rate of 10% between the Ventana IHC assay and the Vysis FISH assay, 257 patients would be eligible for the FPP analysis, which is estimated to occur approximately 35 months after the first patient has been enrolled (i.e., 2 months after the primary IHC analysis) based on the above assumptions.

6.2 SUMMARIES OF CONDUCT OF STUDY

Study enrollment, study treatment administration, reasons for discontinuation from study treatment, and reasons for study termination will be summarized by treatment arm for all...
randomized patients. Violations of inclusion and exclusion criteria, on the basis of information captured on the eCRF, will be reported and summarized by treatment arm.

6.3 SUMMARIES OF TREATMENT GROUP COMPARABILITY

Summaries of treatment group comparability will be based on the ITT population.

Demographic, baseline disease characteristics and lung cancer history will be summarized by treatment arm for all randomized patients, including the randomization stratification factors. Descriptive baseline summaries of continuous data will present the group mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequency and percentages.

Previous and concomitant cancer therapy will also be summarized, as well as anti-cancer subsequent therapy. Previous and concurrent diseases and medications will also be summarized.

6.4 EFFICACY ANALYSES

The primary population for all primary and secondary efficacy analyses will be the ITT population.

6.4.1 Primary Efficacy Endpoint

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an
estimate of the treatment effect expressed as a HR (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[
\text{H}_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)}
\]
\[
\text{versus}
\]
\[
\text{H}_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)}
\]

where SDF denotes the survival distribution function of the parameter PFS.

### 6.4.2 Secondary Efficacy Endpoints

If the primary endpoint of PFS is statistically significant at a two-sided 5% significance level, the following secondary endpoints will be tested in the following sequential order, each at a two-sided 5% significance level:

- PFS by IRC
- Time to CNS progression
- ORR
- OS

**PFS by IRC**

An analysis of PFS on the basis of the IRC assessments will be performed using the same methodology as specified for PFS on the basis of investigator assessment.

**Time to CNS Progression**

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression. An independent central radiological review will be performed for all patients, and the analysis of CNS progression or response will be on the basis of the data from the independent review. All patients will be included in the analysis regardless of their baseline status of CNS metastases. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of preexisting baseline CNS lesions. On the basis of RECIST v1.1, this is defined as a new post-baseline CNS/brain lesion(s) and/or an increase of ≥20% in the sum of longest diameters of the measurable baseline CNS lesions compared to nadir and/or unequivocal progression of non-measurable baseline CNS lesions.

In order to account for the competing risks inherent in such an analysis, HRs, including statistical inference on the basis of a two-sided log-rank test, to compare the risk of CNS progression between the alectinib and crizotinib treatment groups, will be computed on the basis of cause-specific hazard functions.
The probability of CNS progression, non-CNS progression, and death will each be estimated using cumulative incidence functions.

For descriptive purposes, estimates of the CNS progression rates over time with 95% CIs on the basis of cumulative incidence functions will be presented. A Gray’s test to compare the risk of CNS progression between alectinib and crizotinib will also be performed as a supportive analysis.

An exploratory analysis of CNS Time to Progression on the basis of RANO criteria will also be performed on the basis of the IRC assessments.

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

Objective Response Rate

ORR, on the basis of investigator assessment, is defined as the percentage of patients who attain a CR or PR. Per RECIST v1.1, confirmation of objective response is not required for this secondary endpoint. Patients without a post-baseline tumor assessment will be considered non-responders, as will patients with a best overall response of stable disease (SD), PD, or NE (not evaluable).

An estimate of ORR and its two-sided 95% CI will be calculated using the Clopper-Pearson method for each treatment arm. Response rates in the treatment groups will be compared using a stratified Mantel-Haenszel test on the basis of the randomization stratification factors. The difference in ORR between the two treatment arms will be presented together with a two-sided 95% CI on the basis of a normal approximation to the binomial distribution.

DOR

For patients who have experienced an objective response (CR or PR) during the study as assessed by the investigator, DOR is defined as the duration from the first tumor assessment that supports the patient’s objective response (CR or PR, whichever is first recorded) to first documented disease progression or death due to any causes, whichever occurred first. Patients who have not progressed or died at the time of analysis will be censored at the last tumor assessment date. Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing will not be performed. DOR will be estimated using Kaplan-Meier methodology and a HR on the basis of a Cox proportional regression model will be calculated.
Overall Survival

OS is defined as the time from the date of randomization to the date of death due to any cause. Patients who are not reported as having died at the time of analysis will be censored at the date when they were last known to be alive. Patients who do not have post-baseline information will be censored at the date of randomization. OS will be analyzed using the same methodology as specified for the primary endpoint. A survival follow-up will be performed based on more mature data.

6.4.2.1 Sensitivity Analyses

The following sensitivity analyses will be performed on the primary endpoint of PFS:

- The effect of non-protocol-specified anti-cancer therapy prior to progression will be assessed by censoring patients at the last adequate tumor assessment prior to the start of non-protocol-specified anti-cancer therapy.
- The effect of missing tumor assessments will be assessed if the number of missing assessments in either arm is >5%. For patients with progression determined following one or more missing tumor assessments, the progression will be backdated to the first missing tumor assessment.
- The effect of loss to follow-up will be assessed depending on the number of patients who are lost to follow-up. If >5% of patients are lost to follow-up for PFS in either treatment arm, a “worst-case” analysis will be performed in which patients who are lost to follow-up will be considered to have progressed at the last date they were known to be progression-free.

6.4.2.2 Subgroup Analyses

Subgroup analyses of PFS will be performed for patients with baseline CNS metastases and for patients without baseline CNS metastases. In addition, a subgroup analysis of Time to CNS Progression will be performed, excluding patients who had pre-treatment radiation therapy for CNS lesions.

All other subgroup analyses will be specified in the SAP.

6.5 SAFETY ANALYSES

The primary population for all safety analyses will be the SAP as defined in Section 6.

All safety parameters will be summarized in tables to evaluate and compare the safety profile of patients treated with alectinib versus crizotinib in terms of:

- Adverse events including adverse events leading to dose modifications or interruptions, study drug withdrawal, and death
- Severe, serious, and selected adverse events
- Deaths
- Laboratory parameters and abnormalities
- Vital signs
- ECGs
- ECOG PS

Adverse events will be coded using MedDRA and summarized by mapped term and appropriate thesaurus level. All adverse events and routine laboratory parameters will be assessed according to the NCI CTCAE v4.0 grading system. For adverse events, the most extreme severity will be used for reporting. Adverse events will be described by individual listings and by body system, as well as by severity. In tables showing the overall incidence of adverse events, patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency.

Laboratory values will be summarized by treatment arm including summary tables for the shifts in grades from baseline to the worst grade observed during treatment. In order to evaluate and compare hypogonadism in the two treatment arms, testosterone levels in the blood will be summarized for males by treatment arm over time (for details, see Section 6.8).

Descriptive summary tables of change from baseline over time will be provided for vital signs and descriptive statistics will be tabulated for ECOG PS. ECG findings over time will be summarized.

Study drug administration will be summarized by duration and cumulative dose. In addition, treatment exposure will be summarized including the number of doses received, dose intensity, and the percentage of planned dose.

Subgroup analyses will be performed to evaluate the safety profile within the subgroups of patients including by sex, age (<65 vs. ≥65 years), and race (non-Asian vs. Asian).

An IDMC will review the safety data collected during the conduct of the study. Safety monitoring will be performed periodically. Further details will be outlined in the IDMC Charter.

6.6 PHARMACOKINETIC ANALYSES

Standard NCA may be conducted for PK data collected from patients participating in serial/intensive PK collections for relevant analytes, as data allow, as appropriate, and if needed. PK parameters, including but not limited to AUC, maximum concentration (C_{max}), and time to maximum concentration (T_{max}), will be calculated on the basis of the available data as appropriate and where data allow. Additional PK parameters may be calculated as deemed appropriate.

Individual and mean plasma concentrations at each sampling timepoint and/or PK parameters for alectinib and metabolite(s) will be listed, as appropriate.
Summary statistics (e.g., means, standard deviation, coefficient of variation %, geometric means, medians and ranges) for plasma concentrations and/or PK parameters for alectinib and metabolite(s) will be presented by treatment and nominal collection times (plasma concentrations only), as appropriate. Additional plots or summary statistics may be constructed or calculated, as appropriate.

Results of PK and/or any PK/pharmacodynamic analyses may be reported outside the clinical study report.

Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be used to analyze the sparse and/or serial/intensive plasma concentration-time data for alectinib. The PK data from this study may be pooled with data from other studies. Population and individual PK parameters will be estimated and the influence of various covariates (such as age, gender, and body weight) on these parameters will be investigated.

Exploratory analyses will be conducted to investigate the relationship between alectinib PK exposure and efficacy/safety parameters.

Details of the mixed-effects modeling and exploratory analyses will be reported in a document separate from the clinical study report.

6.7 PATIENT-REPORTED OUTCOME ANALYSES

The following PRO endpoints will be analyzed and PRO data will be presented separately from adverse event data.

6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms

TTD from baseline will be assessed at every study visit (Week 4, Week 8, and then after every 4 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at post-treatment Visit (4 weeks after permanent treatment discontinuation); and at subsequent 8-weekly survival follow-up visits for 6 months, for the following lung cancer symptoms: cough (Question 31 on the QLQ-LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale (Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), arm/shoulder pain (Question 41 on the QLQ-LC13) and fatigue multi-item subscale (Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. TTD will be analyzed for the ITT population. If a baseline or post-baseline PRO evaluation is not available, TTD will be censored at the date of randomization. If they have not deteriorated, patients will be censored at the last time when they completed an assessment for cough, dyspnea (single item), dyspnea (subscale items), chest pain, arm/shoulder pain, and fatigue.
6.7.2 Additional Patient-Reported Outcomes

PROs of HRQoL, lung cancer–related symptoms, and health status will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13.

Summary statistics (mean, standard deviation, median, and range) of linear transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire, and the QLQ-LC13 according to the EORTC scoring manual guidelines. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. Only patients with a baseline assessment and at least one post-treatment assessment will be included in the analyses.

6.8 EXPLORATORY ANALYSES

The EQ-5D-3L is a generic PRO instrument that is used for across diseases and indications cost-effectiveness analyses. This instrument quantifies the QoL of various health outcomes and is applicable to a wide range of health states. Analyses of this outcome will be exploratory and will generate utility scores for use in economic models for reimbursement purposes only. The PRO will be administered every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months (see Appendix 1).

It has been reported that crizotinib therapy triggers rapid suppression of testosterone levels in men causing rapid-onset hypogonadism. It is unknown if reductions in testosterone reflect an effect of crizotinib on ALK or on some combination of the drug’s targets (i.e., c-MET) (Weickhardt et al. 2012; Weickhardt et al. 2013). Total testosterone and free testosterone levels (either by direct measurement or by calculation using albumin, and sex hormone-binding globulin (SHBG) calculator: (http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m.

The Abbott Vysis FISH test will be used as an exploratory assay after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between Vysis FISH and Ventana IHC for the detection of ALK-positive NSCLC. The FPP will be a secondary analysis population for efficacy and safety. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population.
ALK plasma assays (PCR and/or sequencing) will be used as exploratory assays for ALK positive and consented ALK negative patients. Results from these analyses will be used to quantify the degree of correlation between ALK plasma tests and Ventana IHC and Vysis FISH for the detection of ALK positive NSCLC. The ALK plasma assay population may be used for exploratory efficacy and safety analysis. This analysis population will be used to support diagnostic development. Assays from this population may be used for the registration of a plasma assay as a companion diagnostic. This analysis will be dependent on the successful technical development of a plasma ALK assay. Results of exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure ALK rearrangements in circulating tumor cells will be communicated outside the main study report.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

The Sponsor will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC using eCRFs. Sites will be responsible for data entry into the EDC system. In the event of discrepant data, the Sponsor will request data clarification from the sites, which the sites will resolve electronically in the EDC system.

The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. Central laboratory data or other electronic data will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle and process the electronic transfer of these data.

eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

ePRO data will be collected through use of an electronic device provided by an ePRO vendor. The device is designed for entry of data in a way that is attributable, secure, and accurate, in compliance with the FDA regulations for electronic records (21 CFR Part 11). The ePRO device data are available for view access only via secure access to a web server. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.
7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.

At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.

7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patients will use an ePRO device to capture PRO data. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be reviewed by site staff via secure access to a web server.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The investigator will receive patient data for the site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required. In addition, the Sponsor will receive all patient data in a machine-readable format on a compact disc.

7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.
Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by applicable health authorities.

7.5 USE OF COMPUTERIZED SYSTEMS

When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS

Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a United States IND application will comply with FDA regulations and applicable local, state, and federal laws. Studies conducted in the European Union or European Economic Area will comply with the EU Clinical Trial Directive (2001/20/EC).
8.2 INFORMED CONSENT

The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child's Assent or Caregiver's Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the "Consent Forms") before IRB/EC submission. The final IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to allow any remaining specimens to be used for exploratory research. Patients who decline to participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient's legally authorized representative. All signed and dated Consent Forms must remain in each patient’s study file or in the site file and must be available for verification by study monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a
separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.

8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site’s study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which includes an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL DEVIATIONS

The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.

9.3 SITE INSPECTIONS

Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients’ medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE

Steering Committee is established to provide the study Sponsor with recommendations related to any aspect of the trial, specifically study design, data interpretation, exploratory analyses, or alternate changes to the trial that may assist in patient accrual, data collection, analysis, and interpretation of the study results. The Sponsor is ultimately responsible for all decisions regarding the study.

The test for the study inclusion criteria of ALK-positive NSCLC will be performed at Sponsor’s designated central laboratories and assessed by Ventana IHC test.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised. Details of the composition, roles, and responsibilities, and processes of the IDMC are documented in a separate IDMC charter. The IDMC will review safety data and can make recommendations to the
Sponsor to stop or amend the study on the basis of safety findings. The frequency of these reviews as well as the data to be reviewed will be agreed with the IDMC and outlined in the separate IDMC charter. No stopping for early proof of efficacy will result from any of these regular safety reviews. IDMC review meetings will be held in a blinded manner to the Sponsor.

An IRC will review the tumor assessments to determine the secondary endpoints of the overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1. In addition to the secondary endpoint of time to CNS progression together with C-ORR, C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the tumor assessments on the basis of RANO criteria.

The independent review of MRI and CT scans will NOT determine either eligibility OR patient treatment. All treatment decisions will be made by the investigator using local assessments.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


The results of this study may be published or presented at scientific congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.
Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).
10. REFERENCES


Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3

Crizotinib SmPC [resource on Internet]. [cited 2014 Jan 20]. Available from:


Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.

## Appendix 1
Schedule of Assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test(^a)</td>
<td>x</td>
<td>To be repeated as necessary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination(^b)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>ECOG PS</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>ECG(^c)</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Hematology, Coagulation</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) To be repeated as necessary

\(^b\) Physical examination includes full-body examination

\(^c\) ECG is performed at baseline and subsequent visits

\(^d\) Tests are performed at baseline and subsequent visits
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td>x x x x x x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mandatory tumor sample for ALK testing&lt;sup&gt;a&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional plasma sample from centrally confirmed ALK negative patients</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(20 ml of blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional tumor sample</td>
<td>x&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x&lt;sup&gt;d&lt;/sup&gt;</td>
<td>x&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma sample for ALK fusion detection in nucleic acids (20 mL of blood)</td>
<td>x&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma for detection of ALK mutation status (20 mL of blood)</td>
<td>Days -28 to 0</td>
<td>Days -3 to 0</td>
<td>x</td>
<td>x'</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Visit 0 (Baseline)</td>
<td>Visit 1 (Week 4)</td>
<td>x'</td>
<td>x'</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Visit 2 (Week 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood sample for pharmacogenomics research at pre-dose (3 mL of blood) 1</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor assessment k</td>
<td>x'</td>
<td>x'</td>
<td>x</td>
<td>x'</td>
<td></td>
</tr>
<tr>
<td>MRI scan of the brain</td>
<td>x'</td>
<td>x'</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>PK samples (2 mL blood)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>PRO (EORTC QLQ-C30/LC13; EQ-5D)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total testosterone, (either by direct measurement or by calculation using albumin, and SHBG), FSH, and LH&lt;sup&gt;$^t$&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
</tr>
<tr>
<td>Adverse events&lt;sup&gt;$^a$&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
</tr>
<tr>
<td>Subsequent therapy for NSCLC</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
</tr>
<tr>
<td>Drug dispensing and accountability&lt;sup&gt;$^t$&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
</tr>
<tr>
<td>Blood Sample for Roche Clinical Repository (10 mL)</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
<td>&lt;sup&gt;x&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and
Appendix 1
Schedule of Assessments (cont.)

Treatment of Cancer Quality of Life Questionnaire–Core; EQ-5D = EuroQoL 5 Dimension; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NSCLC = non–small cell lung cancer; PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal.

Notes: First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided—within ≤24 hours. Post-baseline assessments are to be performed within ±1 week for the first two 4-weekly and subsequent 8-weekly assessments.

a Urine or serum, to be repeated as necessary.
b Including an ophthalmologic examination if clinically indicated.
c At screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), last treatment visit, and as clinically indicated throughout the study.
d Screening laboratory assessment done within 3 days can be counted as the baseline assessment.
e Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 10 to 15 unstained 5-µm slides are required. Tumor ALK status will be assessed by central laboratory before randomization.
f Optional tumor sample could be taken from the tumor block obtained at screening.
g At the time of disease progression from progressive lesions.
h Mandatory blood sample (20 mL) for detection of ALK rearrangements in nucleic acids in plasma collected at baseline only.
i Blood sample (20 mL) to obtain plasma for exploratory biomarkers will be collected at Visit 0 (baseline), during the study every second visit (i.e., every 16 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression.
j This sample is required in all patients in alectinib arm, and in those patients in the crizotinib arm who wish to participate in optional genomics sequencing.
k Tumor assessment consists at minimum of a CT/MRI scan of chest and abdomen (for imaging of liver and adrenal glands). Patients who are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP >1.5 × ULN) of bone metastasis should undergo radionuclide bone scan. Clinical lesions should be assessed with caliper measurement and documented by color photography, including a ruler to estimate the size of the lesion. Post-baseline assessments are to be performed within ±1 week for the 8-weekly assessments. If there is suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be performed as soon as possible before the next scheduled evaluation.
l Screening tumor assessment done within 14 days will be counted as the baseline assessment.
m Tumor assessment can be performed whenever clinically indicated. Brain assessment scans should be performed at every systemic imaging tumor assessment. Tumor assessment should continue until disease progression if a patient discontinues treatment prior to PD, regardless of
whether they subsequently receive non-study, anti-cancer therapy (a use of subsequent non-study, anti-cancer therapy prior to disease progression would be considered a protocol violation).

If treatment was permanently discontinued due to disease progression.

Pre-dose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit. The pre-dose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits. Remind the patient not to take a daily dose at home on the day of scheduled study visit. For a subset of patients on alectinib treatment (10%–15%, or at least approximately n=20) participating in serial/intensive PK sample collection, additional PK will be collected on Visits 0 (baseline) and 1 (Week 4) at pre-dose (within 2 hours before intake of study medication), 1, 2, 4, 6, and 8 hours post-dose.

PRO questionnaires are to be completed every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow up visit (every 8 weeks) after post-treatment visit for 6 months. Further guidelines on PRO questionnaire administration will be provided in the study manual.

Performed every 8 weeks after post-treatment visit during the first 6 months and then every 12 weeks or performed as appropriate. The PRO assessments should be performed during the first 6 months. For patients who discontinue treatment for reasons other than disease progression and who progress within the first 6 months of survival follow-up, PRO measures will be administered every 4 weeks until disease progression and then decreased to every 8 weeks until 6 months post treatment. For patients who discontinue treatment for reasons other than disease progression and have not yet progressed at 6 months post treatment, PRO measures will be administered every 4 weeks until disease progression and will no longer be required thereafter.

Male patients only, using institutional standard assay. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m. Albumin and SHBG measurements are not required when a direct assessment of free testosterone is available. If free testosterone level cannot be directly assessed, it will be calculated from albumin and SHBG using a free testosterone calculator: http://www.issam.ch/freetesto.htm.

Graded according to NCI CTCAE (version 4.0). Serious adverse events collection must start from first study-specific procedure.

For details on drug dispensing and accountability, see Section 4.3.3.
## Appendix 2
### Schedule of Alectinib Pharmacokinetic Assessments

<table>
<thead>
<tr>
<th>Visit</th>
<th>Timepoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 0 (baseline)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>All subsequent visits (every 8 weeks) until PD or death/withdrawal from study prior to PD</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 0 (baseline) and Visit 1 (Week 4)(^a)</td>
<td>Pre-dose (within 2 hours before intake of alectinib), 1, 2, 4, 6, and 8 hours post-dose</td>
</tr>
</tbody>
</table>

PD = progressive disease; PK = Pharmacokinetic

\(^a\) For patients participating in the serial/intensive PK sample collection only.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters

This representative list is not intended to be an exhaustive list. Each patient’s concomitant medications should be carefully considered by the investigator with regard to the risk-benefit for the particular patient and appropriate monitoring, including any concomitant medication, dose adjustment, or therapeutic alternatives, which should be determined by the investigator caring for the patient.

<table>
<thead>
<tr>
<th>CYP3A Inducers</th>
<th>CYP3A Potent Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>avasimibe, aminoglutethimide, barbiturates, carbamazepine, dexamethasone, efavirenz, ethosuximide, garlic supplements, glucocorticoids, glutethimide, griseofulvin, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, primidone, rifabutin, rifampin, rifapentine, St. John’s wort, troglitazone</td>
<td>aprepitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice, indinavir, irtraconazole, ketoconazole, lopinavir, mibeferdin, nefazodone, nefinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-gp Substrates</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>aliskiren, ambrisentan, colchicine, dabigatran, digoxin, everolimus, fexofenadine, imatinib, laptatinib, maraviroc, nilotinib, posaconazole, pravastatin, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan</td>
<td>avasimibe, carbamazepine, phenytoin, rifampin, St John’s wort, tipranavir</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dual UGT1A1/CYP3A Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>buprenorphine, raltegravir</td>
<td>atazanavir</td>
<td>rifampin</td>
</tr>
</tbody>
</table>


This information in this appendix is adapted from Levien and Baker 2003, Zhang 2010, and FDA Guidance on Drug-Drug Interactions.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters (cont.)

Also see:

- http://medicine.iupui.edu/clinpharm/ddis/table.aspx

Potent inhibitors of CYP3A are those considered to be “strong CYP3A inhibitors” previously shown to result in a ≥ 5-fold increase in the AUC of a concomitantly administered CYP3A substrate. These are based on the available published literature and, thus, are not considered exhaustive or inclusive. See FDA Guidance on Drug-Drug Interactions for further detail.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication

Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1,¹ are presented below, with slight modifications and the addition of explanatory text as needed for clarity.²

MEASURABILITY OF TUMOR AT BASELINE

DEFINITIONS

At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as described below.

**Measurable tumor lesions**

**Tumor lesions**

Tumor lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size as follows:

- 10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than 5 mm)
- 10-mm caliper measurement by clinical examination (lesions that cannot be accurately measured with calipers should be recorded as non-measurable)
- 20 mm by chest X-ray

**Malignant lymph nodes**

To be considered pathologically enlarged and measurable, a lymph node must be ≥15 mm in the short axis when assessed by CT scan (CT scan slice thickness is recommended to be no greater than 5 mm). At baseline and follow-up, only the short axis will be measured and followed. See also notes below on “Baseline Documentation of Target and Non-Target Lesions” for information on lymph node measurement.

**Non-Measurable tumor lesions**

Non-measurable tumor lesions encompass small lesions (longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal mass/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques.

² For consistency within this document, the section numbers and cross-references to other sections within the article have been deleted and minor formatting changes have been made.
Special considerations regarding lesion measurability

Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.

Bone lesions

Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.

Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques, such as CT or MRI, can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

Blastic bone lesions are non-measurable.

Cystic lesions

Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

Lesions with prior local treatment

Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.

TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS

Measurement of lesions

All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.

Method of assessment

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study. Imaging-based evaluation should always be the preferred option.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Clinical lesions
Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules). For the case of clinical lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is required.

Chest X-Ray
Chest CT is preferred over chest X-Ray, particularly when progression is an important endpoint, because CT is more sensitive than X-Ray, particularly in identifying new lesions. However, lesions on chest X-Ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

CT, MRI
CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan on the basis of the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable.

If, prior to enrollment, it is known that a patient is unable to undergo CT scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the study should be guided by the tumor type under investigation and the anatomic location of the disease. For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible. Each case should be discussed with the radiologist to determine if the substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of target lesions on a different modality and interpretation of non-target disease or new lesions because the same lesion may appear to have a different size using a new modality.

Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement.

Endoscopy, laparoscopy, tumor markers, cytology, histology
The utilization of these techniques for objective tumor evaluation cannot generally be advised.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

TUMOR RESPONSE EVALUATION

ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE

To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable lesion, as detailed above.

BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS

When more than one measurable lesion is present at baseline, all lesions, up to a maximum of five lesions total and a maximum of two lesions per organ, representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline. This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions (albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size is >10 mm by CT scan).

Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but, in addition, the lesions should lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.

Lymph nodes merit special mention since they are normal anatomical structures that may be visible by imaging even if not involved by tumor. As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥ 10 mm but <15 mm) should be considered non-target lesions. Nodes that have a short axis of <10 mm are considered non-pathological and should not be recorded or followed.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum of diameters. If lymph nodes are to be included in the sum, then, as noted above, only the short axis is added.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

into the sum. The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions or sites of disease, including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression.”

In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).

RESPONSE CRITERIA
Evaluation of target lesions
This section provides the definitions of the criteria used to determine objective tumor response for target lesions.

- **CR**: Disappearance of all target lesions
  Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- **PR**: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
- **PD**: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
  The appearance of one or more new lesions is also considered progression.
- **SD**: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Special notes on the assessment of target lesions
**Lymph nodes**
Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to < 10 mm on study. This means that when lymph nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm.

**Target lesions that become too small to measure**
During the study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3

134
small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as target lesions at baseline become so faint on the CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being too small to measure. When this occurs, it is important that a value be recorded on the CRF, as follows:

If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.

If the lesion is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned and BML (below measurable limit) should be ticked. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned in this circumstance as well and BML should also be ticked).

To reiterate: If the radiologist is able to provide an actual measure, this measurement should be recorded, even if it is below 5 mm, and, in that case, BML should not be ticked.

Lesions that split or coalesce on treatment
When non-nodal lesions fragment, the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.

Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the group of non-target lesions. Whereas some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the timepoints specified in the protocol.

- CR: Disappearance of all non-target lesions
  All lymph nodes must be non-pathological in size ( < 10 mm short axis).
- Non-CR/Non-PD: Persistence of one or more non-target lesions
- PD: Unequivocal progression of existing non-target lesions
  The appearance of one or more new lesions is also considered progression.
Special notes on assessment of progression of non-target disease
When the patient also has measurable disease
In this setting, to achieve unequivocal progression on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease in a magnitude that, even in the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

When the patient has only non-measurable disease
This circumstance arises in some Phase III trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden on the basis of the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic disease from localized to widespread. Examples may be described in protocols as “sufficient to require a change in therapy”. If unequivocal progression is seen, the patient should be considered to have had overall PD at that point. Though it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore, the increase must be substantial.

New lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly important when the patient’s baseline lesions show PR or CR (e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not).

A lesion identified during the study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

If a new lesion is equivocal (e.g., because of its small size) continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.

**EVALUATION OF RESPONSE**

**Timepoint response (overall response)**

It is assumed that at each protocol-specified timepoint, a response assessment occurs. Table 1 provides a summary of the overall response status calculation at each timepoint for patients who have measurable disease at baseline.

When patients have non-measurable (therefore non-target) disease only, Table 2 is to be used.

**Table 1  Timepoint Response: Patients with Target Lesions (with or without Non-Target Lesions)**

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.
Table 2  Timepoint Response: Patients with Non-Target Lesions Only

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD a</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease.

a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can be measured is not advised.

Missing assessments and not-evaluable designation

When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at that timepoint. If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response. This would be most likely to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three measured lesions and during the study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution of the missing lesion).

If one or more target lesions were not assessed either because the scan was not done or because the scan could not be assessed due to poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable. Similarly, if one or more non-target lesions are not assessed, the response for non-target lesions should be “unable to assess”, except where there is clear progression. Overall response would be “unable to assess” if either the target response or the non-target response is “unable to assess”, except where this is clear evidence of progression, as this equates with the case being not evaluable at that timepoint.
Table 3  Best Overall Response When Confirmation Is Required

<table>
<thead>
<tr>
<th>Overall Response at First Timepoint</th>
<th>Overall Response at Subsequent Timepoint</th>
<th>Best Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR a</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

a If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even disease meeting PR criteria relative to baseline, qualifies as PD at that point (since disease must have reappeared after CR). Best response would depend on whether the minimum duration for SD was met. However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint. Under these circumstances, the original CR should be changed to PR and the best response is PR.

Special notes on response assessment

When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (<10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document objective
progression even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stopping study therapy. The objective response status of such patients is to be determined by evaluation of target and non-target disease as shown in Table 1 to Table 3.

For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non-target lesion, as appropriate. This is to avoid an incorrect assessment of complete response if the primary tumor is still present but not evaluated as a target or non-target lesion.
## Appendix 5
### Eastern Cooperative Oncology Group Performance Status Scale

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework or office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt; 50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to a bed or chair &gt; 50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>
## Appendix 6

### EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires

#### EORTC QLQ-C30 (version 3)

We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will remain strictly confidential.

Please fill in your initials: 

Your birthdate (Day, Month, Year):

Today's date (Day, Month, Year): 31

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>2. Do you have any trouble taking a long walk?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>3. Do you have any trouble taking a short walk outside of the house?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4. Do you need to stay in bed or a chair during the day?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5. Do you need help with eating, dressing, washing yourself or using the toilet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**During the past week:**

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Were you limited in doing either your work or other daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7. Were you limited in pursuing your hobbies or other leisure time activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>8. Were you short of breath?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>9. Have you had pain?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>10. Did you need to rest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>11. Have you had trouble sleeping?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>12. Have you felt weak?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>13. Have you lacked appetite?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>14. Have you felt nauseated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>15. Have you vomited?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>16. Have you been constipated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Please go on to the next page.
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>17. Have you had diarrhea?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>18. Were you tired?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>19. Did pain interfere with your daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>21. Did you feel tense?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>22. Did you worry?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>23. Did you feel irritable?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>24. Did you feel depressed?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>25. Have you had difficulty remembering things?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>26. Has your physical condition or medical treatment interfered with your family life?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>27. Has your physical condition or medical treatment interfered with your social activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>28. Has your physical condition or medical treatment caused you financial difficulties?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

For the following questions please circle the number between 1 and 7 that best applies to you:

29. How would you rate your overall health during the past week?          
    1 2 3 4 5 6 7
    Very poor  Excellent

30. How would you rate your overall quality of life during the past week?  
    1 2 3 4 5 6 7
    Very poor  Excellent

© Copyright 1999 EORTC Quality of Life Group. All rights reserved. Version 3.0
## EORTC QLQ - LC13

Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems **during the past week**. Please answer by circling the number that best applies to you.

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. How much did you cough?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>32. Did you cough up blood?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>33. Were you short of breath when you rested?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>34. Were you short of breath when you walked?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>35. Were you short of breath when you climbed stairs?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>36. Have you had a sore mouth or tongue?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>37. Have you had trouble swallowing?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>38. Have you had tingling hands or feet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>39. Have you had hair loss?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>40. Have you had pain in your chest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>41. Have you had pain in your arm or shoulder?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>42. Have you had pain in other parts of your body?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>If yes, where</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43. Did you take any medicine for pain?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>1. No</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, how much did it help?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

© QLQ-C30-LC13 Copyright 1994 EORTC Quality of life Group. All rights reserved
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

Health Questionnaire

(English version for the US)

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

**Mobility**
- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

**Self-Care**
- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

**Usual Activities (e.g. work, study, housework, family or leisure activities)**
- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

**Pain/Discomfort**
- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

**Anxiety/Depression**
- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 7
Modification of Diet in Renal Disease (MDRD) Formula

The estimating glomerular filtration rate (eGFR) will be calculated on the basis of the following formula:

\[
eGFR \left[ \text{mL/min/1.73 m}^2 \right] = 175 \times \text{SCRT}^{-1.154} \times \text{AGE}^{-0.203} \times 0.742 \times 1.212 \text{ (if African American)}
\]

where \( \text{SCRT} \) = serum creatinine in conventional units, i.e. mg/dL. The following conversion factor should be used in case the serum creatinine value is provided by the lab in \( \mu \text{mol/L} \) units:

\[
\text{Serum creatinine [mg/dL]} = \text{Serum creatinine [} \mu \text{mol/L]} \times 0.0113
\]

References:

Appendix 8
Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry

Overview
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA anti-ALK [D5F3]) IHC assay will be used to determine anaplastic lymphoma kinase (ALK) IHC status and to select patients with positive ALK for enrollment in Study BO28984. The anti-ALK (D5F3) rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib. For Study BO28984, the VENTANA anti-ALK (D5F3) assay will be used for investigational purposes only.

VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with a VENTANA automated slide stainer. It is indicated as an aid in identifying patients eligible for treatment with alectinib.

Device Description
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary antibody, the BenchMark® automated slide staining platform, OptiView DAB detection kit, OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA anti-ALK 2-in-1 cell line control slides or other appropriate system run control.

Scoring System
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern. Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish non-specific staining from specific ALK positivity. Samples must be assessed for morphological damage and the presence of viable tumor versus necrosis. Light, granular, cytoplasmic stippling in alveolar macrophages can occur on anti-ALK (D5F3) and/or NRC slides as an artifact of the detection system. This staining artifact should be noted on the Slide Evaluation Form comment field but should NOT be interpreted as ALK-positive staining. Some background staining has also been observed on normal mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also should not be interpreted as ALK-positive staining. Case slide sets failing to show specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be considered ALK-positive. Refer to VENTANA ALK Scoring Interpretation Guide for non-small cell lung carcinoma (NSCLC) for additional information.
## Appendix 9

**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms**

<table>
<thead>
<tr>
<th>Gene</th>
<th>CHST</th>
<th>CYP</th>
<th>Enzyme Family</th>
<th>Transporter</th>
<th>Other</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>CHST13</td>
<td>CYP3A5</td>
<td>HNMT</td>
<td>SLC22A3</td>
<td>UGT1A4</td>
<td>ADRB3</td>
</tr>
<tr>
<td>ABCB11</td>
<td>CHST2</td>
<td>CYP3A7</td>
<td>MAOA</td>
<td>SLC22A4</td>
<td>UGT1A5</td>
<td>ALG10B</td>
</tr>
<tr>
<td>ABCB4</td>
<td>CHST3</td>
<td>CYP46A1</td>
<td>MAOB</td>
<td>SLC22A5</td>
<td>UGT1A6</td>
<td>APOA1</td>
</tr>
<tr>
<td>ABCB7</td>
<td>CHST4</td>
<td>CYP4A11</td>
<td>MAT1A</td>
<td>SLC22A6</td>
<td>UGT1A7</td>
<td>APOC3</td>
</tr>
<tr>
<td>ABCC1</td>
<td>CHST5</td>
<td>CYP4B1</td>
<td>METTL1</td>
<td>SLC22A7</td>
<td>UGT1A8</td>
<td>ARHGAP24</td>
</tr>
<tr>
<td>ABCC2</td>
<td>CHST6</td>
<td>CYP4F11</td>
<td>NAT1</td>
<td>SLC22A8</td>
<td>UGT1A9</td>
<td>ATF3</td>
</tr>
<tr>
<td>ABCC3</td>
<td>CHST7</td>
<td>CYP4F12</td>
<td>NAT2</td>
<td>SLC25A27</td>
<td>UGT2A1</td>
<td>ATIC</td>
</tr>
<tr>
<td>ABCC4</td>
<td>CHST8</td>
<td>CYP4F2</td>
<td>NNMT</td>
<td>SLC28A1</td>
<td>UGT2B11</td>
<td>BIRC2</td>
</tr>
<tr>
<td>ABCC5</td>
<td>CHST9</td>
<td>CYP4F3</td>
<td>NQO1</td>
<td>SLC28A2</td>
<td>UGT2B15</td>
<td>BIRC3</td>
</tr>
<tr>
<td>ABCC6</td>
<td>COMT</td>
<td>CYP4F8</td>
<td>NR1I2</td>
<td>SLC28A3</td>
<td>UGT2B17</td>
<td>C3orf38</td>
</tr>
<tr>
<td>ABCC8</td>
<td>CROT</td>
<td>CYP4Z1</td>
<td>NR1I3</td>
<td>SLC29A1</td>
<td>UGT2B28</td>
<td>CALCA</td>
</tr>
<tr>
<td>ABCC9</td>
<td>CYP11A1</td>
<td>CYP51A1</td>
<td>NR3C1</td>
<td>SLC29A2</td>
<td>UGT2B4</td>
<td>CASP9</td>
</tr>
<tr>
<td>ABCG1</td>
<td>CYP11B1</td>
<td>CYP7A1</td>
<td>ORM1</td>
<td>SLC5A6</td>
<td>UGT2B7</td>
<td>CD33</td>
</tr>
<tr>
<td>ABCG2</td>
<td>CYP11B2</td>
<td>CYP7B1</td>
<td>ORM2</td>
<td>SLC6A6</td>
<td>UGT8</td>
<td>CD36</td>
</tr>
<tr>
<td>ABP1</td>
<td>CYP17A1</td>
<td>CYP8B1</td>
<td>PGAP3</td>
<td>SLC7A5</td>
<td>VKORC1</td>
<td>CD44</td>
</tr>
<tr>
<td>ADH1A</td>
<td>CYP19A1</td>
<td>DCK</td>
<td>PMNT</td>
<td>SLC7A7</td>
<td>XDH</td>
<td>CDK4</td>
</tr>
<tr>
<td>ADH1B</td>
<td>CYP1A1</td>
<td>DPYD</td>
<td>PON1</td>
<td>SLC7A8</td>
<td>CDK6</td>
<td>KCNIP4</td>
</tr>
<tr>
<td>ADH1C</td>
<td>CYP1A2</td>
<td>EPHX1</td>
<td>PON2</td>
<td>SLC01A2</td>
<td>CEBPB</td>
<td>KRT18</td>
</tr>
<tr>
<td>ADH4</td>
<td>CYP1B1</td>
<td>EPHX2</td>
<td>PON3</td>
<td>SLC01B1</td>
<td>CEP44</td>
<td>KRT8</td>
</tr>
<tr>
<td>ADH5</td>
<td>CYP20A1</td>
<td>FAAH</td>
<td>POR</td>
<td>SLC01B3</td>
<td>CES1</td>
<td>LEP</td>
</tr>
<tr>
<td>ADH6</td>
<td>CYP21A2</td>
<td>FMO1</td>
<td>PPARD</td>
<td>SLC02B1</td>
<td>CTLA4</td>
<td>LEPR</td>
</tr>
<tr>
<td>ADH7</td>
<td>CYP24A1</td>
<td>FMO2</td>
<td>PPARG</td>
<td>SLC03A1</td>
<td>CYP3A</td>
<td>LMX1A</td>
</tr>
<tr>
<td>AHR</td>
<td>CYP26A1</td>
<td>FMO3</td>
<td>PPP1R9A</td>
<td>SLC04A1</td>
<td>EGFR</td>
<td>LPL</td>
</tr>
</tbody>
</table>

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 3
### Appendix 9

**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms (cont.)**

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKAP9</td>
<td>CYP26C1</td>
<td>FMO4</td>
<td>PRSS53</td>
</tr>
<tr>
<td>ALB</td>
<td>CYP27A1</td>
<td>FMO5</td>
<td>PTGIS</td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>CYP27B1</td>
<td>FMO6</td>
<td>QPRT</td>
</tr>
<tr>
<td>ALDH2</td>
<td>CYP2A13</td>
<td>G6PD</td>
<td>RALBP1</td>
</tr>
<tr>
<td>ALDH3A1</td>
<td>CYP2A6</td>
<td>GSTA1</td>
<td>RPL13</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>CYP2A7</td>
<td>GSTA2</td>
<td>RXRA</td>
</tr>
<tr>
<td>AOX1</td>
<td>CYP2B6</td>
<td>GSTA3</td>
<td>SERPINA7</td>
</tr>
<tr>
<td>APOA2</td>
<td>CYP2B7P1</td>
<td>GSTA4</td>
<td>SLC10A1</td>
</tr>
<tr>
<td>ARNT</td>
<td>CYP2C18</td>
<td>GSTA5</td>
<td>SLC10A2</td>
</tr>
<tr>
<td>ARSA</td>
<td>CYP2C19</td>
<td>GSTM1</td>
<td>SLC13A1</td>
</tr>
<tr>
<td>ATP7A</td>
<td>CYP2C8</td>
<td>GSTM2</td>
<td>SLC15A1</td>
</tr>
<tr>
<td>ATP7B</td>
<td>CYP2C9</td>
<td>GSTM3</td>
<td>SLC15A2</td>
</tr>
<tr>
<td>CA5P</td>
<td>CYP2D6</td>
<td>GSTM4</td>
<td>SLC16A1</td>
</tr>
<tr>
<td>CBR1</td>
<td>CYP2E1</td>
<td>GSTM5</td>
<td>SLC19A1</td>
</tr>
<tr>
<td>CBR3</td>
<td>CYP2F1</td>
<td>GSTO1</td>
<td>SLC22A1</td>
</tr>
<tr>
<td>CDA</td>
<td>CYP2J2</td>
<td>GSTP1</td>
<td>SLC22A11</td>
</tr>
<tr>
<td>CES2</td>
<td>CYP2S1</td>
<td>GSTT1</td>
<td>SLC22A12</td>
</tr>
<tr>
<td>CHST1</td>
<td>CYP39A1</td>
<td>GSTT2</td>
<td>SLC22A13</td>
</tr>
<tr>
<td>CHST10</td>
<td>CYP3A4</td>
<td>GSTZ1</td>
<td>SLC22A14</td>
</tr>
<tr>
<td>CHST11</td>
<td>CYP3A43</td>
<td>HMGR</td>
<td>SLC22A2</td>
</tr>
</tbody>
</table>
Appendix 10 Formulae for the Calculation of QTcF and RR

**QTcF —Fridericia’s correction for QTc measurement (if not provided directly by the ECG machine):**

\[
\text{QTcF (ms)} = \frac{\text{QT (ms) 3RR/1000}}{}
\]

**RR Interval Formula (if not provided directly by the ECG machine):**

\[
\text{RR (ms)} = \frac{60000}{\text{heart rate (bpm)}}
\]
PROTOCOL

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE–POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 2
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [Redacted]
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [Redacted]
SPONSOR: F. Hoffmann-La Roche Ltd
DATE FINAL: Version 1: 10 February 2014
DATE AMENDED: Version 2: See electronic date stamp below.

PROTOCOL AMENDMENT APPROVAL

<table>
<thead>
<tr>
<th>Approver’s Name</th>
<th>Title</th>
<th>Date and Time (UTC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Redacted]</td>
<td>Clinical Science Leader</td>
<td>08-Oct-2014 13:34:01</td>
</tr>
</tbody>
</table>

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984       Report Number 1078196

2408
PROTOCOL AMENDMENT, VERSION 2: RATIONALE

Protocol BO28984 has been amended to comply with questions addressed during the assessment of the Voluntary Harmonisation Procedure VHP444 (VHP201415), Western Institutional Review Board request (dated June 5, 2014) to further specify protocol inclusion criterion, FDA request (dated July 10, 2014) to revise crizotinib dose modification criteria for non-hematologic toxicities to conform to the most recent FDA—approved label, as well as feedback from various other Health Authorities/Ethic Committees. Protocol BO28984 has been amended to include the latest clinical and safety information.

The main changes to the protocol are as follows:

- Study rationale (Section 1.3 and Section 3.3.3) supplemented with latest crizotinib data from the recently published PROFILE 1014 study that lead to reassessment of assumptions for median progression-free survival (PFS) without impacting a target HR for the study. This amendment text was introduced throughout the Protocol and Section 6, Statistical Considerations and Analysis Plan.

- Inclusion criteria (Section 4.1.1) of an adequate renal function and Guidelines for Management of Specific Adverse Events with Alectinib (Table 2) were modified to use measure of an estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation.

- Specified inclusion criteria (Section 4.1.1) by adding statement that asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice.

- Exclusion criteria (Section 4.1.2) of symptomatic bradycardia have been specified by removing the reference to <45 beats per minute.

- Section 4.3.4 amended to describe post-trial access to alectinib

- Permitted Therapy (Section 4.4.1) and Safety of Crizotinib Management of Adverse Events (Section 5.1.4, Table 4) revised as per latest prescribing information for crizotinib (USPI May 2014; EU SmPC 16 June 2014).

- Local therapy (e.g., stereotactic radiotherapy or surgery) in case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases) added to the list of Permitted Therapy (Section 4.4.1.) for further clarity.

- Added information on events of bradycardia reported with alectinib (Section 5.1.2.8)

- Based on an updated directive from the European Parliament that was released April 2014 superseding the previous Directive (CT3) updated language of the Protocol BO28984 (Section 5.3.1 and Section 5.6) referring to a suspected causal relationship to the investigational medicinal product that occurs after the end of the clinical trial.

- Introduced Section 5.3.5.13, Adverse Events in Individuals Not Enrolled in the Study
• Section 9.5, Publication of Data and Protection of Trade Secrets, amended to further describe publication of data and protection of trade secrets.

Additional minor changes have been made to improve clarity and consistency. This amendment represents cumulative changes to the original protocol.
PROTOCOL AMENDMENT, VERSION 2:
SUMMARY OF CHANGES

GLOBAL CHANGES
The UTN number was added to the title pages as applicable.

The protocol was clarified to indicate that the Ventana IHC and the Vysis FISH should be used.

The planned competitive recruitment period was changed from 25 to 24 months. The final analysis of the primary endpoint will occur when 170 patients, instead of 169 patients, have progressed or died; this is expected to occur at approximately 33 months, not 31 months.

PROTOCOL SYNOPSIS
The protocol synopsis has been updated to reflect the changes to the protocol, where applicable.

SECTION 1.1: Background on Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
Currently, the only approved medicine treatment for treatment-naïve ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), receptor d’origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

SECTION 1.3: Study Rationale and Benefit-Risk Assessment
Crizotinib is the only first-generation ALK inhibitor that is currently approved and has been registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The previous clinical studies reported at present demonstrate that the median PFS with crizotinib ranged from 7.7 to 9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013), while published clinical evidence on crizotinib’s efficacy in ALK-positive NSCLC first line treatment setting is still limited. The PROFILE 1014 study, a Phase III study of crizotinib compared with standard pemetrexed–platinum–based chemotherapy, was presented at the ASCO 2014 congress (Mok et al. 2014). The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p <0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively.

Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for treatment-naïve ALK-positive advanced NSCLC patients.
Alectinib was granted approval in Japan on 4 July 2014 for ALK fusion gene-positive, unresectable, recurrent, or advanced NSCLC.

SECTION 3.1: DESCRIPTION OF STUDY
The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

SECTION 3.3.3: Rationale for Control Group
There are no publicly available Phase III data yet for crizotinib in the first-line setting. The randomized Phase III PROFILE 1014 study, which began in January 2011, is currently being conducted to assess the efficacy of crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC. The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p < 0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively (Mok et al. 2014). The authors concluded that these findings establish crizotinib as the standard of care for patients with previously untreated advanced ALK-positive non-squamous NSCLC (Mok et al. 2014). The estimated primary completion date of this study is November 2013 (ClinicalTrials.gov), with data expected to be reported in 2014. If PROFILE 1014 reported data will drastically differ from previously reported information, the study assumptions might be reevaluated.

SECTION 3.3.5: Rationale for Primary Endpoint Selection
The assumed median PFS of patients in the alectinib treatment arm is 15.1 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 135 months.

SECTION 4.1.1: Inclusion Criteria
- Adequate renal function:
  An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of
  Calculated creatinine clearance at least 45 mL/min/1.73 m²
• Prior brain or leptomeningeal metastases allowed if asymptomatic and diagnosed incidentally at study baseline. Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.

SECTION 4.1.2: Exclusion Criteria
• Liver disease characterized by:
  ALT or AST >3 × ULN (≥5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  OR
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  OR
  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
• National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication.
• History of organ transplant.
• Co-administration of anti-cancer therapies other than those administered in this study.
• Patients with baseline QTc >470 ms or patients with symptomatic bradycardia <45 beats per minute.

SECTION 4.3.1.1: Alectinib
Alectinib comes in a hard capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmelllose calcium, hydroxypropyl cellulose, sodium lauryl sulfate (SLS), and magnesium stearate as excipients.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).
The formulation contains SLS as a surfactant excipient. This excipient is known to be associated potentially with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

**SECTION 4.3.2.2: Crizotinib**

If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. *If vomiting occurs after taking a dose of crizotinib, the next dose should be taken as scheduled.*

**SECTION 4.3.4: Post-Trial Access to Alectinib**

The Sponsor does not intend to provide alectinib or other study interventions to patients after conclusion of the study or any earlier patient withdrawal, under this protocol. The Sponsor will offer post-trial access to the study drug alectinib free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below.

A patient will be eligible to receive study drug after the end of the study if all of the following conditions are met:

- The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being
- There are no appropriate alternative treatments available to the patient
- The patient and his or her doctor comply with and satisfy any legal or regulatory requirements that apply to them

A patient will not be eligible to receive study drug after the end of the study if any of the following conditions are met:

- The study drug is commercially marketed in the patient's country and is reasonably accessible to the patient (e.g., is covered by the patient's insurance or would not otherwise create a financial hardship for the patient)
- The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for ALK-positive NSCLC
- The Sponsor has reasonable safety concerns regarding the study drug as treatment for ALK-positive NSCLC
- Provision of study drug is not permitted under the laws and regulations of the patient’s country

*The Roche Global Policy on Continued Access to Investigational Medicinal Product is available at the following Web site:*

http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
SECTION 4.4.1: **Permitted Therapy**

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 28 days prior to screening to the study completion/discontinuation visit.

The medications and/or treatments below are permitted:

- **Gastric pH-elevating medications** (such as proton pump inhibitors, H$_2$ blockers, or antacids)
- **Local therapy** (e.g., stereotactic radiotherapy or surgery) may be given to patients with isolated asymptomatic CNS progression (e.g., new CNS oligometastases).

Caution should be exercised when the following are co-administered with crizotinib:

- Bradycardia has been reported during clinical studies; therefore, the use of crizotinib in combination with other agents known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) should be avoided to the extent possible. Use crizotinib with caution owing to the risk of excessive bradycardia when used in combination with other bradycardic agents (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, beta-blockers, clonidine, guanfacine, digoxin, mefloquine, anticholinesterases, pilocarpine).

- The aqueous solubility of crizotinib is pH dependent, with higher pH resulting in lower solubility. Drugs that elevate the gastric pH (such as proton pump inhibitors, H$_2$ blockers, or antacids) may decrease the solubility of crizotinib and subsequently reduce its bioavailability.

- The inhibitory effect of crizotinib on uridine 5'-diphospho-glucuronosyltransferases (UGTs), notably UGT1A1, has not been established. Therefore, caution should be exercised when crizotinib and substrates of UGTs, such as paracetamol or morphine, are combined.

SECTION 4.5.8.1: **Laboratory Assessments**

- Urinalysis: Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein albumin and creatinine will be measured by dipstick test in order to assess micro- and macroproteinuria.

SECTION 4.5.8.2: **Pre-Treatment Tumor Samples (Mandatory)**

The tumor sample may also be tested for the presence of EGFR mutations, if requested by the investigator.

SECTION 4.5.8.3: **Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)**

Optional additional pre-treatment tumor samples and fresh post-treatment tumor biopsy at disease progression or permanent treatment discontinuation withdrawal from treatment (at the last treatment or post-progression visit) may be collected, with proper informed consent.
SECTION 4.5.8.4: Blood and Plasma Samples (Mandatory)

Mandatory blood samples will be obtained to determine:

- ALK mutations assessment in circulating tumor cells. It will require 2042 mL of blood sample to be collected (2 tubes of 106 mL each) at baseline and at disease progression (at the last treatment or post-progression visit). It should match in time to tumor progression (CNS and/or systemic disease progression).

- All patients who are randomized in alectinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alectinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Sections 4.5.8.4.1 and 4.5.8.5).

- Patients in the crizotinib arm who opt in to optional genomics sequencing will provide a 3 mL blood sample. This 3 mL blood sample will be used as a source of healthy tissue. This sample is required for all patients in the crizotinib arm who wish to participate in the optional genomic sequencing (see Section 4.5.8.4.1).

Optional blood samples will be collected to obtain:

- A source of healthy tissue for patients who agreed to participate in the optional genomic sequencing assessment. For patients in the crizotinib arm, a 3-mL blood sample will be drawn at baseline. For patients in the alectinib arm, a source of healthy tissue will be used as a portion of the sample for the pharmacogenomics research (see Section 4.5.8.4.1).

- A portion of this blood sample will also be used as a source of healthy tissue for the patients receiving alectinib treatment who agree to participate in the optional genomic sequencing research.

For biomarkers, a total maximum of 4335 mL of blood will be collected at baseline (20 mL for plasma purification and determination of mutation status in ALK and other escape genes, 2042 mL for ALK fusion detection in circulating tumor cells, and 3 mL for pharmacogenomics research), 20 mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 32 mL will be collected at disease progression (CNS and/or systemic disease progression) (20 mL for plasma purification for determination of mutation status in ALK and other escape genes and 2042 mL for ALK fusion detection in circulating tumor cells).

SECTION 4.5.8.5: Samples for Pharmacokinetic Assessments

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual. Actual sampling times will be recorded for each PK sample in the eCRF.
SECTION 4.5.9: Electrocardiograms
All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug administration) as well as prior to meals and should not be obtained within 3 hours after any meal.

SECTION 4.5.11.3: Sample Collection
For RCR purposes, 10 mL of blood will be collected. Any remaining tissue samples from study-related or non-study-related procedures that are performed during the study may also be collected for RCR purposes. For all samples, dates of consent and specimen collection should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.

SECTION 5.1.2.8: Cardiovascular Effects (QT Interval Prolongation)
Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse events, and decreases in heart rate based on ECG and pulse measurements, have also been reported.

In case of bradycardia, concomitant medications must be evaluated to identify those that are known to cause bradycardia, as well as anti-hypertensive medications; discontinuation or dose reduction of these concomitant medications must be considered.

SECTION 5.2: SAFETY PARAMETERS AND DEFINITIONS
Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest, performing measurement of protocol-specified safety laboratory assessments, measuring measurement of protocol-specified vital signs; and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study.

SECTION 5.3.1: Adverse Event Reporting Period
After initiation of study drug, all AEs, regardless of relationship to study drug, will be reported until 4 weeks after the last dose of study drug. After this period, the investigator should report any SAEs that are believed to be related to study drug treatment is not required to actively monitor patients for AEs; however, the Sponsor should be notified if the investigator becomes aware of any post study SAEs or non-SAEs of special interest (see Section 5.6).

SECTION 5.3.5.3: Persistent or Recurrent Adverse Events
A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time
the event is first reported. If a persistent AE becomes more severe, the most extreme intensity/severity should also be recorded on the Adverse Event eCRF.

SECTION 5.3.5.4: Abnormal Laboratory Values
Observations of the same clinically significant laboratory abnormality from visit to visit should only not be repeatedly recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent AEs). The initial severity of the event should be recorded, and the severity or seriousness should be updated any time the event worsens.

SECTION 5.3.5.5: Abnormal Vital Sign Values
Observations of the same clinically significant vital sign abnormality from visit to visit should only not be repeatedly recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent adverse events). The initial severity of the event should be recorded, and the severity or seriousness should be updated any time the event worsens.

SECTION 5.3.5.11: Adverse Events Associated with an Overdose or Error in Drug Administration
This section header was revised as shown above.

SECTION 5.3.5.13: Adverse Events in Individuals Not Enrolled in the Study
If an AE inadvertently occurs in an individual not enrolled in the study, the Adverse Event Form provided to investigators should be completed and submitted to Roche or its designee, either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

SECTION 5.4.2.1: Events That Occur Prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. A paper Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators and fax cover sheet should be completed and submitted faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address numbers provided to investigators (see "Protocol Administrative and Contact Information & List of Investigators").

SECTION 5.4.2.2: Events That Occur After Study Drug Initiation
In the event that the EDC system is unavailable, a paper Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators and fax cover sheet should be completed and submitted faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address numbers provided to investigators (see "Protocol Administrative and Contact Information & List of Investigators").
SECTION 5.4.3.1: Pregnancies in Female Patients

In the event that the EDC system is unavailable, a paper Clinical Trial Pregnancy Reporting Form should be completed and faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators (see “Protocol Administrative and Contact Information & List of Investigators”). Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

SECTION 5.5.1: Investigator Follow-Up

If, after follow-up, return to baseline status or stabilization cannot be established, an explanation should be recorded on the Adverse Event eCRF.

SECTION 5.6: POST-STUDY ADVERSE EVENTS

At the time of study completion or study discontinuation, the investigator should instruct each patient to report to the investigator any subsequent AEs that the patient’s personal physician believes could be related to prior study drug treatment or study procedures. The Sponsor should be notified if the investigator becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug), if the event is believed to be related to study drug treatment. However, the Sponsor should be notified if the investigator becomes aware of any death, other SAE, or non-SAE of special interest occurring after the end of the AE reporting period, regardless of causality. The Sponsor should also be notified if the investigator becomes aware of the development of cancer or a congenital anomaly/birth defect in a subsequently conceived offspring of a female patient exposed to study drug or the female partner of a male patient exposed to study drug.

The investigator should report these events directly to Roche or its designee, either by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number or email address provided to investigators (see “Protocol Administrative and Contact Information & List of Investigators”).

SECTION 6.1: DETERMINATION OF SAMPLE SIZE

At the time of writing the initial protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study
of patients who had received ≥ 1 line of chemotherapy (with 85% patients having received ≥ 2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of a median PFS of 9.8 months for the crizotinib arm has been reassessed on the basis of data from the Phase III study PROFILE 1014 to 10.9 months assumed. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 9.8 to 10.9 months median PFS to 15.1 to 16.8 months) will be targeted.

In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 245 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 1706 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events level of enrollment is estimated to occur approximately 334 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 246 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size (N=286), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude.

At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 10694 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.
SECTION 9.5: PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


The results of this study may be published or presented at scientific congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

If this is foreseen, the investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

TABLE 2: Guidelines for Management of Specific Adverse Events with Alectinib

Table 4 has been modified to reflect changes to the protocol.

TABLE 4: Crizotinib Dose Modification-Non-Hematologic Toxicities

Table 4 has been modified to reflect changes to the protocol.

TABLE 5: Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE

The title of Table 5 has been updated.

APPENDIX 1: Schedule of Assessments

The Schedule of Assessments has been revised to reflect the changes to the protocol.
APPENDIX 4: Response Evaluation Criteria in Solid Tumors (RECIST)  
Version 1.1: Excerpt from Original Publication

- **CR**: Disappearance of all non-target lesions and (if applicable) normalization of tumor marker level. 
  All lymph nodes must be non-pathological in size (< 10 mm short axis).

- **Non-CR/Non-PD**: Persistence of one or more non-target lesions and/or (if applicable) maintenance of tumor marker level above the normal limits.

SAMPLE INFORMED CONSENT FORMS

The sample Informed Consent Forms have been revised to reflect the changes to the protocol.
# TABLE OF CONTENTS

**PROTOCOL AMENDMENT ACCEPTANCE FORM .................................................** 23  
**PROTOCOL SYNOPSIS ..................................................................................** 24  
1. **BACKGROUND ..........................................................................................** 35  
   1.1 Background on Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer ................................ 35  
   1.2 Background on Alectinib ......................................................................... 37  
   1.3 Study Rationale and Benefit-Risk Assessment ....................................... 42  
2. **OBJECTIVES ................................................................................................** 44  
   2.1 Efficacy Objectives .................................................................................. 44  
   2.2 Safety Objectives .................................................................................... 45  
   2.3 Pharmacokinetic Objectives .................................................................... 45  
   2.4 Patient-Reported Outcome Objectives .................................................. 45  
   2.5 Exploratory Objectives .......................................................................... 45  
3. **STUDY DESIGN ..........................................................................................** 46  
   3.1 Description of Study ................................................................................ 46  
   3.2 End of Study ............................................................................................ 48  
   3.3 Rationale for Study Design ...................................................................... 48  
   3.3.1 Rationale for Alectinib Dosage .............................................................. 48  
   3.3.2 Rationale for Patient Population ........................................................... 49  
   3.3.3 Rationale for Control Group ................................................................. 49  
   3.3.4 Rationale for Open-Label Design ........................................................ 50  
   3.3.5 Rationale for Primary Endpoint Selection ......................................... 51  
   3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression .......... 52  
   3.3.7 Rationale for PK Sample Collection Schedule .................................... 53  
   3.3.8 Rationale for Biomarker Assessments ............................................... 54  
   3.3.9 Rationale for PRO Assessments ......................................................... 54  
   3.4 Outcome Measures .................................................................................. 55  
   3.4.1 Efficacy Outcome Measures ............................................................... 55  
   3.4.2 Safety Outcome Measures ................................................................... 56  
   3.4.3 Pharmacokinetic Outcome Measures ................................................. 56
3.4.4 Patient-Reported Outcome Measures ........................................... 57
3.4.5 Exploratory Outcome Measures ............................................... 57

4. MATERIALS AND METHODS ........................................................................ 57
4.1 Patients ........................................................................................................ 57
4.1.1 Inclusion Criteria .............................................................................. 57
4.1.2 Exclusion Criteria .............................................................................. 59
4.2 Method of Treatment Assignment and Blinding ..................................... 60
4.3 Study Treatment .................................................................................... 60
4.3.1 Formulation, Packaging, and Handling ............................................ 60
4.3.1.1 Alectinib .................................................................................. 60
4.3.1.2 Crizotinib ............................................................................... 61
4.3.2 Dosage, Administration, and Compliance ........................................ 61
4.3.2.1 Alectinib .................................................................................. 61
4.3.2.2 Crizotinib ............................................................................... 61
4.3.3 Investigational Medicinal Product Accountability ................................ 62
4.3.4 Post-Trial Access to Alectinib ............................................................ 62
4.4 Concomitant Therapy ............................................................................ 63
4.4.1 Permitted Therapy ............................................................................ 63
4.4.2 Prohibited Therapy .......................................................................... 65
4.4.3 Prohibited Food ................................................................................ 66
4.5 Study Assessments .................................................................................. 66
4.5.1 Informed Consent Forms and Screening Log .................................... 66
4.5.2 Medical History and Demographic Data .......................................... 66
4.5.3 Corticosteroid Use for CNS Metastases .......................................... 66
4.5.4 Physical Examinations ...................................................................... 67
4.5.5 Vital Signs .......................................................................................... 67
4.5.6 ECOG Performance Status ............................................................... 67
4.5.7 Tumor and Response Evaluations .................................................... 67
4.5.8 Laboratory, Biomarker, and Other Biological Sample ....................... 69
4.5.8.1 Laboratory Assessments ............................................................ 69
4.5.8.2 Pre-Treatment Tumor Samples (Mandatory) ................................. 69
4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional) .............................................................. 70
4.5.8.4 Blood and Plasma Samples ............................................................................................................. 70
4.5.8.5 Samples for Pharmacokinetic Assessments .................................................................................. 72
4.5.9 Electrocardiograms ............................................................................................................................ 72
4.5.10 Patient-Reported Outcomes ............................................................................................................ 73
4.5.11 Samples for Roche Clinical Repository .......................................................................................... 73
4.5.11.1 Overview of the Roche Clinical Repository ................................................................................. 73
4.5.11.2 Approval by the Institutional Review Board or Ethics Committee ............................................. 74
4.5.11.3 Sample Collection ......................................................................................................................... 74
4.5.11.4 Confidentiality ............................................................................................................................... 74
4.5.11.5 Consent to Participate in the Roche Clinical Repository .............................................................. 75
4.5.11.6 Withdrawal from the Roche Clinical Repository .......................................................................... 75
4.5.11.7 Monitoring and Oversight ........................................................................................................... 76
4.6 Patient, Treatment, Study, and Site Discontinuation .......................................................................... 76
4.6.1 Patient Discontinuation ..................................................................................................................... 76
4.6.2 Study Treatment Discontinuation ...................................................................................................... 76
4.6.3 Study and Site Discontinuation ......................................................................................................... 77

5. ASSESSMENT OF SAFETY ..................................................................................................................... 77
5.1 Safety Plan ........................................................................................................................................... 77
5.1.1 Adverse Events Collection ................................................................................................................ 77
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data ........................................................................................................................................ 78
5.1.2.1 Interstitial Lung Disease .............................................................................................................. 78
5.1.2.2 Hepatobiliary Laboratory Test Elevations ..................................................................................... 78
5.1.2.3 Hematologic Abnormalities ......................................................................................................... 78
5.1.2.4 Gastrointestinal Disorders ......................................................................................................... 79
5.1.2.5 Skin Disorders ............................................................................................................................. 79
5.1.2.6 Vision Disorders ............................................................................................................................ 79
5.1.2.7 Edema ........................................................................................................................................... 80
5.1.2.8 Cardiovascular Effects ........................................................... 80
5.1.2.9 Abnormal Renal Function .................................................. 80
5.1.2.10 Muscular Adverse Events and CKP Elevations .............. 81
5.1.3 Management of Specific Adverse Events with Alectinib ........................................................... 82
5.1.4 Safety of Crizotinib and Management of Adverse Events ................................................................................. 86
5.2 Safety Parameters and Definitions ........................................89
5.2.1 Adverse Events .....................................................................89
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor) ........................................................... 90
5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor) ..............................90
5.3 Methods and Timing for Capturing and Assessing Safety Parameters ........................................................... 91
5.3.1 Adverse Event Reporting Period ........................................ 91
5.3.2 Eliciting Adverse Event Information ................................... 91
5.3.3 Assessment of Severity of Adverse Events ...................... 91
5.3.4 Assessment of Causality of Adverse Events ..................... 92
5.3.5 Procedures for Recording Adverse Events ............................ 93
5.3.5.1 Diagnosis Versus Signs and Symptoms ......................... 93
5.3.5.2 Adverse Events that are Secondary to Other Events ............................................................................. 93
5.3.5.3 Persistent or Recurrent Adverse Events ......................... 93
5.3.5.4 Abnormal Laboratory Values ........................................ 94
5.3.5.5 Abnormal Vital Sign Values .......................................... 95
5.3.5.6 Abnormal Liver Function Tests ....................................... 95
5.3.5.7 Deaths ................................................................................... 95
5.3.5.8 Preexisting Medical Conditions ....................................... 96
5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer .......................................................................... 96
5.3.5.10 Hospitalization or Prolonged Hospitalization ................ 96
5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration ............................................. 97
5.3.5.12 Patient-Reported Outcome Data ..................................... 97
5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study ................................................................................................................. 97

5.4 Immediate Reporting Requirements from Investigator to Sponsor ................................................................................................. 97

5.4.1 Emergency Medical Contacts ................................................................................................................................................................. 98

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest ...................................................................................................................... 98

5.4.2.1 Events That Occur Prior to Study Drug Initiation ................................................................................................................................. 98

5.4.2.2 Events That Occur After Study Drug Initiation ................................................................................................................................. 98

5.4.3 Reporting Requirements for Pregnancies ............................................................................................................................................. 99

5.4.3.1 Pregnancies in Female Patients ............................................................................................................................................................... 99

5.4.3.2 Pregnancies in Female Partners of Male Patients ................................................................................................................................ 99

5.4.3.3 Abortions ................................................................................................................................................................................................. 100

5.4.3.4 Congenital Anomalies/Birth Defects ....................................................................................................................................................... 100

5.5 Follow-Up of Patients after Adverse Events ........................................................................................................................................... 100

5.5.1 Investigator Follow-Up ............................................................................................................................................................................. 100

5.5.2 Sponsor Follow-Up .................................................................................................................................................................................. 100

5.6 Post-study Adverse Events ............................................................................................................................................................................ 101

5.7 Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Ethics Committees .................................................................................................................................................. 101

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN ......................................................................................................................... 101

6.1 Determination of Sample Size .................................................................................................................................................................. 102

6.2 Summaries of Conduct of Study ................................................................................................................................................................. 103

6.3 Summaries of Treatment Group Comparability ......................................................................................................................................... 104

6.4 Efficacy Analyses ............................................................................................................................................................................................ 104

6.4.1 Primary Efficacy Endpoint ............................................................................................................................................................................ 104

6.4.2 Secondary Efficacy Endpoints ................................................................................................................................................................. 105

6.4.2.1 Sensitivity Analyses ..................................................................................................................................................................................... 107

6.4.2.2 Subgroup Analyses .................................................................................................................................................................................. 107

6.5 Safety Analyses ............................................................................................................................................................................................... 107

6.6 Pharmacokinetic Analyses .......................................................................................................................................................................... 108

6.7 Patient-Reported Outcome Analyses .......................................................................................................................................................... 109
Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia) ................................................................. 87
Table 4 Crizotinib Dose Modification—Non-Hematologic Toxicities .......... 88
Table 5 Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE .................................................. 92

LIST OF FIGURES

Figure 1 Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013) .................. 38
Figure 2 Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ........................................................................ 40
Figure 3 Best Percent Change in Size of Target Lesions from Baseline as Assessed by the Investigator in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ........................................................................ 41
Figure 4 Summary of Study Design ........................................................................ 47

LIST OF APPENDICES

Appendix 1 Schedule of Assessments ....................................................................... 124
Appendix 2 Schedule of Alectinib Pharmacokinetic Assessments .............................. 130
Appendix 3 List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters ................................................. 131
Appendix 4 Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication .................................................. 133
Appendix 5 Eastern Cooperative Oncology Group Performance Status Scale ................................................................. 144
Appendix 6 EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires .................. 145
Appendix 7 Modification of Diet in Renal Disease (MDRD) Formula ........................ 151
Appendix 8 Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry .... 152
Appendix 9 Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms ................................................................. 153
PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 2
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [redacted]
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [redacted]
SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

________________________________________
Principal Investigator’s Name (print)

________________________________________
Principal Investigator’s Signature Date

Please return a copy of the form to your local study monitor. Please retain the original for your study files.
PROTOCOL SYNOPSIS

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 2
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
UTN NUMBER: [redacted]
TEST PRODUCT: Alectinib (RO5424802)
PHASE: Phase III
INDICATION: Anaplastic lymphoma kinase–positive (ALK-positive) non–small cell lung cancer (NSCLC)
SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives
The primary efficacy objective for this study is as follows:
• To evaluate and compare the efficacy of alectinib compared with crizotinib in patients with treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as measured by investigator-assessed progression-free survival (PFS)

The secondary efficacy objectives for this study are as follows:
• To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of Independent Review Committee (IRC) review of radiographs by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the overall survival (OS)

Safety Objective
The safety objective for this study is as follows:
• To evaluate the safety and tolerability of alectinib compared with crizotinib
Pharmacokinetic Objective
The secondary pharmacokinetic (PK) objective for this study is as follows:
• To characterize the pharmacokinetics of alectinib and metabolite(s)

Patient-Reported Outcome Objectives
The secondary patient-reported outcome (PRO) objectives for this study are as follows:
• To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm/shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain).
• To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13.

Exploratory Objectives
The exploratory objectives for this study are as follows:
• To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement.
• To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone, albumin and sex hormone-binding globulin (SHBG) to calculate free testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood.
• To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
• To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
• To investigate molecular mechanisms of resistance to ALK inhibitors.
• To investigate detection of ALK mutations in plasma and circulating tumor cells.

Study Design
Description of Study
This is a randomized, active controlled, multicenter Phase III open-label study in patients with treatment-naïve ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide. Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally twice daily (BID), taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases) a local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment...
beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

**Number of Patients**

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

**Target Population**

**Inclusion Criteria**

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old.
- Life expectancy of at least 12 weeks.
- ECOG PS of 0-2.
- Patients had no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC.
- Adequate hematologic function:
  - Platelet count ≥ 100 x 10^9/L
  - ANC ≥ 1500 cells/μL
  - Hemoglobin ≥ 9.0 g/dL
- Adequate renal function:
  - An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m^2
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- Measurable disease (by RECIST v1.1) prior to the administration of study treatment.
- Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
- For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
• For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate <1% per year. Barrier methods must always be supplemented with the use of a spermicide.

• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• Able and willing to provide written informed consent prior to performing any study related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome device.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

• Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

• Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection.

• Liver disease characterized by:
  ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  OR
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  OR
  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

• National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication.

• History of organ transplant.

• Co-administration of anti-cancer therapies other than those administered in this study.

• Patients with baseline QTc>470 ms or symptomatic bradycardia.

• Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib except for oral corticosteroids up to 20 mg of prednisolone equivalent per day

• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment.
- History of hypersensitivity to any of the additives in the alectinib drug formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulfate [SLS], magnesium stearate).
- History of hypersensitivity to any of the additives in the crizotinib drug formulation (silica, colloidal anhydrous cellulose, microcrystalline calcium hydrogen phosphate, anhydrous sodium starch glycolate, magnesium stearate).
- Pregnant or lactating women.
- Known HIV positivity or AIDS-related illness.
- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study.
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.

Length of Study
The time from first patient screened to end of study, defined below, will be approximately 43 months.

End of Study
This study is event-driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Outcome Measures
Efficacy Outcome Measures
The efficacy outcome measures for this study are as follows:
- PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.
- ORR, which is defined as the percentage of patients who attain complete response (CR) or partial response (PR); response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.
- Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.
- DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.
• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

Safety Outcome Measures
The secondary safety outcome measures for this study are as follows:
• Serious and non-serious adverse events
• Safety laboratory tests values
• Vital signs (blood pressure, heart rate), ECG
• Physical examination

Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:
• Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment
• Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%−15%, at least approximately n=20)
• PK parameters will be determined as appropriate and where data allow:
  - The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach.
  - The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  - Non-compartmental analysis may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

Patient-Reported Outcome Measures
The PRO measures for this study are as follows:
• EORTC QLQ-C30 and the EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).
• The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:
• EQ-5D-3L to generate utility scores for use in economic models for reimbursement.
• Total testosterone, albumin and SHBG to calculate free testosterone level, FSH, and LH, in blood to measure an onset of hypogonadism in adult men.
• The FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naïve NSCLC that is ALK-positive by FISH test.
• Post progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors.
• ALK mutation status in plasma DNA to monitor efficacy and disease progression.
• ALK fusion status in circulating tumor cells in blood.

Investigational Medicinal Products
Test Product
Alectinib comes in a hard capsule dosage form containing the following active ingredient:
[Chemical name] 9-Ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate.

Alectinib capsules should be stored in accordance with the storage instructions on the label. Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

**Comparator**

Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (Xalkori®).

**Non-Investigational Medicinal Products**

Standard-of-care therapy administered to all patients in addition to test product or comparator.

**Statistical Methods**

**Primary Analysis**

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of PFS of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[
H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \\
\text{versus} \\
H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)}
\]

where SDF denotes the survival distribution function of the parameter PFS.

**Determination of Sample Size**

The focus of this clinical trial is hypothesis testing, and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of initially writing the protocol, there were no Phase III data available on crizotinib in the first line setting in ALK-positive patients. The median PFS for crizotinib administered as second line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).
Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed based on data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted. In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

**Interim Analyses**

No interim analysis for efficacy or futility is planned.
### LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma kinase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration–time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C-DOR</td>
<td>CNS duration of response</td>
</tr>
<tr>
<td>C-ORR</td>
<td>CNS objective response rate</td>
</tr>
<tr>
<td>C-PR</td>
<td>CNS progression rate</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>DOT</td>
<td>duration of treatment</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>Eastern Cooperative Oncology Group Performance Status</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EML4</td>
<td>echinoderm microtubule-associated protein-like 4</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for the Research and Treatment of Cancer</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-3L</td>
<td>EuroQoL 5 Dimension</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FISH</td>
<td>fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FPP</td>
<td>FISH Positive Population</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (application)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRC</td>
<td>Independent Review Committee</td>
</tr>
<tr>
<td>ITT</td>
<td>intent to treat</td>
</tr>
<tr>
<td>IxRS</td>
<td>interactive voice or web-based response system</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>MET</td>
<td>mesenchymal-epithelial transition factor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NCA</td>
<td>non-compartmental analysis</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>not evaluable</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non–small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>patient-reported outcome</td>
</tr>
<tr>
<td>QLQ-C30</td>
<td>Quality of Life Questionnaire–Core</td>
</tr>
<tr>
<td>QLQ-LC13</td>
<td>Quality of Life Questionnaire lung cancer module</td>
</tr>
<tr>
<td>RANO</td>
<td>Revised Assessment in Neuro Oncology</td>
</tr>
<tr>
<td>RCR</td>
<td>Roche Clinical Repository</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>ROS1</td>
<td>c-ros oncogene 1</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Safety Analysis Population</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SDF</td>
<td>survival distribution function</td>
</tr>
<tr>
<td>SLS</td>
<td>sodium lauryl sulfate</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TTD</td>
<td>time to deterioration</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine 5'-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
1. BACKGROUND

1.1 BACKGROUND ON ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON–SMALL CELL LUNG CANCER

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Lung cancer was estimated to cause 160,340 deaths in the United States in 2012, accounting for 28% of all cancer-related deaths according to the report from the American Lung Association (Lung Cancer Fact Sheet). There is an annual incidence of 310,000 cases of NSCLC in men in the Europe with a mortality of 276,000 deaths (GLOBOCAN 2008). Among women in the Europe, there is an annual incidence of 107,000 cases and a mortality of 91,000 deaths. In total, there are 417,000 cases of NSCLC and 367,000 deaths in Europe each year, which represents a major health problem. Survival rates for lung cancer tend to be much lower than other common cancers because of its late diagnosis and limited effective therapy in the advanced stage. The expected 5-year survival rate for all patients in whom lung cancer is diagnosed is 16.3% compared with 65.2% for colon cancer, 90.0% for breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012). Conventional anti-cancer therapies are far from satisfactory, and there is an unmet medical need for the development of new therapies for NSCLC.

Recent progress in the identification of genetic mutations or chromosomal rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other genes has provided new opportunities to use targeted therapeutic agents for the treatment of NSCLC, when the tumor is identified as having these mutations (Katayama et al. 2011; Doebele et al. 2012).

Approximately 5% of NSCLC cases have been shown to harbor the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; Ou et al. 2012). The formation of the resulting ALK fusion protein results in activation and dysregulation of the gene’s expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these genes. This is further supported by reports that the TFG and KIF5B genes can also serve as ALK fusion partners in some NSCLC patients. Expression of these ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced proliferation. ALK gene alterations are generally in a mutually exclusive relationship with mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism after treatment with crizotinib (Doebele et al. 2012). Inhibition of ALK activity in Ba/F3 cells transfected with the EML4-ALK fusion protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models harboring the EML4-ALK and

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2
nucleophosmin-ALK fusion proteins, respectively. Hence, ALK appears to be a suitable therapeutic target for NSCLC with ALK gene rearrangements.

Wild-type ALK is hardly expressed at all in most normal human tissues, being expressed at higher levels in a few limited types of tissue such as developing and mature nervous system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997). By contrast, an aberrant ALK with constitutively active kinase results from the formation of the EML4-ALK fusion gene by chromosomal translocation.

Currently, the only approved medicine for treatment-naïve ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), recepteur d'origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

Crizotinib was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test in August 2011. The approval was based on two single-arm trials. The primary endpoint of both trials was ORR as assessed by the investigator. In one study, the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks, and, in other study, the ORR was 61% (95% CI: 52%, 70%) with a median response duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012). In November 2013, the FDA granted regular approval for crizotinib on the basis of demonstrating superior progression-free survival (PFS) and ORR for crizotinib compared with chemotherapy in patients with ALK-positive NSCLC whose disease progressed after platinum-based doublet chemotherapy (PROFILE 1007 study). An open-label active-controlled multinational randomized trial enrolled 347 patients with ALK-positive metastatic NSCLC. Patients were required to have disease progression following platinum-based chemotherapy. The trial demonstrated significantly prolonged PFS with crizotinib treatment compared with chemotherapy (HR=0.49 [95% CI: 0.37, 0.64], p<0.0001). Median PFS was 7.7 months for patients treated with crizotinib and 3.0 months for patients treated with chemotherapy. The ORR was significantly higher for patients treated with crizotinib (65% vs. 20%), with median response durations of 7.4 months for patients treated with crizotinib and 5.6 months for patients treated with chemotherapy. No difference in overall survival (OS) was noted between the two groups (HR=1.02 [95% CI: 0.68%, 1.54%]) in a planned interim analysis (Shaw et al. 2013). Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue (National Cancer Institute 2013). These results showed that an ALK inhibitor is effective in patients with NSCLC harboring ALK fusion genes. Crizotinib has subsequently been approved in other countries, such as Japan, Korea, Canada, and Switzerland. In the European Union, crizotinib was conditionally approved in October 2012 for the treatment of adults with previously treated ALK positive NSCLC.
Although substantial benefit has been observed with crizotinib therapy, relapse remains the norm. Studies with patients who had progression with crizotinib treatment reveal two main reasons for treatment failure: the development of resistance because of secondary (e.g., gatekeeper) mutations (predominantly in ALK or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease). The CNS is the primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC treated with crizotinib (Costa et al. 2011; Chun et al. 2012; Weickhardt et al. 2012). Significant morbidity is associated with brain metastases as a function of brain involvement, and because of treatment (corticosteroids, surgery, and radiation) required for disease control.

A new generation of ALK inhibitors will have the potential to overcome these two major limitations of crizotinib treatment to offer patients a better chance of prolonged remission and minimize the development of CNS metastases and the attendant comorbidity.

1.2 BACKGROUND ON ALECTINIB

Alectinib (also RO5424802 or CH5424802) is a newly developed small molecule, highly selective, and potent oral next-generation ALK inhibitor with a benzo[b]carbazole scaffold. In enzyme inhibition assays performed in vitro, this compound has been shown to selectively inhibit ALK. The compound also shows high antitumor activity both in vitro and in vivo against tumor cell lines with some type of ALK gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an ALK translocation and a neuroblastoma line harboring amplified ALK gene.

Nonclinical pharmacology studies showed that alectinib is efficacious in a model of tumors expressing an ALK fusion bearing the L1196M mutation, which is associated with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC xenografts that are already maximally suppressed by crizotinib. Alectinib also prolongs survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth in an intracranial model monitored using bioluminescence.

The clinical development program for alectinib, to date, comprises three ongoing Phase I/II studies in patients with ALK-positive NSCLC. The ongoing Phase I/II studies are as follows: Study AF-001JP, which is being conducted in Japan; Study NP28761/AF-002JG, which is being conducted in United States and Canada; and Study NP28673, which is being conducted globally.

The first-in-human study AF-001JP is an open-label Phase I/II study being conducted in Japan. This study is assessing the pharmacokinetics, safety, and efficacy of alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy. This study has completed enrollment, but it is still ongoing. A total of 70 patients were included (24 patients in the Phase I portion and 46 patients in the Phase II portion of the study). In the Phase I
portion of the study, at the data cutoff date of 31 July 2012, 24 patients were treated at doses of 20–300 mg twice daily (BID). No dose-limiting toxicities (DLTs) or adverse events of Grade 4 were noted up to the highest dose; thus, 300 mg BID was evaluated in the Phase II portion of the study without further escalating the dose. In the Phase II portion of the study, 46 patients were treated with the highest evaluated dose of 300 mg BID, of whom 43 achieved an objective response (93.5%; 95% CI: 82.1%, 98.6%) and 7 patients had a complete response (CR) on the basis of an independent radiological review in the 12-month follow-up analysis (data cutoff for response data: 18 April 2013). The median duration of treatment (DOT) in the study has not been achieved at that date because 86% of patients were still on treatment in the study, but the projected median DOT is more than 14 months as data mature.

Figure 1 shows the waterfall plot of the best change from baseline in the size of target lesions by an independent radiological review. Table 1 shows the objective response rate (ORR) by time interval. The majority (86%) of patients had a time to response of within 6 weeks after administration of the first dose.

Figure 1  Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013)
Two of 7 patients who were assessed as having a CR had lymph nodes as the target lesions. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), the percent change from baseline for patients with CR can be less than 100% when lymph nodes are identified as the target lesions. Therefore, they were assessed as having CR, although their tumor change from baseline was less than 100%.

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP

<table>
<thead>
<tr>
<th>Response (Data Cutoff Date: 18 April 2013)</th>
<th>IRC Assessment (N = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
</tr>
<tr>
<td>Partial response</td>
<td>36</td>
</tr>
<tr>
<td>Stable disease</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2</td>
</tr>
<tr>
<td>Total response</td>
<td>43</td>
</tr>
<tr>
<td>Overall response rate (95% CI)</td>
<td>93.5% (82.1%, 98.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to Response</th>
<th>IRC Assessment (N = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to ≤ 3 weeks</td>
<td>22 (51%)</td>
</tr>
<tr>
<td>&gt; 3 to ≤ 6 weeks</td>
<td>15 (35%)</td>
</tr>
<tr>
<td>&gt; 6 to ≤ 9 weeks</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>&gt; 9 weeks</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>

IRC = Independent Review Committee.

In Study NP28761/AF-002JG (crizotinib-failed ALK-positive NSCLC patients), the Phase I portion has completed enrollment. Two ‘bridging’ cohorts of patients receiving alectinib using the 150-mg capsule at 600 and 900 mg BID were included in Study NP28761/AF-002JG to transition/facilitate the planned formulation for the Phase II trials. A total of 47 patients were enrolled in Phase I (Part 1). There does not appear to be any substantial difference in pharmacokinetics between the two formulations (20/40-mg capsule and the 150-mg capsule) at the 600-mg dose on the basis of available data.

The radiological imaging analysis performed in 44 evaluable patients who had a baseline scan and at least one follow-up scan (data cutoff date: 12 September 2013) has shown that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort have achieved a confirmed partial response (PR), as assessed by the investigator. Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort have achieved a PR, as assessed by the investigator, which is still to be confirmed. Three patients (all in the 600-mg BID
dosage cohort) were unevaluable. The ORR was 54.5% (i.e., 24 of 44 evaluable patients who had a baseline scan and at least one post-treatment scan available to determine overall response, or who had a best overall response of progressive disease [PD] determined by the investigator, on the basis of symptomatic progression [3 patients]), including unconfirmed responses across all dose cohorts. Thirty-three of the 47 (70%) treated patients were still receiving study treatment. The durations of dosing by cohort are shown in Figure 2.

Figure 2 Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013)

The waterfall plot for the 42 patients, with a post-baseline radiological tumor assessment, is shown in Figure 3. On the basis of the data analyzed at that date, 27 patients experienced tumor shrinkage of >30%, of whom 23 patients were assessed as experiencing PR (9 of which are still to be confirmed by a second tumor assessment).
Study NP28673 started enrollment on 20 June 2013 and no data were available to report at this time.

The benefit of alectinib on CNS activity has been described by the DOT (before progression) or ORR in patients with brain metastases at baseline in the two active studies: Study AF-001JP in Japan and Study NP28761/AF-002JG in the United States. In Phase II of Study AF-001JP, 14 of the 46 (30%) crizotinib-naïve patients had documented CNS lesions before enrollment into the trial. Three of these 14 patients were asymptomatic and had not received prior CNS radiation. At the clinical cutoff date of 18 March 2013, 5 of the 14 patients were off-study because of systemic disease progression or an adverse event. Nine patients remain in the study with DOT ranging from 10 to 18 months (none of these patients presented signs or evidence of systemic disease or CNS progression).

Similarly, in Study NP28761/AF-002JG, among the 47 patients enrolled (data cutoff date: 12 September 2013), 21 patients (45%) were known to have brain metastases at baseline. Of these 21 patients, 11 (52%) achieved an ORR as determined by Independent Review Committee (IRC; data cutoff date: 12 September 2013) (Inoue et al. 2013). Moreover, of these 21 patients, 17 remained on active study treatment and 4 discontinued study treatment because of systemic PD (1 patient had
both systemic disease and CNS progression). No patient discontinued because of CNS progression alone.

In addition, 2 patients with leptomeningeal carcinomatosis received benefit from alectinib treatment. One patient with leptomeningeal spread in Study NP28761/AF-002JG achieved PR after 6 weeks of treatment. Another patient with leptomeningeal carcinomatosis but without systemic lesions was treated under a single-patient Investigational New Drug (IND) application because of ineligibility to enter either of the two Phase II alectinib studies (because of the high intake of dexamethasone for symptom control). After 6 weeks of treatment, this patient achieved CR as demonstrated by complete disappearance of gadolinium enhancement on magnetic resonance imaging (MRI) and disappearance of positive CSF cytology. This patient has been able to reduce corticosteroids to physiological replacement dose only.

See the Alectinib Investigator's Brochure for additional details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Over the past 10 years, the treatment of NSCLC has become increasingly focused on guiding treatment based on the presence or absence of an actionable mutation. Numerous oncogenes have now been identified in NSCLC, including mutations in the genes coding for EGFR, KRAS, phosphoinositide-3-kinase, catalytic, α polypeptide, and human EGFR 2 (Pao and Girard 2011). As described in previous sections, a translocation in the gene encoding the receptor tyrosine kinase ALK, leading to the expression of ALK fusion proteins, was identified as an oncogenic driver in a subset of patients with NSCLC (Soda et al. 2007). ALK rearrangements are found in approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012;).

Crizotinib is the first ALK inhibitor that is approved and has been registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The previous clinical studies reported that the median PFS with crizotinib ranged from 7.7 to 9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013). The PROFILE 1014 study, a Phase III study of crizotinib compared with standard pemetrexed–platinum–based chemotherapy, was presented at the ASCO 2014 congress (Mok et al. 2014). The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p <0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively.
Although substantial benefit has been observed with crizotinib therapy, relapse eventually occurs. Two main reasons for this are the development of resistance because of secondary (e.g., gatekeeper) mutations or CNS relapse (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). This could be due to the fact that crizotinib is a P-gp substrate and has a low penetration in the CNS. Thus ALK-positive NSCLC treated with crizotinib has impaired control of brain metastases relative to other sites of systemic disease, with 46% of progressions in patients treated with crizotinib involving the CNS (Costa et al. 2011; Weickhardt et al. 2012). The CNS becomes a sanctuary site for ALK-positive NSCLC treated with crizotinib—a physiologic and anatomic mechanism of drug resistance.

Alectinib is a highly selective and potent, oral next generation ALK inhibitor. Clinical data from the Phase II portion of the still ongoing Study AF-001JP, assessing alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy, reported that the median treatment duration in the study has not been achieved as 86% of patients were still active on the study, but the projected median DOT is estimated to be at least 14 months as data mature (Inoue et al. 2013).

Moreover, alectinib is lipophilic drug and not a P-glycoprotein (P-gp) substrate, thus, could penetrate through the blood-brain barrier and has the potential to reach higher concentration in brain as compared with substrates of the P-gp, such as crizotinib. This has been shown in the nonclinical setting on the basis of the prolongation of survival in a mouse model with implanted CNS lesions and in a tissue distribution study with a single oral dose of $^{14}$C-alectinib at 1 mg/kg to albino rats (Ou et al. 2013). Preliminary clinical data from the Phase I/II studies show consistent therapeutic efficacy of alectinib in brain metastases.

The clinical efficacy data is compelling given the shown activity for a longer progression free interval with alectinib and improved activity in the CNS, thus delaying the impact of CNS metastases on neurologic function along with the morbidities associated with treatment like brain radiation, surgery and corticosteroid use required for disease control. The currently available clinical safety data is supportive for an acceptable safety and tolerability profile with alectinib. Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for treatment-naïve ALK-positive advanced NSCLC patients.

Alectinib was granted approval in Japan on 4 July 2014 for ALK fusion gene-positive, unresectable, recurrent, or advanced NSCLC.

In this proposed Phase III study, treatment-naïve patients with ALK-positive advanced NSCLC will be enrolled and will be randomized to receive either crizotinib or alectinib treatment. The results of this study will determine whether alectinib treatment has superior efficacy compared with crizotinib.
The first Phase I dose-escalation study of alectinib conducted only in Japan (Study AF001-JP), with a dose schedule of 20, 40, 80, 160, 240, and 300 mg BID orally, showed that alectinib was generally well tolerated without major toxicities. Of the 58 patients who received treatment with 300 mg BID alectinib in Study AF-001JP, 27 experienced Grade 3 adverse events and 9 experienced serious adverse events. No deaths were reported during this study and up to 28 days after treatment discontinuation. There were 5 adverse events leading to treatment discontinuation in Part 2 (brain edema, sclerosing cholangitis, interstitial lung disease [ILD], ALT increased, and tumor hemorrhage). Alectinib was well tolerated at all doses investigated in this study. Its adverse event profile was consistent with the one known to be associated with TKIs. In the Phase II Study NP28761/AF-002JG, alectinib was well tolerated, with no DLTs or treatment-related dose modifications up to 600 mg BID. Two DLTs were reported at 900 mg BID. The recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best balance between clinical safety, efficacy, and pharmacokinetic (PK) data as observed in the Phase I/II studies (see Section 3.3.1).

On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks, specifically:

- Available nonclinical and clinical data demonstrate that alectinib is active in NSCLC in crizotinib-naïve patients as well as after progression on prior crizotinib therapy
- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with TKIs.

Identified and potential risks associated with alectinib treatment will continue to be closely monitored throughout the clinical program. Patient safety during the alectinib program is ensured by: targeting the most appropriate patient population, stringent safety monitoring by the Sponsor and Independent Data Monitoring Committee (IDMC), and by protocol-specified study drug interruption criteria.

2. **OBJECTIVES**

2.1 **EFFICACY OBJECTIVES**

The primary efficacy objective for this study is as follows:

- To evaluate and compare the efficacy of alectinib compared with crizotinib in patients with treatment-naïve ALK-positive advanced NSCLC, as measured by investigator-assessed PFS

The secondary efficacy objectives for this study are as follows:

- To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of IRC review of radiographs by RECIST v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the OS

2.2 SAFETY OBJECTIVES
The secondary safety objective for this study is as follows:
• To evaluate the safety and tolerability of alectinib compared with crizotinib

2.3 PHARMACOKINETIC OBJECTIVES
The secondary PK objective for this study is as follows:
• To characterize the pharmacokinetics of alectinib and metabolite(s)

2.4 PATIENT-REPORTED OUTCOME OBJECTIVES
The secondary patient-reported outcome (PRO) objectives for this study are as follows:
• To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm/shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain).
• To evaluate and compare PROs of (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13.

2.5 EXPLORATORY OBJECTIVES
The exploratory objectives for this study are as follows:
• To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement.
• To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone, albumin and sex hormone-binding globulin (SHBG) to calculate free testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood.
• To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
• To investigate molecular mechanisms of resistance to ALK inhibitors.
• To investigate detection of ALK mutations in plasma and circulating tumor cells.

3. STUDY DESIGN
3.1 DESCRIPTION OF STUDY
This is a randomized, active-controlled, multicenter Phase III open-label study in patients with treatment-naïve ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by Ventana immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide.

The primary endpoint of the study is investigator-assessed PFS.

Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. The first dose of the study drug should be administered as soon as possible after randomization, preferably within 24 hours, and no later than 48 hours after randomization.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from their respective treatment.
Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Approximately 286 patients (143 per treatment arm) will be enrolled into the study over a planned competitive recruitment period of 24 months. Patients inappropriately randomized into the study will not be replaced. The final analysis evaluating the primary endpoint of investigator-assessed PFS will occur when approximately 170 patients have progressed or died which is expected to occur approximately 33 months after the first patient has been enrolled. Data collection will continue for each patient until death or study closure, whichever occurs first.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised as outlined in Section 9.4.

A summary of the study design is shown in Figure 4.

A schedule of assessments is provided in Appendix 1.

**Figure 4  Summary of Study Design**

```
Screening assessment

- 28 days

1:1 Randomization with stratification (n=286)

≤ 24 hours

600 mg BID alectinib

250 mg BID crizotinib

Until disease progression, unacceptable toxicity, withdrawal of consent, or death

Subsequent therapy for NSCLC and Survival follow-up
```
3.2 END OF STUDY

This study is event-driven, with a recruitment period of approximately 24 months. The required number of events for the final analysis of the primary endpoint is expected approximately 33 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Alectinib Dosage

Selection of the alectinib dose for the study is based on the clinical safety, efficacy, and PK data observed in the Phase I/II studies, AF-001JP and NP28761/AF-002JG, and the supportive nonclinical data for alectinib.

The first-in-human study, AF-001JP evaluated escalating doses of alectinib in an accelerated titration scheme to rapidly identify the maximum tolerated dose (MTD). All doses, including the highest evaluated dose in the study, 300 mg BID, were well tolerated with no DLTs observed at any dose. The highest tested dose, 300 mg BID, was further evaluated in the Phase II portion of the study and demonstrated robust efficacy and good safety with an ORR by IRC of 93.5% (43/46 patients; 95% CI: 82.1%, 98.6%).

With no MTD determined in Study AF-001JP, dose escalation progressed in the United States Study NP28761/AF-002JG using a modified 3+3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation. The starting dose in Study NP28761/AF-002JG was the highest dosage evaluated in Study AF-001JP, 300 mg BID. Following multiple dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, median alectinib exposure (area under the concentration time curve [AUC] from 0 to 10 hours) appeared to be approximately two-fold lower compared with that in patients from Study AF-001JP, which demonstrated the robust efficacy and safety. Dose escalation progressed with evaluation of higher doses of alectinib up to 900 mg BID.

In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts, up to dose-level of 900 mg BID. However, 2 patients in the subsequent 900 mg BID bridging cohort experienced a DLT; 1 patient had Grade 3 headache and 1 patient had Grade 3 neutropenia, and both patients continued study treatment at a reduced dosage of 600 mg BID. Overall, alectinib was well tolerated in the study population.
Importantly, administration of 600 mg BID provides systemic exposures that meet or exceed exposures achieved in patients receiving 300 mg BID in Study AF-001JP, demonstrating its robust efficacy and safety in crizotinib-naïve patients. Further, in Study NP28761/AF-002JG, the 600-mg BID regimen has demonstrated promising activity in crizotinib-resistant patients, including activity in patients with CNS metastases while being tolerated by patients. On the basis of available preclinical data, administration of alectinib 600 mg BID provides systemic exposures within the expected range (on the basis of regression of available data) for tumor regression observed in mouse xenograft models.

Thus, on the basis of nonclinical and clinical data, a dosing regimen of 600 mg BID of alectinib has been chosen as the optimal therapeutic dose level with the best balance between efficacy and safety.

Alectinib 600 mg should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

### 3.3.2 Rationale for Patient Population

The study population will comprise patients with non-resectable, locally advanced and metastatic NSCLC who have been shown to be ALK-positive by Ventana IHC test performed at central laboratories specially designated for the study. Patients should not have received any prior treatment for advanced NSCLC (treatment-naïve).

Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted therapies. The clinical practice guidelines recommend targeted treatment for patients with metastatic, oncogene-driven disease as first-line systemic therapy (i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive NSCLC) (NCCN 2014).

To be eligible for the study, determination of ALK positivity will be performed centrally by the IHC assay (see Appendix 8) that is being developed by Ventana Medical Systems as a companion diagnostic to alectinib. IHC may replace fluorescence in situ hybridization (FISH)-based identification of ALK rearrangement as the standard companion diagnostic in the future. IHC is faster, easier to perform in local laboratories, and requires less equipment compared with the FISH assay. In addition, IHC has high concordance with FISH and a lower false-negative rate (Kim et al. 2011).

### 3.3.3 Rationale for Control Group

Targeted therapy (including ALK-targeted therapy) is likely to have a greater antitumor effect than standard chemotherapy, offering patients a higher response rate and longer durability of response with less toxicity compared with any potential chemotherapy options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013).
Crizotinib (Xalkori) is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). It is the only first-generation ALK inhibitor that has been approved in multiple countries worldwide for the treatment of ALK-positive NSCLC.

In the United States, in November 2013, crizotinib has been granted a regular approval for ALK-positive NSCLC setting, regardless of treatment line (XALKORI® U.S. Package Insert), whereas in Europe, crizotinib is currently approved conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC).

The NCCN guidelines recommend crizotinib as first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014).

The randomized Phase III PROFILE 1014 study was conducted to assess the efficacy of crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC. The study met its primary objective of prolonging PFS in previously untreated patients with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months (HR: 0.454; 95% CI: 0.346, 0.596; p <0.0001) for crizotinib and pemetrexed-platinum-based chemotherapy, respectively (Mok et al. 2014). The authors concluded that these findings establish crizotinib as the standard of care for patients with previously untreated advanced ALK-positive non-squamous NSCLC (Mok et al. 2014).

Crizotinib will be dosed as per standard dose recommendations from prescribing information—patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death. See Section 5.1.4 for criteria for dosing interruption and/or dose reduction for treatment with crizotinib.

### 3.3.4 Rationale for Open-Label Design

An open-label study design is more appropriate for patients enrolled in this particular trial for a number of reasons defined below, and with the ultimate goal to ensure patient compliance as much as possible.

For a blinded study design, all enrolled patients would be required to take five large capsules twice per day. This high pill count results from the difference in capsule size between crizotinib (size 0) and alectinib (size 1). Each dose would comprise one 250 mg capsule of crizotinib or matching placebo and four 150 mg capsules of alectinib or matching placebo. In order to blind, crizotinib capsules must be over-encapsulated. That furthermore increase the size of a capsule – from size 0 to size 00 (double zero). Size 00 is usually the largest capsule size used orally for humans. For some patients size 00 capsules are too large to swallow. This high pill count of large capsules is
considered to be a significant burden to patients and increases the risk of non-compliance.

Additionally, a blinded study would increase the complexity of standard dose reductions. Dose interruption or dose reduction may be required on the basis of individual safety and tolerability. The standard dose reductions for crizotinib would be 200 mg BID (different capsule, size 1), followed by 250 mg QD. Dose reductions for alectinib would occur in 150 mg steps. In a double blind study, these multiple step dose reductions introduce a high level of complexity and potential for error.

In order to avoid a significant burden to patients with high pill count, increased risk of non-compliance, and complexity of standard dose reductions, adequate steps have been taken to ensure the validity of the data in an open-label study design. These include performing a supportive analysis of efficacy on the basis of determining progression by an IRC, performing sensitivity analyses to demonstrate the robustness of the primary endpoint, defining progression using established response evaluation criteria (RECIST v1.1), performing tumor assessment at the same frequency in both arms and adhering to protocol-defined schedules, and finalizing before trial start the strategy for the final analysis of the primary endpoint, including predefined methods for handling missing data and censoring rules. Efficacy analyses will only be performed at the pre-specified analysis timepoints in the protocol (final analysis once 170 PFS events have occurred and survival follow-up analysis at 143 events).

3.3.5 Rationale for Primary Endpoint Selection

The investigator-assessed PFS (which will be supported by IRC-assessed PFS analysis, one of the secondary endpoints of the study) is the primary endpoint for this trial.

PFS, as an endpoint, can reflect tumor growth and can be assessed before the determination of a survival benefit, and its determination is not generally confounded by subsequent therapies. Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit of the new treatment compared with available therapies (Guidance for Industry 2007; European Medicines Agency 2012). A PFS HR of 0.65 will be targeted, which constitutes a clinically meaningful benefit in this patient population as it will delay the use of platinum-based chemotherapy and will potentially reduce the frequency of CNS relapse and the morbidity associated with treating CNS metastases.

The assumed median PFS of patients in the alectinib treatment arm is 16.8 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 13 months. Patients with ALK-positive NSCLC treated with crizotinib in the second-line setting had a median PFS of 7.7 months and an interim median OS of 20.3 months (Shaw et al. 2013), which equated to a post-progression survival of 12.6 months. This lengthy post-progression survival provides an opportunity for
subsequent treatment with other ALK inhibitors, several additional lines of chemotherapy, or participation in additional clinical trials.

Patients in both study arms who experience disease progression on study treatment will likely be treated with other subsequent treatment options, including ALK inhibitors. The availability of crizotinib on the market, as well as the likely availability of other next-generation ALK TKIs, and the availability of other investigational agents in clinical trials offer potential treatment options to patients in the study who will eventually have disease progression. Subsequent therapies frequently confound the detection of an OS benefit, particularly in a setting with a long post-progression survival, such as ALK-positive NSCLC. This has been observed in trials for EGFR TKIs, in which strong PFS benefits were observed without evidence of OS benefit (Rosell et al. 2009; Fukuoka et al. 2011).

The long post-progression survival and the confounding effects of subsequent lines of therapy indicate that it would be difficult to detect an OS benefit in this setting. Nevertheless, OS is one of the study's secondary endpoints. The crossover from the crizotinib arm to alectinib will not be allowed in this study, with the aim of preserving the trial's ability to potentially demonstrate some degree of treatment benefit of alectinib in OS. However, the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.

To ensure the validity of the PFS as the primary endpoint, a number of measures have been implemented: full IRC assessment to support the analysis of the primary endpoint, a substantial target magnitude of benefit (target HR = 0.65) and study assessments that will allow a robust evaluation of risk-benefit (standard RECIST criteria to define progression with fixed assessment intervals that are identical in both treatment arms and a robust definition of PFS and prospectively defined methods to assess, quantify, and analyze PFS, including censoring methods and sensitivity analyses).

3.3.6 **Rationale for Secondary Endpoint of Time to CNS Progression**

Lung cancer is the most common type of cancer to spread to the brain, with at least 40% of people with lung cancer developing brain metastases at some point during their disease. ALK-positive NSCLC has a propensity to metastasize to the brain, and crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease (Chun et al. 2012).

Delaying or preventing the development of CNS metastases would provide patients with clinically meaningful benefit by avoiding consequences of neurological deficits from brain metastasis or by delaying/preventing long-term side effects associated with steroid use and brain irradiation.
Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase II studies. See Section 1.2 and Alectinib Investigator's Brochure for additional details.

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression is documented. The aim of the pre-specified analysis will be to evaluate whether alectinib significantly delays or prevents the development of CNS metastases.

Randomization of the Phase III study will be stratified by the presence or absence of CNS metastasis at baseline.

Imaging analysis by consistently used uniform image acquisition technique (MRI scans) will be performed routinely at baseline and at subsequent follow-up assessments along with every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical suspicion of CNS metastasis) in order to achieve an accurate determination of time to CNS progression. This ensures that early brain metastatic lesions are detected and that assessment bias between the two arms is avoided by having regularly scheduled scans.

An independent central radiological review will be performed for all patients and the analysis of time to CNS progression, or response will be based on the data from the independent review. The review will be based on the standard RECIST v1.1 criteria to assess the CNS lesions, and a second independent review on the basis of the RANO criteria, which are typically used to assess brain tumors (Wen et al. 2010), will be performed. The assessment will be performed independently from the overall disease progression assessment.

### 3.3.7 Rationale for PK Sample Collection Schedule

To date, the pharmacokinetics of alectinib have been characterized in chemotherapy-failed, crizotinib-naïve patients with NSCLC in Study AF-001JP and in patients who have failed chemotherapy and crizotinib treatment in Study NP28761/AF-002JG and Study NP28673. In order to better understand the pharmacokinetics of alectinib and to further support the development of a robust population PK model for alectinib in order to better understand, identify, and characterize variables which lead to changes in exposure, characterization of alectinib pharmacokinetics will be done in this study. This study will include PK assessment of alectinib in ALK inhibitor treatment-naïve patients with ALK-positive advanced NSCLC by collecting trough samples from all patients receiving alectinib. Serial/intensive PK samples will be collected from a subset of patients (10%–15% [at least n=20] of patients receiving alectinib) to facilitate the PK assessment. The data that will be collected from this study will enable more robust understanding of alectinib pharmacokinetics in the global crizotinib-naïve population including investigation and potential identification of sources of variability influencing alectinib pharmacokinetics and/or response to alectinib therapy. Results from PK data
collection in this study and analyses of PK data could help support optimal use of alectinib therapy.

3.3.8 Rationale for Biomarker Assessments

There are several molecular mechanisms of resistance to crizotinib reported in the literature: increased copy number of ALK gene, increased expression of ALK mRNA, secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased copy number, increased phosphorylation, or point mutations) in escape genes like EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). In order to investigate molecular mechanisms of resistance to ALK inhibitors and ALK mutation status, tumor samples will be collected before treatment and at the time of disease progression with the goal of sequencing nucleic acids. Two types of approaches will be used: 1) targeted sequencing of a panel of genes known to be involved in cancer and 2) unbiased genomic sequencing.

ALK rearrangements can be monitored in circulating tumor cells in blood (Ilie et al. 2012; Pailler et al. 2013). Intact tumor cells are released into the circulation; hence, using specific surface markers, it is possible to selectively separate them from the remaining cells in the blood. This allows downstream analysis like IHC or FISH, and in rare occasions, there is enough material to perform reverse transcription–polymerase chain reaction or sequencing to detect mutant mRNA. The presence of ALK rearrangements will be investigated in circulating tumor cells before treatment and at the end of study. This information will be used to investigate the use of blood as a surrogate of tumor for diagnostic purposes and to monitor the presence of ALK rearrangements in circulating tumor cells in the blood before and after treatment.

Mutations in cancer genes appearing from drug resistance can be monitored in circulating nucleic acids in plasma (Forshew et al. 2012). Tumor nucleic acids are shed into circulation in amounts that allow direct amplification by polymerase chain reaction and sequencing. Plasma samples will be collected before treatment and at certain timepoints during treatment, to monitor mutations in ALK and other genes involved in resistance to ALK inhibitors. Information from mutated genes in the tumor will be correlated with mutations in plasma DNA.

Determination of ALK positivity will be initially performed by Ventana IHC (see Appendix 8). In addition, the Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. For exploratory purposes, other methods to determine ALK positivity (e.g., reverse transcription-polymerase chain reaction) may also be used.

3.3.9 Rationale for PRO Assessments

In the treatment of lung cancer, it is important to both increase survival and palliate symptoms because disease symptoms have negative impacts on HRQoL.
This is especially true for trials that use PFS as a primary endpoint, where it is important to translate the delay in disease progression into an endpoint that is meaningful to patients.

Pain (chest; arm/shoulder), dyspnea, cough, and fatigue have been regarded as the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC. The BR.21 study (erlotinib vs. chemotherapy in second- or third-line NSCLC) demonstrated that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ-C30 and QLQ-LC13 was consistent with superior PFS, OS, and quality-of-life benefits in the erlotinib arm as compared with the placebo arm (Aaronson et al. 1993; Bergman et al. 1994; Bezjak et al. 2006). Additionally, patients in the crizotinib PROFILE 1005 trial reported clinically significant (10 points) improvements in the pain, cough, dyspnea, and fatigue symptom scales seen as early as 2 weeks on treatment (Crinò et al. 2011).

The EORTC QLQ-C30 and QLQ-LC13 were used in the Phase III PROFILE 1007 study (second-line crizotinib vs. chemotherapy). The study reported significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than with chemotherapy (p < 0.001 for all comparisons, without adjustment for multiple testing). Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. There was also a significantly greater overall improvement from baseline in the global quality of life among patients who received crizotinib treatment than among those who received chemotherapy (p < 0.001). In all domains measuring functioning, except for the domain measuring cognitive functioning, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Shaw et al. 2013).

Therefore, to assess the quality of life of patients in this trial, PRO data will be collected from patients enrolled in this study using the validated questionnaires EORTC QLQ-C30 and QLQ-LC13.

3.4 OUTCOME MEASURES

3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

- PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.
• ORR, which is defined as the percentage of patients who attain CR or PR; response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.

• Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.

• DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

3.4.2 Safety Outcome Measures

The safety outcome measures for this study are as follows:

• Serious and non-serious adverse events

• Safety laboratory tests values

• Vital signs (blood pressure, heart rate), ECG

• Physical examination

3.4.3 Pharmacokinetic Outcome Measures

The PK outcome measures for this study are as follows:

• Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment. See Appendix 1 and Appendix 2 for PK sampling times.

• Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n=20). See Appendix 1 and Appendix 2 for PK sampling times.

• PK parameters will be determined as appropriate and where data allow:

  The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.

  Non-compartmental analysis (NCA) may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.
3.4.4 Patient-Reported Outcome Measures

The PRO measures included for this study are as follows and will be administered to patients every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months:

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

3.4.5 Exploratory Outcome Measures

The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for reimbursement.
- Total testosterone, albumin and SHBG to calculate free testosterone, FSH, and LH, in blood to measure an onset of hypogonadism in adult men.
- The FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naïve NSCLC that is ALK-positive by FISH test.
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors.
- ALK mutation status in plasma DNA to monitor efficacy and disease progression.
- ALK fusion status in circulating tumor cells in blood.

4. MATERIALS AND METHODS

4.1 PATIENTS

Target population is patients with treatment-naïve ALK-positive non-resectable, locally advanced and metastatic NSCLC.

4.1.1 Inclusion Criteria

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥ 18 years old.
• Life expectancy of at least 12 weeks.
• ECOG PS of 0–2.
• Patients had no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC.
• Adequate hematologic function:
  - Platelet count $\geq 100 \times 10^9$/L
  - ANC $\geq 1500$ cells/$\mu$L
  - Hemoglobin $\geq 9.0$ g/dL
• Adequate renal function:
  - An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m$^2$
• Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
• Measurable disease (by RECIST v1.1) prior to the administration of study treatment.
• Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
• For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
• For women who are not postmenopausal ($\geq 12$ months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abistent or use single or combined contraceptive methods that result in a failure rate of $<1\%$ per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of $<1\%$ per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of $<1\%$ per year. Barrier methods must always be supplemented with the use of a spermicide.
• For men: agreement to remain abistent or use a condom plus an additional contraceptive method that together result in a failure rate of $<1\%$ per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of
the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

- Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.

4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

- Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection.

- Liver disease characterized by:
  
  ALT or AST >3 × ULN (≥5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements

  OR

  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices

  OR

  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

- National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication.

- History of organ transplant.

- Co-administration of anti-cancer therapies other than those administered in this study.

- Patients with baseline QTc > 470 ms or symptomatic bradycardia.

- Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3) except for oral corticosteroids up to 20 mg of prednisolone equivalent per day.

- Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment. (See Section 4.4.2 for further details.)
- History of hypersensitivity to any of the additives in the alectinib drug formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulfate [SLS], magnesium stearate).

- History of hypersensitivity to any of the additives in the crizotinib drug formulation (silica, colloidal anhydrous cellulose, microcrystalline calcium hydrogen phosphate, anhydrous sodium starch glycolate, magnesium stearate).

- Pregnant or lactating women.

- Known HIV positivity or AIDS-related illness.

- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study.

- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

This is an open-label trial, for which the rationale is described in Section 3.3.4.

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block-stratified randomization procedure and over a planned recruitment period of 24 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Central randomization and drug pack number allocations will be performed and managed by an IxRS. Further details will be provided in an IxRS manual.

The independent review of scans for the secondary endpoints of PFS on the basis of IRC and time to CNS progression will be performed in a blinded fashion.

4.3 STUDY TREATMENT

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Alectinib

Alectinib comes in a hard capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, sodium lauryl sulfate (SLS), and magnesium stearate as excipients.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

The formulation contains SLS as an excipient. This excipient is known to be associated potentially with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

For further details, see the alectinib Investigator's Brochure.

4.3.1.2 Crizotinib
Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (XALKORI® U.S. Package Insert).

4.3.2 Dosage, Administration, and Compliance
4.3.2.1 Alectinib
Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

If a patient misses a dose, it can be taken within 4 hours of the scheduled time. If the time is greater than 4 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

Guidelines for dosage modifications and treatment interruptions or discontinuation due to specified adverse events are provided in Section 5.1.3.

Any overdose or incorrect administration of study drug should be noted on the Study Drug Administration electronic Case Report Form (eCRF). Adverse events associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF.

4.3.2.2 Crizotinib
Crizotinib 250 mg (one 250-mg capsule) should be administered orally BID with or without food (in the morning and evening).
If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose of crizotinib, the next dose should be taken as scheduled.

If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily. Guidelines for dosage modification and treatment interruption or discontinuation are provided in Section 5.1.4.

Any overdose or incorrect administration of crizotinib should be noted on the crizotinib Administration eCRF. Adverse events associated with an overdose or incorrect administration of crizotinib should be recorded on the Adverse Event eCRF.

**4.3.3 Investigational Medicinal Product Accountability**

All investigational medicinal products (IMPs) required for completion of this study (alectinib and crizotinib) will be provided by the Sponsor where required by local health authority regulations. The study site will acknowledge receipt of IMPs and confirm the shipment condition and content. Any damaged shipments will be replaced.

IMPs will either be disposed of at the study site according to the study site’s institutional standard operating procedure or returned to the Sponsor with the appropriate documentation. The site’s method of IMP destruction must be agreed to by the Sponsor. The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.

Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the study site should be recorded on the Drug Inventory Log.

**4.3.4 Post-Trial Access to Alectinib**

The Sponsor will offer post-trial access to the study drug alectinib free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below.

A patient will be eligible to receive study drug after the end of the study if all of the following conditions are met:

- The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being
- There are no appropriate alternative treatments available to the patient
- The patient and his or her doctor comply with and satisfy any legal or regulatory requirements that apply to them
A patient will not be eligible to receive study drug after the end of the study if any of the following conditions are met:

- The study drug is commercially marketed in the patient’s country and is reasonably accessible to the patient (e.g., is covered by the patient’s insurance or would not otherwise create a financial hardship for the patient)
- The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for ALK-positive NSCLC
- The Sponsor has reasonable safety concerns regarding the study drug as treatment for ALK-positive NSCLC
- Provision of study drug is not permitted under the laws and regulations of the patient’s country

The Roche Global Policy on Continued Access to Investigational Medicinal Product is available at the following Web site:

http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf

4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from screening to the study completion/discontinuation visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

All therapy and/or medication administered to manage adverse events should be recorded on the Adverse Event eCRF.

The medications and/or treatments below are permitted:

- Anticoagulants and antithrombotic agents (i.e., coumadin-derived anticoagulants, unfractionated heparin or low-molecular heparins, aspirin (≤325 mg/day), and clopidogrel.
- Systemic corticosteroid should be no more than oral 20 mg prednisone equivalent daily. Inhalation corticosteroid is allowed. Steroid equivalence converter could be found at: http://www.medcalc.com/steroid.html
- Acetaminophen up to 2 g/day
- Gastric pH-elevating medications (such as proton pump inhibitors, H₂ blockers, or antacids)
- Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients with isolated asymptomatic CNS progression (e.g., new CNS oligometastases).
Caution should be exercised when the following are co-administered with alectinib:

- For medications that are substrates of P-gp transporter or breast cancer resistance protein transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of these transporters. Substrates with a narrow therapeutic index (e.g., methotrexate, digoxin) should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

- For medications that are inhibitors of P-gp transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. The major metabolite of alectinib, M4, has been shown to be a substrate of this transporter. Strong inhibitors of P-gp should be avoided, if possible (see Appendix 3).

- For medications that are metabolized by CYP3A and CYP2C8, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of CYP3A and CYP2C8, including potential time-dependent inhibition. Sensitive CYP3A and CYP2C8 substrates should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

Caution should be exercised when the following are co-administered with crizotinib:

- Crizotinib has been shown to be a moderate inhibitor of CYP3A. Dose reduction maybe needed for co-administered drugs that are predominantly metabolized by CYP3A in patients receiving crizotinib. Concurrent use of CYP3A substrates with narrow therapeutic indices should be avoided (see Appendix 3).

- On the basis of an in vitro study, crizotinib is predicted to inhibit intestinal P-gp. Therefore, administration of crizotinib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their therapeutic effect and adverse reactions (see Appendix 3). Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.

- Bradycardia has been reported during clinical studies; therefore, the use of crizotinib in combination with other agents known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) should be avoided to the extent possible.
• In vitro studies in human hepatocytes indicated that crizotinib may induce preganane X receptor and constitutive androstane receptor–regulated enzymes (e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1). However, there was no observed induction in vivo when crizotinib was coadministered with the CYP3A probe substrate midazolam. Caution should be exercised in administering crizotinib in combination with medicinal products that are predominantly metabolized by these enzymes. Of note, the effectiveness of concomitant administration of oral contraceptives may be altered.

• In vitro studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered drugs that are metabolized by CYP2B6 (e.g., bupropion, efavirenz).

4.4.2 Prohibited Therapy
Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) is prohibited during the study and for at least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless otherwise specified below. Exceptions to the below listed concomitant therapies restrictions (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) may be made if the rationale is discussed and documented between the investigator and the Sponsor’s Clinical Pharmacologist.

• Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s wort [Hypericum perforatum]) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drugs (see Appendix 3).

• Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug treatment and while on treatment with study drug (see Appendix 3).

• Any concomitant medications known to affect QT interval duration, including but not limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone, and quinidine, within 2 weeks before the first dose of study drug treatment and while on treatment with study drugs and through the end of the study.

• Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents (other than study drug treatment), ergot derivatives, probenecid, and bile acid-binding resins while on study treatment.

• Systemic chemotherapy.

• Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions or for pain control. If palliative radiation is indicated for bone metastases, palliative radiation may start within 24 hours of the last dose of alectinib, unless, in the judgment of the investigator, patient safety will require a longer washout period prior to palliative therapy. Dosing of alectinib may resume with the resolution of any radiation toxicity to ≤ Grade 1.

• Additional investigational drug (except for during the follow-up period).
The above lists of medications are not necessarily comprehensive. Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication is metabolized by or strongly inhibits or induces CYP3A. In addition, the investigator should contact the Medical Monitor if questions arise regarding medications not listed above.

http://medicine.iupui.edu/clinpharm/ddis/table.aspx

4.4.3 Prohibited Food
Use of grapefruit or grapefruit juice should be avoided during the study and for at least 14 days prior to the initiation of study treatment (either alectinib or crizotinib) because it is a potent CYP3A inhibitor and may increase plasma concentration of either alectinib or crizotinib.

4.5 STUDY ASSESSMENTS
See Appendix 1 for the schedule of assessments performed during the study.

4.5.1 Informed Consent Forms and Screening Log
Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site.

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

4.5.2 Medical History and Demographic Data
Medical history includes clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 28 days prior to the screening visit.

Demographic data will include age, sex, and self-reported race/ethnicity.

4.5.3 Corticosteroid Use for CNS Metastases
For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake should be captured at all tumor assessment visits and compared with the corticosteroid intake at the time of the last disease assessment. The changes will be recorded as
Increased, Unchanged, or Decreased. Increases and decreases in corticosteroid intake should be clinically justified. Increases in corticosteroid dose for reasons other than for CNS metastases control do not need to be taken into consideration when making this comparison. As per Section 4.4.1 of the protocol, systemic corticosteroid use cannot exceed oral 20 mg of prednisone equivalent daily.

4.5.4 **Physical Examinations**

A complete physical examination at screening and baseline should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems as well as height and weight. Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.

At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations should be performed. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant abnormalities should be recorded as adverse events on the Adverse Event eCRF.

Note: for patients with known CNS metastases, a neurological examination must be performed at each tumor assessment visit and compared with the neurological examination performed at the time of the last disease assessment. Definition of clear neurological worsening is difficult to describe because progression in the CNS can present in numerous ways. Accordingly, evaluation of neurological function at each disease assessment will be based purely on the investigator’s assessment of the patient’s neurological state compared with the neurological function at the time of the last disease assessment. Neurological status will be recorded as Improved, Stable, or Worsened.

4.5.5 **Vital Signs**

Vital signs will include measurements of respiratory rate, oxygen saturation, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

4.5.6 **ECOG Performance Status**

PS will be measured using the ECOG Performance Status Scale (see Appendix 5). It is recommended, where possible, that a patient’s PS be assessed by the same person throughout the study.

4.5.7 **Tumor and Response Evaluations**

Disease burden must be documented at screening and re-assessed at each subsequent tumor evaluation. Response will be assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4). For assessing response in patients with measurable disease, the preferred radiologic tumor response assessment is CT scan.
with intravenous contrast. If intravenous contrast is contraindicated, a non-contrast-enhanced chest CT scan will be acceptable for chest lesions, and MRI can be used for non-chest lesions. If contrast-enhanced MRI is contraindicated, then non-contrast-enhanced MRI will suffice. Positron emission tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesion as per RECIST v1.1 (see Appendix 4).

The same radiographic procedure used to define measurable disease sites at screening must be used throughout the study (e.g., the same contrast protocol for CT scans). Assessments should be performed by the same evaluator to ensure internal consistency across visits.

CT/MRI scans of chest and abdomen, and MRI scans of the brain should be performed for all patients as described in Schedule of Assessments (see Appendix 1) at screening then every 8 weeks subsequently until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression and at the post-treatment visit (4 weeks after permanent treatment discontinuation). CT/MRI scans of the neck bone and pelvis should be included if clinically indicated. At the investigator’s discretion, CT/MRI scans may be repeated at any time if PD is suspected.

Note: Brain imaging should be performed using MRI with the following image acquisition requirements:

- Minimum sequences required:
  - Pre-contrast T1, T2/FLAIR
  - Post-contrast T1, with two orthogonal planes (or a volume acquisition) recommended
- Recommended slice thickness ≤5 mm with no gap

Patients with known or suspected bone metastases should undergo radionuclide bone scan at screening. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions and do not need to be repeated routinely but can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered measurable lesions of the soft tissue component and meets the definition of measurability and should be followed by cross-sectional imaging.
4.5.8  Laboratory, Biomarker, and Other Biological Sample

4.5.8.1  Laboratory Assessments

Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells])
- Coagulation (PT [or INR], and aPTT)
- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase (GGT); calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone, albumin and SHBG to calculate free testosterone, FSH, and LH [for male patients only])
- Urinalysis: Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine protein will be measured by dipstick test in order to assess micro- and macroproteinuria.
- Pregnancy test. All women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile will have a serum pregnancy test at screening, within 3 days of dosing. Urine pregnancy tests will be performed anytime during the course of the study, as per investigator’s discretion. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

4.5.8.2  Pre-Treatment Tumor Samples (Mandatory)

Mandatory pre-treatment tumor samples will be collected to centrally examine ALK status by Ventana IHC (eligibility criteria) and Vysis FISH. Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred source, but if blocks are not available, unstained slides (ten to fifteen 5-µm slides cut less than 3 months before screening) are also accepted. Remaining tumor blocks will be returned to the sites; slides will not be returned.

For fresh tumor biopsies (guided by ultrasound or CT scan), acceptable methods include core biopsies for lung and liver lesions and bronchoscopic biopsies for lung lesions. The minimum size for the biopsy needle recommended is 20G.

Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by Ventana IHC (see Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) for possible companion diagnostic development. Additionally, other ALK assays may be used for testing patient samples to establish performance characteristics of these assays for...
diagnostic development. Testing may be performed on all screened patients (screen-
failed and enrolled). These additional testing data will have no impact on eligibility, and 
testing will be performed only after eligibility is established for each patient. In addition, 
local ALK test information, baseline demographic, and disease-related characteristic 
data for all screened patients may be collected in order to support potential registration 
of a companion diagnostic assay for alectinib.

The tumor sample may also be tested for the presence of EGFR mutations, if requested 
by the investigator.

Pre-treatment tumor samples may be used, after proper informed consent is obtained, 
for genomic sequencing.

For sample handling procedures, storage conditions and shipment instructions, see the 
laboratory manual.

4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)
Pre-treatment tumor samples (preferably formalin-fixed blocks but if not available a 
minimum of 10-15 unstained 5 µm slides) for ALK testing is a mandatory requirement for 
this study. Optional additional pre-treatment tumor samples and fresh post-treatment 
tumor biopsy at disease progression or permanent treatment discontinuation (at the last 
treatment or post-progression visit) may be collected, with proper informed consent. 
These samples will be used to help to understand molecular mechanisms of resistance 
to ALK inhibitors by genomic sequencing. Remaining tumor blocks will be returned to 
the sites, slides will not be returned.

These specimens will be destroyed within 5 years after the date of final closure of the 
clinical database. Other residual tissue material (slides, extracts, etc.) will be destroyed 
within 5 years after the date of final closure of the clinical database.

On the basis of continuous analysis of the data in this study and other studies, or on the 
basis of data from literature, collection of optional tumor biopsies with exploratory 
purposes may be stopped at any time if the data from the samples collected do not 
produce useful information.

4.5.8.4 Blood and Plasma Samples
Mandatory plasma samples will be obtained to determine:

- Mutations status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 
  20 mL of blood to be collected at baseline, treatment Visit 3 (Week 16), and 
  subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for 
  detailed information) until disease progression and during post-progression on 
treatment in case of isolated, asymptomatic CNS progression. For sample handling 
procedures, storage conditions and shipment instructions, see the laboratory 
manual. These samples will not be taken in countries where regulatory agency or 
Institutional Review Board (IRB) does not allow genetic testing.
Mandatory blood samples will be obtained to determine:

- ALK mutations assessment in circulating tumor cells. It will require 20 mL of blood sample to be collected (2 tubes of 10 mL each) at baseline and at disease progression (at the last treatment or post-progression visit). It should match in time to tumor progression (CNS and/or systemic disease progression).
- All patients who are randomized in alectinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alectinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Section 4.5.8.4.1).

Optional blood samples will be collected to obtain:

- A source of healthy tissue for patients who agreed to participate in the optional genomic sequencing assessment. For patients in the crizotinib arm, a 3-mL blood sample will be drawn at baseline. For patients in the alectinib arm, a source of healthy tissue will be used as a portion of the sample for the pharmacogenomics research (see Section 4.5.8.4.1)
- A portion of this blood sample will also be used as a source of healthy tissue for the patients receiving alectinib treatment who agree to participate in the optional genomic sequencing research.

For biomarkers, a maximum of 43 mL of blood will be collected at baseline (20 mL for plasma purification and determination of mutation status in ALK and other escape genes, 20 mL for ALK fusion detection in circulating tumor cells, and 3 mL for pharmacogenomics research), 20 mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 32 mL will be collected at disease progression (CNS and/or systemic disease progression) (20 mL for plasma purification for determination of mutation status in ALK and other escape genes and 20 mL for ALK fusion detection in circulating tumor cells).

Details of sample handling procedures, sample storage and shipment will be described in a separate laboratory manual.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma and circulating tumor cell samples with exploratory purposes may be stopped at any time if they are deemed not informative.

4.5.8.4.1 Samples for Pharmacogenomic Assessments
One sample (approximately 3 mL of whole blood) will be collected from all patients on alectinib treatment. Samples will be used for the evaluation of genetic polymorphisms of drug metabolic enzymes including, but not limited to, CYP2C9, CYP3A4/5, and UGT1A1, and transporters (e.g., organic anion transporter polypeptide 1B1) and for genetic variants that could contribute to potentially drug-related liver safety assessments (including but not limited to human leukocyte antigen, see Appendix 9 for more details).
For sample handling procedures, storage conditions, and shipment instructions, see the laboratory manual. Only in circumstances where there is concern for collection of this genetic material for above evaluations can this assessment be considered not mandatory as part of study assessments in this study. Results of any analyses from these samples will be reported outside the clinical study report.

4.5.8.5 Samples for Pharmacokinetic Assessments
PK samples will be collected in all patients on alectinib treatment, as indicated in Appendix 1 and Appendix 2 for the analysis of alectinib and its major metabolite(s) (RO5468924, RO5507197, and/or others, if applicable and if appropriate, and if assays are available). Residual samples following PK analysis may be used to evaluate profiling for alectinib metabolite(s).

All trough/pre-dose PK samples should be collected within 2 hours BEFORE the morning doses of study medications.

Serial/intensive samples will be collected in a subset of patients (10%–15% [at least n = 20] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

Plasma concentrations for alectinib and its metabolite(s), if applicable, will be measured by specific and validated liquid chromatography tandem mass spectrometry methods.

For each sample, approximately 2 mL of venous blood will be collected for alectinib PK analysis at the timepoints specified in the PK schedule in Appendix 1 and Appendix 2.

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual.

These samples will be destroyed when the final Clinical Study Report is complete.

On the basis of continuous analysis of the data in this study and other studies, any sample type collection may be stopped at any time if the data from the samples collected do not produce useful information or at the discretion of the Sponsor.

4.5.9 Electrocardiograms
An ECG will be recorded at specified timepoints as outlined in the schedule of assessments (see Appendix 1) at screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), and at the last treatment visit and as clinically indicated throughout the study. All ECG recordings must be performed using a standard high-quality, high-fidelity digital electrocardiograph machine equipped with computer-based interval measurements. All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug
administration) as well as prior to meals. Circumstances that may induce changes in heart rate, including environmental distractions (e.g., television, radio, conversation), should be avoided during the pre-ECG resting period and during ECG recording.

Patients must have been in a supine or semi-supine position for at least 5 minutes prior to the recording being taken. The same recording position (supine or semi-supine) and the same equipment should be used for each patient throughout the study. The ECG printout must be (1) reviewed by a medically qualified member of the study team at the site, (2) annotated to indicate any clinical finding, and (3) dated and signed by this person and filed in the patient notes. ECG parameters will be entered on the ECG eCRF. The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula.

If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5. Management of QT interval prolongation should be done according to guidance provided in Section 5.1.3.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory. Guidance for abnormal ECG results (QT prolongation) is provided in Table 2.

4.5.10 Patient-Reported Outcomes

PROs (EORTC QLQ-C30, QLQ-L13, and EQ-5D) will be collected to more fully characterize the clinical profile of alectinib. The instruments will be translated as required in the local language. To ensure instrument validity and that data standards meet health authority requirements, the PROs scheduled for administration during a clinic visit (EORTC QLQ-C30, QLQ-L13, and EQ-5D) should be completed prior to the performance of non-PRO assessments and the administration of study treatment.

Patients will use an ePRO device to capture PRO data. The ePRO device and instructions for completing the PRO questionnaires electronically will be provided by the investigator staff. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be accessed by appropriate study personnel securely via the Internet.

4.5.11 Samples for Roche Clinical Repository

4.5.11.1 Overview of the Roche Clinical Repository

The Roche Clinical Repository (RCR) is a centrally administered group of facilities used for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.
Specimens for the RCR will be collected from patients who give specific consent to participate in optional research. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

4.5.11.2 Approval by the Institutional Review Board or Ethics Committee

Collection and submission of biological samples to the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site's IRB or Ethics Committee (EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol (Section 4.5.11) will not be applicable at that site.

4.5.11.3 Sample Collection

For RCR purposes, 10 mL of blood will be collected. Any remaining tissue samples from study-related or non-study-related procedures that are performed during the study may also be collected for RCR purposes. For all samples, date of consent should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.

RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be subject to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

4.5.11.4 Confidentiality

Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure
A database system. Access to the linking key is restricted to authorized individuals and is monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche's Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

4.5.11.5 Consent to Participate in the Roche Clinical Repository

The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the objectives, methods, and potential hazards of participation in the RCR. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to provide optional RCR specimens. Patients who decline to participate will not provide a separate signature.

The investigator should document whether the patient has given consent to participate by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's specimens and data will continue to be used as part of the RCR research.

4.5.11.6 Withdrawal from the Roche Clinical Repository

Patients who give consent to provide RCR specimens have the right to withdraw their specimens from the RCR at any time for any reason. If a patient wishes to withdraw consent to the testing of his or her specimens, the investigator must inform the Medical Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research
Sample Withdrawal of Informed Consent eCRF. The patient will be provided with instructions on how to withdraw consent after the trial is closed. A patient's withdrawal from Study BO28984 does not, by itself, constitute withdrawal of specimens from the RCR. Likewise, a patient’s withdrawal from the RCR does not constitute withdrawal from Study BO28984.

4.5.11.7 Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a quality-controlled, auditable, and appropriately validated laboratory information management system, to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the Informed Consent Form. Roche monitors and auditors will have direct access to appropriate parts of records relating to patient participation in the RCR for the purposes of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the RCR samples.

4.6 PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION

4.6.1 Patient Discontinuation
Patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the investigator has the right to withdraw a patient from the study at any time. Reasons for withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize the patient’s safety if he or she continues in the study
- Investigator or Sponsor determines it is in the best interest of the patient

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. Patients who withdraw consent for treatment should continue to be followed for tumor assessments until progression and for OS, provided they have not withdrawn consent for the study. However, patients will not be followed for any reason after consent for the study has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study Treatment Discontinuation
Patients must discontinue study treatment if they experience any of the following:

- Pregnancy
- Inability to tolerate study medication on the basis of the investigator judgment

See guidelines for managing adverse events and for comprehensive guidance on study drug discontinuation in Section 5.1.3.
Patients who discontinue study drug prematurely will be asked to return to the clinic for tumor assessments until progression as per study schedule (see Appendix 1).

The primary reason for premature study drug discontinuation should be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.3 Study and Site Discontinuation
The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

- The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
- Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

- Excessively slow recruitment
- Poor protocol adherence
- Inaccurate or incomplete data recording
- Non-compliance with the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice
- No study activity (i.e., all patients have completed and all obligations have been fulfilled)

5. ASSESSMENT OF SAFETY

5.1 SAFETY PLAN

5.1.1 Adverse Events Collection
After informed consent has been obtained but prior to initiation of study treatment, only serious adverse events (SAEs) caused by a protocol-mandated intervention should be reported (e.g., SAEs related to invasive procedures such as biopsies). After the first dose of study treatment and up to the 4-week follow-up after the last dose of study treatment, all adverse events (AEs) regardless of seriousness, causality assessment, or actions taken reported by the investigator or designated medically qualified study site personnel will be collected as described below. At each visit, the investigator or designated medically qualified study site personnel will ask the patient if any untoward medical event occurred since the last visit. It is the investigator’s responsibility to record all AEs in the source patient’s medical records.

All serious and non-SAEs will be reported on the standard AE/SAE eCRF.
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data

Events described in Section 5.1.2.1 through Section 5.1.2.10 will be closely monitored and represent selected AEs for this study.

A more detailed safety profile of alectinib is provided in the alectinib Investigator’s Brochure.

5.1.2.1 Interstitial Lung Disease

TKIs, including ALK inhibitor crizotinib, have been associated with the occurrence of treatment-related ILD (including fatalities).

See Section 5.1.3 for management and follow-up.

5.1.2.2 Hepatobiliary Laboratory Test Elevations

Hepatobiliary findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. The findings were at or close to clinically relevant exposures. Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT and liver weight, vacuolation/degeneration/necrosis of bile duct epithelium, inflammatory cell infiltration in Glisson’s sheath, enlargement/focal necrosis of hepatocytes, and enlargement of Kupffer cells.

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved.

In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and fatal cases of hepatic failure have been reported.

See Section 5.1.3 for management and follow-up.

5.1.2.3 Hematologic Abnormalities

Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. Findings were at or close to clinically relevant exposures. Hematologic adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have been observed with most TKIs, including ALK inhibitor crizotinib.

Hematologic abnormalities of neutropenia, leukopenia, thrombocytopenia, and anemia have been reported with alectinib administration. Neutrophil counts generally decreased early and remained stable thereafter.

See Section 5.1.3 for management and follow-up.
5.1.2.4 Gastrointestinal Disorders
GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported with alectinib. Similar GI disorders have been observed with other TKIs, including ALK inhibitor crizotinib.

SLS (sodium lauryl sulfate, syn. sodium dodecyl sulfate) is a surfactant excipient in the clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical ingredient). This excipient is a known GI irritant and may be associated with GI AEs including nausea, vomiting, diarrhea, and abdominal pain. Of note, GI tract toxicity as the safety determinant of SLS is not because of systemic toxicity, but a consequence of local irritation to the GI tract. In general, when mixed with diet, higher levels of SLS—a known GI tract mucosal irritant—are tolerated versus gavage administrations.

See Section 5.1.3 for management and follow-up.

5.1.2.5 Skin Disorders
Results of an in vitro phototoxicity study indicated that alectinib may have phototoxic potential.

Skin rash has been reported with majority of TKIs including those targeting the ALK receptor (Hartmann et al. 2009).

Cases of skin rash and photosensitivity have been reported with alectinib and were generally Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.6 Vision Disorders
In the rat quantitative whole body autoradiography study, tissue radioactivity disappeared over time, following a time course comparable to that of plasma radioactivity, except for melanin-containing tissues such as uveal tract of eyes, which had much higher and more sustained exposure in pigmented rats. This is consistent with what is commonly observed for lipophilic basic drugs.

Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and vitreous floaters, have been reported with several TKIs, including ALK inhibitors (crizotinib) (Shaw et al. 2013).

Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and vision impaired, have been reported with alectinib and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.
5.1.2.7 Edema
Most TKIs, including ALK inhibitor crizotinib, have been associated with edema. Events of edema have been reported with alectinib, mostly Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.8 Cardiovascular Effects
QT interval prolongation appears to be an off-target class effect of some TKIs, including ALK inhibitor crizotinib (Shah et al. 2013; XALKORI® U.S. Package Insert). Many TKIs have been associated with bradycardia and hypertension.

In the in vitro study of the cardiovascular system, alectinib inhibited the hERG current (IC$_{20}$: 58 ng/mL; IC$_{50}$: 217 ng/mL). Because plasma protein binding by alectinib is ≥99%, the plasma concentration of alectinib required to induce the same inhibition in vivo would be 100 or more times greater than the concentration required in vitro. In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration [C$_{max}$]: 279 ng/mL).

In a preliminary non-Good Laboratory Practice telemetry study in conscious cynomolgus monkeys, a slight hypotensive effect (approximately 10 mmHg) was seen when alectinib was administered at 20 and 60 mg/kg orally with no effects on ECG or heart rate. The hypotensive effect of alectinib observed in monkeys was considered to likely be caused by vasodilatation induced by L-type Ca$^{2+}$ channel inhibition.

Events of bradycardia have been reported with alectinib. Preliminary heart rate data (based on ECG and pulse measurements) from the ongoing alectinib clinical trials show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic. In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse events, and decreases in heart rate based on ECG and pulse measurements, have also been reported.

In case of bradycardia, concomitant medications must be evaluated to identify those that are known to cause bradycardia, as well as anti-hypertensive medications; discontinuation or dose reduction of these concomitant medications must be considered.

See Section 5.1.3 for management and follow-up.

5.1.2.9 Abnormal Renal Function
In the 2-week non-human primate study at 60 mg/kg, an increase in creatinine was observed but no changes were observed in histopathology. In all other non-human primate studies, no changes in creatinine were observed.

Serum creatinine increases have been reported with alectinib treatment and were generally Grades 1 and 2.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
See Section 5.1.3 for management and follow-up.

5.1.2.10 Muscular Adverse Events and CPK Elevations

Postmarketing experience with some TKIs includes reports of myopathy and rhabdomyolysis (Hohenegger 2012).

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment.

See Section 5.1.3 for management and follow-up and Table 2 for guidelines for managing AEs.
### 5.1.3 Management of Specific Adverse Events with Alectinib

#### Table 2 Guidelines for Management of Specific Adverse Events with Alectinib

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Interstitial lung disease                  | - Patients should be monitored for pulmonary symptoms indicative of pneumonitis.  
- Study drug should be permanently discontinued in patients diagnosed with interstitial lung disease. |
| Hepatobiliary AE and laboratory test elevations | Liver test laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4 and Section 5.3.5.6.  
- If ALT or AST > 3 × baseline, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry about symptoms.  
  If upon repeat testing the transaminases remain >3 × baseline, but are not >5 × baseline or not accompanied with bilirubin increases or do not match any other rule for permanent discontinuation, then monitoring can continue as per investigator judgment, and dose modification is not necessary.  
- At any time during the study treatment, if symptoms compatible with liver injury are observed, liver enzymes should be measured as soon as possible.  
- Study drug treatment has to be permanently discontinued if any of the following occurs:  
  - First observation of ALT or AST > 8 × ULN  
  - ALT or AST > 5 × ULN for more than 2 weeks  
  - First observation of ALT or AST > 3 × ULN and total bilirubin > 2 × ULN  
  - First observation of ALT or AST > 3 × ULN and the appearance of jaundice or signs of hepatic dysfunction or other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (>5%)).  
- Following study drug discontinuation, weekly monitoring of laboratory values should continue until the abnormal values have normalized to pre-treatment levels and/or an adequate explanation of the abnormal value is found.  
- Resumption of study drug is not allowed in patients discontinuing because of any of the above criteria. |
<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic abnormalities</td>
<td>Hematologic laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</td>
</tr>
<tr>
<td></td>
<td>• In case of hematologic toxicity: Grade 4 (neutropenia, thrombocytopenia): Give supportive treatment per treating physician. First episode: Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL. Upon resumption, reduce alectinib dose by 150 mg (1 capsule) BID (450 mg BID). Second episode: Reduce dose by another 150 mg (1 capsule) BID (300 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td></td>
<td>• In case of hematologic toxicity: Grade 3 (neutropenia, thrombocytopenia): Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL. Give supportive treatment per treating physician. If improvement to Grade ≤2 does not occur within 3 weeks, permanently discontinue alectinib.</td>
</tr>
<tr>
<td></td>
<td>• In case of hematologic toxicity: Grade 1 or 2 (neutropenia, thrombocytopenia) no action is required.</td>
</tr>
<tr>
<td>Gastrointestinal tract AEs (e.g., nausea, vomiting, diarrhea)</td>
<td>The events are expected to be minimized by taking the study drug with meal. In case GI events occur, appropriate measures should be taken in accordance with local clinical practice guidelines. If GI toxicities are observed and not tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower.</td>
</tr>
<tr>
<td>Skin disorder AEs (e.g., phototoxicity, rash)</td>
<td>Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 5 days after study drug discontinuation. Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least SPF &gt;30 to help protect against potential sunburn.</td>
</tr>
<tr>
<td>Vision disorders</td>
<td>Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice guidelines, if vision disorders persist or worsen in severity, and to advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder.</td>
</tr>
<tr>
<td>Edema</td>
<td>Physical examinations will be performed routinely in clinical trials. In case edema events occur, appropriate measures should be taken in accordance with local clinical practice guidelines.</td>
</tr>
</tbody>
</table>
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| QT prolongation        | • Grade 1 (450–480 ms): no action required  
• Grade 2 (481–500 ms):  
  First and second episodes: Continue study medication and monitoring  
  Third episode: Decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID)  
• Grade 3 (≥501 ms on at least two separate ECGs):  
  Temporarily interrupt alectinib and refer patient to a cardiologist  
  First episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (450 mg BID)  
  Second episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (300 mg BID)  
  Third episode: Permanently discontinue alectinib  
• Grade 4 (≥501 ms or >60 ms change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia):  
  Discontinue alectinib permanently and admit patient into the hospital for monitoring |
| Abnormal kidney function AEs | Kidney function laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
• If, at any time during the study treatment, eGFR decreases by >50% of the baseline visit value, the patient has to be carefully monitored. All of the underlying factors that may have acutely impacted serum creatinine levels need to be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.).  
• Any eGFR decrease by >50% of the baseline visit value requires repeat testing.  
  If, at the repeat test, the eGFR decrease is still >50% of the baseline visit value, the treatment with alectinib should be interrupted.  
• Alectinib treatment may be resumed with caution if the eGFR value has increased to approximately the baseline visit value. |
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscular AEs and/or CPK elevations</td>
<td>CPK laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</td>
</tr>
<tr>
<td></td>
<td>• Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms.</td>
</tr>
<tr>
<td></td>
<td>• At the first occurrence of any of asymptomatic CPK values ($&gt;10 \times \text{ULN}$, symptomatic CPK $&gt;5 \times \text{ULN}$, or in the presence of severe muscular symptoms with CPK $&gt;\text{ULN}$ but $\leq 5 \times \text{ULN}$) at any time during the study treatment, the patient requires monitoring of the CPK values until they are normalized to pre-treatment levels or a reasonable explanation for the CPK elevation and the symptoms is established.</td>
</tr>
</tbody>
</table>
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Other AEs (including bradycardia) or laboratory abnormalities: | • Grade 3 or 4:  
Temporarily interrupt alectinib for a maximum of 3 weeks. If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib.  
First episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID).  
Second episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by another 150 mg (1 capsule) BID (300 mg BID).  
Third episode: Permanently discontinue alectinib.  
• Grade 2 (except any symptoms and signs that can be corrected with supportive care):  
Temporarily interrupt alectinib and resume if recovering to Grade ≤ 1 or baseline if clinically indicated.  
First episode: If improvement to Grade ≤ 1 or baseline within 10 days, continue same dose of alectinib. If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID when resuming treatment (450 mg BID).  
Second episode: If improvement to Grade ≤ 1 or baseline within 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID or 300 mg BID if after first episode dose was reduced to 450 mg BID). If improvement occurs after 10 days, decrease the current dose of alectinib by 300 mg (2 capsules) when resuming treatment (300 mg BID or 150 mg BID if after first episode dose was reduced to 450 mg BID).  
Third episode: Permanently discontinue alectinib.  
• Grade 1: no action required |

ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate.  
Note: Diarrhea, nausea, and vomiting should be handled with best supportive care first before considering dose modification. Preexisting pleural effusion will not be considered as an adverse event.

### 5.1.4 Safety of Crizotinib and Management of Adverse Events

Dosing interruption and/or dose reduction may be required on the basis of individual safety and tolerability. If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily on the basis of individual safety and tolerability (XALKORI® U.S. Package Insert; Crizotinib SmPC). Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Table 3 and Table 4.
### Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia)

<table>
<thead>
<tr>
<th>CTCAE&lt;sup&gt;a&lt;/sup&gt; Grade</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events

<sup>b</sup> In case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of a third episode of Grade 4 hematologic toxicity.
### Table 4    Crizotinib Dose Modification—Non-Hematologic Toxicities

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Crizotinib Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT or AST elevation &gt;5 × ULN with total bilirubin ≤1.5 × ULN</td>
<td>Withhold until recovery to baseline or ≤3 × ULN, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
<tr>
<td>ALT or AST elevation &gt;3 × ULN with concurrent total bilirubin elevation &gt;1.5 × ULN (in the absence of cholestasis or hemolysis)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Any Grade drug-related ILD/pneumonitis</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>QTc &gt;500 ms on at least 2 separate ECGs</td>
<td>Withhold until recovery to baseline or &lt;481 ms, then resume at reduced dose. Crizotinib must be permanently discontinued in case of recurrence (i.e., QTc &gt;500 ms on at least 2 separate ECGs).</td>
</tr>
<tr>
<td>QTc &gt;500 ms or ≥60 ms change from baseline with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt;60 bpm, symptomatic, may be severe and medically significant, medical intervention indicated)</td>
<td>Withhold until recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm. Evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If a contributing concomitant medication is identified and discontinued or its dose is adjusted, resume crizotinib at previous dose upon recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm. If no contributing concomitant medication is identified or if contributing concomitant medication is identified but not discontinued or its dose was not modified, resume crizotinib at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. Prevent recurrence if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at 250 mg once daily upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring. Crizotinib must be permanently discontinued in case of recurrence.</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt;60 bpm, life-threatening consequences, urgent intervention indicated)</td>
<td>Permanently discontinue</td>
</tr>
</tbody>
</table>
Gastrointestinal events were commonly reported with crizotinib in clinical trials. Nausea, diarrhea, vomiting, and constipation were the most commonly reported gastrointestinal events and were primarily Grade 1 in severity. Supportive care for gastrointestinal events may include standard antiemetic and/or anti-diarrheal or laxative medicinal products. In clinical studies with crizotinib, events of gastrointestinal perforations were reported (XALKORI® U.S. Package Insert; Crizotinib SmPC).

Blood counts and liver function tests including ALT, AST, and total bilirubin should be monitored per local prescribing information for crizotinib.

See local prescribing information for further crizotinib safety information.

5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest, performing protocol-specified safety laboratory assessments, measuring protocol-specified vital signs, and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 5.4.

5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation where a patient is administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition).
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug
- AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
5.2.2 **Serious Adverse Events (Immediately Reportable to the Sponsor)**

An SAE is any AE that meets any of the following criteria:

- *Is* fatal (i.e., the AE actually causes or leads to death)
- *Is* life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate risk of death)
  
  This does not include any AE that had it occurred in a more severe form or was allowed to continue might have caused death.

- Requires or prolongs inpatient hospitalization (see Section 5.3.5.9)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient’s ability to conduct normal life functions)
- *Is a* congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- *Is a* significant medical event in the investigator’s judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the eCRF.

SAEs are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions).

5.2.3 **Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)**

Non-SAEs of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). AEs of special interest for this study are the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law (see Section 5.3.5.6)
• Suspected transmission of an infectious agent by the study drug, as defined below:
   Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.

5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4–5.6. For each AE recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient’s medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting SAEs).

After initiation of study drug, all AEs will be reported until 4 weeks after the last dose of study drug. After this period, the investigator should report any SAEs that are believed to be related to study drug treatment (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all patient evaluation timepoints. Examples of non-directive questions include the following:

   "How have you felt since your last clinic visit?"
   "Have you had any new or changed health problems since you were last here?"

5.3.3 Assessment of Severity of Adverse Events

The AE severity grading scale for the NCI CTCAE (v4.0) will be used for assessing AE severity. Table 5 will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.
Table 5  **Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living&lt;sup&gt;b,c&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences or urgent intervention indicated&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>Death related to adverse event&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.

Note: On the basis of the most recent version of NCI CTCAE (v4.0), which can be found at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

<sup>a</sup> Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

<sup>b</sup> Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one’s self, using the toilet, and taking medications, as performed by patients who are not bedridden.

<sup>c</sup> If an event is assessed as a “significant medical event,” it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

<sup>d</sup> Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

### 5.3.4 Assessment of Causality of Adverse Events

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating “yes” or “no” accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (as applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event
5.3.5  Procedures for Recording Adverse Events

Investigators should use correct medical terminology/concepts when recording AEs on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one AE term should be recorded in the event field on the Adverse Event eCRF.

5.3.5.1  Diagnosis Versus Signs and Symptoms

A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

5.3.5.2  Adverse Events that are Secondary to Other Events

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event on the Adverse Event eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

5.3.5.3  Persistent or Recurrent Adverse Events

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported. If a persistent AE becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes
serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event eCRF should be updated by changing the event from "non-serious" to "serious," providing the date that the event became serious, and completing all data fields related to SAEs.

A recurrent AE is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Is clinically significant in the investigator's judgment

Note: For oncology trials, certain abnormal values may not qualify as AEs.

It is the investigator's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., ALP and bilirubin 5 times the ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent AEs).
5.3.5.5 Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Is clinically significant in the investigator’s judgment

It is the investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded one on the Adverse Event eCRF (see Section 5.3.5.3 for details on recording persistent adverse events).

5.3.5.6 Abnormal Liver Function Tests
The finding of an elevated ALT or AST (>3×baseline value) in combination with either an elevated total bilirubin (>2×ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, investigators must report as an AE the occurrence of either of the following:

- Treatment-emergent ALT or AST >3×baseline value in combination with total bilirubin >2×ULN (of which ≥35% is direct bilirubin)
- Treatment-emergent ALT or AST >3×baseline value in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or a non-SAE of special interest (see Section 5.4.2).

5.3.5.7 Deaths
For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-specified AE reporting period (see Section 5.3.1) that are attributed by the investigator solely to progression of NSCLC should be recorded only on the Study Completion/Early Discontinuation eCRF. All other on-study deaths, regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and
immediately reported to the Sponsor (see Section 5.4.2). An independent monitoring committee will monitor the frequency of deaths from all causes.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. The term “sudden death” should be used only for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, "unexplained death" should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), "unexplained death" should be replaced by the established cause of death.

During survival follow-up, deaths attributed to progression of NSCLC should be recorded only on the Survival eCRF.

5.3.5.8 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not be recorded as AEs. These data will be captured as efficacy assessment data only. In most cases, the expected pattern of progression will be based on RECIST criteria v1.1 (Appendix 4). In rare cases, the determination of clinical progression will be based on symptomatic deterioration. However, every effort should be made to document progression using objective criteria. If there is any uncertainty as to whether an event is due to disease progression, it should be reported as an AE.

5.3.5.10 Hospitalization or Prolonged Hospitalization
Any AE that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 5.2.2), except as outlined below.
The following hospitalization scenarios are not considered to be AEs:

- Hospitalization for respite care
- Planned hospitalization required by the protocol
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:
  
  The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease
  
  The patient has not experienced an AE
- Hospitalization due solely to progression of the underlying cancer

5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration

An overdose is the accidental or intentional use of a drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE. All AEs associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF. If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

AE reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. However, if any PRO responses suggestive of a possible AE are identified during site review of the PRO data, the investigator will determine whether the criteria for an AE have been met and, if so, will report the event on the Adverse Event eCRF.

5.3.5.13 Adverse Events in Individuals Not Enrolled in the Study

If an AE inadvertently occurs in an individual not enrolled in the study, the Adverse Event Form provided to investigators should be completed and submitted to Roche or its designee, either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- SAEs
• Non-SAEs of special interest
• Pregnancies

The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:
• New signs or symptoms or a change in the diagnosis
• Significant new diagnostic test results
• Change in causality based on new information
• Change in the event’s outcome, including recovery
• Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts

Medical Monitor (Roche Medical Responsible) Contact Information
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the Roche Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Roche Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk as well as Medical Monitor contact information will be distributed to all investigators.

This list can be generated using contact numbers found at the following link:

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest

5.4.2.1 Events That Occur Prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

5.4.2.2 Events That Occur After Study Drug Initiation
After initiation of study drug, SAEs and non-SAEs of special interest will be reported until 4 weeks after the last dose of study drug. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) system.
A report will be generated and sent to Roche Safety Risk Management by the EDC system.

In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

Instructions for reporting post-study AEs are provided in Section 5.6.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. A pregnancy report will automatically be generated and sent to Roche Safety Risk Management. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In the event that the EDC system is unavailable, the Clinical Trial Pregnancy Reporting Form provided to investigators should be completed and submitted to Roche or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3.2 Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the
Pregnancy Report eCRF with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

In the event that the EDC system is unavailable, follow reporting instructions provided in Section 5.4.3.1.

5.4.3.3 Abortions
Any abortion should be classified as an SAE (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study drug or the female partner of a male patient exposed to study drug should be classified as an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.5 FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS

5.5.1 Investigator Follow-Up
The investigator should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented on the Adverse Event eCRF and in the patient’s medical record to facilitate source data verification.

All pregnancies reported during the study should be followed until pregnancy outcome. If the EDC system is not available at the time of pregnancy outcome, follow reporting instructions provided in Section 5.4.3.1.

5.5.2 Sponsor Follow-Up
For SAEs, non-SAEs of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.
5.6 POST-STUDY ADVERSE EVENTS

The Sponsor should be notified if the investigator becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug), if the event is believed to be related to study drug treatment.

The investigator should report these events directly to Roche or its designee, either by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number or email address provided to investigators.

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all SAEs and non-SAEs of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single AE cases, the Sponsor will assess the expectedness of these events using the following reference documents:

- Alectinib Investigator’s Brochure
- Local prescribing information for crizotinib

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator’s assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis population for efficacy is the intent-to-treat (ITT) population defined as all randomized patients. Patients will be assigned to the treatment group to which they were randomized.

The primary analysis population for safety is the Safety Analysis Population (SAP) defined as all patients who received at least one dose of study medication. Patients will be assigned to treatment groups as treated, and all patients who received any dose of alectinib will be included in the alectinib treatment arm.

A secondary analysis population for efficacy and safety is the FISH Positive Population (FPP). For efficacy, this is defined as all patients in the ITT population who were ALK-positive using the Vysis FISH assay. Patients will be assigned to the treatment
group to which they were randomized. For safety, this is defined as all patients in the SAP who were ALK-positive using the Vysis FISH assay. Patients will be assigned to treatment groups as treated. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population and the same prespecified testing strategy of secondary endpoints defined in Section 6.4.2 will be applied.

The final analysis of the primary endpoint of PFS will occur when 170 PFS events have occurred, on the basis of the investigators’ assessments. On the basis of the assumptions outlined in Section 6.1, this is estimated to occur approximately 33 months after the first patient has been enrolled. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Hypothesis tests will be two-sided unless otherwise indicated.

The baseline value of any variable will be defined as the last available value recorded prior to the first administration of alectinib or crizotinib.

Further details of all analyses will be provided in the Statistical Analysis Plan.

6.1 DETERMINATION OF SAMPLE SIZE

The focus of this clinical trial is hypothesis testing (Section 6.4.1), and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of writing the initial protocol, there were no Phase III data available on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%). The Phase III PROFILE 1014 study of crizotinib versus standard pemetrexed-platinum-based chemotherapy in previously untreated patients with ALK-positive non-squamous NSCLC reported a median PFS of 10.9 months for crizotinib (Mok et al. 2014).

Thus, an initial assumption of median PFS of 9.8 months for the crizotinib arm has been reassessed on the basis of data from the Phase III study PROFILE 1014 to 10.9 months. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 10.9 months median PFS to 16.8 months) will be targeted.
In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 24 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patient per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 170 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This number of PFS events is estimated to occur approximately 33 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 24 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size (N = 286), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude. At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 106 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.

A follow-up analysis will be performed based on the FPP. This will occur once 170 PFS events have occurred in the FPP to ensure 80% power of the log-rank test assuming a hazard ratio of 0.65 in this sub-population. Based on a potential discrepancy/technical failure rate of 10% between the Ventana IHC assay and the Vysis FISH assay, 257 patients would be eligible for the FPP analysis, which is estimated to occur approximately 35 months after the first patient has been enrolled (i.e., 2 months after the primary IHC analysis) based on the above assumptions.

### 6.2 SUMMARIES OF CONDUCT OF STUDY

Study enrollment, study treatment administration, reasons for discontinuation from study treatment, and reasons for study termination will be summarized by treatment arm for all
randomized patients. Violations of inclusion and exclusion criteria, on the basis of information captured on the eCRF, will be reported and summarized by treatment arm.

6.3 SUMMARIES OF TREATMENT GROUP COMPARABILITY

Summaries of treatment group comparability will be based on the ITT population.

Demographic, baseline disease characteristics and lung cancer history will be summarized by treatment arm for all randomized patients, including the randomization stratification factors. Descriptive baseline summaries of continuous data will present the group mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequency and percentages.

Previous and concomitant cancer therapy will also be summarized, as well as anti-cancer subsequent therapy. Previous and concurrent diseases and medications will also be summarized.

6.4 EFFICACY ANALYSES

The primary population for all primary and secondary efficacy analyses will be the ITT population.

6.4.1 Primary Efficacy Endpoint

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an
estimate of the treatment effect expressed as an HR (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[ H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \]
\[ \text{versus} \]
\[ H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)} \]

where SDF denotes the survival distribution function of the parameter PFS.

**6.4.2 Secondary Efficacy Endpoints**

If the primary endpoint of PFS is statistically significant at a two-sided 5% significance level, the following secondary endpoints will be tested in the following sequential order, each at a two-sided 5% significance level:

- PFS by IRC
- Time to CNS progression
- ORR
- OS

**PFS by IRC**

An analysis of PFS on the basis of the IRC assessments will be performed using the same methodology as specified for PFS on the basis of investigator assessment.

**Time to CNS Progression**

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression. An independent central radiological review will be performed for all patients, and the analysis of CNS progression or response will be on the basis of the data from the independent review. All patients will be included in the analysis regardless of their baseline status of CNS metastases. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of preexisting baseline CNS lesions. On the basis of RECIST v1.1, this is defined as a new post-baseline CNS/brain lesion(s) and/or an increase of ≥20% in the sum of longest diameters of the measurable baseline CNS lesions compared to nadir and/or unequivocal progression of non-measurable baseline CNS lesions.

In order to account for the competing risks inherent in such an analysis, HRs, including statistical inference on the basis of a two-sided log-rank test, to compare the risk of CNS progression between the alectinib and crizotinib treatment groups, will be computed on the basis of cause-specific hazard functions.
The probability of CNS progression, non-CNS progression, and death will each be estimated using cumulative incidence functions.

For descriptive purposes, estimates of the CNS progression rates over time with 95% CIs on the basis of cumulative incidence functions will be presented. A Gray’s test to compare the risk of CNS progression between alectinib and crizotinib will also be performed as a supportive analysis.

An exploratory analysis of CNS Time to Progression on the basis of RANO criteria will also be performed on the basis of the IRC assessments.

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

**Objective Response Rate**

ORR, on the basis of investigator assessment, is defined as the percentage of patients who attain a CR or PR. Per RECIST v1.1, confirmation of objective response is not required for this secondary endpoint. Patients without a post-baseline tumor assessment will be considered non-responders, as will patients with a best overall response of stable disease (SD), PD, or NE (not evaluable).

An estimate of ORR and its two-sided 95% CI will be calculated using the Clopper-Pearson method for each treatment arm. Response rates in the treatment groups will be compared using a stratified Mantel-Haenszel test on the basis of the randomization stratification factors. The difference in ORR between the two treatment arms will be presented together with a two-sided 95% CI on the basis of a normal approximation to the binomial distribution.

**DOR**

For patients who have experienced an objective response (CR or PR) during the study as assessed by the investigator, DOR is defined as the duration from the first tumor assessment that supports the patient’s objective response (CR or PR, whichever is first recorded) to first documented disease progression or death due to any causes, whichever occurred first. Patients who have not progressed or died at the time of analysis will be censored at the last tumor assessment date. Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing will not be performed. DOR will be estimated using Kaplan-Meier methodology and a HR on the basis of a Cox proportional regression model will be calculated.
Overall Survival
OS is defined as the time from the date of randomization to the date of death due to any cause. Patients who are not reported as having died at the time of analysis will be censored at the date when they were last known to be alive. Patients who do not have post-baseline information will be censored at the date of randomization. OS will be analyzed using the same methodology as specified for the primary endpoint. A survival follow-up will be performed based on more mature data.

6.4.2.1 Sensitivity Analyses
The following sensitivity analyses will be performed on the primary endpoint of PFS:

- The effect of non–protocol-specified anti-cancer therapy prior to progression will be assessed by censoring patients at the last adequate tumor assessment prior to the start of non–protocol-specified anti-cancer therapy.

- The effect of missing tumor assessments will be assessed if the number of missing assessments in either arm is >5%. For patients with progression determined following one or more missing tumor assessments, the progression will be backdated to the first missing tumor assessment.

- The effect of loss to follow-up will be assessed depending on the number of patients who are lost to follow-up. If >5% of patients are lost to follow-up for PFS in either treatment arm, a “worst-case” analysis will be performed in which patients who are lost to follow-up will be considered to have progressed at the last date they were known to be progression-free.

6.4.2.2 Subgroup Analyses
Subgroup analyses of PFS will be performed for patients with baseline CNS metastases and for patients without baseline CNS metastases. In addition, a subgroup analysis of Time to CNS Progression will be performed, excluding patients who had pre-treatment radiation therapy for CNS lesions.

All other subgroup analyses will be specified in the SAP.

6.5 SAFETY ANALYSES
The primary population for all safety analyses will be the SAP as defined in Section 6.

All safety parameters will be summarized in tables to evaluate and compare the safety profile of patients treated with alectinib versus crizotinib in terms of:

- Adverse events including adverse events leading to dose modifications or interruptions, study drug withdrawal, and death

- Severe, serious, and selected adverse events

- Deaths

- Laboratory parameters and abnormalities

- Vital signs
Adverse events will be coded using MedDRA and summarized by mapped term and appropriate thesaurus level. All adverse events and routine laboratory parameters will be assessed according to the NCI CTCAE v4.0 grading system. For adverse events, the most extreme severity will be used for reporting. Adverse events will be described by individual listings and by body system, as well as by severity. In tables showing the overall incidence of adverse events, patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency.

Laboratory values will be summarized by treatment arm including summary tables for the shifts in grades from baseline to the worst grade observed during treatment. In order to evaluate and compare hypogonadism in the two treatment arms, testosterone levels in the blood will be summarized for males by treatment arm over time (for details, see Section 6.8).

Descriptive summary tables of change from baseline over time will be provided for vital signs and descriptive statistics will be tabulated for ECOG PS. ECG findings over time will be summarized.

Study drug administration will be summarized by duration and cumulative dose. In addition, treatment exposure will be summarized including the number of doses received, dose intensity, and the percentage of planned dose.

Subgroup analyses will be performed to evaluate the safety profile within the subgroups of patients including by sex, age (<65 vs. ≥65 years), and race (non-Asian vs. Asian).

An IDMC will review the safety data collected during the conduct of the study. Safety monitoring will be performed periodically. Further details will be outlined in the IDMC Charter.

6.6 PHARMACOKINETIC ANALYSES

Standard NCA may be conducted for PK data collected from patients participating in serial/intensive PK collections for relevant analytes, as data allow, as appropriate, and if needed. PK parameters, including but not limited to AUC, maximum concentration ($C_{\text{max}}$), and time to maximum concentration ($T_{\text{max}}$), will be calculated on the basis of the available data as appropriate and where data allow. Additional PK parameters may be calculated as deemed appropriate.

Individual and mean plasma concentrations at each sampling timepoint and/or PK parameters for alectinib and metabolite(s) will be listed, as appropriate.

Summary statistics (e.g., means, standard deviation, coefficient of variation %, geometric means, medians and ranges) for plasma concentrations and/or PK
Parameters for alectinib and metabolite(s) will be presented by treatment and nominal collection times (plasma concentrations only), as appropriate. Additional plots or summary statistics may be constructed or calculated, as appropriate.

Results of PK and/or any PK/pharmacodynamic analyses may be reported outside the clinical study report.

Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be used to analyze the sparse and/or serial/intensive plasma concentration-time data for alectinib. The PK data from this study may be pooled with data from other studies. Population and individual PK parameters will be estimated and the influence of various covariates (such as age, gender, and body weight) on these parameters will be investigated.

Exploratory analyses will be conducted to investigate the relationship between alectinib PK exposure and efficacy/safety parameters.

Details of the mixed-effects modeling and exploratory analyses will be reported in a document separate from the clinical study report.

6.7 PATIENT-REPORTED OUTCOME ANALYSES

The following PRO endpoints will be analyzed and PRO data will be presented separately from adverse event data.

6.7.1 Time to Deterioration of Patient-Reported Lung Cancer Symptoms

TTD from baseline will be assessed at every study visit (Week 4, Week 8, and then after every 4 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at post-treatment Visit (4 weeks after permanent treatment discontinuation); and at subsequent 8-weekly survival follow-up visits for 6 months, for the following lung cancer symptoms: cough (Question 31 on the QLQ-LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale (Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), arm/shoulder pain (Question 41 on the QLQ-LC13) and fatigue multi-item subscale (Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm.

Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. TTD will be analyzed for the ITT population. If a baseline or post-baseline PRO evaluation is not available, TTD will be censored at the date of randomization. If they have not deteriorated, patients will be censored at the last time when they completed an assessment for cough, dyspnea (single item), dyspnea (subscale items), chest pain, arm/shoulder pain, and fatigue.
6.7.2 Additional Patient-Reported Outcomes

PROs of HRQoL, lung cancer-related symptoms, and health status will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13.

Summary statistics (mean, standard deviation, median, and range) of linear transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire, and the QLQ-LC13 according to the EORTC scoring manual guidelines. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. Only patients with a baseline assessment and at least one post-treatment assessment will be included in the analyses.

6.8 EXPLORATORY ANALYSES

The EQ-5D-3L is a generic PRO instrument that is used for across diseases and indications cost-effectiveness analyses. This instrument quantifies the QoL of various health outcomes and is applicable to a wide range of health states. Analyses of this outcome will be exploratory and will generate utility scores for use in economic models for reimbursement purposes only. The PRO will be administered every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months (see Appendix 1).

It has been reported that crizotinib therapy triggered rapid suppression of testosterone levels in men causing rapid-onset hypogonadism. Whether reductions in testosterone reflect an effect of crizotinib on ALK or on some combination of the drug's targets (i.e., c-MET) is unknown (Weickhardt et al. 2012, 2013). Total testosterone, albumin, and sex hormone-binding globulin (SHBG) to calculate free testosterone (calculator: http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m.

The Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between Vysis FISH and Ventana IHC for the detection of ALK-positive NSCLC. The FPP will be a secondary analysis population for efficacy and safety. This analysis population will be used to perform a supportive analysis of the study data based on the Vysis FISH assay rather than the Ventana IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the Ventana IHC companion diagnostic, in which case all analyses will be based on this population.

Results of exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure
ALK rearrangements in circulating tumor cells will be communicated outside the main study report.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

The Sponsor will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC using eCRFs. Sites will be responsible for data entry into the EDC system. In the event of discrepant data, the Sponsor will request data clarification from the sites, which the sites will resolve electronically in the EDC system.

The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. Central laboratory data or other electronic data will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle and process the electronic transfer of these data.

eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

ePRO data will be collected through use of an electronic device provided by an ePRO vendor. The device is designed for entry of data in a way that is attributable, secure, and accurate, in compliance with the FDA regulations for electronic records (21 CFR Part 11). The ePRO device data are available for view access only via secure access to a web server. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.

At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.
7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patients will use an ePRO device to capture PRO data. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be reviewed by site staff via secure access to a web server.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The investigator will receive patient data for the site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records as source data. Acknowledgement of receipt of the compact disc is required. In addition, the Sponsor will receive all patient data in a machine-readable format on a compact disc.

7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by applicable health authorities.
7.5 USE OF COMPUTERIZED SYSTEMS

When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS

Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a United States IND application will comply with FDA regulations and applicable local, state, and federal laws. Studies conducted in the European Union or European Economic Area will comply with the EU Clinical Trial Directive (2001/20/EC).

8.2 INFORMED CONSENT

The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child’s Assent or Caregiver’s Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor’s sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the "Consent Forms") before IRB/EC.
submission. The final IRB/EC–approved Consent Forms must be provided to the
Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of
remaining mandatory samples for optional exploratory research. The investigator or
authorized designee will explain to each patient the objectives of the exploratory
research. Patients will be told that they are free to refuse to participate and may
withdraw their specimens at any time and for any reason during the storage period. A
separate, specific signature will be required to document a patient's agreement to allow
any remaining specimens to be used for exploratory research. Patients who decline to
participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient before his or her
participation in the study. The case history or clinical records for each patient shall
document the informed consent process and that written informed consent was obtained
prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures
or when new information becomes available that may affect the willingness of the patient
to participate. The final revised IRB/EC–approved Consent Forms must be provided to
the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a
significant new information/findings addendum in accordance with applicable laws and
IRB/EC policy) during their participation in the study. For any updated or revised
Consent Forms, the case history or clinical records for each patient shall document the
informed consent process and that written informed consent was obtained using the
updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient’s
legally authorized representative. All signed and dated Consent Forms must remain in
each patient’s study file or in the site file and must be available for verification by study
monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization
to allow use and disclosure of personal health information in compliance with the U.S.
Health Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a
separate Authorization Form for patient authorization for use and disclosure of personal
health information under the HIPAA regulations, the review, approval, and other
processes outlined above apply except that IRB review and approval may not be
required per study site policies.
8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site’s study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which includes an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL DEVIATIONS
The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.

9.3 SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients’ medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE
Steering Committee is established to provide the study Sponsor with recommendations related to any aspect of the trial, specifically study design, data interpretation, exploratory analyses, or alternate changes to the trial that may assist in patient accrual, data collection, analysis, and interpretation of the study results. The Sponsor is ultimately responsible for all decisions regarding the study.

The test for the study inclusion criteria of ALK-positive NSCLC will be performed at Sponsor’s designated central laboratories and assessed by Ventana IHC test.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised. Details of the composition, roles, and responsibilities, and processes of the IDMC are documented in a separate IDMC charter. The IDMC will review safety data and can make recommendations to the Sponsor to stop or amend the study on the basis of safety findings. The frequency of these reviews as well as the data to be reviewed will be agreed with the IDMC and outlined in the separate IDMC charter. No stopping for early proof of efficacy will result from any of these regular safety reviews. IDMC review meetings will be held in a blinded manner to the Sponsor.
An IRC will review the tumor assessments to determine the secondary endpoints of the overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1. In addition to the secondary endpoint of time to CNS progression together with C-ORR, C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the tumor assessments on the basis of RANO criteria.

The independent review of MRI and CT scans will NOT determine either eligibility OR patient treatment. All treatment decisions will be made by the investigator using local assessments.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site:


The results of this study may be published or presented at scientific congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).
10. REFERENCES


Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2


Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984  Report Number 1078196

121


Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.

## Appendix 1
### Schedule of Assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days -28 to 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days -3 to 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 0 (Baseline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td></td>
<td></td>
<td>All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent Visits (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Informed consent:** x
- **Demographics:** x
- **Medical history:** x
- **Pregnancy test**: x
- **To be repeated as necessary**: x
- **Physical examination**: x
- **Vital signs:** x
- **ECOG PS:** x
- **ECG**: x
- **Hematology, Coagulation**: x
- **Biochemistry**: x
- **Urinalysis**: x

- a To be repeated as necessary
- b
- c
- d
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Mandatory tumor sample for ALK testing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional tumor sample</td>
<td>x^f</td>
<td>x^0</td>
<td>x^0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for ALK fusion detection in circulating tumor cells (20 mL of blood)</td>
<td>x</td>
<td>x^h</td>
<td>x^h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma for detection of ALK mutation status (20 mL of blood)</td>
<td>x</td>
<td>x^l</td>
<td>x^l</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood sample for pharmacogenomics research at pre-dose (3 mL of blood)¹</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor assessment²</td>
<td>x¹</td>
<td>x¹</td>
<td>x³</td>
<td>x⁴</td>
<td></td>
</tr>
<tr>
<td>MRI scan of the brain</td>
<td>x¹</td>
<td>x¹</td>
<td>x³</td>
<td>x⁴</td>
<td></td>
</tr>
<tr>
<td>PK samples (2 mL blood)⁵</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>PRO (EORTC QLQ-C30/LC13; EQ-5D⁶)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>

¹ Days -28 to 0
² Days -3 to 0
³ Visit 0 (Baseline)
⁴ Visit 1 (Week 4)
⁵ Visit 2 (Week 8)
⁶ All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD
⁷ Blood sample for pharmacogenomics research at pre-dose (3 mL of blood)
⁸ Tumor assessment
⁹ MRI scan of the brain
¹⁰ PK samples (2 mL blood)
¹¹ PRO (EORTC QLQ-C30/LC13; EQ-5D)
### Appendix 1
#### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days -28 to 0</td>
<td>Visit 0 (Baseline)</td>
<td>Visit 1 (Week 4)</td>
<td>Visit 2 (Week 8)</td>
<td>All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD</td>
</tr>
<tr>
<td>Days -3 to 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total testosterone, albumin, and SHBG to calculate free testosterone, FSH, and LH†</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Adverse events*</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Subsequent therapy for NSCLC</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Drug dispensing and accountability†</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Blood Sample for Roche Clinical Repository (10 mL)</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>

ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTC = circulating tumor cells; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire–Core; EQ-5D = EuroQoL 5 Dimension;
Appendix 1
Schedule of Assessments (cont.)

FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NSCLC = non-small cell lung cancer; PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal.

Notes: First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided—within ≤ 24 hours.
Post-baseline assessments are to be performed within ± 1 week for the first two 4 weekly and subsequent 8 weekly assessments.

a Urine or serum, to be repeated as necessary.
b Including an ophthalmologic examination if clinically indicated.
c At screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), last treatment visit, and as clinically indicated throughout the study.
d Screening laboratory assessment done within 3 days can be counted as the baseline assessment.
e Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 10 to 15 unstained 5-µm slides are required. Tumor ALK status will be assessed by central laboratory before randomization.
f Optional tumor sample could be taken from the tumor block obtained at screening.
g At the time of disease progression from progressive lesions.
h Mandatory blood sample (20 mL) for CTCs should match in time to tumor progression (CNS progression and/or systemic disease progression) at discretion of the investigator.
i Blood sample (20 mL) to obtain plasma for exploratory biomarkers will be collected at Visit 0 (baseline), during the study every second visit (i.e., every 16 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression.
j This sample is required in all patients in alectinib arm, and in those patients in the crizotinib arm who wish to participate in optional genomics sequencing.
k Tumor assessment consists at minimum of a CT/MRI scan of chest and abdomen (for imaging of liver and adrenal glands). Patients who are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP > 1.5 × ULN) of bone metastasis should undergo radionuclide bone scan. Post-baseline assessments are to be performed within ± 1 week for the 8 weekly assessments. If there is suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be performed as soon as possible before the next scheduled evaluation.
l Screening tumor assessment done within 14 days will be counted as the baseline assessment.
m Tumor assessment can be performed whenever clinically indicated. Brain assessment scans should be performed at every systemic imaging tumor assessment. Tumor assessment should continue until disease progression if a patient discontinues treatment prior to PD, regardless of whether they subsequently receive non-study, anti-cancer therapy (a use of subsequent non-study, anti-cancer therapy prior to disease progression would be considered a protocol violation).
Appendix 1
Schedule of Assessments (cont.)

n If treatment was permanently discontinued due to disease progression.

o Pre-dose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit. The pre-dose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits. Remind the patient not to take a daily dose at home on the day of scheduled study visit. For a subset of patients on alectinib treatment (10%–15%, at least n = 20) participating in serial/intensive PK sample collection, additional PK will be collected on Visits 0 (baseline) and 1 (Week 4) at pre-dose (within 2 hours before intake of study medication), 1, 2, 4, 6, 8, 10, and 12 hours post-dose.

p PRO questionnaires are to be completed every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow up visit (every 8 weeks) after post-treatment visit for 6 months. Further guidelines on PRO questionnaire administration will be provided in the study manual.

q Performed every 8 weeks after post-treatment visit during the first 6 months and then every 12 weeks or performed as appropriate. The PRO assessments should be performed during the first 6 months.

r Male patients only, using institutional standard assay. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m. Free testosterone calculator: http://www.issam.ch/freetesto.htm.

s Graded according to NCI CTCAE (version 4.0). Serious adverse events collection must start from first study-specific procedure.

t For details on drug dispensing and accountability, see Section 4.3.3.
## Appendix 2
### Schedule of Alectinib Pharmacokinetic Assessments

<table>
<thead>
<tr>
<th>Visit</th>
<th>Timepoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 0 (baseline)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>All subsequent visits (every 8 weeks) until PD or death/withdrawal from study prior to PD</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 0 (baseline) and Visit 1 (Week 4)*</td>
<td>Pre-dose (within 2 hours before intake of alectinib), 1, 2, 4, 6, 8, 10, and 12** hours post-dose</td>
</tr>
</tbody>
</table>

PD = progressive disease; PK = Pharmacokinetic

*a For patients participating in the serial/intensive PK sample collection only.

**b A time window of ±1 hour may be considered for the 12-hour PK sample only.
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters

This representative list is not intended to be an exhaustive list. Each patient’s concomitant medications should be carefully considered by the investigator with regard to the risk-benefit for the particular patient and appropriate monitoring, including any concomitant medication, dose adjustment, or therapeutic alternatives, which should be determined by the investigator caring for the patient.

<table>
<thead>
<tr>
<th>CYP3A Inducers</th>
<th>CYP3A Potent Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>avasimibe, aminoglutethimide, barbiturates, carbamazepine, dexamethasone, efavirenz, ethosuximide, garlic supplements, glucocorticoids, glutethimide, griseofulvin, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, primidone, rifabutin, rifampin, rifapentine, St. John's wort, troglitazone</td>
<td>apremitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-gp</th>
<th>Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substrates</td>
<td>aliskiren, ambrisentan, colchicine, dabigatan, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, pravastatin, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan</td>
<td>amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir, quercetin, quinidine, ranolazine, verapamil</td>
<td>avasimibe, carbamazepine, phenytoin, rifampin, St John’s wort, tipranavir</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dual UGT1A1/CYP3A</th>
<th>Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substrates</td>
<td>buprenorphine, raltegravir</td>
<td>atazanavir</td>
<td>rifampin</td>
</tr>
</tbody>
</table>

| Sensitive CYP3A and 2C8 substrates | Alfentanil, apremitant, budesonide, buspirone, conivaptan, darifenacin, darunavir, dasatinib, dronedarone, eletriptan, eplerenone, everolimus, felodipine, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, quetiapine, saquinavir, sildenafil, simvastatin, sirolimus, tolvaptan, tipranavir, triazolam, ticagrelor, vardenafil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine, repaglinide, paclitaxol |

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 2

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters (cont.)

This information in this appendix is adapted from Levien and Baker 2003\(^1\), Zhang 2010\(^2\), and FDA Guidance on Drug-Drug Interactions.

Also see:

- [http://medicine.iupui.edu/clinpharm/ddis/table.aspx](http://medicine.iupui.edu/clinpharm/ddis/table.aspx)

Potent inhibitors of CYP3A are those considered to be “strong CYP3A inhibitors” previously shown to result in a \( \geq 5 \)-fold increase in the AUC of a concomitantly administered CYP3A substrate. These are based on the available published literature and, thus, are not considered exhaustive or inclusive. See FDA Guidance on Drug-Drug Interactions for further detail.

---

Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication

Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, are presented below, with slight modifications and the addition of explanatory text as needed for clarity.

MEASURABILITY OF TUMOR AT BASELINE

DEFINITIONS

At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as described below.

Measurable tumor lesions

Tumor lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size as follows:

- 10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than 5 mm)
- 10-mm caliper measurement by clinical examination (lesions that cannot be accurately measured with calipers should be recorded as non-measurable)
- 20 mm by chest X-ray

Malignant lymph nodes

To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in the short axis when assessed by CT scan (CT scan slice thickness is recommended to be no greater than 5 mm). At baseline and follow-up, only the short axis will be measured and followed. See also notes below on “Baseline Documentation of Target and Non-Target Lesions” for information on lymph node measurement.

Non-Measurable tumor lesions

Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or pathological lymph nodes with ≥10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal mass/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques.

---

2 For consistency within this document, the section numbers and cross-references to other sections within the article have been deleted and minor formatting changes have been made.
Special considerations regarding lesion measurability

Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.

Bone lesions

Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.

Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques, such as CT or MRI, can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

Blastic bone lesions are non-measurable.

Cystic lesions

Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

Lesions with prior local treatment

Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.

TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS

Measurement of lesions

All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.

Method of assessment

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study. Imaging-based evaluation should always be the preferred option.
Clinical lesions
Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is suggested.

Chest X-Ray
Chest CT is preferred over chest X-Ray, particularly when progression is an important endpoint, because CT is more sensitive than X-Ray, particularly in identifying new lesions. However, lesions on chest X-Ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

CT, MRI
CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan on the basis of the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable.

If, prior to enrollment, it is known that a patient is unable to undergo CT scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the study should be guided by the tumor type under investigation and the anatomic location of the disease. For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible. Each case should be discussed with the radiologist to determine if the substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of target lesions on a different modality and interpretation of non-target disease or new lesions because the same lesion may appear to have a different size using a new modality.

Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement.

Endoscopy, laparoscopy, tumor markers, cytology, histology
The utilization of these techniques for objective tumor evaluation cannot generally be advised.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

TUMOR RESPONSE EVALUATION

ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE

To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable lesion, as detailed above.

BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS

When more than one measurable lesion is present at baseline, all lesions, up to a maximum of five lesions total and a maximum of two lesions per organ, representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline. This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions (albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size is > 10 mm by CT scan).

Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but, in addition, the lesions should lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.

Lymph nodes merit special mention since they are normal anatomical structures that may be visible by imaging even if not involved by tumor. As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥ 15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥ 10 mm but < 15 mm) should be considered non-target lesions. Nodes that have a short axis of < 10 mm are considered non-pathological and should not be recorded or followed.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum of diameters. If lymph nodes are to be included in the sum, then, as noted above, only the short axis is added.
into the sum. The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions or sites of disease, including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression”.

In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).

**RESPONSE CRITERIA**

**Evaluation of target lesions**

This section provides the definitions of the criteria used to determine objective tumor response for target lesions.

- **CR**: Disappearance of all target lesions
  
  Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

- **PR**: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

- **PD**: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
  
  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
  
  The appearance of one or more new lesions is also considered progression.

- **SD**: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

**Special notes on the assessment of target lesions**

**Lymph nodes**

Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to < 10 mm on study. This means that when lymph nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm.

**Target lesions that become too small to measure**

During the study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as
target lesions at baseline become so faint on the CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being too small to measure. When this occurs, it is important that a value be recorded on the CRF, as follows:

If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.

If the lesion is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned and BML (below measurable limit) should be ticked. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned in this circumstance as well and BML should also be ticked).

To reiterate: if the radiologist is able to provide an actual measure, this measurement should be recorded, even if it is below 5 mm, and, in that case, BML should not be ticked.

Lesions that split or coalesce on treatment
When non-nodal lesions fragment, the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.

Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the group of non-target lesions. Whereas some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the timepoints specified in the protocol.

- CR: Disappearance of all non-target lesions
  All lymph nodes must be non-pathological in size (< 10 mm short axis).
- Non-CR/Non-PD: Persistence of one or more non-target lesions
- PD: Unequivocal progression of existing non-target lesions
  The appearance of one or more new lesions is also considered progression.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Special notes on assessment of progression of non-target disease

When the patient also has measurable disease

In this setting, to achieve unequivocal progression on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease in a magnitude that, even in the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

When the patient has only non-measurable disease

This circumstance arises in some Phase III trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden on the basis of the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic disease from localized to widespread. Examples may be described in protocols as “sufficient to require a change in therapy”. If unequivocal progression is seen, the patient should be considered to have had overall PD at that point. Though it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore, the increase must be substantial.

New lesions

The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly important when the patient’s baseline lesions show PR or CR (e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not).

A lesion identified during the study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

If a new lesion is equivocal (e.g., because of its small size) continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.

EVALUATION OF RESPONSE

Timepoint response (overall response)

It is assumed that at each protocol-specified timepoint, a response assessment occurs. Table 1 provides a summary of the overall response status calculation at each timepoint for patients who have measurable disease at baseline.

When patients have non-measurable (therefore non-target) disease only, Table 2 is to be used.

Table 1  Timepoint Response: Patients with Target Lesions (with or without Non-Target Lesions)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Table 2  Timepoint Response: Patients with Non-Target Lesions Only

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease.

<sup>a</sup> “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can be measured is not advised.

Missing assessments and not-evaluable designation

When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at that timepoint. If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response. This would be most likely to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three measured lesions and during the study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution of the missing lesion).

If one or more target lesions were not assessed either because the scan was not done or because the scan could not be assessed due to poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable. Similarly, if one or more non-target lesions are not assessed, the response for non-target lesions should be “unable to assess”, except where there is clear progression. Overall response would be “unable to assess” if either the target response or the non-target response is “unable to assess”, except where this is clear evidence of progression, as this equates with the case being not evaluable at that timepoint.
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

Table 3  Best Overall Response When Confirmation Is Required

<table>
<thead>
<tr>
<th>Overall Response at First Timepoint</th>
<th>Overall Response at Subsequent Timepoint</th>
<th>Best Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR a</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

a If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even disease meeting PR criteria relative to baseline, qualifies as PD at that point (since disease must have reappeared after CR). Best response would depend on whether the minimum duration for SD was met. However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint. Under these circumstances, the original CR should be changed to PR and the best response is PR.

Special notes on response assessment
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (< 10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document objective progression even after discontinuation of treatment. Symptomatic deterioration is not a
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

descriptor of an objective response; it is a reason for stopping study therapy. The objective response status of such patients is to be determined by evaluation of target and non-target disease as shown in Table 1 to Table 3.

For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non-target lesion, as appropriate. This is to avoid an incorrect assessment of complete response if the primary tumor is still present but not evaluated as a target or non-target lesion.
## Appendix 5

### Eastern Cooperative Oncology Group Performance Status Scale

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework or office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to a bed or chair &gt;50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>
## Appendix 6

### EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires

**EORTC QLQ-C30 (version 3)**

We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will remain strictly confidential.

Please fill in your initials: ____________________________

<table>
<thead>
<tr>
<th>Your birthdate (Day, Month, Year):</th>
<th>[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Today's date (Day, Month, Year):</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>2. Do you have any trouble taking a long walk?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>3. Do you have any trouble taking a short walk outside of the house?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4. Do you need to stay in bed or a chair during the day?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5. Do you need help with eating, dressing, washing yourself, or using the toilet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**During the past week:**

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Were you limited in doing either your work or other daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7. Were you limited in pursuing your hobbies or other leisure time activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>8. Were you short of breath?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>9. Have you had pain?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>10. Did you need to rest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>11. Have you had trouble sleeping?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>12. Have you felt weak?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>13. Have you lacked appetite?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>14. Have you felt nauseated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>15. Have you vomited?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>16. Have you been constipated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Please go on to the next page.
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

During the past week:

17. Have you had diarrhea?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

18. Were you tired?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

19. Did pain interfere with your daily activities?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

21. Did you feel tense?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

22. Did you worry?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

23. Did you feel irritable?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

24. Did you feel depressed?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

25. Have you had difficulty remembering things?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

26. Has your physical condition or medical treatment interfered with your family life?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

27. Has your physical condition or medical treatment interfered with your social activities?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

28. Has your physical condition or medical treatment caused you financial difficulties?  
   | Not at All | A Little | Quite a Bit | Very Much |
   | 1          | 2        | 3          | 4         |

For the following questions please circle the number between 1 and 7 that best applies to you

29. How would you rate your overall health during the past week?  
   | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
   |  |  |  |  |  |  |  |
   Very poor  Excellent

30. How would you rate your overall quality of life during the past week?  
   | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
   |  |  |  |  |  |  |  |
   Very poor  Excellent

© Copyright 1999 EORTC Quality of Life Group. All rights reserved. Version 3.0
## EORTC QLQ - LC13

Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems during the past week. Please answer by circling the number that best applies to you.

### During the past week:

<table>
<thead>
<tr>
<th></th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. How much did you cough?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>32. Did you cough up blood?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>33. Were you short of breath when you rested?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>34. Were you short of breath when you walked?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>35. Were you short of breath when you climbed stairs?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>36. Have you had a sore mouth or tongue?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>37. Have you had trouble swallowing?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>38. Have you had tingling hands or feet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>39. Have you had hair loss?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>40. Have you had pain in your chest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>41. Have you had pain in your arm or shoulder?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>42. Have you had pain in other parts of your body?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

If yes, where ________________

| 43. Did you take any medicine for pain? |
|---|---|---|---|
| 1 | No | 2 | Yes |

If yes, how much did it help? | 1 | 2 | 3 | 4 |
Health Questionnaire

(English version for the US)
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

**Mobility**
- I have no problems in walking about  
- I have some problems in walking about  
- I am confined to bed

**Self-Care**
- I have no problems with self-care  
- I have some problems washing or dressing myself  
- I am unable to wash or dress myself

**Usual Activities (e.g. work, study, household, family or leisure activities)**
- I have no problems with performing my usual activities  
- I have some problems with performing my usual activities  
- I am unable to perform my usual activities

**Pain/Discomfort**
- I have no pain or discomfort  
- I have moderate pain or discomfort  
- I have extreme pain or discomfort

**Anxiety/Depression**
- I am not anxious or depressed  
- I am moderately anxious or depressed  
- I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 7
Modification of Diet in Renal Disease (MDRD) Formula

The estimating glomerular filtration rate (eGFR) will be calculated on the basis of the following formula:

\[
eGFR = 175 \times eGFR - 1.154 \times \text{AGE} - 0.203 \times 0.742 \text{ if female} \times 1.212 \text{ if African American} \text{ (conventional units)}
\]

Appendix 8
Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry

Overview
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA anti-ALK [D5F3]) IHC assay will be used to determine anaplastic lymphoma kinase (ALK) IHC status and to select patients with positive ALK for enrollment in Study BO28984. The anti-ALK (D5F3) rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib. For Study BO28984, the VENTANA anti-ALK (D5F3) assay will be used for investigational purposes only.

VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with using a VENTANA automated slide stainer. It is indicated as an aid in identifying patients eligible for treatment with alectinib.

Device Description
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary antibody, the BenchMark® automated slide staining platform, OptiView DAB detection kit, OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA anti-ALK 2-in-1 cell line control slides or other appropriate system run control.

Scoring System
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern. Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish non-specific staining from specific ALK positivity. Samples must be assessed for morphological damage and the presence of viable tumor versus necrosis. Light, granular, cytoplasmic stippling in alveolar macrophages can occur on anti-ALK (D5F3) and/or NRC slides as an artifact of the detection system. This staining artifact should be noted on the Slide Evaluation Form comment field but should NOT be interpreted as ALK-positive staining. Some background staining has also been observed on normal mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also should not be interpreted as ALK-positive staining. Case slide sets failing to show specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be considered ALK-positive. Refer to VENTANA ALK Scoring Interpretation Guide for non-small cell lung carcinoma (NSCLC) for additional information.
### Appendix 9

**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms**

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
<th>Gene Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>CHST13</td>
<td>CYP3A5</td>
<td>HNMT</td>
<td>SLC22A3</td>
<td>UGT1A4</td>
</tr>
<tr>
<td>ABCB11</td>
<td>CHST2</td>
<td>CYP3A7</td>
<td>MAOA</td>
<td>SLC22A4</td>
<td>UGT1A5</td>
</tr>
<tr>
<td>ABCB4</td>
<td>CHST3</td>
<td>CYP46A1</td>
<td>MAOB</td>
<td>SLC22A5</td>
<td>UGT1A6</td>
</tr>
<tr>
<td>ABCB7</td>
<td>CHST4</td>
<td>CYP4A11</td>
<td>MAT1A</td>
<td>SLC22A6</td>
<td>UGT1A7</td>
</tr>
<tr>
<td>ABCB11</td>
<td>CHST5</td>
<td>CYP4B1</td>
<td>METTL1</td>
<td>SLC22A7</td>
<td>UGT1A8</td>
</tr>
<tr>
<td>ABCB2</td>
<td>CHST6</td>
<td>CYP4F11</td>
<td>NAT1</td>
<td>SLC22A8</td>
<td>UGT1A9</td>
</tr>
<tr>
<td>ABCB3</td>
<td>CHST7</td>
<td>CYP4F12</td>
<td>NAT2</td>
<td>SLC25A27</td>
<td>UGT2A1</td>
</tr>
<tr>
<td>ABCB4</td>
<td>CHST8</td>
<td>CYP4F2</td>
<td>NNMT</td>
<td>SLC28A1</td>
<td>UGT2B11</td>
</tr>
<tr>
<td>ABCB5</td>
<td>CHST9</td>
<td>CYP4F3</td>
<td>NR1I2</td>
<td>SLC28A3</td>
<td>UGT2B17</td>
</tr>
<tr>
<td>ABCB6</td>
<td>COMT</td>
<td>CYP4F8</td>
<td>NR1I2</td>
<td>SLC29A1</td>
<td>UGT2B28</td>
</tr>
<tr>
<td>ABCB8</td>
<td>CROT</td>
<td>CYP4Z1</td>
<td>NR1I3</td>
<td>SLC29A2</td>
<td>UGT2B4</td>
</tr>
<tr>
<td>ABCB9</td>
<td>CYP11A1</td>
<td>CYP51A1</td>
<td>NR3C1</td>
<td>SLC29A2</td>
<td>UGT2B4</td>
</tr>
<tr>
<td>ABCG1</td>
<td>CYP11B1</td>
<td>CYP7A1</td>
<td>ORM1</td>
<td>SLC5A6</td>
<td>UGT2B7</td>
</tr>
<tr>
<td>ABCG2</td>
<td>CYP11B2</td>
<td>CYP7B1</td>
<td>ORM2</td>
<td>SLC6A6</td>
<td>UGT8</td>
</tr>
<tr>
<td>ABP1</td>
<td>CYP17A1</td>
<td>CYP8B1</td>
<td>PGAP3</td>
<td>SLC7A5</td>
<td>VKORC1</td>
</tr>
<tr>
<td>ADH1A</td>
<td>CYP19A1</td>
<td>DCK</td>
<td>PNMT</td>
<td>SLC7A7</td>
<td>XDH</td>
</tr>
<tr>
<td>ADH1B</td>
<td>CYP1A1</td>
<td>DPYD</td>
<td>PON1</td>
<td>SLC7A8</td>
<td>CDK6</td>
</tr>
<tr>
<td>ADH1C</td>
<td>CYP1A2</td>
<td>EPHX1</td>
<td>PON2</td>
<td>SLCO1A2</td>
<td>CEBPB</td>
</tr>
<tr>
<td>ADH4</td>
<td>CYP1B1</td>
<td>EPHX2</td>
<td>PON3</td>
<td>SLCO1B1</td>
<td>CEP44</td>
</tr>
<tr>
<td>ADH5</td>
<td>CYP20A1</td>
<td>FAAH</td>
<td>POR</td>
<td>SLCO1B3</td>
<td>CES1</td>
</tr>
<tr>
<td>ADH6</td>
<td>CYP21A2</td>
<td>FMO1</td>
<td>PPARD</td>
<td>SLCO2B1</td>
<td>CTLA4</td>
</tr>
<tr>
<td>ADH7</td>
<td>CYP24A1</td>
<td>FMO2</td>
<td>PPARG</td>
<td>SLCO3A1</td>
<td>CYP3A</td>
</tr>
<tr>
<td>AHR</td>
<td>CYP26A1</td>
<td>FMO3</td>
<td>PPP1R9A</td>
<td>SLCO4A1</td>
<td>EGFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LPL</td>
</tr>
</tbody>
</table>
Appendix 9
Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms (cont.)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKAP9</td>
<td>CYP26C1</td>
<td>FMO4</td>
<td>PRSS53</td>
<td>SLCO5A1</td>
<td>ETNK2</td>
</tr>
<tr>
<td>ALB</td>
<td>CYP27A1</td>
<td>FMO5</td>
<td>PTGIS</td>
<td>SPG7</td>
<td>FASLG</td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>CYP27B1</td>
<td>FMO6</td>
<td>QPRT</td>
<td>SPN</td>
<td>FMO5</td>
</tr>
<tr>
<td>ALDH2</td>
<td>CYP2A13</td>
<td>G6PD</td>
<td>RALBP1</td>
<td>SULT1A1</td>
<td>FOS</td>
</tr>
<tr>
<td>ALDH3A1</td>
<td>CYP2A6</td>
<td>GSTA1</td>
<td>RPL13</td>
<td>SULT1A2</td>
<td>FPGS</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>CYP2A7</td>
<td>GSTA2</td>
<td>RXRA</td>
<td>SULT1A3</td>
<td>GGH</td>
</tr>
<tr>
<td>AOX1</td>
<td>CYP2B6</td>
<td>GSTA3</td>
<td>SERPINA7</td>
<td>SULT1B1</td>
<td>GPNMB</td>
</tr>
<tr>
<td>APOA2</td>
<td>CYP2B7P1</td>
<td>GSTA4</td>
<td>SLC10A1</td>
<td>SULT1C2</td>
<td>GPT</td>
</tr>
<tr>
<td>ARNT</td>
<td>CYP2C18</td>
<td>GSTA5</td>
<td>SLC10A2</td>
<td>SULT1C4</td>
<td>GPX1</td>
</tr>
<tr>
<td>ARSA</td>
<td>CYP2C19</td>
<td>GSTM1</td>
<td>SLC13A1</td>
<td>SULT1E1</td>
<td>GPX3</td>
</tr>
<tr>
<td>ATP7A</td>
<td>CYP2C8</td>
<td>GSTM2</td>
<td>SLC15A1</td>
<td>SULT2A1</td>
<td>GPX4</td>
</tr>
<tr>
<td>ATP7B</td>
<td>CYP2C9</td>
<td>GSTM3</td>
<td>SLC15A2</td>
<td>SULT2B1</td>
<td>GYS1</td>
</tr>
<tr>
<td>CA5P</td>
<td>CYP2D6</td>
<td>GSTM4</td>
<td>SLC16A1</td>
<td>SULT4A1</td>
<td>GYS2</td>
</tr>
<tr>
<td>CBR1</td>
<td>CYP2E1</td>
<td>GSTM5</td>
<td>SLC19A1</td>
<td>TBXAS1</td>
<td>HCP5</td>
</tr>
<tr>
<td>CBR3</td>
<td>CYP2F1</td>
<td>GSTO1</td>
<td>SLC22A1</td>
<td>TPMT</td>
<td>HGF</td>
</tr>
<tr>
<td>CDA</td>
<td>CYP2J2</td>
<td>GSTP1</td>
<td>SLC22A11</td>
<td>TPSG1</td>
<td>HLA-A</td>
</tr>
<tr>
<td>CES2</td>
<td>CYP2S1</td>
<td>GSTT1</td>
<td>SLC22A12</td>
<td>TYMS</td>
<td>HLA-B</td>
</tr>
<tr>
<td>CHST1</td>
<td>CYP3A11</td>
<td>GSTT2</td>
<td>SLC22A13</td>
<td>UGT1A1</td>
<td>HLA-DQA1</td>
</tr>
<tr>
<td>CHST10</td>
<td>CYP3A4</td>
<td>GSTZ1</td>
<td>SLC22A14</td>
<td>UGT1A10</td>
<td>HLA-DQB1</td>
</tr>
<tr>
<td>CHST11</td>
<td>CYP3A43</td>
<td>HMGCR</td>
<td>SLC22A2</td>
<td>UGT1A3</td>
<td>HLA-DRB1</td>
</tr>
</tbody>
</table>
PROTOCOL

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE–POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984

VERSION NUMBER: 1

EUDRACT NUMBER: 2013-004133-33

IND NUMBER: 111723

TEST PRODUCT: Alectinib (RO5424802)

MEDICAL MONITOR: 

SPONSOR: F. Hoffmann-La Roche Ltd

DATE FINAL: See electronic date stamp below

FINAL PROTOCOL APPROVAL

Approver's Name: Company Signatory

Date and Time (UTC): 10-Feb-2014 23:21:31

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196
TABLE OF CONTENTS

PROTOCOL ACCEPTANCE FORM .......................................................... 9

PROTOCOL SYNOPSIS ...................................................................... 10

1. BACKGROUND ............................................................................. 21
   1.1 Background on Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer ........................................... 21
   1.2 Background on Alectinib ........................................................ 23
   1.3 Study Rationale and Benefit-Risk Assessment ...................... 28

2. OBJECTIVES ................................................................................ 30
   2.1 Efficacy Objectives ............................................................. 30
   2.2 Safety Objectives ............................................................... 31
   2.3 Pharmacokinetic Objectives ............................................. 31
   2.4 Patient-Reported Outcome Objectives .............................. 31
   2.5 Exploratory Objectives ..................................................... 31

3. STUDY DESIGN .......................................................................... 31
   3.1 Description of Study ............................................................. 31
   3.2 End of Study ....................................................................... 33
   3.3 Rationale for Study Design .................................................. 34
      3.3.1 Rationale for Alectinib Dosage ...................................... 34
      3.3.2 Rationale for Patient Population .................................. 35
      3.3.3 Rationale for Control Group ........................................ 35
      3.3.4 Rationale for Open-Label Design ................................. 36
      3.3.5 Rationale for Primary Endpoint Selection .................. 37
      3.3.6 Rationale for Secondary Endpoint of Time to CNS Progression................................................................. 38
      3.3.7 Rationale for PK Sample Collection Schedule ............... 39
      3.3.8 Rationale for Biomarker Assessments ......................... 39
      3.3.9 Rationale for PRO Assessments .................................. 40
   3.4 Outcome Measures ........................................................... 41
      3.4.1 Efficacy Outcome Measures ....................................... 41
      3.4.2 Safety Outcome Measures ........................................... 42

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

2563
3.4.3 Pharmacokinetic Outcome Measures ........................................... 42
3.4.4 Patient-Reported Outcome Measures ........................................ 42
3.4.5 Exploratory Outcome Measures .............................................. 43

4. MATERIALS AND METHODS ................................................................... 43
4.1 Patients .......................................................................................... 43
4.1.1 Inclusion Criteria ....................................................................... 43
4.1.2 Exclusion Criteria ...................................................................... 44
4.2 Method of Treatment Assignment and Blinding ............................ 46
4.3 Study Treatment ............................................................................ 46
4.3.1 Formulation, Packaging, and Handling .................................... 46
4.3.1.1 Alectinib ................................................................................. 46
4.3.1.2 Crizotinib ................................................................................. 47
4.3.2 Dosage, Administration, and Compliance ................................ 47
4.3.2.1 Alectinib ................................................................................. 47
4.3.2.2 Crizotinib ................................................................................. 47
4.3.3 Investigational Medicinal Product Accountability .................... 48
4.3.4 Post-Trial Access to Alectinib .................................................. 48
4.4 Concomitant Therapy .................................................................... 48
4.4.1 Permitted Therapy ..................................................................... 48
4.4.2 Prohibited Therapy .................................................................. 50
4.4.3 Prohibited Food ......................................................................... 51
4.5 Study Assessments ........................................................................ 51
4.5.1 Informed Consent Forms and Screening Log .............................. 51
4.5.2 Medical History and Demographic Data ................................... 51
4.5.3 Corticosteroid Use for CNS Metastases .................................... 51
4.5.4 Physical Examinations ............................................................... 52
4.5.5 Vital Signs ................................................................................ 52
4.5.6 ECOG Performance Status ....................................................... 52
4.5.7 Tumor and Response Evaluations ............................................. 52
4.5.8 Laboratory, Biomarker, and Other Biological Sample ................ 54
4.5.8.1 Laboratory Assessments ........................................................ 54
4.5.8.2 Pre-Treatment Tumor Samples (Mandatory) ......................... 54
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)</td>
<td>55</td>
</tr>
<tr>
<td>4.5.8.4 Blood and Plasma Samples (Mandatory)</td>
<td>55</td>
</tr>
<tr>
<td>4.5.8.5 Samples for Pharmacokinetic Assessments</td>
<td>57</td>
</tr>
<tr>
<td>4.5.9 Electrocardiograms</td>
<td>57</td>
</tr>
<tr>
<td>4.5.10 Patient-Reported Outcomes</td>
<td>58</td>
</tr>
<tr>
<td>4.5.11 Samples for Roche Clinical Repository</td>
<td>58</td>
</tr>
<tr>
<td>4.5.11.1 Overview of the Roche Clinical Repository</td>
<td>58</td>
</tr>
<tr>
<td>4.5.11.2 Approval by the Institutional Review Board or Ethics Committee</td>
<td>59</td>
</tr>
<tr>
<td>4.5.11.3 Sample Collection</td>
<td>59</td>
</tr>
<tr>
<td>4.5.11.4 Confidentiality</td>
<td>59</td>
</tr>
<tr>
<td>4.5.11.5 Consent to Participate in the Roche Clinical Repository</td>
<td>60</td>
</tr>
<tr>
<td>4.5.11.6 Withdrawal from the Roche Clinical Repository</td>
<td>60</td>
</tr>
<tr>
<td>4.5.11.7 Monitoring and Oversight</td>
<td>61</td>
</tr>
<tr>
<td>4.6 Patient, Treatment, Study, and Site Discontinuation</td>
<td>61</td>
</tr>
<tr>
<td>4.6.1 Patient Discontinuation</td>
<td>61</td>
</tr>
<tr>
<td>4.6.2 Study Treatment Discontinuation</td>
<td>61</td>
</tr>
<tr>
<td>4.6.3 Study and Site Discontinuation</td>
<td>62</td>
</tr>
<tr>
<td>5. ASSESSMENT OF SAFETY</td>
<td>62</td>
</tr>
<tr>
<td>5.1 Safety Plan</td>
<td>62</td>
</tr>
<tr>
<td>5.1.1 Adverse Events Collection</td>
<td>62</td>
</tr>
<tr>
<td>5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data</td>
<td>63</td>
</tr>
<tr>
<td>5.1.2.1 Interstitial Lung Disease</td>
<td>63</td>
</tr>
<tr>
<td>5.1.2.2 Hepatobiliary Laboratory Test Elevations</td>
<td>63</td>
</tr>
<tr>
<td>5.1.2.3 Hematologic Abnormalities</td>
<td>63</td>
</tr>
<tr>
<td>5.1.2.4 Gastrointestinal Disorders</td>
<td>64</td>
</tr>
<tr>
<td>5.1.2.5 Skin Disorders</td>
<td>64</td>
</tr>
<tr>
<td>5.1.2.6 Vision Disorders</td>
<td>64</td>
</tr>
<tr>
<td>5.1.2.7 Edema</td>
<td>65</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>5.1.2.8</td>
<td>Cardiovascular Effects (QT Interval Prolongation)</td>
</tr>
<tr>
<td>5.1.2.9</td>
<td>Abnormal Renal Function</td>
</tr>
<tr>
<td>5.1.2.10</td>
<td>Muscular Adverse Events and CPK Elevations</td>
</tr>
<tr>
<td>5.1.3</td>
<td>Management of Specific Adverse Events with Alectinib</td>
</tr>
<tr>
<td>5.1.4</td>
<td>Safety of Crizotinib and Management of Adverse Events</td>
</tr>
<tr>
<td>5.2</td>
<td>Safety Parameters and Definitions</td>
</tr>
<tr>
<td>5.2.1</td>
<td>Adverse Events</td>
</tr>
<tr>
<td>5.2.2</td>
<td>Serious Adverse Events (Immediately Reportable to the Sponsor)</td>
</tr>
<tr>
<td>5.2.3</td>
<td>Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)</td>
</tr>
<tr>
<td>5.3</td>
<td>Methods and Timing for Capturing and Assessing Safety Parameters</td>
</tr>
<tr>
<td>5.3.1</td>
<td>Adverse Event Reporting Period</td>
</tr>
<tr>
<td>5.3.2</td>
<td>Eliciting Adverse Event Information</td>
</tr>
<tr>
<td>5.3.3</td>
<td>Assessment of Severity of Adverse Events</td>
</tr>
<tr>
<td>5.3.4</td>
<td>Assessment of Causality of Adverse Events</td>
</tr>
<tr>
<td>5.3.5</td>
<td>Procedures for Recording Adverse Events</td>
</tr>
<tr>
<td>5.3.5.1</td>
<td>Diagnosis Versus Signs and Symptoms</td>
</tr>
<tr>
<td>5.3.5.2</td>
<td>Adverse Events that are Secondary to Other Events</td>
</tr>
<tr>
<td>5.3.5.3</td>
<td>Persistent or Recurrent Adverse Events</td>
</tr>
<tr>
<td>5.3.5.4</td>
<td>Abnormal Laboratory Values</td>
</tr>
<tr>
<td>5.3.5.5</td>
<td>Abnormal Vital Sign Values</td>
</tr>
<tr>
<td>5.3.5.6</td>
<td>Abnormal Liver Function Tests</td>
</tr>
<tr>
<td>5.3.5.7</td>
<td>Deaths</td>
</tr>
<tr>
<td>5.3.5.8</td>
<td>Preexisting Medical Conditions</td>
</tr>
<tr>
<td>5.3.5.9</td>
<td>Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>5.3.5.10</td>
<td>Hospitalization or Prolonged Hospitalization</td>
</tr>
<tr>
<td>5.3.5.11</td>
<td>Adverse Events Associated with an Overdose</td>
</tr>
<tr>
<td>5.3.5.12</td>
<td>Patient-Reported Outcome Data</td>
</tr>
</tbody>
</table>
5.4 Immediate Reporting Requirements from
Investigator to Sponsor.......................................................... 80
5.4.1 Emergency Medical Contacts ............................................. 81
5.4.2 Reporting Requirements for Serious Adverse
Events and Non-Serious Adverse Events of
Special Interest........................................................................ 81
5.4.2.1 Events That Occur Prior to Study Drug Initiation .............. 81
5.4.2.2 Events That Occur After Study Drug Initiation ................. 81
5.4.3 Reporting Requirements for Pregnancies............................ 82
5.4.3.1 Pregnancies in Female Patients ..................................... 82
5.4.3.2 Pregnancies in Female Partners of Male Patients .......... 82
5.4.3.3 Abortions ....................................................................... 83
5.4.3.4 Congenital Anomalies/Birth Defects ................................. 83
5.5 Follow-Up of Patients After Adverse Events ....................... 83
5.5.1 Investigator Follow-Up...................................................... 83
5.5.2 Sponsor Follow-Up ............................................................... 83
5.6 Post-Study Adverse Events...................................................... 84
5.7 Expedited Reporting to Health Authorities,
Investigators, Institutional Review Boards, and
Ethics Committees....................................................................... 84

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN .......... 84
6.1 Determination of Sample Size .............................................. 85
6.2 Summaries of Conduct of Study ........................................... 87
6.3 Summaries of Treatment Group Comparability .................. 87
6.4 Efficacy Analyses .................................................................. 87
6.4.1 Primary Efficacy Endpoint ................................................ 87
6.4.2 Secondary Efficacy Endpoints .......................................... 88
6.4.2.1 Sensitivity Analyses....................................................... 90
6.4.2.2 Subgroup Analyses....................................................... 90
6.5 Safety Analyses....................................................................... 90
6.6 Pharmacokinetic Analyses.................................................... 91
6.7 Patient-Reported Outcome Analyses .................................... 92
6.7.1 Time to Deterioration of Patient-Reported Lung
Cancer Symptoms...................................................................... 92
6.7.2 Additional Patient-Reported Outcomes .................................. 93
6.8 Exploratory Analyses ............................................................... 93

7. DATA COLLECTION AND MANAGEMENT .................................................. 94
  7.1 Data Quality Assurance .............................................................. 94
  7.2 Electronic Case Report Forms ................................................... 94
  7.3 Electronic Patient-Reported Outcome Data .................................. 95
  7.4 Source Data Documentation ....................................................... 95
  7.5 Use of Computerized Systems .................................................. 96
  7.6 Retention of Records ............................................................... 96

8. ETHICAL CONSIDERATIONS ............................................................... 96
  8.1 Compliance With Laws and Regulations ..................................... 96
  8.2 Informed Consent ..................................................................... 96
  8.3 Institutional Review Board or Ethics Committee .......................... 98
  8.4 Confidentiality .......................................................................... 98
  8.5 Financial Disclosure ............................................................... 98

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION .................................................. 99
  9.1 Study Documentation ................................................................ 99
  9.2 Protocol Violations ................................................................. 99
  9.3 Site Inspections ....................................................................... 99
  9.4 Administrative Structure .......................................................... 99
  9.5 Publication of Data and Protection of Trade Secrets ......................... 100
  9.6 Protocol Amendments ............................................................ 100

10. REFERENCES ..................................................................................... 101
LIST OF TABLES

Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP .......................................................... 25
Table 2  Guidelines for Management of Specific Adverse Events with Alectinib ...................................................................................... 66
Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia) ........................................................................... 71
Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities ................................................................................................. 71
Table 5  Adverse Event Severity Grading Scale .............................................................................................................................. 75

LIST OF FIGURES

Figure 1  Change in Size of Target Lesions as Assessed by the Independent Review Committee in Part 2 of Study AF-001JP Using RECIST v1.1 (Data Cutoff Date: 18 April 2013) ................. 24
Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) ................................................................. 26
Figure 3  Best Percent Change in Size of Target Lesions from Baseline as Assessed by the Investigator in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013) .................................................................... 27
Figure 4  Summary of Study Design ............................................................................................................................................. 33

LIST OF APPENDICES

Appendix 1  Schedule of Assessments ................................................................................................................................. 106
Appendix 2  Schedule of Alectinib Pharmacokinetic Assessments .............................................................................................. 112
Appendix 3  List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters .............................................. 113
Appendix 4  Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication ................. 115
Appendix 5  Eastern Cooperative Oncology Group Performance Status Scale .................................................................................. 126
Appendix 6  EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires ....... 127
Appendix 7  Modification of Diet in Renal Disease (MDRD) Formula ....... 133
Appendix 8  Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry .......................................................... 134
Appendix 9  Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms .................................................................................. 135
PROTOCOL ACCEPTANCE FORM

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE–POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 1
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
TEST PRODUCT: Alectinib (RO5424802)
MEDICAL MONITOR: [Redacted]
SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

________________________________________________________________________
Principal Investigator’s Name (print)

________________________________________________________________________
Principal Investigator’s Signature Date

Please return a copy of the form to your local study monitor. Please retain the original for your study files.
PROTOCOL SYNOPSIS

TITLE: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE–POSITIVE ADVANCED NON–SMALL CELL LUNG CANCER

PROTOCOL NUMBER: BO28984
VERSION NUMBER: 1
EUDRACT NUMBER: 2013-004133-33
IND NUMBER: 111723
TEST PRODUCT: Alectinib (RO5424802)
PHASE: Phase III
INDICATION: Anaplastic lymphoma kinase–positive (ALK-positive) non–small cell lung cancer (NSCLC)
SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives
The primary efficacy objective for this study is as follows:
• To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as measured by investigator-assessed progression-free survival (PFS)

The secondary efficacy objectives for this study are as follows:
• To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
• To evaluate and compare the time to progression in the CNS on the basis of Independent Review Committee (IRC) review of radiographs by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
• To evaluate and compare the PFS assessment by the IRC
• To evaluate and compare the overall survival (OS)

Safety Objective
The safety objective for this study is as follows:
• To evaluate the safety and tolerability of alectinib compared to crizotinib

Pharmacokinetic Objective
The secondary pharmacokinetic (PK) objective for this study is as follows:
• To characterize the pharmacokinetics of alectinib and metabolite(s)
Patient-Reported Outcome Objectives
The secondary patient-reported outcome (PRO) objectives for this study are as follows:

- To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm/shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain).
- To evaluate and compare PROs of health-related quality of life (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13.

Exploratory Objectives
The exploratory objectives for this study are as follows:

- To evaluate and compare patient's health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement.
- To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone, albumin and sex hormone-binding globulin (SHBG) to calculate free testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood.
- To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
- To investigate molecular mechanisms of resistance to ALK inhibitors.
- To investigate detection of ALK mutations in plasma and circulating tumor cells.

Study Design
Description of Study
This is a randomized, active controlled, multicenter Phase III open-label study in patients with treatment-naïve ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.

This study will comprise approximately 180 centers, in around 30 countries worldwide. Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally twice daily (BID), taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food. Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases) a local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for
OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

**Number of Patients**

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block stratified randomization procedure and over a planned recruitment period of 25 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

**Target Population**

**Inclusion Criteria**

- Patients must meet the following criteria for study entry:
  - Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIb not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
  - Age ≥ 18 years old.
  - Life expectancy of at least 12 weeks.
  - ECOG PS of 0-2.
  - Patients had no prior systemic treatment for advanced or recurrent (Stage IIIb not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC.
  - Adequate hematologic function:
    - Platelet count ≥ 100 × 10^9/L
    - ANC ≥ 1500 cells/μL
    - Hemoglobin ≥ 9.0 g/dL
  - Adequate renal function:
    - Calculated creatinine clearance at least 45 mL/min
  - Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
  - Measurable disease (by RECIST v1.1) prior to the administration of study treatment.
  - Prior brain or leptomeningeal metastases allowed if asymptomatic and diagnosed incidentally at study baseline. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment at least 14 days before enrollment and be clinically stable.
  - For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
  - For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate <1% per year. Barrier methods must always be supplemented with the use of a spermicide.
• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• Able and willing to provide written informed consent prior to performing any study related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome device.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

• Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

• Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection.

• Liver disease characterized by:
  - ALT or AST >3 × ULN (≥5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  - Impaired excretory function (e.g., hyperbiliirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  - Acute viral or active autoimmune, alcoholic, or other types of hepatitis

• National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication.

• History of organ transplant.

• Co-administration of anti-cancer therapies other than those administered in this study.

• Patients with baseline QTc >470 ms or patients with symptomatic bradycardia <45 beats per minute.

• Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib except for oral corticosteroids up to 20 mg of prednisolone equivalent per day

• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment.

• History of hypersensitivity to any of the additives in the alectinib drug formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulfate [SLS], magnesium stearate).

• History of hypersensitivity to any of the additives in the crizotinib drug formulation (silica, colloidal anhydrous cellulose, microcrystalline calcium hydrogen phosphate, anhydrous sodium starch glycolate, magnesium stearate).

• Pregnant or lactating women.

• Known HIV positivity or AIDS-related illness.
• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study.
• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.

Length of Study
The time from first patient screened to end of study, defined below, will be approximately 43 months.

End of Study
This study is event-driven, with a recruitment period of approximately 25 months. The required number of events for the final analysis of the primary endpoint is expected approximately 31 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Outcome Measures
Efficacy Outcome Measures
The efficacy outcome measures for this study are as follows:
• PFS, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.
• ORR, which is defined as the percentage of patients who attain complete response (CR) or partial response (PR); response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.
• Time to CNS progression, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.
• DOR, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.
• OS, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.

Safety Outcome Measures
The secondary safety outcome measures for this study are as follows:
• Serious and non-serious adverse events
• Safety laboratory tests values
• Vital signs (blood pressure, heart rate), ECG
• Physical examination
Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:

- Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment
- Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n = 20)
- PK parameters will be determined as appropriate and where data allow:
  - The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach.
  - The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.
  - Non-compartmental analysis may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

Patient-Reported Outcome Measures
The PRO measures for this study are as follows:

- EORTC QLQ-C30 and the EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).
- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.

Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for reimbursement.
- Total testosterone, albumin and SHBG to calculate free testosterone level, FSH, and LH, in blood to measure an onset of hypogonadism in adult men.
- The FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naive NSCLC that is ALK-positive by FISH test.
- Post progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors.
- ALK mutation status in plasma DNA to monitor efficacy and disease progression.
- ALK fusion status in circulating tumor cells in blood.

Investigational Medicinal Products
Test Product
Alectinib comes in a capsule dosage form containing the following active ingredient:
[Chemical name] 9-Ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate.
Alectinib capsules should be stored in accordance with the storage instructions on the label.
Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

Comparator
Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.
For further details, see the local prescribing information for crizotinib (Xalkori®).
Non-Investigational Medicinal Products
Standard-of-care therapy administered to all patients in addition to test product or comparator.

Statistical Methods
Primary Analysis
PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.

The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of PFS of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[
H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \\
\text{versus} \\
H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)}
\]

where SDF denotes the survival distribution function of the parameter PFS.

Determination of Sample Size
The focus of this clinical trial is hypothesis testing, and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of writing the protocol, there are no Phase III data on crizotinib in the first line setting in ALK-positive patients. The median PFS for crizotinib administered as second line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥ 1 line of chemotherapy (with 85% patients having received ≥ 2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%).

A median PFS of 9.8 months for the crizotinib arm has been assumed. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 9.8 months median PFS to 15.1 months) will be targeted. In this study, 286 patients will be enrolled in a 1:1 randomization allocation.

Enrollment will take approximately 25 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patients per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1
• Months 13–14: 14 patients per month
• Month 15 onwards: 15 patients per month

A total of 169 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This level of enrollment is estimated to occur approximately 31 months after the first patient has been enrolled.

**Interim Analyses**

No interim analysis for efficacy or futility is planned.
# LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma kinase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration–time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C-DOR</td>
<td>CNS duration of response</td>
</tr>
<tr>
<td>C-ORR</td>
<td>CNS objective response rate</td>
</tr>
<tr>
<td>C-PR</td>
<td>CNS progression rate</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>DOT</td>
<td>duration of treatment</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>Eastern Cooperative Oncology Group Performance Status</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EML4</td>
<td>echinoderm microtubule-associated protein-like 4</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for the Research and Treatment of Cancer</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-3L</td>
<td>EuroQoL 5 Dimension</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FISH</td>
<td>fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FPP</td>
<td>FISH Positive Population</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (application)</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRC</td>
<td>Independent Review Committee</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>IXRS</td>
<td>interactive voice or web-based response system</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>MET</td>
<td>mesenchymal-epithelial transition factor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NCA</td>
<td>non-compartmental analysis</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>not evaluable</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non-small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>patient-reported outcome</td>
</tr>
<tr>
<td>QLQ-C30</td>
<td>Quality of Life Questionnaire–Core</td>
</tr>
<tr>
<td>QLQ-LC13</td>
<td>Quality of Life Questionnaire lung cancer module</td>
</tr>
<tr>
<td>RANO</td>
<td>Revised Assessment in Neuro Oncology</td>
</tr>
<tr>
<td>RCR</td>
<td>Roche Clinical Repository</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>ROS1</td>
<td>c-ros oncogene 1</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Safety Analysis Population</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SDF</td>
<td>survival distribution function</td>
</tr>
<tr>
<td>SLS</td>
<td>sodium lauryl sulfate</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TTD</td>
<td>time to deterioration</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine 5’-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
1. BACKGROUND

1.1 BACKGROUND ON ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON–SMALL CELL LUNG CANCER

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Lung cancer was estimated to cause 160,340 deaths in the United States in 2012, accounting for 28% of all cancer-related deaths according to the report from the American Lung Association (Lung Cancer Fact Sheet). There is an annual incidence of 310,000 cases of NSCLC in men in the Europe with a mortality of 276,000 deaths (GLOBOCAN 2008). Among women in the Europe, there is an annual incidence of 107,000 cases and a mortality of 91,000 deaths. In total, there are 417,000 cases of NSCLC and 367,000 deaths in Europe each year, which represents a major health problem. Survival rates for lung cancer tend to be much lower than other common cancers because of its late diagnosis and limited effective therapy in the advanced stage. The expected 5-year survival rate for all patients in whom lung cancer is diagnosed is 16.3% compared with 65.2% for colon cancer, 90.0% for breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012). Conventional anti-cancer therapies are far from satisfactory, and there is an unmet medical need for the development of new therapies for NSCLC.

Recent progress in the identification of genetic mutations or chromosomal rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other genes has provided new opportunities to use targeted therapeutic agents for the treatment of NSCLC, when the tumor is identified as having these mutations (Katayama et al. 2011; Doebele et al. 2012).

Approximately 5% of NSCLC cases have been shown to harbor the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; Ou et al. 2012). The formation of the resulting ALK fusion protein results in activation and dysregulation of the gene’s expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these genes. This is further supported by reports that the TFG and KIF5B genes can also serve as ALK fusion partners in some NSCLC patients. Expression of these ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced proliferation. ALK gene alterations are generally in a mutually exclusive relationship with mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism after treatment with crizotinib (Doebele et al. 2012). Inhibition of ALK activity in Ba/F3 cells transfected with the EML4-ALK fusion protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models harboring the EML4-ALK and
nucleophosmin-ALK fusion proteins, respectively. Hence, ALK appears to be a suitable therapeutic target for NSCLC with ALK gene rearrangements.

Wild-type ALK is hardly expressed at all in most normal human tissues, being expressed at higher levels in a few limited types of tissue such as developing and mature nervous system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997). By contrast, an aberrant ALK with constitutively active kinase results from the formation of the EML4-ALK fusion gene by chromosomal translocation.

Currently, the only approved treatment for ALK-positive NSCLC is crizotinib (Xalkori®, Pfizer, Inc.), an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR, c-Met), recepteur d’origine nantais (RON), and c-ros oncogene 1 (ROS1) (Sahu et al. 2013).

Crizotinib was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test in August 2011. The approval was based on two single-arm trials. The primary endpoint of both trials was ORR as assessed by the investigator. In one study, the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks, and, in other study, the ORR was 61% (95% CI: 52%, 70%) with a median response duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012). In November 2013, the FDA granted regular approval for crizotinib on the basis of demonstrating superior PFS and ORR for crizotinib compared with chemotherapy in patients with ALK-positive NSCLC whose disease progressed after platinum-based doublet chemotherapy (PROFILE 1007 study). An open-label active-controlled multinational randomized trial enrolled 347 patients with ALK-positive metastatic NSCLC. Patients were required to have disease progression following platinum-based chemotherapy. The trial demonstrated significantly prolonged PFS with crizotinib treatment compared with chemotherapy (HR = 0.49 [95% CI: 0.37, 0.64], p < 0.0001). Median PFS was 7.7 months for patients treated with crizotinib and 3.0 months for patients treated with chemotherapy. The ORR was significantly higher for patients treated with crizotinib (65% vs. 20%), with median response durations of 7.4 months for patients treated with crizotinib and 5.6 months for patients treated with chemotherapy. No difference in overall survival (OS) was noted between the two groups (HR = 1.02 [95% CI: 0.68%, 1.54%]) in a planned interim analysis (Shaw et al. 2013).

Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue (National Cancer Institute 2013). These results showed that an ALK inhibitor is effective in patients with NSCLC harboring ALK fusion genes. Crizotinib has subsequently been approved in other countries, such as Japan, Korea, Canada, and Switzerland. In the European Union, crizotinib was conditionally approved in October 2012 for the treatment of adults with previously treated ALK positive NSCLC.
Although substantial benefit has been observed with crizotinib therapy, relapse remains the norm. Studies with patients who had progression with crizotinib treatment reveal two main reasons for treatment failure: the development of resistance because of secondary (e.g., gatekeeper) mutations (predominantly in ALK or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease). The CNS is the primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC treated with crizotinib (Costa et al. 2011; Chun et al. 2012; Weickhardt et al. 2012). Significant morbidity is associated with brain metastases as a function of brain involvement, and because of treatment (corticosteroids, surgery, and radiation) required for disease control.

A new generation of ALK inhibitors will have the potential to overcome these two major limitations of crizotinib treatment to offer patients a better chance of prolonged remission and minimize the development of CNS metastases and the attendant comorbidity.

1.2 BACKGROUND ON ALECTINIB

Alectinib (also RO5424802 or CH5424802) is a newly developed small molecule, highly selective, and potent oral next-generation ALK inhibitor with a benzo[b]carbazole scaffold. In enzyme inhibition assays performed in vitro, this compound has been shown to selectively inhibit ALK. The compound also shows high antitumor activity both in vitro and in vivo against tumor cell lines with some type of ALK gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an ALK translocation and a neuroblastoma line harboring amplified ALK gene.

Nonclinical pharmacology studies showed that alectinib is efficacious in a model of tumors expressing an ALK fusion bearing the L1196M mutation, which is associated with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC xenografts that are already maximally suppressed by crizotinib. Alectinib also prolongs survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth in an intracranial model monitored using bioluminescence.

The clinical development program for alectinib, to date, comprises three ongoing Phase I/II studies in patients with ALK-positive NSCLC. The ongoing Phase I/II studies are as follows: Study AF-001JP, which is being conducted in Japan; Study NP28761/AF-002JG, which is being conducted in North America; and Study NP28673, which is being conducted globally.

The first-in-human study AF-001JP is an open-label Phase I/II study being conducted in Japan. This study is assessing the pharmacokinetics, safety, and efficacy of alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy. This study has completed enrollment, but it is still ongoing. A total of 70 patients were included (24 patients in the Phase I portion and 46 patients in the Phase II portion of the study). In the Phase I
portion of the study, at the data cutoff date of 31 July 2012, 24 patients were treated at
doses of 20–300 mg twice daily (BID). No dose-limiting toxicities (DLTs) or adverse
events of Grade 4 were noted up to the highest dose; thus, 300 mg BID was evaluated
in the Phase II portion of the study without further escalating the dose. In the Phase II
portion of the study, 46 patients were treated with the highest evaluated dose of 300 mg
BID, of whom 43 achieved an objective response (93.5%; 95% CI: 82.1%, 98.6%) and
7 patients had a complete response (CR) on the basis of an independent radiological
review in the 12-month follow-up analysis (data cutoff for response data: 18 April 2013).
The median duration of treatment (DOT) in the study has not been achieved at that date
because 86% of patients were still on treatment in the study, but the projected median
DOT is more than 14 months as data mature.

Figure 1 shows the waterfall plot of the best change from baseline in the size of target
lesions by an independent radiological review. Table 1 shows the objective response
rate (ORR) by time interval. The majority (86%) of patients had a time to response of
within 6 weeks after administration of the first dose.

Figure 1 Change in Size of Target Lesions as Assessed by the
Independent Review Committee in Part 2 of Study AF-001JP
Using RECIST v1.1 (Data Cutoff Date: 18 April 2013)
Two of 7 patients who were assessed as having a CR had lymph nodes as the target lesions. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), the percent change from baseline for patients with CR can be less than 100% when lymph nodes are identified as the target lesions. Therefore, they were assessed as having CR, although their tumor change from baseline was less than 100%.

**Table 1  Overall Response Rates and Time to Response in Patients in Part 2 of Study AF-001JP**

<table>
<thead>
<tr>
<th>Response (Data Cutoff Date: 18 April 2013)</th>
<th>IRC Assessment (N = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
</tr>
<tr>
<td>Partial response</td>
<td>36</td>
</tr>
<tr>
<td>Stable disease</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2</td>
</tr>
<tr>
<td>Total response</td>
<td>43</td>
</tr>
<tr>
<td>Overall response rate (95% CI)</td>
<td>93.5% (82.1%, 98.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to Response</th>
<th>IRC Assessment (N = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to ≤3 weeks</td>
<td>22 (51%)</td>
</tr>
<tr>
<td>&gt;3 to ≤6 weeks</td>
<td>15 (35%)</td>
</tr>
<tr>
<td>&gt;6 to ≤9 weeks</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>&gt;9 weeks</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>

IRC = Independent Review Committee.

In Study NP28761/AF-002JG (crizotinib-failed ALK-positive NSCLC patients), the Phase I portion has completed enrollment. Two ‘bridging’ cohorts of patients receiving alectinib using the 150-mg capsule at 600 and 900 mg BID were included in Study NP28761/AF-002JG to transition/facilitate the planned formulation for the Phase II trials. A total of 47 patients were enrolled in Phase I (Part 1). There does not appear to be any substantial difference in pharmacokinetics between the two formulations (20/40-mg capsule and the 150-mg capsule) at the 600-mg dose on the basis of available data.

The radiological imaging analysis performed in 44 evaluable patients who had a baseline scan and at least one follow-up scan (data cutoff date: 12 September 2013) has shown that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort have achieved a confirmed partial response (PR), as assessed by the investigator. Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort have achieved a PR, as assessed by the investigator, which is still to be confirmed. Three patients (all in the 600-mg BID
dosage cohort) were unevaluable. The ORR was 54.5% (i.e., 24 of 44 evaluable patients who had a baseline scan and at least one post-treatment scan available to determine overall response, or who had a best overall response of progressive disease [PD] determined by the investigator, on the basis of symptomatic progression [3 patients]), including unconfirmed responses across all dose cohorts. Thirty-three of the 47 (70%) treated patients were still receiving study treatment. The durations of dosing by cohort are shown in Figure 2.

Figure 2  Duration of Dosing by Cohort in Patients in Part 1 of Study NP28761/AF-002JG (Data Cutoff Date: 12 September 2013)

The waterfall plot for the 42 patients, with a post-baseline radiological tumor assessment, is shown in Figure 3. On the basis of the data analyzed at that date, 27 patients experienced tumor shrinkage of >30%, of whom 23 patients were assessed as experiencing PR (9 of which are still to be confirmed by a second tumor assessment).
Study NP28673 started enrollment on 20 June 2013 and no data were available to report at this time.

The benefit of alectinib on CNS activity has been described by the DOT (before progression) or ORR in patients with brain metastases at baseline in the two active studies: Study AF-001JP in Japan and Study NP28761/AF-002JG in the United States. In Phase II of Study AF-001JP, 14 of the 46 (30%) crizotinib-naive patients had documented CNS lesions before enrollment into the trial. Three of these 14 patients were asymptomatic and had not received prior CNS radiation. At the clinical cutoff date of 18 March 2013, 5 of the 14 patients were off-study because of systemic disease progression or an adverse event. Nine patients remain in the study with DOT ranging from 10 to 18 months (none of these patients presented signs or evidence of systemic disease or CNS progression).

Similarly, in Study NP28761/AF-002JG, among the 47 patients enrolled (data cutoff date: 12 September 2013), 21 patients (45%) were known to have brain metastases at baseline. Of these 21 patients, 11 (52%) achieved an ORR as determined by Independent Review Committee (IRC; data cutoff date: 12 September 2013) (Inoue et al. 2013). Moreover, of these 21 patients, 17 remained on active study treatment and 4 discontinued study treatment because of systemic PD (1 patient had
both systemic disease and CNS progression). No patient discontinued because of CNS progression alone.

In addition, 2 patients with leptomeningeal carcinomatosis received benefit from alectinib treatment. One patient with leptomeningeal spread in Study NP28761/AF-002JG achieved PR after 6 weeks of treatment. Another patient with leptomeningeal carcinomatosis but without systemic lesions was treated under a single-patient Investigational New Drug (IND) application because of ineligibility to enter either of the two Phase II alectinib studies (because of the high intake of dexamethasone for symptom control). After 6 weeks of treatment, this patient achieved CR as demonstrated by complete disappearance of gadolinium enhancement on magnetic resonance imaging (MRI) and disappearance of positive CSF cytology. This patient has been able to reduce corticosteroids to physiological replacement dose only.

See the Alectinib Investigator’s Brochure for additional details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Over the past 10 years, the treatment of NSCLC has become increasingly focused on guiding treatment based on the presence or absence of an actionable mutation. Numerous oncogenes have now been identified in NSCLC, including mutations in the genes coding for EGFR, KRAS, phosphoinositide-3-kinase, catalytic, α polypeptide, and human EGFR 2 (Pao and Girard 2011). As described in previous sections, a translocation in the gene encoding the receptor tyrosine kinase ALK, leading to the expression of ALK fusion proteins, was identified as an oncogenic driver in a subset of patients with NSCLC (Soda et al. 2007). ALK rearrangements are found in approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012:).

Crizotinib is the only first-generation ALK inhibitor that is currently approved and has been registered in multiple countries worldwide for the treatment of ALK-positive NSCLC. Crizotinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI) targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). The clinical studies reported at present demonstrate that median PFS with crizotinib ranged from 7.7–9.7 months (Camidge et al. 2012, Kim et al. 2013, Shaw et al. 2013), while published clinical evidence on crizotinib’s efficacy in ALK-positive NSCLC first line treatment setting is still limited.

Although substantial benefit has been observed with crizotinib therapy, relapse eventually occurs. Two main reasons for this are the development of resistance because of secondary (e.g., gatekeeper) mutations or CNS relapse (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). This could be due to the fact that crizotinib is a P-gp substrate and has a low penetration in the CNS. Thus
ALK-positive NSCLC treated with crizotinib has impaired control of brain metastases relative to other sites of systemic disease, with 46% of progressions in patients treated with crizotinib involving the CNS (Costa et al. 2011; Weickhardt et al. 2012). The CNS becomes a sanctuary site for ALK-positive NSCLC treated with crizotinib—a physiologic and anatomic mechanism of drug resistance.

Alectinib is a highly selective and potent, oral next generation ALK inhibitor. Clinical data from the Phase II portion of the still ongoing Study AF-001JP, assessing alectinib in patients with ALK-positive NSCLC who are crizotinib-naïve and have disease progression after at least one line of chemotherapy, reported that the median treatment duration in the study has not been achieved as 86% of patients were still active on the study, but the projected median DOT is estimated to be at least 14 months as data mature (Inoue et al. 2013).

Moreover, alectinib is lipophilic drug and not a P-glycoprotein (P-gp) substrate, thus, could penetrate through the blood-brain barrier and has the potential to reach higher concentration in brain as compared to substrates of the P-gp such as crizotinib. This has been shown in the nonclinical setting on the basis of the prolongation of survival in a mouse model with implanted CNS lesions and in a tissue distribution study with a single oral dose of $^{14}$C-alectinib at 1 mg/kg to albino rats (Ou et al. 2013). Preliminary clinical data from the Phase I/II studies show consistent therapeutic efficacy of alectinib in brain metastases.

The clinical efficacy data is compelling given the shown activity for a longer progression free interval with alectinib and improved activity in the CNS, thus delaying the impact of CNS metastases on neurologic function along with the morbidities associated with treatment like brain radiation, surgery and corticosteroid use required for disease control. The currently available clinical safety data is supportive for an acceptable safety and tolerability profile with alectinib. Altogether, it would be important to compare alectinib to crizotinib as a therapeutic option for ALK-positive advanced NSCLC patients.

In this proposed Phase III study, treatment-naïve patients with ALK-positive advanced NSCLC will be enrolled and will be randomized to receive either crizotinib or alectinib treatment. The results of this study will determine whether alectinib treatment has superior efficacy compared to crizotinib.

The first Phase I dose-escalation study of alectinib conducted only in Japan (Study AF001-JP), with a dose schedule of 20, 40, 80, 160, 240, and 300 mg BID orally, showed that alectinib was generally well tolerated without major toxicities. Of the 58 patients who received treatment with 300 mg BID alectinib in Study AF-001JP, 27 experienced Grade 3 adverse events and 9 experienced serious adverse events. No deaths were reported during this study and up to 28 days after treatment discontinuation. There were 5 adverse events leading to treatment discontinuation in Part 2 (brain edema, sclerosing cholangitis, interstitial lung disease [ILD], ALT increased, and tumor
Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1

2.

OBJECTIVES

2.1 EFFICACY OBJECTIVES

The primary efficacy objective for this study is as follows:

- To evaluate and compare the efficacy of alectinib compared to crizotinib in patients with treatment-naïve ALK-positive advanced NSCLC, as measured by investigator-assessed PFS

The secondary efficacy objectives for this study are as follows:

- To evaluate and compare the Objective Response Rate (ORR) and Duration of Response (DOR)
- To evaluate and compare the time to progression in the CNS on the basis of IRC review of radiographs by RECIST v1.1 and Revised Assessment in Neuro Oncology (RANO) criteria, as well as:
  - To evaluate CNS objective response rate (C-ORR) in patients with CNS metastases who have measurable disease in the CNS at baseline
  - To assess CNS duration of response (C-DOR) in patients who have a CNS Objective Response
  - To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of cumulative incidence
- To evaluate and compare the PFS assessment by the IRC
- To evaluate and compare the OS

hemorrhage). Alectinib was well tolerated at all doses investigated in this study. Its adverse event profile was consistent with the one known to be associated with TKIs. In the Phase II Study NP28761/AF-002JG, alectinib was well tolerated, with no DLTs or treatment-related dose modifications up to 600 mg BID. Two DLTs were reported at 900 mg BID. The recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best balance between clinical safety, efficacy, and pharmacokinetic (PK) data as observed in the Phase I/II studies (see Section 3.3.1).

On the basis of available preliminary data, the estimated benefits of alectinib treatment outweigh the risks, specifically:

- Available nonclinical and clinical data demonstrate that alectinib is active in NSCLC in crizotinib-naïve patients as well as after progression on prior crizotinib therapy
- Clinical safety data in humans up to 900 mg BID demonstrate that its safety profile is consistent to the one known to be associated with TKIs.

Identified and potential risks associated with alectinib treatment will continue to be closely monitored throughout the clinical program. Patient safety during the alectinib program is ensured by: targeting the most appropriate patient population, stringent safety monitoring by the Sponsor and Independent Data Monitoring Committee (IDMC), and by protocol-specified study drug interruption criteria.
2.2 SAFETY OBJECTIVES

The secondary safety objective for this study is as follows:

- To evaluate the safety and tolerability of alectinib compared to crizotinib

2.3 PHARMACOKINETIC OBJECTIVES

The secondary PK objective for this study is as follows:

- To characterize the pharmacokinetics of alectinib and metabolite(s)

2.4 PATIENT-REPORTED OUTCOME OBJECTIVES

The secondary patient-reported outcome (PRO) objectives for this study are as follows:

- To evaluate and compare time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, arm/shoulder pain, and fatigue as measured by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire—Core (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) as well as a composite of three symptoms (cough, dyspnea, chest pain).

- To evaluate and compare PROs of (HRQoL), patient functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and EORTC QLQ-LC13.

2.5 EXPLORATORY OBJECTIVES

The exploratory objectives for this study are as follows:

- To evaluate and compare patient’s health status as assessed by the EuroQoL 5 Dimension (EQ-5D-3L) questionnaire to generate utility scores for use in economic models for reimbursement.

- To evaluate and compare an onset of hypogonadism in adult men by measuring total testosterone, albumin and sex hormone-binding globulin (SHBG) to calculate free testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in blood.

- To evaluate and compare efficacy and safety in patients with treatment-naïve ALK-positive NSCLC as assessed by the FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).

- To investigate molecular mechanisms of resistance to ALK inhibitors.

- To investigate detection of ALK mutations in plasma and circulating tumor cells.

3. STUDY DESIGN

3.1 DESCRIPTION OF STUDY

This is a randomized, active-controlled, multicenter Phase III open-label study in patients with treatment-naïve ALK-positive advanced NSCLC. All patients are required to provide pretreatment tumor tissue to confirm the presence of ALK rearrangement (by immunohistochemistry [IHC] test). Patients will be randomized 1:1 into one of the two treatment arms to receive either alectinib or crizotinib.
This study will comprise approximately 180 centers, in around 30 countries worldwide.

The primary endpoint of the study is investigator-assessed PFS.

Central randomization will be performed via an interactive voice or web-based response system (IxRS) using the following stratification factors: Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no). An IxRS manual containing relevant information will be provided to each study site.

The experimental arm will receive alectinib at 600 mg orally BID, taken with food. The control arm will receive crizotinib at 250 mg orally BID, taken with or without food.

Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death. After progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.

In case of isolated asymptomatic CNS progression (e.g., new CNS oligometastases), local therapy can be given (e.g., stereotactic radiotherapy or surgery) followed by continuation of either alectinib (in alectinib arm) or crizotinib (in crizotinib arm) until systemic disease progression and/or symptomatic CNS progression. The decision to continue the treatment beyond isolated, asymptomatic CNS progression is at the investigator’s discretion for patients who can continue to benefit from their respective treatment.

Patients who discontinue treatment prior to disease progression (e.g., due to unacceptable toxicity or withdrawal of consent) will continue to be followed until disease progression and for OS regardless of whether they subsequently receive non-study anti-cancer therapy. Data for subsequent therapy will be collected for the analysis of OS.

Approximately 286 patients (143 per treatment arm) will be enrolled into the study over a planned competitive recruitment period of 25 months. Patients inappropriately randomized into the study will not be replaced. The final analysis evaluating the primary endpoint of investigator-assessed PFS will occur when approximately 169 patients have progressed or died which is expected to occur approximately 31 months after the first patient has been enrolled. Data collection will continue for each patient until death or study closure, whichever occurs first.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised as outlined in Section 9.4.

A summary of the study design is shown in Figure 4.
A schedule of assessments is provided in Appendix 1.

**Figure 4  Summary of Study Design**

- **Screening assessment**
  - 28 days

- **1:1 Randomization with stratification (n=286)**
  - ≤ 24 hours

- **600 mg BID alectinib**
- **250 mg BID crizotinib**

Until disease progression, unacceptable toxicity, withdrawal of consent, or death

Subsequent therapy for NSCLC and Survival follow-up

### 3.2 END OF STUDY

This study is event-driven, with a recruitment period of approximately 25 months. The required number of events for the final analysis of the primary endpoint is expected approximately 31 months after the first patient has been enrolled. Patients are to be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Follow-up for survival will continue until the survival follow-up analysis or the Sponsor decides to end the trial, whichever occurs first. The study will formally end once the survival follow-up analysis is complete.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.
3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Alectinib Dosage

Selection of the alectinib dose for the study is based on the clinical safety, efficacy, and PK data observed in the Phase I/II studies, AF-001JP and NP28761/AF-002JG, and the supportive nonclinical data for alectinib.

The first-in-human study, AF-001JP evaluated escalating doses of alectinib in an accelerated titration scheme to rapidly identify the maximum tolerated dose (MTD). All doses, including the highest evaluated dose in the study, 300 mg BID, were well tolerated with no DLTs observed at any dose. The highest tested dose, 300 mg BID, was further evaluated in the Phase II portion of the study and demonstrated robust efficacy and good safety with an ORR by IRC of 93.5% (43/46 patients; 95% CI: 82.1%, 98.6%).

With no MTD determined in Study AF-001JP, dose escalation progressed in the United States Study NP28761/AF-002JG using a modified 3+3 design, where 3 patients were assessed for DLT evaluation whereas additional patients were enrolled for PK evaluation. The starting dose in Study NP28761/AF-002JG was the highest dosage evaluated in Study AF-001JP, 300 mg BID. Following multiple dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, median alectinib exposure (area under the concentration time curve [AUC] from 0 to 10 hours) appeared to be approximately two-fold lower compared with that in patients from Study AF-001JP, which demonstrated the robust efficacy and safety. Dose escalation progressed with evaluation of higher doses of alectinib up to 900 mg BID.

In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts, up to dose-level of 900 mg BID. However, 2 patients in the subsequent 900 mg BID bridging cohort experienced a DLT; 1 patient had Grade 3 headache and 1 patient had Grade 3 neutropenia, and both patients continued study treatment at a reduced dosage of 600 mg BID. Overall, alectinib was well tolerated in the study population.

Importantly, administration of 600 mg BID provides systemic exposures that meet or exceed exposures achieved in patients receiving 300 mg BID in Study AF-001JP, demonstrating its robust efficacy and safety in crizotinib-naïve patients. Further, in Study NP28761/AF-002JG, the 600-mg BID regimen has demonstrated promising activity in crizotinib-resistant patients, including activity in patients with CNS metastases while being tolerated by patients. On the basis of available preclinical data, administration of alectinib 600 mg BID provides systemic exposures within the expected range (on the basis of regression of available data) for tumor regression observed in mouse xenograft models.

Thus, on the basis of nonclinical and clinical data, a dosing regimen of 600 mg BID of alectinib has been chosen as the optimal therapeutic dose level with the best balance between efficacy and safety.
Alectinib 600 mg should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

3.3.2 Rationale for Patient Population
The study population will comprise patients with non-resectable, locally advanced and metastatic NSCLC who have been shown to be ALK-positive by IHC test performed at central laboratories specially designated for the study. Patients should not have received any prior treatment for advanced NSCLC (treatment-naïve).

Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted therapies. The clinical practice guidelines recommend targeted treatment for patients with metastatic, oncogene-driven disease as first-line systemic therapy (i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive NSCLC) (NCCN 2014).

To be eligible for the study, determination of ALK positivity will be performed centrally by the IHC assay (see Appendix 8) that is being developed by Ventana Medical Systems as a companion diagnostic to alectinib. IHC may replace fluorescence in situ hybridization (FISH)-based identification of ALK rearrangement as the standard companion diagnostic in the future. IHC is faster, easier to perform in local laboratories, and requires less equipment compared with the FISH assay. In addition, IHC has high concordance with FISH and a lower false-negative rate (Kim et al. 2011).

3.3.3 Rationale for Control Group
Targeted therapy (including ALK-targeted therapy) is likely to have a greater antitumor effect than standard chemotherapy, offering patients a higher response rate and longer durability of response with less toxicity compared with any potential chemotherapy options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013).

Crizotinib (Xalkori) is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013, Shaw et al. 2013). It is the only first-generation ALK inhibitor that has been approved in multiple countries worldwide for the treatment of ALK-positive NSCLC.

In the United States, in November 2013, crizotinib has been granted a regular approval for ALK-positive NSCLC setting, regardless of treatment line (XALKORI® U.S. Package Insert), whereas in Europe, crizotinib is currently approved conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC).

The NCCN guidelines recommend crizotinib as first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014).

There are no publicly available Phase III data yet for crizotinib in the first-line setting. The randomized Phase III PROFILE 1014 study, which began in January 2011, is
currently being conducted to assess the efficacy of crizotinib versus standard
platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin) as first-line
treatment for patients with ALK-positive, non-squamous NSCLC. The estimated primary
completion date of this study is November 2013 (ClinicalTrials.gov), with data expected
to be reported in 2014. If PROFILE 1014 reported data will drastically differ from
previously reported information, the study assumptions might be reevaluated.

Crizotinib will be dosed as per standard dose recommendations from prescribing
information—patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with
or without food until disease progression, unacceptable toxicity, withdrawal of consent,
or death. See Section 5.1.4 for criteria for dosing interruption and/or dose reduction for
treatment with crizotinib.

3.3.4 Rationale for Open-Label Design

An open-label study design is more appropriate for patients enrolled in this particular trial
for a number of reasons defined below, and with the ultimate goal to ensure patient
compliance as much as possible.

For a blinded study design, all enrolled patients would be required to take five large
capsules twice per day. This high pill count results from the difference in capsule size
between crizotinib (size 0) and alectinib (size 1). Each dose would comprise one 250
mg capsule of crizotinib or matching placebo and four 150 mg capsules of alectinib or
matching placebo. In order to blind, crizotinib capsules must be over-encapsulated. That
furthermore increase the size of a capsule – from size 0 to size 00 (double zero). Size 00
is usually the largest capsule size used orally for humans. For some patients size 00
capsules are too large to swallow. This high pill count of large capsules is considered to
be a significant burden to patients and increases the risk of non-compliance.

Additionally, a blinded study would increase the complexity of standard dose reductions.
Dose interruption or dose reduction may be required on the basis of individual safety and
tolerability. The standard dose reductions for crizotinib would be 200 mg BID (different
capsule, size 1), followed by 250 mg QD. Dose reductions for alectinib would occur in
150 mg steps. In a double blind study, these multiple step dose reductions introduce a
high level of complexity and potential for error.

In order to avoid a significant burden to patients with high pill count, increased risk of
non-compliance, and complexity of standard dose reductions, adequate steps have been
taken to ensure the validity of the data in an open-label study design. These include
performing a supportive analysis of efficacy on the basis of determining progression by
an IRC, performing sensitivity analyses to demonstrate the robustness of the primary
endpoint, defining progression using established response evaluation criteria
(RECIST v1.1), performing tumor assessment at the same frequency in both arms and
adhering to protocol-defined schedules, and finalizing before trial start the strategy for
the final analysis of the primary endpoint, including predefined methods for handling
missing data and censoring rules. Efficacy analyses will only be performed at the pre-specified analysis timepoints in the protocol (final analysis once 169 PFS events have occurred and survival follow-up analysis at 143 events).

3.3.5 **Rationale for Primary Endpoint Selection**

The investigator-assessed PFS (which will be supported by IRC-assessed PFS analysis, one of the secondary endpoints of the study) is the primary endpoint for this trial.

PFS, as an endpoint, can reflect tumor growth and can be assessed before the determination of a survival benefit, and its determination is not generally confounded by subsequent therapies. Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit of the new treatment compared to available therapies (Guidance for Industry 2007; European Medicines Agency 2012). A PFS HR of 0.65 will be targeted, which constitutes a clinically meaningful benefit in this patient population as it will delay the use of platinum-based chemotherapy and will potentially reduce the frequency of CNS relapse and the morbidity associated with treating CNS metastases.

The assumed median PFS of patients in the alectinib treatment arm is 15.1 months, and an OS of more than 30 months is expected, which equates to a post-progression survival of at least 15 months. Patients with ALK-positive NSCLC treated with crizotinib in the second-line setting had a median PFS of 7.7 months and an interim median OS of 20.3 months (Shaw et al. 2013), which equated to a post-progression survival of 12.6 months. This lengthy post-progression survival provides an opportunity for subsequent treatment with other ALK inhibitors, several additional lines of chemotherapy, or participation in additional clinical trials.

Patients in both study arms who experience disease progression on study treatment will likely be treated with other subsequent treatment options, including ALK inhibitors. The availability of crizotinib on the market, as well as the likely availability of other next-generation ALK TKIs, and the availability of other investigational agents in clinical trials offer potential treatment options to patients in the study who will eventually have disease progression. Subsequent therapies frequently confound the detection of an OS benefit, particularly in a setting with a long post-progression survival, such as ALK-positive NSCLC. This has been observed in trials for EGFR TKIs, in which strong PFS benefits were observed without evidence of OS benefit (Rosell et al. 2009; Fukuoka et al. 2011).

The long post-progression survival and the confounding effects of subsequent lines of therapy indicate that it would be difficult to detect an OS benefit in this setting. Nevertheless, OS is one of the study’s secondary endpoints. The crossover from the crizotinib arm to alectinib will not be allowed in this study, with the aim of preserving the trial’s ability to potentially demonstrate some degree of treatment benefit of alectinib in
OS. However, the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.

To ensure the validity of the PFS as the primary endpoint, a number of measures have been implemented: full IRC assessment to support the analysis of the primary endpoint, a substantial target magnitude of benefit (target HR = 0.65) and study assessments that will allow a robust evaluation of risk-benefit (standard RECIST criteria to define progression with fixed assessment intervals that are identical in both treatment arms and a robust definition of PFS and prospectively defined methods to assess, quantify, and analyze PFS, including censoring methods and sensitivity analyses).

3.3.6 **Rationale for Secondary Endpoint of Time to CNS Progression**

Lung cancer is the most common type of cancer to spread to the brain, with at least 40% of people with lung cancer developing brain metastases at some point during their disease. ALK-positive NSCLC has a propensity to metastasize to the brain, and crizotinib has impaired control of brain metastases in comparison to other sites of systemic disease (Chun et al. 2012).

Delaying or preventing the development of CNS metastases would provide patients with clinically meaningful benefit by avoiding consequences of neurological deficits from brain metastasis or by delaying/preventing long-term side effects associated with steroid use and brain irradiation.

Preliminary evidence of CNS benefit with alectinib has been observed in patients in the two ongoing Phase II studies. See Section 1.2 and Alectinib Investigator's Brochure for additional details.

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression is documented. The aim of the pre-specified analysis will be to evaluate whether alectinib significantly delays or prevents the development of CNS metastases.

Randomization of the Phase III study will be stratified by the presence or absence of CNS metastasis at baseline.

Imaging analysis by consistently used uniform image acquisition technique (MRI scans) will be performed routinely at baseline and at subsequent follow-up assessments along with every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical suspicion of CNS metastasis) in order to achieve an accurate determination of time to CNS progression. This ensures that early brain metastatic lesions are detected and that assessment bias between the two arms is avoided by having regularly scheduled scans.
An independent central radiological review will be performed for all patients and the analysis of time to CNS progression, or response will be based on the data from the independent review. The review will be based on the standard RECIST v1.1 criteria to assess the CNS lesions, and a second independent review on the basis of the RANO criteria, which are typically used to assess brain tumors (Wen et al. 2010), will be performed. The assessment will be performed independently from the overall disease progression assessment.

3.3.7 Rationale for PK Sample Collection Schedule

To date, the pharmacokinetics of alectinib have been characterized in chemotherapy-failed, crizotinib-naïve patients with NSCLC in Study AF-001JP and in patients who have failed chemotherapy and crizotinib treatment in Study NP28761/AF-002JG and Study NP28673. In order to better understand the pharmacokinetics of alectinib and to further support the development of a robust population PK model for alectinib in order to better understand, identify, and characterize variables which lead to changes in exposure, characterization of alectinib pharmacokinetics will be done in this study. This study will include PK assessment of alectinib in ALK inhibitor treatment-naïve patients with ALK-positive advanced NSCLC by collecting trough samples from all patients receiving alectinib. Serial/intensive PK samples will be collected from a subset of patients (10%–15% [at least n = 20] of patients receiving alectinib) to facilitate the PK assessment. The data that will be collected from this study will enable more robust understanding of alectinib pharmacokinetics in the global crizotinib-naïve population including investigation and potential identification of sources of variability influencing alectinib pharmacokinetics and/or response to alectinib therapy. Results from PK data collection in this study and analyses of PK data could help support optimal use of alectinib therapy.

3.3.8 Rationale for Biomarker Assessments

There are several molecular mechanisms of resistance to crizotinib reported in the literature: increased copy number of ALK gene, increased expression of ALK mRNA, secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased copy number, increased phosphorylation, or point mutations) in escape genes like EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013). In order to investigate molecular mechanisms of resistance to ALK inhibitors and ALK mutation status, tumor samples will be collected before treatment and at the time of disease progression with the goal of sequencing nucleic acids. Two types of approaches will be used: 1) targeted sequencing of a panel of genes known to be involved in cancer and 2) unbiased genomic sequencing.

ALK rearrangements can be monitored in circulating tumor cells in blood (Ilie et al. 2012; Pailler et al. 2013). Intact tumor cells are released into the circulation; hence, using specific surface markers, it is possible to selectively separate them from the remaining cells in the blood. This allows downstream analysis like IHC or FISH, and in rare
occasions, there is enough material to perform reverse transcription–polymerase chain reaction or sequencing to detect mutant mRNA. The presence of ALK rearrangements will be investigated in circulating tumor cells before treatment and at the end of study. This information will be used to investigate the use of blood as a surrogate of tumor for diagnostic purposes and to monitor the presence of ALK rearrangements in circulating tumor cells in the blood before and after treatment.

Mutations in cancer genes appearing from drug resistance can be monitored in circulating nucleic acids in plasma (Forshew et al. 2012). Tumor nucleic acids are shed into circulation in amounts that allow direct amplification by polymerase chain reaction and sequencing. Plasma samples will be collected before treatment and at certain timepoints during treatment, to monitor mutations in ALK and other genes involved in resistance to ALK inhibitors. Information from mutated genes in the tumor will be correlated with mutations in plasma DNA.

Determination of ALK positivity will be initially performed by IHC (see Appendix 8). In addition, the Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. For exploratory purposes, other methods to determine ALK positivity (e.g., reverse transcription-polymerase chain reaction) may also be used.

### 3.3.9 Rationale for PRO Assessments

In the treatment of lung cancer, it is important to both increase survival and palliate symptoms because disease symptoms have negative impacts on HRQoL (Hyde and Hyde 1974; Hopwood and Stephens 1995; Sarna et al. 2008). This is especially true for trials that use PFS as a primary endpoint, where it is important to translate the delay in disease progression into an endpoint that is meaningful to patients.

Pain (chest; arm/shoulder), dyspnea, cough, and fatigue have been regarded as the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC. The BR.21 study (erlotinib vs. chemotherapy in second- or third-line NSCLC) demonstrated that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ-C30 and QLQ-LC13 was consistent with superior PFS, OS, and quality-of-life benefits in the erlotinib arm as compared with the placebo arm (Aaronson et al. 1993; Bergman et al. 1994; Bezjak et al. 2006). Additionally, patients in the crizotinib PROFILE 1005 trial reported clinically significant (10 points) improvements in the pain, cough, dyspnea, and fatigue symptom scales seen as early as 2 weeks on treatment (Crinò et al. 2011).

The EORTC QLQ-C30 and QLQ-LC13 were used in the Phase III PROFILE 1007 study (second-line crizotinib vs. chemotherapy). The study reported significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than
with chemotherapy (p < 0.001 for all comparisons, without adjustment for multiple testing). Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. There was also a significantly greater overall improvement from baseline in the global quality of life among patients who received crizotinib treatment than among those who received chemotherapy (p < 0.001). In all domains measuring functioning, except for the domain measuring cognitive functioning, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Shaw et al. 2013).

Therefore, to assess the quality of life of patients in this trial, PRO data will be collected from patients enrolled in this study using the validated questionnaires EORTC QLQ-C30 and QLQ-LC13.

3.4 OUTCOME MEASURES

3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

- **PFS**, which is defined as the time from randomization to the first documented disease progression, as determined by the investigators (primary endpoint) or IRC (secondary endpoint) using RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event will be censored at the last tumor assessment either during follow-up or during study treatment. Patients with no post-baseline assessments will be censored at the date of randomization.

- **ORR**, which is defined as the percentage of patients who attain CR or PR; response, as determined by the investigators using RECIST v1.1. Patients without any assessments will be regarded as non-responders.

- **Time to CNS progression**, which is defined as the time from randomization to the first occurrence of disease progression in the CNS as determined by IRC using RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in patients with CNS metastases who have measurable disease in the CNS at baseline, C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 months.

- **DOR**, which is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first). This will only be calculated for patients who have a best overall response of CR or PR. Patients who do not progress or die after they have had a response are censored at the date of their last tumor measurement.

- **OS**, which is defined as the time from randomization to death from any cause. Patients without an event will be censored at the last date known to be alive. Patients without any follow-up information will be censored at the date of randomization.
3.4.2 **Safety Outcome Measures**

The safety outcome measures for this study are as follows:

- Serious and non-serious adverse events
- Safety laboratory tests values
- Vital signs (blood pressure, heart rate), ECG
- Physical examination

3.4.3 **Pharmacokinetic Outcome Measures**

The PK outcome measures for this study are as follows:

- Sparse (pre-dose) PK samples for measurement of alectinib and its major metabolite(s) will be collected in all study patients receiving alectinib treatment. See Appendix 1 and Appendix 2 for PK sampling times.
- Serial/intensive PK sampling will be collected in a subset of consenting patients enrolled to receive alectinib treatment (approximately 10%–15%, at least approximately n=20). See Appendix 1 and Appendix 2 for PK sampling times.
- PK parameters will be determined as appropriate and where data allow:
  
  The pharmacokinetics of alectinib (and metabolite[s], if appropriate) will be described, and the between-patient variability will be estimated using a population PK approach. The potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of alectinib will also be explored and quantified.

  Non-compartmental analysis (NCA) may be conducted in patients undergoing serial/intensive PK sample collection, as appropriate and where data allow.

3.4.4 **Patient-Reported Outcome Measures**

The PRO measures included for this study are as follows and will be administered to patients every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months:

- The EORTC QLQ-C30 and EORTC QLQ-LC13 to determine the impact of alectinib compared with crizotinib as measured by TTD in patient-reported lung cancer symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in arm/shoulder, fatigue).
- The EORTC QLQ-C30 and EORTC QLQ-LC13 to measure PROs of HRQoL, patient functioning, and side effects of therapy compared between patients treated with alectinib and those treated with crizotinib.
3.4.5 Exploratory Outcome Measures

The exploratory outcome measures for this study are as follows:

- EQ-5D-3L to generate utility scores for use in economic models for reimbursement.
- Total testosterone, albumin and SHBG to calculate free testosterone, FSH, and LH, in blood to measure an onset of hypogonadism in adult men.
- The FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) to evaluate and compare efficacy and safety in patients with treatment-naïve NSCLC that is ALK-positive by FISH test.
- Post-progression tumor mutation status to study molecular mechanisms of resistance to ALK inhibitors.
- ALK mutation status in plasma DNA to monitor efficacy and disease progression.
- ALK fusion status in circulating tumor cells in blood.

4. MATERIALS AND METHODS

4.1 PATIENTS

Target population is patients with treatment-naïve ALK-positive non-resectable, locally advanced and metastatic NSCLC.

4.1.1 Inclusion Criteria

Patients must meet the following criteria for study entry:

- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIb not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana IHC test. Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at designated central laboratories.
- Age ≥18 years old.
- Life expectancy of at least 12 weeks.
- ECOG PS of 0–2.
- Patients had no prior systemic treatment for advanced or recurrent (Stage IIIb not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC.
- Adequate hematologic function:
  - Platelet count ≥100 × 10^9/L
  - ANC ≥1500 cells/μL
  - Hemoglobin ≥9.0 g/dL
- Adequate renal function:
  - Calculated creatinine clearance at least 45 mL/min
- Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
• Measurable disease (by RECIST v1.1) prior to the administration of study treatment.

• Prior brain or leptomeningeal metastases allowed if asymptomatic and diagnosed incidentally at study baseline. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment at least 14 days before enrollment and be clinically stable.

• For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.

• For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide.

• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• Able and willing to provide written informed consent prior to performing any study-related procedures and to comply with the study protocol, including patients must be willing and able to use the electronic patient-reported outcome (ePRO) device.

4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

• Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).

• Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection.
• Liver disease characterized by:
  ALT or AST > 3 × ULN (≥ 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
  OR
  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
  OR
  Acute viral or active autoimmune, alcoholic, or other types of hepatitis

• National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication.

• History of organ transplant.

• Co-administration of anti-cancer therapies other than those administered in this study.

• Patients with baseline QTc > 470 ms or patients with symptomatic bradycardia < 45 beats per minute.

• Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib or crizotinib (see Appendix 3) except for oral corticosteroids up to 20 mg of prednisolone equivalent per day.

• Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment. (See Section 4.4.2 for further details.)

• History of hypersensitivity to any of the additives in the alectinib drug formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulfate [SLS], magnesium stearate).

• History of hypersensitivity to any of the additives in the crizotinib drug formulation (silica, colloidal anhydrous cellulose, microcrystalline calcium hydrogen phosphate, anhydrous sodium starch glycolate, magnesium stearate).

• Pregnant or lactating women.

• Known HIV positivity or AIDS-related illness.

• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study.
• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

This is an open-label trial, for which the rationale is described in Section 3.3.4.

Approximately 286 patients will be randomly assigned in a 1:1 allocation ratio to the two treatment arms via a block-stratified randomization procedure and over a planned recruitment period of 25 months.

Randomization will guard against systematic selection bias and should ensure the comparability of treatment groups. To assist balance in important prognostic factors, randomization will be stratified by ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no).

Central randomization and drug pack number allocations will be performed and managed by an IxRS. Further details will be provided in an IxRS manual.

The independent review of scans for the secondary endpoints of PFS on the basis of IRC and time to CNS progression will be performed in a blinded fashion.

4.3 STUDY TREATMENT

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Alectinib

Alectinib comes in a capsule dosage form containing the following active ingredient:

[Chemical name] 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride

Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate.

Alectinib capsules should be stored in accordance with the storage instructions on the label.

Alectinib capsules should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

The formulation contains SLS as a surfactant excipient. This excipient is known to be associated potentially with GI adverse events such as nausea, vomiting, diarrhea, and abdominal pain.

For further details, see the alectinib Investigator's Brochure.
4.3.1.2 Crizotinib
Crizotinib comes in a hard capsule dosage form. Each capsule contains 250 mg or 200 mg crizotinib. Crizotinib hard capsules should be stored in accordance with the storage instructions on the label. Crizotinib capsules should be administered orally BID.

For further details, see the local prescribing information for crizotinib (XALKORI® U.S. Package Insert).

4.3.2 Dosage, Administration, and Compliance
4.3.2.1 Alectinib
Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food (within 30 minutes after a meal, in the morning and evening).

If a patient misses a dose, it can be taken within 4 hours of the scheduled time. If the time is greater than 4 hours, or if the patient vomits the dose, the patient should wait until the next scheduled time and take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose.

Guidelines for dosage modifications and treatment interruptions or discontinuation due to specified adverse events are provided in Section 5.1.3.

Any overdose or incorrect administration of study drug should be noted on the Study Drug Administration electronic Case Report Form (eCRF). Adverse events associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF.

4.3.2.2 Crizotinib
Crizotinib 250 mg (one 250-mg capsule) should be administered orally BID with or without food (in the morning and evening).

If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose.

If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily. Guidelines for dosage modification and treatment interruption or discontinuation are provided in Section 5.1.4.

Any overdose or incorrect administration of crizotinib should be noted on the crizotinib Administration eCRF. Adverse events associated with an overdose or incorrect administration of crizotinib should be recorded on the Adverse Event eCRF.
4.3.3 Investigational Medicinal Product Accountability

All investigational medicinal products (IMPs) required for completion of this study (alectinib and crizotinib) will be provided by the Sponsor where required by local health authority regulations. The study site will acknowledge receipt of IMPs and confirm the shipment condition and content. Any damaged shipments will be replaced.

IMPs will either be disposed of at the study site according to the study site’s institutional standard operating procedure or returned to the Sponsor with the appropriate documentation. The site's method of IMP destruction must be agreed to by the Sponsor. The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.

Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the study site should be recorded on the Drug Inventory Log.

4.3.4 Post-Trial Access to Alectinib

The Sponsor does not intend to provide alectinib or other study interventions to patients after conclusion of the study or any earlier patient withdrawal, under this protocol.

4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant medication includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 28 days prior to screening to the study completion/discontinuation visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

All therapy and/or medication administered to manage adverse events should be recorded on the Adverse Event eCRF.

The medications and/or treatments below are permitted:

- Anticoagulants and antithrombotic agents (i.e., coumadin-derived anticoagulants, unfractionated heparin or low-molecular heparins, aspirin (≤325 mg/day), and clopidogrel.
- Systemic corticosteroid should be no more than oral 20 mg prednisone equivalent daily. Inhalation corticosteroid is allowed. Steroid equivalence converter could be found at: http://www.medcalc.com/steroid.html
- Acetaminophen up to 2 g/day

Caution should be exercised when the following are co-administered with alectinib:

- For medications that are substrates of P-gp transporter or breast cancer resistance protein transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have
potential for inhibition of these transporters. Substrates with a narrow therapeutic index (e.g., methotrexate, digoxin) should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

- For medications that are inhibitors of P-gp transporter, the investigator should use caution and monitoring when considering concomitant use of alectinib. The major metabolite of alectinib, M4, has been shown to be a substrate of this transporter. Strong inhibitors of P-gp should be avoided, if possible (see Appendix 3).

- For medications that are metabolized by CYP3A and CYP2C8, the investigator should use caution and monitoring when considering concomitant use of alectinib. Alectinib has been shown to have potential for inhibition of CYP3A and CYP2C8, including potential time-dependent inhibition. Sensitive CYP3A and CYP2C8 substrates should be avoided. If co-administration cannot be avoided, it is recommended that drug levels and/or signs for toxicity are carefully monitored (see Appendix 3).

Caution should be exercised when the following are co-administered with crizotinib:

- Crizotinib has been shown to be a moderate inhibitor of CYP3A. Dose reduction maybe needed for co-administered drugs that are predominantly metabolized by CYP3A in patients receiving crizotinib. Concurrent use of CYP3A substrates with narrow therapeutic indices should be avoided (see Appendix 3).

- On the basis of an in vitro study, crizotinib is predicted to inhibit intestinal P-gp. Therefore, administration of crizotinib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their therapeutic effect and adverse reactions (see Appendix 3). Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.

- Bradycardia has been reported during clinical studies; therefore, use crizotinib with caution owing to the risk of excessive bradycardia when used in combination with other bradycardic agents (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, beta-blockers, clonidine, guanfacine, digoxin, mefloquine, anticholinesterases, pilocarpine).

- The aqueous solubility of crizotinib is pH dependent, with higher pH resulting in lower solubility. Drugs that elevate the gastric pH (such as proton pump inhibitors, H$_2$ blockers, or antacids) may decrease the solubility of crizotinib and subsequently reduce its bioavailability.

- The inhibitory effect of crizotinib on uridine 5'-diphospho-glucuronosyltransferases (UGTs), notably UGT1A1, has not been established. Therefore, caution should be exercised when crizotinib and substrates of UGTs, such as paracetamol or morphine, are combined.
• In vitro studies in human hepatocytes indicated that crizotinib may induce
pregnane X receptor and constitutive androstane receptor–regulated enzymes
(e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1). However, there was no
observed induction in vivo when crizotinib was coadministered with the CYP3A
probe substrate midazolam. Caution should be exercised in administering crizotinib
in combination with medicinal products that are predominantly metabolized by these
enzymes. Of note, the effectiveness of concomitant administration of oral
contraceptives may be altered.

• In vitro studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore,
    crizotinib may have the potential to increase plasma concentrations of
    coadministered drugs that are metabolized by CYP2B6 (e.g., bupropion, efavirenz).

### 4.4.2 Prohibited Therapy

Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or
homeopathic remedies, nutritional supplements) is prohibited during the study and for at
least 14 days prior to initiation of study treatment (either alectinib or crizotinib), unless
otherwise specified below. Exceptions to the below listed concomitant therapies
restrictions (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic
remedies, nutritional supplements) may be made if the rationale is discussed and
documented between the investigator and the Sponsor’s Clinical Pharmacologist.

• Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin,
carbamazepine, and St. John’s wort [Hypericum perforatum]) within 2 weeks or
5 half-lives (whichever is longer) before the first dose of study drug treatment and
while on treatment with study drugs (see Appendix 3).

• Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives
(whichever is longer) before the first dose of study drug treatment and while on
treatment with study drug (see Appendix 3).

• Any concomitant medications known to affect QT interval duration, including but not
limited to the following drugs: amiodarone, cisapride, clarithromycin, methadone,
and quinidine, within 2 weeks before the first dose of study drug treatment and while
on treatment with study drugs and through the end of the study.

• Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents
(other than study drug treatment), ergot derivatives, probenecid, and bile
acid-binding resins while on study treatment.

• Systemic chemotherapy.

• Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions
or for pain control. If palliative radiation is indicated for bone metastases, palliative
radiation may start within 24 hours of the last dose of alectinib, unless, in the
judgment of the investigator, patient safety will require a longer washout period prior
to palliative therapy. Dosing of alectinib may resume with the resolution of any
radiation toxicity to ≤ Grade 1.

• Additional investigational drug (except for during the follow-up period).
The above lists of medications are not necessarily comprehensive. Thus, the investigator should consult the prescribing information for any concomitant medication as well as the Internet references provided below when determining whether a certain medication is metabolized by or strongly inhibits or induces CYP3A. In addition, the investigator should contact the Medical Monitor if questions arise regarding medications not listed above.

http://medicine.iupui.edu/clinpharm/ddis/table.aspx

4.4.3 Prohibited Food
Use of grapefruit or grapefruit juice should be avoided during the study and for at least 14 days prior to the initiation of study treatment (either alectinib or crizotinib) because it is a potent CYP3A inhibitor and may increase plasma concentration of either alectinib or crizotinib.

4.5 STUDY ASSESSMENTS
See Appendix 1 for the schedule of assessments performed during the study.

4.5.1 Informed Consent Forms and Screening Log
Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site. All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

4.5.2 Medical History and Demographic Data
Medical history includes clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 28 days prior to the screening visit.

Demographic data will include age, sex, and self-reported race/ethnicity.

4.5.3 Corticosteroid Use for CNS Metastases
For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake should be captured at all tumor assessment visits and compared to the corticosteroid intake at the time of the last disease assessment. The changes will be recorded as
Increased, Unchanged, or Decreased. Increases and decreases in corticosteroid intake should be clinically justified. Increases in corticosteroid dose for reasons other than for CNS metastases control do not need to be taken into consideration when making this comparison. As per Section 4.4.1 of the protocol, systemic corticosteroid use cannot exceed oral 20 mg of prednisone equivalent daily.

4.5.4 Physical Examinations
A complete physical examination at screening and baseline should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems as well as height and weight. Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.

At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations should be performed. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant abnormalities should be recorded as adverse events on the Adverse Event eCRF.

Note: for patients with known CNS metastases, a neurological examination must be performed at each tumor assessment visit and compared to the neurological examination performed at the time of the last disease assessment. Definition of clear neurological worsening is difficult to describe because progression in the CNS can present in numerous ways. Accordingly, evaluation of neurological function at each disease assessment will be based purely on the investigator’s assessment of the patient’s neurological state compared to the neurological function at the time of the last disease assessment. Neurological status will be recorded as Improved, Stable, or Worsened.

4.5.5 Vital Signs
Vital signs will include measurements of respiratory rate, oxygen saturation, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

4.5.6 ECOG Performance Status
PS will be measured using the ECOG Performance Status Scale (see Appendix 5). It is recommended, where possible, that a patient’s PS be assessed by the same person throughout the study.

4.5.7 Tumor and Response Evaluations
Disease burden must be documented at screening and re-assessed at each subsequent tumor evaluation. Response will be assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and other modalities (e.g., MRI, brain scans), using RECIST v1.1 (see Appendix 4). For assessing response in patients with measurable disease, the preferred radiologic tumor response assessment is CT scan.
with intravenous contrast. If intravenous contrast is contraindicated, a non-contrast-enhanced chest CT scan will be acceptable for chest lesions, and MRI can be used for non-chest lesions. If contrast-enhanced MRI is contraindicated, then non-contrast-enhanced MRI will suffice. Positron emission tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesion as per RECIST v1.1 (see Appendix 4).

The same radiographic procedure used to define measurable disease sites at screening must be used throughout the study (e.g., the same contrast protocol for CT scans). Assessments should be performed by the same evaluator to ensure internal consistency across visits.

CT/MRI scans of chest and abdomen, and MRI scans of the brain should be performed for all patients as described in Schedule of Assessments (see Appendix 1) at screening then every 8 weeks subsequently until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression and at the post-treatment visit (4 weeks after permanent treatment discontinuation). CT/MRI scans of the neck bone and pelvis should be included if clinically indicated. At the investigator’s discretion, CT/MRI scans may be repeated at any time if PD is suspected.

Note: Brain imaging should be performed using MRI with the following image acquisition requirements:

- Minimum sequences required:
  - Pre-contrast T1, T2/FLAIR
  - Post-contrast T1, with two orthogonal planes (or a volume acquisition) recommended

- Recommended slice thickness ≤5 mm with no gap

Patients with known or suspected bone metastases should undergo radionuclide bone scan at screening. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions and do not need to be repeated routinely but can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered measurable lesions of the soft tissue component and meets the definition of measurability and should be followed by cross-sectional imaging.
4.5.8 Laboratory, Biomarker, and Other Biological Sample

4.5.8.1 Laboratory Assessments

Samples for the following laboratory tests will be sent to the study site’s local laboratory for analysis:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells])
- Coagulation (PT [or INR], and aPTT)
- Serum chemistry (sodium, potassium, chloride, bicarbonate, fasting glucose, BUN or urea, creatinine [including calculated eGFR using the Modification of Diet in Renal Disease formula, see Appendix 7]; CPK; gamma-glutamyl transferase (GGT); calcium; total and direct bilirubin; total protein; albumin; ALT; AST; alkaline phosphatase [ALP]; phosphorus; magnesium; thyroid-stimulating hormone; and total testosterone, albumin and SHBG to calculate free testosterone, FSH, and LH [for male patients only])
- Urinalysis: Urine samples will be collected according to the schedule of assessments (Appendix 1) (first morning urine sample for baseline and end of treatment visit, spot urine for rest of visits). Urine albumin and creatinine will be measured in order to assess micro- and macroalbuminuria.
- Pregnancy test. All women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile will have a serum pregnancy test at screening, within 3 days of dosing. Urine pregnancy tests will be performed anytime during the course of the study, as per investigator’s discretion. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

4.5.8.2 Pre-Treatment Tumor Samples (Mandatory)

Mandatory pre-treatment tumor samples will be collected to centrally examine ALK status by IHC (eligibility criteria) and FISH. Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred source, but if blocks are not available, unstained slides (ten to fifteen 5-µm slides cut less than 3 months before screening) are also accepted. Remaining tumor blocks will be returned to the sites; slides will not be returned.

For fresh tumor biopsies (guided by ultrasound or CT scan), acceptable methods include core biopsies for lung and liver lesions and bronchoscopic biopsies for lung lesions. The minimum size for the biopsy needle recommended is 20G.

Central ALK testing to determine or confirm patient ALK status will be performed at a Sponsor designated central laboratory. After completion of ALK testing for enrollment with a pre-specified ALK test by IHC (Appendix 8), patient samples will also be centrally tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott) for possible companion diagnostic development. Additionally, other ALK assays may be used for testing patient samples to establish performance characteristics of these assays for diagnostic
development. Testing may be performed on all screened patients (screen-failed and enrolled). These additional testing data will have no impact on eligibility, and testing will be performed only after eligibility is established for each patient. In addition, local ALK test information, baseline demographic, and disease-related characteristic data for all screened patients may be collected in order to support potential registration of a companion diagnostic assay for alectinib.

Pre-treatment tumor samples may be used, after proper informed consent is obtained, for genomic sequencing.

For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual.

4.5.8.3 Pre- and Fresh Post-Treatment Tumor Biopsies (Optional)
Pre-treatment tumor samples (preferably formalin-fixed blocks but if not available a minimum of 10-15 unstained 5 µm slides) for ALK testing is a mandatory requirement for this study. Optional additional pre-treatment tumor samples and fresh post-treatment tumor biopsy at disease progression or withdrawal from treatment (at the last treatment or post-progression visit) may be collected, with proper informed consent. These samples will be used to help to understand molecular mechanisms of resistance to ALK inhibitors by genomic sequencing. Remaining tumor blocks will be returned to the sites, slides will not be returned.

These specimens will be destroyed within 5 years after the date of final closure of the clinical database. Other residual tissue material (slides, extracts, etc.) will be destroyed within 5 years after the date of final closure of the clinical database.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of optional tumor biopsies with exploratory purposes may be stopped at any time if the data from the samples collected do not produce useful information.

4.5.8.4 Blood and Plasma Samples (Mandatory)
Mandatory plasma samples will be obtained to determine:

- Mutations status in ALK and other escape genes (e.g., EGFR, KRAS). It will require 20 mL of blood to be collected at baseline, treatment Visit 3 (Week 16), and subsequently at every second treatment visit (every 16 weeks) (see Appendix 1 for detailed information) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression. For sample handling procedures, storage conditions and shipment instructions, see the laboratory manual. These samples will not be taken in countries where regulatory agency or Institutional Review Board (IRB) does not allow genetic testing.
Mandatory blood samples will be obtained to determine:

- ALK mutations assessment in circulating tumor cells. It will require 12 mL of blood sample to be collected (2 tubes of 6 mL each) at baseline and at disease progression (at the last treatment or post-progression visit). It should match in time to tumor progression (CNS and/or systemic disease progression).

- All patients who are randomized in alectinib arm will also participate in retrospective pharmacogenomic research to understand inter-individual variability of safety and pharmacokinetics of alectinib. For this purpose, a 3-mL blood sample will be drawn at baseline (see Sections 4.5.8.4.1 and 4.5.8.5).

- Patients in the crizotinib arm who opt-in to optional genomics sequencing will provide a 3-mL blood sample. This 3-mL blood sample will be used as a source of healthy tissue. This sample is required for all patients in the crizotinib arm who wish to participate in the optional genomic sequencing (see Section 4.5.8.4.1).

For biomarkers, a total of 35 mL of blood will be collected at baseline (20 mL for plasma purification and determination of mutation status in ALK and other escape genes, 12 mL for ALK fusion detection in circulating tumor cells, and 3 mL for pharmacogenomics research), 20 mL of blood (for plasma purification and determination of mutation status in ALK and other escape genes) will be collected at Visit 3 (Week 16) and subsequently at every second visit (every 16 weeks), and 32 mL will be collected at disease progression (CNS and/or systemic disease progression) (20 mL for plasma purification for determination of mutation status in ALK and other escape genes and 12 mL for ALK fusion detection in circulating tumor cells).

Details of sample handling procedures, sample storage and shipment will be described in a separate laboratory manual.

On the basis of continuous analysis of the data in this study and other studies, or on the basis of data from literature, collection of plasma and circulating tumor cell samples with exploratory purposes may be stopped at any time if they are deemed not informative.

**4.5.8.4.1 Samples for Pharmacogenomic Assessments**

One sample (approximately 3 mL of whole blood) will be collected from all patients on alectinib treatment. Samples will be used for the evaluation of genetic polymorphisms of drug metabolic enzymes including, but not limited to, CYP2C9, CYP3A4/5, and UGT1A1, and transporters (e.g., organic anion transporter polypeptide 1B1) and for genetic variants that could contribute to potentially drug-related liver safety assessments (including but not limited to human leukocyte antigen, see Appendix 9 for more details).

For sample handling procedures, storage conditions, and shipment instructions, see the laboratory manual. Only in circumstances where there is concern for collection of this genetic material for above evaluations can this assessment be considered not mandatory as part of study assessments in this study. Results of any analyses from these samples will be reported outside the clinical study report.
4.5.8.5 Samples for Pharmacokinetic Assessments

PK samples will be collected in all patients on alectinib treatment, as indicated in Appendix 1 and Appendix 2 for the analysis of alectinib and its major metabolite(s) (ROS468924, RO5507197, and/or others, if applicable and if appropriate, and if assays are available). Residual samples following PK analysis may be used to evaluate profiling for alectinib metabolite(s).

All trough/pre-dose PK samples should be collected within 2 hours BEFORE the morning doses of study medications.

Serial/intensive samples will be collected in a subset of patients (10%–15% [at least \(n = 20\)] of patients receiving alectinib) on Visit 0 (baseline, after the first dose) and Visit 1 (Week 4) at the timepoints specified in Appendix 2.

Plasma concentrations for alectinib and its metabolite(s), if applicable, will be measured by specific and validated liquid chromatography tandem mass spectrometry methods.

For each sample, approximately 2 mL of venous blood will be collected for alectinib PK analysis at the timepoints specified in the PK schedule in Appendix 1 and Appendix 2.

Patients who permanently discontinue from study drugs will also discontinue from all PK assessments. The procedures for the collection, handling, storage, and shipping of plasma samples for the PK analysis are specified in the Laboratory Manual. Actual sampling times will be recorded for each PK sample in the eCRF.

These samples will be destroyed when the final Clinical Study Report is complete.

On the basis of continuous analysis of the data in this study and other studies, any sample type collection may be stopped at any time if the data from the samples collected do not produce useful information or at the discretion of the Sponsor.

4.5.9 Electrocardiograms

An ECG will be recorded at specified timepoints as outlined in the schedule of assessments (Appendix 1) at screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), and at the last treatment visit and as clinically indicated throughout the study. All ECG recordings must be performed using a standard high-quality, high-fidelity digital electrocardiograph machine equipped with computer-based interval measurements. All ECGs are to be obtained prior to other procedures scheduled at that same time (e.g., vital sign measurements, blood draws, study drug administration) and should not be obtained within 3 hours after any meal. Circumstances that may induce changes in heart rate, including environmental distractions (e.g., television, radio, conversation), should be avoided during the pre-ECG resting period and during ECG recording.
Patients must have been in a supine or semi-supine position for at least 5 minutes prior to the recording being taken. The same recording position (supine or semi-supine) and the same equipment should be used for each patient throughout the study. The ECG printout must be (1) reviewed by a medically qualified member of the study team at the site, (2) annotated to indicate any clinical finding, and (3) dated and signed by this person and filed in the patient notes. ECG parameters will be entered on the ECG eCRF. The following parameters should be captured on the eCRF: heart rate, RR, PQ, QRS and QT duration, and QT interval corrected using Fridericia’s formula.

If any ECG abnormality is associated with an adverse event, it must be recorded and managed as described in Section 5. Management of QT interval prolongation should be done according to guidance provided in Section 5.1.3.

If considered appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central laboratory. Guidance for abnormal ECG results (QT prolongation) is provided in Table 2.

4.5.10 Patient-Reported Outcomes

PROs (EORTC QLQ-C30, QLQ-L13, and EQ-5D) will be collected to more fully characterize the clinical profile of alectinib. The instruments will be translated as required in the local language. To ensure instrument validity and that data standards meet health authority requirements, the PROs scheduled for administration during a clinic visit (EORTC QLQ-C30, QLQ-L13, and EQ-5D) should be completed prior to the performance of non-PRO assessments and the administration of study treatment.

Patients will use an ePRO device to capture PRO data. The ePRO device and/or instructions for completing the PRO questionnaires electronically will be provided by the investigator staff. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be accessed by appropriate study personnel securely via the Internet.

4.5.11 Samples for Roche Clinical Repository

4.5.11.1 Overview of the Roche Clinical Repository

The Roche Clinical Repository (RCR) is a centrally administered group of facilities used for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.
Specimens for the RCR will be collected from patients who give specific consent to participate in optional research. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

4.5.11.2 Approval by the Institutional Review Board or Ethics Committee

Collection and submission of biological samples to the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site's IRB or Ethics Committee (EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol (Section 4.5.11) will not be applicable at that site.

4.5.11.3 Sample Collection

For RCR purposes, 10 mL of blood will be collected. For all samples, dates of consent and specimen collection should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual.

RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be patient to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

4.5.11.4 Confidentiality

Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure database system. Access to the linking key is restricted to authorized individuals and is
monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche’s Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

4.5.11.5 Consent to Participate in the Roche Clinical Repository
The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the objectives, methods, and potential hazards of participation in the RCR. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to provide optional RCR specimens. Patients who decline to participate will not provide a separate signature.

The investigator should document whether the patient has given consent to participate by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's specimens and data will continue to be used as part of the RCR research.

4.5.11.6 Withdrawal from the Roche Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their specimens from the RCR at any time for any reason. If a patient wishes to withdraw consent to the testing of his or her specimens, the investigator must inform the Medical Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research Sample Withdrawal of Informed Consent eCRF. The patient will be provided with

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984  Report Number 1078196

2621
instructions on how to withdraw consent after the trial is closed. A patient's withdrawal from Study BO28984 does not, by itself, constitute withdrawal of specimens from the RCR. Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from Study BO28984.

4.5.11.7 Monitoring and Oversight

RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a quality-controlled, auditable, and appropriately validated laboratory information management system, to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the Informed Consent Form. Roche monitors and auditors will have direct access to appropriate parts of records relating to patient participation in the RCR for the purposes of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the RCR samples.

4.6 PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION

4.6.1 Patient Discontinuation

Patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the investigator has the right to withdraw a patient from the study at any time. Reasons for withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study
- Investigator or Sponsor determines it is in the best interest of the patient

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. Patients who withdraw consent for treatment should continue to be followed for tumor assessments until progression and for OS, provided they have not withdrawn consent for the study. However, patients will not be followed for any reason after consent for the study has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study Treatment Discontinuation

Patients must discontinue study treatment if they experience any of the following:

- Pregnancy
- Inability to tolerate study medication on the basis of the investigator judgment

See guidelines for managing adverse events and for comprehensive guidance on study drug discontinuation in Section 5.1.3.
Patients who discontinue study drug prematurely will be asked to return to the clinic for tumor assessments until progression as per study schedule (see Appendix 1).

The primary reason for premature study drug discontinuation should be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.3 **Study and Site Discontinuation**

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

- The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
- Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

- Excessively slow recruitment
- Poor protocol adherence
- Inaccurate or incomplete data recording
- Non-compliance with the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice
- No study activity (i.e., all patients have completed and all obligations have been fulfilled)

5. **ASSESSMENT OF SAFETY**

5.1 **SAFETY PLAN**

5.1.1 **Adverse Events Collection**

After informed consent has been obtained but prior to initiation of study treatment, only serious adverse events (SAEs) caused by a protocol-mandated intervention should be reported (e.g., SAEs related to invasive procedures such as biopsies). After the first dose of study treatment and up to the 4-week follow-up after the last dose of study treatment, all adverse events (AEs) regardless of seriousness, causality assessment, or actions taken reported by the investigator or designated medically qualified study site personnel will be collected as described below. At each visit, the investigator or designated medically qualified study personnel will ask the patient if any untoward medical event occurred since the last visit. It is the investigator’s responsibility to record all AEs in the source patient’s medical records.

All serious and non-SAEs will be reported on the standard AE/SAE eCRF.
5.1.2 Adverse Events Relating to ALK Inhibitors and/or the Tyrosine Kinase Inhibitor Class and Alectinib Data

Events described in Section 5.1.2.1 through Section 5.1.2.10 will be closely monitored and represent selected AEs for this study.

A more detailed safety profile of alectinib is provided in the alectinib Investigator's Brochure.

5.1.2.1 Interstitial Lung Disease

TKIs, including ALK inhibitor crizotinib, have been associated with the occurrence of treatment-related ILD (including fatalities).

See Section 5.1.3 for management and follow-up.

5.1.2.2 Hepatobiliary Laboratory Test Elevations

Hepatobiliary findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. The findings were at or close to clinically relevant exposures. Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT and liver weight, vacuolation/degeneration/necrosis of bile duct epithelium, inflammatory cell infiltration in Glisson’s sheath, enlargement/focal necrosis of hepatocytes, and enlargement of Kupffer cells.

Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin levels, have been observed after alectinib administration. AST, ALT, and total bilirubin levels temporarily increased in the initial stages of treatment and then improved.

In patients treated with other tyrosine kinase ALK inhibitor drugs, abnormal liver function tests and fatal cases of hepatic failure have been reported.

See Section 5.1.3 for management and follow-up.

5.1.2.3 Hematologic Abnormalities

Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity studies with alectinib, and findings in the 13-week studies were similar to those of the 4-week studies. Findings were at or close to clinically relevant exposures. Hematologic adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have been observed with most TKIs, including ALK inhibitor crizotinib.

Hematologic abnormalities of neutropenia, leukopenia, thrombocytopenia, and anemia have been reported with alectinib administration. Neutrophil counts generally decreased early and remained stable thereafter.

See Section 5.1.3 for management and follow-up.
5.1.2.4 **Gastrointestinal Disorders**

GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported with alectinib. Similar GI disorders have been observed with other TKIs, including ALK inhibitor crizotinib.

SLS (syn. sodium dodecyl sulfate)) is a surfactant excipient in the clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical ingredient). This excipient is a known GI irritant and may be associated with GI AEs including nausea, vomiting, diarrhea, and abdominal pain. Of note, GI tract toxicity as the safety determinant of SLS is not because of systemic toxicity, but a consequence of local irritation to the GI tract. In general, when mixed with diet, higher levels of SLS—a known GI tract mucosal irritant—are tolerated versus gavage administrations.

See Section 5.1.3 for management and follow-up.

5.1.2.5 **Skin Disorders**

Results of an in vitro phototoxicity study indicated that alectinib may have phototoxic potential.

Skin rash has been reported with majority of TKIs including those targeting the ALK receptor (Hartmann et al. 2009).

Cases of skin rash and photosensitivity have been reported with alectinib and were generally Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.6 **Vision Disorders**

In the rat quantitative whole body autoradiography study, tissue radioactivity disappeared over time, following a time course comparable to that of plasma radioactivity, except for melanin-containing tissues such as uveal tract of eyes, which had much higher and more sustained exposure in pigmented rats. This is consistent with what is commonly observed for lipophilic basic drugs.

Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and vitreous floaters, have been reported with several TKIs, including ALK inhibitors (crizotinib) (Shaw et al. 2013).

Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and vision impaired, have been reported with alectinib and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.
5.1.2.7 Edema
Most TKIs, including ALK inhibitor crizotinib, have been associated with edema. Events of edema have been reported with alectinib, mostly Grade 1 or 2.

See Section 5.1.3 for management and follow-up.

5.1.2.8 Cardiovascular Effects (QT Interval Prolongation)
QT interval prolongation appears to be an off-target class effect of some TKIs, including ALK inhibitor crizotinib (Shah et al. 2013; XALKORI® U.S. Package Insert). Many TKIs have been associated with bradycardia and hypertension.

In the in vitro study of the cardiovascular system, alectinib inhibited the hERG current (IC$_{20}$: 58 ng/mL; IC$_{50}$: 217 ng/mL). Because plasma protein binding by alectinib is ≥99%, the plasma concentration of alectinib required to induce the same inhibition in vivo would be 100 or more times greater than the concentration required in vitro. In the monkey telemetry study, there were no effects on the ECG, any of the other cardiovascular parameters or body temperature at doses up to 15 mg/kg (mean maximum concentration [C$_{max}$]: 279 ng/mL).

In a preliminary non- Good Laboratory Practice telemetry study in conscious cynomolgus monkeys, a slight hypotensive effect (approximately 10 mmHg) was seen when alectinib was administered at 20 and 60 mg/kg orally with no effects on ECG or heart rate. The hypotensive effect of alectinib observed in monkeys was considered to likely be caused by vasodilatation induced by L-type Ca$^{2+}$ channel inhibition.

Events of bradycardia have been reported with alectinib.

See Section 5.1.3 for management and follow-up.

5.1.2.9 Abnormal Renal Function
In the 2-week non-human primate study at 60 mg/kg, an increase in creatinine was observed but no changes were observed in histopathology. In all other non-human primate studies, no changes in creatinine were observed.

Serum creatinine increases have been reported with alectinib treatment and were generally Grades 1 and 2.

See Section 5.1.3 for management and follow-up.

5.1.2.10 Muscular Adverse Events and CPK Elevations
Postmarketing experience with some TKIs includes reports of myopathy and rhabdomyolysis (Hohenegger 2012).

Blood CPK increases, generally Grades 1 and 2, and muscular AEs have been reported with alectinib treatment.

Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1

Clinical Study Report: RO5424802 - F. Hoffmann-La Roche Ltd
Protocol BO28984 Report Number 1078196

65
See Section 5.1.3 for management and follow-up and Table 2 for guidelines for managing AEs.

5.1.3 Management of Specific Adverse Events with Alectinib

Table 2 Guidelines for Management of Specific Adverse Events with Alectinib

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial lung disease</td>
<td>• Patients should be monitored for pulmonary symptoms indicative of pneumonitis.</td>
</tr>
<tr>
<td></td>
<td>• Study drug should be permanently discontinued in patients diagnosed with interstitial lung disease.</td>
</tr>
<tr>
<td>Hepatobiliary AE and laboratory test elevations</td>
<td>Liver test laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4 and Section 5.3.5.6.</td>
</tr>
<tr>
<td></td>
<td>• If ALT or AST $&gt;3 \times \text{baseline}$, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry about symptoms.</td>
</tr>
<tr>
<td></td>
<td>• At any time during the study treatment, if symptoms compatible with liver injury are observed, liver enzymes should be measured as soon as possible.</td>
</tr>
<tr>
<td></td>
<td>• Study drug treatment has to be permanently discontinued if any of the following occurs:</td>
</tr>
<tr>
<td></td>
<td>First observation of ALT or AST $&gt;8 \times \text{ULN}$</td>
</tr>
<tr>
<td></td>
<td>ALT or AST $&gt;5 \times \text{ULN}$ for more than 2 weeks</td>
</tr>
<tr>
<td></td>
<td>First observation of ALT or AST $&gt;3 \times \text{ULN}$ and total bilirubin $&gt;2 \times \text{ULN}$</td>
</tr>
<tr>
<td></td>
<td>First observation of ALT or AST $&gt;3 \times \text{ULN}$ and the appearance of jaundice or signs of hepatic dysfunction or other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia $[&gt;5%]$).</td>
</tr>
<tr>
<td></td>
<td>• Following study drug discontinuation, weekly monitoring of laboratory values should continue until the abnormal values have normalized to pre-treatment levels and/or an adequate explanation of the abnormal value is found.</td>
</tr>
<tr>
<td></td>
<td>• Resumption of study drug is not allowed in patients discontinuing because of any of the above criteria.</td>
</tr>
</tbody>
</table>
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
</table>
| Hematologic abnormalities    | Hematologic laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.  
  • In case of hematologic toxicity: Grade 4 (neutropenia, thrombocytopenia):  
    Give supportive treatment per treating physician.  
    First episode: Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL. Upon resumption, reduce alectinib dose by 150 mg (1 capsule) BID (450 mg BID).  
    Second episode: Reduce dose by another 150 mg (1 capsule) BID (300 mg BID).  
    Third episode: Permanently discontinue alectinib.  
  • In case of hematologic toxicity: Grade 3 (neutropenia, thrombocytopenia):  
    Temporarily interrupt alectinib until ANC is above 1200/µL and platelets are above 75 K/µL.  
    Give supportive treatment per treating physician.  
    If improvement to Grade ≤2 does not occur within 3 weeks, permanently discontinue alectinib.  
  • In case of hematologic toxicity: Grade 1 or 2 (neutropenia, thrombocytopenia) no action is required.                                                                                                                                                                                                                                           |
| Gastrointestinal tract AEs   | The events are expected to be minimized by taking the study drug with meal. In case GI events occur, appropriate measures should be taken in accordance with local clinical practice guidelines. If GI toxicities are observed and not tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower.                                                                                                                  |
| (e.g., nausea, vomiting,    |                                                                                                                                                                                                                                                                                                                                                     |
| diarrhea)                   |                                                                                                                                                                                                                                                                                                                                                     |
| Skin disorder AEs           | Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 5 days after study drug discontinuation. Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least SPF > 30 to help protect against potential sunburn.                                                                                                             |
| (e.g., phototoxicity, rash) |                                                                                                                                                                                                                                                                                                                                                     |
| Vision disorders            | Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice guidelines, if vision disorders persist or worsen in severity, and to advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder.                                                                                 |
| Edema                       | Physical examinations will be performed routinely in clinical trials. In case edema events occur, appropriate measures should be taken in accordance with local clinical practice guidelines                                                                                                                           |
Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>QT prolongation</td>
<td>• Grade 1 (450–480 ms): no action required</td>
</tr>
<tr>
<td></td>
<td>• Grade 2 (481–500 ms):</td>
</tr>
<tr>
<td></td>
<td>First and second episodes: Continue study medication and monitoring</td>
</tr>
<tr>
<td></td>
<td>Third episode: Decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID)</td>
</tr>
<tr>
<td></td>
<td>• Grade 3 (≥501 ms on at least two separate ECGs):</td>
</tr>
<tr>
<td></td>
<td>Temporarily interrupt alectinib and refer patient to a cardiologist</td>
</tr>
<tr>
<td></td>
<td>First episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (450 mg BID)</td>
</tr>
<tr>
<td></td>
<td>Second episode: If improvement to Grade ≤1 or baseline, restart with a dose of alectinib decreased by 150 mg (1 capsule) BID (300 mg BID)</td>
</tr>
<tr>
<td></td>
<td>Third episode: Permanently discontinue alectinib</td>
</tr>
<tr>
<td></td>
<td>• Grade 4 (≥501 ms or &gt;60 ms change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia):</td>
</tr>
<tr>
<td></td>
<td>Discontinue alectinib permanently and admit patient into the hospital for monitoring</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Abnormal kidney function AEs</th>
<th>Kidney function laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• If, at any time during the study treatment, serum creatinine increases by ≥100% over the baseline visit value, the patient has to be carefully monitored. All of the underlying factors that may have acutely impacted serum creatinine levels need to be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.).</td>
</tr>
<tr>
<td></td>
<td>• Any serum creatinine value that is increased by ≥100% over the baseline visit value requires repeat testing.</td>
</tr>
<tr>
<td></td>
<td>If, at the repeat test, the serum creatinine value is still ≥100% over the baseline visit value, the treatment with alectinib should be interrupted.</td>
</tr>
<tr>
<td></td>
<td>• Alectinib treatment may be resumed with caution if the serum creatinine value has decreased to approximately the baseline visit value.</td>
</tr>
<tr>
<td>Event</td>
<td>Action to Be Taken</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Muscular AEs and/or CPK elevations</td>
<td>CPK laboratory abnormalities are to be reported as AEs only if fulfilling the criteria listed in Section 5.3.5.4.</td>
</tr>
<tr>
<td></td>
<td>• Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms.</td>
</tr>
<tr>
<td></td>
<td>• At the first occurrence of any of asymptomatic CPK values (&gt;10 × ULN, symptomatic CPK &gt; 5 × ULN, or in the presence of severe muscular symptoms with CPK &gt; ULN but ≤ 5 × ULN) at any time during the study treatment, the patient requires monitoring of the CPK values until they are normalized to pre-treatment levels or a reasonable explanation for the CPK elevation and the symptoms is established.</td>
</tr>
</tbody>
</table>
### Table 2  Guidelines for Management of Specific Adverse Events with Alectinib (cont.)

<table>
<thead>
<tr>
<th>Event</th>
<th>Action to Be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other AEs or laboratory abnormalities:</td>
<td></td>
</tr>
<tr>
<td>• Grade 3 or 4:</td>
<td>Temporarily interrupt alectinib for a maximum of 3 weeks. If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib. First episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by another 150 mg (1 capsule) BID (300 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 2 (except any symptoms and signs that can be corrected with supportive care):</td>
<td>Temporarily interrupt alectinib and resume if recovering to Grade ≤ 1 or baseline if clinically indicated. First episode: If improvement to Grade ≤ 1 or baseline within 10 days, continue same dose of alectinib. If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID when resuming treatment (450 mg BID). Second episode: If improvement to Grade ≤ 1 or baseline within 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) BID (450 mg BID or 300 mg BID if after first episode dose was reduced to 450 mg BID). If improvement occurs after 10 days, decrease the current dose of alectinib by 300 mg (2 capsules) when resuming treatment (300 mg BID or 150 mg BID if after first episode dose was reduced to 450 mg BID). Third episode: Permanently discontinue alectinib.</td>
</tr>
<tr>
<td>• Grade 1:</td>
<td>no action required</td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count.

Note: Diarrhea, nausea, and vomiting should be handled with best supportive care first before considering dose modification. Preexisting pleural effusion will not be considered as an adverse event.

### 5.1.4 Safety of Crizotinib and Management of Adverse Events

Dosing interruption and/or dose reduction may be required on the basis of individual safety and tolerability. If dose reduction is necessary, then the dose of crizotinib should be reduced to 200 mg taken BID. If further dose reduction is necessary, then the dose should be modified to 250 mg taken once daily on the basis of individual safety and tolerability (*XALKORI® U.S. Package Insert; Crizotinib SmPC*). Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Table 3 and Table 4.
### Table 3  Crizotinib Dose Modification—Hematologic Toxicities (Except Lymphopenia)

<table>
<thead>
<tr>
<th>CTCAE^a Grade</th>
<th>Crizotinib Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily^b</td>
</tr>
</tbody>
</table>

^a National Cancer Institute Common Terminology Criteria for Adverse Events

^b In case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of a third episode of Grade 4 hematologic toxicity.

### Table 4  Crizotinib Dose Modification—Non-Hematologic Toxicities

<table>
<thead>
<tr>
<th>CTCAE^a Grade</th>
<th>Crizotinib Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 or 4 ALT or AST elevation with Grade ≤ 1 total bilirubin</td>
<td>Withhold until recovery to Grade ≤ 1 or baseline, then resume at 200 mg BID^b</td>
</tr>
<tr>
<td>Grade 2, 3, or 4 ALT or AST elevation with concurrent Grade 2, 3, or 4 total bilirubin elevation (in the absence of cholestasis or hemolysis)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Any grade pneumonitis^c</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Grade 3 QTc prolongation</td>
<td>Withhold until recovery to Grade ≤ 1, then resume at 200 mg BID^b</td>
</tr>
<tr>
<td>Grade 4 QTc prolongation</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Grade 2 bradycardia (symptomatic, medical intervention indicated) Grade 3 bradycardia (severe, medically significant, medical intervention indicated)</td>
<td>Withhold until recovery to Grade ≤1, evaluate concomitant medications, then resume at 200 mg BID</td>
</tr>
<tr>
<td>Grade 4 bradycardia due to crizotinib (life-threatening consequences, urgent intervention indicated)</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Grade 4 bradycardia associated with concomitant medications known to cause bradycardia or hypotension (life-threatening consequences, urgent intervention indicated)</td>
<td>Withhold until recovery to Grade ≤1 and, if concomitant medications can be discontinued, resume at 250 mg once daily with frequent monitoring.</td>
</tr>
</tbody>
</table>

^a National Cancer Institute Common Terminology Criteria for Adverse Events.

^b In case of second episode, dosing should be withheld until recovery to Grade ≤ 1, then dosing should be resumed at 250 mg once daily. Crizotinib must be permanently discontinued in case of third episode of Grade 3 or 4 non-hematologic toxicity.

^c Not attributable to NSCLC progression, other pulmonary disease, infection, or radiation effect. Crizotinib should be withheld if pneumonitis is suspected and must be permanently discontinued if treatment-related pneumonitis is diagnosed.
Gastrointestinal events were commonly reported with crizotinib in clinical trials. Nausea, diarrhea, vomiting, and constipation were the most commonly reported gastrointestinal events and were primarily Grade 1 in severity. Supportive care for gastrointestinal events may include standard antiemetic and/or antidiarrheal or laxative medicinal products (XALKORI® U.S. Package Insert; Crizotinib SmPC).

See local prescribing information for further crizotinib safety information.

5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording AEs, including SAEs and non-SAEs of special interest; measurement of protocol-specified safety laboratory assessments; measurement of protocol-specified vital signs; and other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 5.4.

5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition).
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug
- AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor)

An SAE is any AE that meets any of the following criteria:

- Fatal (i.e., the AE actually causes or leads to death)
- Life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate risk of death)
  
  This does not include any AE that had it occurred in a more severe form or was allowed to continue might have caused death.
- Requires or prolongs inpatient hospitalization (see Section 5.3.5.9)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient's ability to conduct normal life functions)
- Congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- Significant medical event in the investigator's judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the eCRF.

SAEs are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions).

5.2.3 Non-Serious Adverse Events of Special Interest (Immediately Reportable to the Sponsor)

Non-SAEs of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). AEs of special interest for this study are the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's law (see Section 5.3.5.6)
• Suspected transmission of an infectious agent by the study drug, as defined below:

Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings indicating an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.

5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4−5.6. For each AE recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient’s medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting SAEs).

After initiation of study drug, all AEs, regardless of relationship to study drug, will be reported until 4 weeks after the last dose of study drug. After this period, the investigator is not required to actively monitor patients for AEs; however, the Sponsor should be notified if the investigator becomes aware of any post-study SAEs or non-SAEs of special interest (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all patient evaluation timepoints. Examples of non-directive questions include the following:

"How have you felt since your last clinic visit?"

"Have you had any new or changed health problems since you were last here?"
5.3.3 **Assessment of Severity of Adverse Events**

The AE severity grading scale for the NCI CTCAE (v4.0) will be used for assessing AE severity. **Table 5** will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.

**Table 5  Adverse Event Severity Grading Scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living&lt;sup&gt;b,c&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences or urgent intervention indicated&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>Death related to adverse event&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.

Note: On the basis of the most recent version of NCI CTCAE (v4.0), which can be found at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

<sup>a</sup> Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

<sup>b</sup> Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one's self, using the toilet, and taking medications, as performed by patients who are not bedridden.

<sup>c</sup> If an event is assessed as a "significant medical event," it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

<sup>d</sup> Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

5.3.4 **Assessment of Causality of Adverse Events**

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (as applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
• Presence of non-treatment-related factors that are known to be associated with the occurrence of the event

5.3.5 **Procedures for Recording Adverse Events**

Investigators should use correct medical terminology/concepts when recording AEs on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one AE term should be recorded in the event field on the Adverse Event eCRF.

5.3.5.1 **Diagnosis Versus Signs and Symptoms**

A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

5.3.5.2 **Adverse Events that are Secondary to Other Events**

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event on the Adverse Event eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

5.3.5.3 **Persistent or Recurrent Adverse Events**

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. The initial severity (intensity) of the event will be recorded at the
time the event is first reported. If a persistent AE becomes more severe, the most extreme intensity should also be recorded on the Adverse Event eCRF. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event eCRF should be updated by changing the event from "non-serious" to "serious," providing the date that the event became serious, and completing all data fields related to SAEs.

A recurrent AE is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values

Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Clinically significant in the investigator's judgment

Note: For oncology trials, certain abnormal values may not qualify as AEs.

It is the investigator’s responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., ALP and bilirubin 5 times the ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology changes. The initial severity of the event should be recorded, and the severity or seriousness should be updated any time the event worsens.
5.3.5.5 Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

- Accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Clinically significant in the investigator’s judgment

It is the investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology changes. The initial severity of the event should be recorded, and the severity or seriousness should be updated any time the event worsens.

5.3.5.6 Abnormal Liver Function Tests
The finding of an elevated ALT or AST (>3 \times \text{baseline value}) in combination with either an elevated total bilirubin (>2 \times \text{ULN}) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, investigators must report as an AE the occurrence of either of the following:

- Treatment-emergent ALT or AST >3 \times \text{baseline value} in combination with total bilirubin >2 \times \text{ULN} (of which 35\% is direct bilirubin)
- Treatment-emergent ALT or AST >3 \times \text{baseline value} in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or a no-SAE of special interest (see Section 5.4.2).

5.3.5.7 Deaths
For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-specified AE reporting period (see Section 5.3.1) that are attributed by the investigator solely to progression of NSCLC should be recorded only on the Study Completion/Early Discontinuation eCRF. All other on-study deaths, regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and
immediately reported to the Sponsor (see Section 5.4.2). An independent monitoring committee will monitor the frequency of deaths from all causes.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. The term "sudden death" should be used only for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, "unexplained death" should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), "unexplained death" should be replaced by the established cause of death.

During survival follow-up, deaths attributed to progression of NSCLC should be recorded only on the Survival eCRF.

5.3.5.8 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Non-Small Cell Lung Cancer
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not be recorded as AEs. These data will be captured as efficacy assessment data only. In most cases, the expected pattern of progression will be based on RECIST criteria v1.1 (Appendix 4). In rare cases, the determination of clinical progression will be based on symptomatic deterioration. However, every effort should be made to document progression using objective criteria. If there is any uncertainty as to whether an event is due to disease progression, it should be reported as an AE.

5.3.5.10 Hospitalization or Prolonged Hospitalization
Any AE that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 5.2.2), except as outlined below.
The following hospitalization scenarios are not considered to be AEs:

- Hospitalization for respite care
- Planned hospitalization required by the protocol
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:
  - The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease
  - The patient has not experienced an AE
- Hospitalization due solely to progression of the underlying cancer

5.3.5.11 Adverse Events Associated with an Overdose

An overdose is the accidental or intentional use of a drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE. All AEs associated with an overdose or incorrect administration of study drug should be recorded on the Adverse Event eCRF. If the associated AE fulfills serious criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

AE reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. However, if any PRO responses suggestive of a possible AE are identified during site review of the PRO data, the investigator will determine whether the criteria for an AE have been met and, if so, will report the event on the Adverse Event eCRF.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- SAEs
- Non-SAEs of special interest
- Pregnancies
The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:

- New signs or symptoms or a change in the diagnosis
- Significant new diagnostic test results
- Change in causality based on new information
- Change in the event’s outcome, including recovery
- Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts

Medical Monitor (Roche Medical Responsible) Contact Information

To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the Roche Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Roche Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk and Medical Monitor contact information will be distributed to all investigators (see "Protocol Administrative and Contact Information & List of Investigators Form ").

This list can be generated using contact numbers found at the following link: http://gcpcenter.roche.com/synergy/portal/view/pdq-spi/gcpcenter/34-64711453.

5.4.2 Reporting Requirements for Serious Adverse Events and Non-Serious Adverse Events of Special Interest

5.4.2.1 Events That Occur Prior to Study Drug Initiation

After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported. A paper Serious Adverse Event Reporting Form and fax cover sheet should be completed and faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the event), using the fax numbers provided to investigators (see "Protocol Administrative and Contact Information & List of Investigators ").

5.4.2.2 Events That Occur After Study Drug Initiation

After initiation of study drug, SAEs and non-SAEs of special interest will be reported until 4 weeks after the last dose of study drug. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) system. A report will be generated and sent to Roche Safety Risk Management by the EDC system.
In the event that the EDC system is unavailable, a paper Serious Adverse Event Reporting Form and fax cover sheet should be completed and faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the event), using the fax numbers provided to investigators (see "Protocol Administrative and Contact Information & List of Investigators"). Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

Instructions for reporting post-study AEs are provided in Section 5.6.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnancies in Female Patients

Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. A pregnancy report will automatically be generated and sent to Roche Safety Risk Management. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In the event that the EDC system is unavailable, a paper Clinical Trial Pregnancy Reporting Form and fax cover sheet should be completed and faxed to Roche Safety Risk Management or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), using the fax numbers provided to investigators (see "Protocol Administrative and Contact Information & List of Investigators"). Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3.2 Pregnancies in Female Partners of Male Patients

Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 3 months after the last dose of study drug. A Pregnancy Report eCRF should be completed by the investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and submitted via the EDC system. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the Pregnancy Report eCRF with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the
fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

In the event that the EDC system is unavailable, follow reporting instructions provided in Section 5.4.3.1.

5.4.3.3 Abortions
Any abortion should be classified as an SAE (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study drug or the female partner of a male patient exposed to study drug should be classified as an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.5 FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS

5.5.1 Investigator Follow-Up
The investigator should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented on the Adverse Event eCRF and in the patient’s medical record to facilitate source data verification. If, after follow-up, return to baseline status or stabilization cannot be established, an explanation should be recorded on the Adverse Event eCRF.

All pregnancies reported during the study should be followed until pregnancy outcome. If the EDC system is not available at the time of pregnancy outcome, follow reporting instructions provided in Section 5.4.3.1.

5.5.2 Sponsor Follow-Up
For SAEs, non-SAEs of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.
5.6 POST-STUDY ADVERSE EVENTS

At the time of study completion or study discontinuation, the investigator should instruct each patient to report to the investigator any subsequent AEs that the patient's personal physician believes could be related to prior study drug treatment or study procedures.

The investigator is not required to actively monitor patients for AEs after the end of the AE reporting period (defined as 4 weeks after the last dose of study drug). However, the Sponsor should be notified if the investigator becomes aware of any death, other SAE, or non-SAE of special interest occurring after the end of the AE reporting period, regardless of causality. The Sponsor should also be notified if the investigator becomes aware of the development of cancer or a congenital anomaly/birth defect in a subsequently conceived offspring of a female patient exposed to study drug or the female partner of a male patient exposed to study drug.

The investigator should report these events directly to Roche Safety Risk Management via telephone or via fax machine using the Serious Adverse Event Reporting Form and fax cover sheet (see "Protocol Administrative and Contact Information & List of Investigators").

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all SAEs and non-SAEs of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single AE cases, the Sponsor will assess the expectedness of these events using the following reference documents:

- Alectinib Investigator's Brochure
- Local prescribing information for crizotinib

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis population for efficacy is the intent-to-treat (ITT) population defined as all randomized patients. Patients will be assigned to the treatment group to which they were randomized.
The primary analysis population for safety is the Safety Analysis Population (SAP) defined as all patients who received at least one dose of study medication. Patients will be assigned to treatment groups as treated, and all patients who received any dose of alectinib will be included in the alectinib treatment arm.

A secondary analysis population for efficacy and safety is the FISH Positive Population (FPP). For efficacy, this is defined as all patients in the ITT population who were ALK-positive using the FISH assay. Patients will be assigned to the treatment group to which they were randomized. For safety, this is defined as all patients in the SAP who were ALK-positive using the FISH assay. Patients will be assigned to treatment groups as treated. This analysis population will be used to perform a supportive analysis of the study data based on the FISH assay rather than the IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the IHC companion diagnostic, in which case all analyses will be based on this population and the same prespecified testing strategy of secondary endpoints defined in Section 6.4.2 will be applied.

The final analysis of the primary endpoint of PFS will occur when 169 PFS events have occurred, on the basis of the investigators' assessments. On the basis of the assumptions outlined in Section 6.1, this is estimated to occur approximately 31 months after the first patient has been enrolled. A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died, which is estimated to occur approximately 42 months after the first patient has been enrolled.

Hypothesis tests will be two-sided unless otherwise indicated.

The baseline value of any variable will be defined as the last available value recorded prior to the first administration of alectinib or crizotinib.

Further details of all analyses will be provided in the Statistical Analysis Plan.

6.1 DETERMINATION OF SAMPLE SIZE

The focus of this clinical trial is hypothesis testing (Section 6.4.1), and the primary endpoint of PFS was used to determine the sample size of the study.

At the time of writing the protocol, there are no Phase III data on crizotinib in the first-line setting in ALK-positive patients. The median PFS for crizotinib administered as second-line therapy from the global randomized Phase III PROFILE 1007 study was 7.7 months (95% CI: 6.0%, 8.8%). From the Phase II single arm study of patients who had received ≥1 line of chemotherapy (with 85% patients having received ≥2 prior chemotherapy regimens), the median PFS was 8.5 months (95% CI: 6.2%, 9.9%).
A median PFS of 9.8 months for the crizotinib arm has been assumed. An HR of 0.65 for alectinib versus crizotinib (i.e., an increase from 9.8 months median PFS to 15.1 months) will be targeted.

In this study, 286 patients will be enrolled in a 1:1 randomization allocation. Enrollment will take approximately 25 months on the basis of an assumption of non-linear recruitment as follows:

- Month 1: 1 patients per month
- Month 2: 2 patients per month
- Month 3: 4 patients per month
- Month 4: 6 patients per month
- Month 5: 8 patients per month
- Month 6: 10 patients per month
- Month 7: 12 patients per month
- Months 8–12: 13 patients per month
- Months 13–14: 14 patients per month
- Month 15 onwards: 15 patients per month

A total of 169 PFS events are required to achieve 80% power at a two-sided alpha level of 5%. This level of enrollment is estimated to occur approximately 31 months after the first patient has been enrolled.

No interim analysis for efficacy or futility is planned.

A survival follow-up analysis will be performed once approximately 50% of patients (i.e., 143 patients) have died. The median OS in the crizotinib arm is assumed to be 25 months, and the expected median OS in the alectinib treatment arm is 30 months, equating to an HR of 0.83. On the basis of the sample size (N=286), the trial will not be powered to demonstrate any statistically significant difference in OS of this magnitude. At the time of the final analysis of the primary endpoint of PFS, on the basis of the above assumptions, 94 OS events are expected to have occurred. The survival follow-up analysis is expected to occur approximately 42 months after the first patient has been enrolled.

A follow-up analysis will be performed based on the FPP. This will occur once 169 PFS events have occurred in the FPP to ensure 80% power of the log-rank test assuming a hazard ratio of 0.65 in this sub-population. Based on a potential discrepancy/technical failure rate of 10% between the IHC assay and the FISH assay, 257 patients would be eligible for the FPP analysis, which is estimated to occur approximately 33 months after the first patient has been enrolled (i.e., 2 months after the primary IHC analysis) based on the above assumptions.
6.2 **SUMMARIES OF CONDUCT OF STUDY**

Study enrollment, study treatment administration, reasons for discontinuation from study treatment, and reasons for study termination will be summarized by treatment arm for all randomized patients. Violations of inclusion and exclusion criteria, on the basis of information captured on the eCRF, will be reported and summarized by treatment arm.

6.3 **SUMMARIES OF TREATMENT GROUP COMPARABILITY**

Summaries of treatment group comparability will be based on the ITT population.

Demographic, baseline disease characteristics and lung cancer history will be summarized by treatment arm for all randomized patients, including the randomization stratification factors. Descriptive baseline summaries of continuous data will present the group mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequency and percentages.

Previous and concomitant cancer therapy will also be summarized, as well as anti-cancer subsequent therapy. Previous and concurrent diseases and medications will also be summarized.

6.4 **EFFICACY ANALYSES**

The primary population for all primary and secondary efficacy analyses will be the ITT population.

6.4.1 **Primary Efficacy Endpoint**

PFS is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary endpoint of PFS will be determined on the basis of investigator assessment of progression using RECIST v1.1. Patients who have not experienced disease progression or death at the time of analysis will be censored at the last tumor assessment date either during study treatment or during follow-up. Patients with no post-baseline tumor assessment will be censored at the date of randomization.

Patients who discontinue treatment prior to disease progression (e.g., due to toxicity) will continue on study and will be followed until disease progression and for OS regardless of whether they subsequently receive anti-cancer therapy.

The treatment comparison of PFS will be based on a stratified log-rank test at the 5% level of significance (two-sided). The stratification factors are the randomization stratification factors: ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no), as recorded on the eCRF. Results from an unstratified log-rank test will also be presented.
The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference between the treatment arms. A stratified Cox proportional regression model will be used including treatment in order to provide an estimate of the treatment effect expressed as an HR (alectinib vs. crizotinib), as well as a 95% CI.

The difference between the two treatment groups will be assessed and tested for the following hypothesis: the survival distribution function (SDF) of the alectinib treatment group is the same as for the crizotinib treatment group versus the alternative that the two distributions are different:

\[
H_0: \text{SDF (alectinib)} = \text{SDF (crizotinib)} \\
\text{versus} \\
H_1: \text{SDF (alectinib)} \neq \text{SDF (crizotinib)}
\]

where SDF denotes the survival distribution function of the parameter PFS.

**6.4.2 Secondary Efficacy Endpoints**

If the primary endpoint of PFS is statistically significant at a two-sided 5% significance level, the following secondary endpoints will be tested in the following sequential order, each at a two-sided 5% significance level:

- PFS by IRC
- Time to CNS progression
- ORR
- OS

**PFS by IRC**

An analysis of PFS on the basis of the IRC assessments will be performed using the same methodology as specified for PFS on the basis of investigator assessment.

**Time to CNS Progression**

Time to CNS progression is defined as the time from randomization until radiographic evidence of CNS progression. An independent central radiological review will be performed for all patients, and the analysis of CNS progression or response will be on the basis of the data from the independent review. All patients will be included in the analysis regardless of their baseline status of CNS metastases. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of preexisting baseline CNS lesions. On the basis of RECIST v1.1, this is defined as a new post-baseline CNS/brain lesion(s) and/or an increase of ≥20% in the sum of longest diameters of the measurable baseline CNS lesions compared to nadir and/or unequivocal progression of non-measurable baseline CNS lesions.
In order to account for the competing risks inherent in such an analysis, HRs, including statistical inference on the basis of a two-sided log-rank test, to compare the risk of CNS progression between the alectinib and crizotinib treatment groups, will be computed on the basis of cause-specific hazard functions.

The probability of CNS progression, non-CNS progression, and death will each be estimated using cumulative incidence functions.

For descriptive purposes, estimates of the CNS progression rates over time with 95% CIs on the basis of cumulative incidence functions will be presented. A Gray’s test to compare the risk of CNS progression between alectinib and crizotinib will also be performed as a supportive analysis.

An exploratory analysis of CNS Time to Progression on the basis of RANO criteria will also be performed on the basis of the IRC assessments.

In the subgroup of patients with measurable CNS lesions at baseline, an exploratory analysis of C-ORR defined as the percentage of patients who achieve a best overall response of CR or PR (defined by RECIST v1.1 as a 30% decrease in the sum of longest diameters of measurable CNS lesions referencing baseline) will also be performed. Duration of CNS response will be listed and may be analyzed if there are a sufficient number of CNS responses. An exploratory analysis of these endpoints will also be performed on the basis of RANO criteria assessed by the IRC.

**Objective Response Rate**

ORR, on the basis of investigator assessment, is defined as the percentage of patients who attain a CR or PR. Per RECIST v1.1, confirmation of objective response is not required for this secondary endpoint. Patients without a post-baseline tumor assessment will be considered non-responders, as will patients with a best overall response of stable disease (SD), PD, or NE (not evaluable).

An estimate of ORR and its two-sided 95% CI will be calculated using the Clopper-Pearson method for each treatment arm. Response rates in the treatment groups will be compared using a stratified Mantel-Haenszel test on the basis of the randomization stratification factors. The difference in ORR between the two treatment arms will be presented together with a two-sided 95% CI on the basis of a normal approximation to the binomial distribution.

**DOR**

For patients who have experienced an objective response (CR or PR) during the study as assessed by the investigator, DOR is defined as the duration from the first tumor assessment that supports the patient’s objective response (CR or PR, whichever is first recorded) to first documented disease progression or death due to any causes, whichever occurred first. Patients who have not progressed or died at the time of...
analysis will be censored at the last tumor assessment date. Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing will not be performed. DOR will be estimated using Kaplan-Meier methodology and a HR on the basis of a Cox proportional regression model will be calculated.

**Overall Survival**
OS is defined as the time from the date of randomization to the date of death due to any cause. Patients who are not reported as having died at the time of analysis will be censored at the date when they were last known to be alive. Patients who do not have post-baseline information will be censored at the date of randomization. OS will be analyzed using the same methodology as specified for the primary endpoint. A survival follow-up will be performed based on more mature data.

### 6.4.2.1 Sensitivity Analyses
The following sensitivity analyses will be performed on the primary endpoint of PFS:

- The effect of non-protocol-specified anti-cancer therapy prior to progression will be assessed by censoring patients at the last adequate tumor assessment prior to the start of non-protocol-specified anti-cancer therapy.
- The effect of missing tumor assessments will be assessed if the number of missing assessments in either arm is >5%. For patients with progression determined following one or more missing tumor assessments, the progression will be backdated to the first missing tumor assessment.
- The effect of loss to follow-up will be assessed depending on the number of patients who are lost to follow-up. If >5% of patients are lost to follow-up for PFS in either treatment arm, a “worst-case” analysis will be performed in which patients who are lost to follow-up will be considered to have progressed at the last date they were known to be progression-free.

### 6.4.2.2 Subgroup Analyses
Subgroup analyses of PFS will be performed for patients with baseline CNS metastases and for patients without baseline CNS metastases. In addition, a subgroup analysis of Time to CNS Progression will be performed, excluding patients who had pre-treatment radiation therapy for CNS lesions.

All other subgroup analyses will be specified in the SAP.

### 6.5 SAFETY ANALYSES
The primary population for all safety analyses will be the SAP as defined in Section 6.

All safety parameters will be summarized in tables to evaluate and compare the safety profile of patients treated with alectinib versus crizotinib in terms of:

- Adverse events including adverse events leading to dose modifications or interruptions, study drug withdrawal, and death
• Severe, serious, and selected adverse events
• Deaths
• Laboratory parameters and abnormalities
• Vital signs
• ECGs
• ECOG PS

Adverse events will be coded using MedDRA and summarized by mapped term and appropriate thesaurus level. All adverse events and routine laboratory parameters will be assessed according to the NCI CTCAE v4.0 grading system. For adverse events, the most extreme intensity will be used for reporting. Adverse events will be described by individual listings and by body system, as well as by severity. In tables showing the overall incidence of adverse events, patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency.

Laboratory values will be summarized by treatment arm including summary tables for the shifts in grades from baseline to the worst grade observed during treatment. In order to evaluate and compare hypogonadism in the two treatment arms, testosterone levels in the blood will be summarized for males by treatment arm over time (for details, see Section 6.8).

Descriptive summary tables of change from baseline over time will be provided for vital signs and descriptive statistics will be tabulated for ECOG PS. ECG findings over time will be summarized.

Study drug administration will be summarized by duration and cumulative dose. In addition, treatment exposure will be summarized including the number of doses received, dose intensity, and the percentage of planned dose.

Subgroup analyses will be performed to evaluate the safety profile within the subgroups of patients including by sex, age (<65 vs. ≥65 years), and race (non-Asian vs. Asian).

An IDMC will review the safety data collected during the conduct of the study. Safety monitoring will be performed periodically. Further details will be outlined in the IDMC Charter.

6.6 PHARMACOKINETIC ANALYSES

Standard NCA may be conducted for PK data collected from patients participating in serial/intensive PK collections for relevant analytes, as data allow, as appropriate, and if needed. PK parameters, including but not limited to AUC, maximum concentration (C\text{max}), and time to maximum concentration, will be calculated on the basis of the available data as appropriate and where data allow. Additional PK parameters may be calculated as deemed appropriate.
Individual and mean plasma concentrations at each sampling timepoint and/or PK parameters for alectinib and metabolite(s) will be listed, as appropriate.

Summary statistics (e.g., means, standard deviation, coefficient of variation %, geometric means, medians and ranges) for plasma concentrations and/or PK parameters for alectinib and metabolite(s) will be presented by treatment and nominal collection times (plasma concentrations only), as appropriate. Additional plots or summary statistics may be constructed or calculated, as appropriate.

Results of PK and/or any PK or PK/pharmacodynamic analyses may be reported outside the clinical study report.

Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be used to analyze the sparse and/or serial/intensive plasma concentration-time data for alectinib. The PK data from this study may be pooled with data from other studies. Population and individual PK parameters will be estimated and the influence of various covariates (such as age, gender, and body weight) on these parameters will be investigated.

Exploratory analyses will be conducted to investigate the relationship between alectinib PK exposure and efficacy/safety parameters.

Details of the mixed-effects modeling and exploratory analyses will be reported in a document separate from the clinical study report.

6.7  PATIENT-REPORTED OUTCOME ANALYSES

The following PRO endpoints will be analyzed and PRO data will be presented separately from adverse event data.

6.7.1  Time to Deterioration of Patient-Reported Lung Cancer Symptoms

TTD from baseline will be assessed at every study visit (Week 4, Week 8, and then after every 4 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at post-treatment Visit (4 weeks after permanent treatment discontinuation); and at subsequent 8-weekly survival follow-up visits for 6 months, for the following lung cancer symptoms: cough (Question 31 on the QLQ-LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale (Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), arm/shoulder pain (Question 41 on the QLQ-LC13) and fatigue multi-item subscale (Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm.

Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. TTD will be analyzed for the ITT population. If a baseline or post-baseline PRO evaluation is not available, TTD will be censored at the date of randomization. If they have not deteriorated, patients will be censored at the last
time when they completed an assessment for cough, dyspnea (single item), dyspnea (subscale items), chest pain, arm/shoulder pain, and fatigue.

6.7.2 Additional Patient-Reported Outcomes

PROs of HRQoL, lung cancer–related symptoms, and health status will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13.

Summary statistics (mean, standard deviation, median, and range) of linear transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire, and the QLQ-LC13 according to the EORTC scoring manual guidelines. Completion and compliance rates will be summarized at each timepoint by treatment arm with reasons for missing data. Only patients with a baseline assessment and at least one post-treatment assessment will be included in the analyses.

6.8 EXPLORATORY ANALYSES

The EQ-5D-3L is a generic PRO instrument that is used for across diseases and indications cost-effectiveness analyses. This instrument quantifies the QoL of various health outcomes and is applicable to a wide range of health states. Analyses of this outcome will be exploratory and will generate utility scores for use in economic models for reimbursement purposes only. The PRO will be administered every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow-up visit (every 8 weeks) after post-treatment visit for 6 months (see Appendix 1).

It has been reported that crizotinib therapy triggered rapid suppression of testosterone levels in men causing rapid-onset hypogonadism. Whether reductions in testosterone reflect an effect of crizotinib on ALK or on some combination of the drug’s targets (i.e., c-MET) is unknown (Weickhardt et al. 2012; Weickhardt et al. 2013). Total testosterone, albumin, and sex hormone-binding globulin (SHBG) to calculate free testosterone (calculator: http://www.issam.ch/freetesto.htm) and FSH and LH levels in blood will be measured (see Appendix 1) in male patients enrolled in the study for exploratory analysis of an onset of hypogonadism. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m.

The Abbott Vysis FISH test will be used as an exploratory assay, after patients have been enrolled in this study. Results from these analyses will be used to quantify the degree of correlation between FISH and IHC for the detection of ALK-positive NSCLC. The FPP will be a secondary analysis population for efficacy and safety. This analysis population will be used to perform a supportive analysis of the study data based on the FISH assay rather than the IHC. This population may be used for registration purposes in the unlikely event of registrational failure of the IHC companion diagnostic, in which case all analyses will be based on this population.
Results of exploratory analyses on post-progression tumor samples to measure molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure ALK rearrangements in circulating tumor cells will be communicated outside the main study report.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

The Sponsor will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC using eCRFs. Sites will be responsible for data entry into the EDC system. In the event of discrepant data, the Sponsor will request data clarification from the sites, which the sites will resolve electronically in the EDC system.

The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. Central laboratory data or other electronic data will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle and process the electronic transfer of these data.

eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

ePRO data will be collected through use of an electronic device provided by an ePRO vendor. The device is designed for entry of data in a way that is attributable, secure, and accurate, in compliance with the FDA regulations for electronic records (21 CFR Part 11). The ePRO device data are available for view access only via secure access to a web server. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures.

7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.

At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.
7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patients will use an ePRO device to capture PRO data. The data will be transmitted via pre-specified transmission method (e.g., web or wireless) automatically after entry to a centralized database at the ePRO vendor. The data can be reviewed by site staff via secure access to a web server.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The investigator will receive patient data for the site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records as source data. Acknowledgement of receipt of the compact disc is required. In addition, the Sponsor will receive all patient data in a machine-readable format on a compact disc.

7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by applicable health authorities.
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS
Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a United States IND application will comply with FDA regulations and applicable local, state, and federal laws. Studies conducted in the European Union or European Economic Area will comply with the EU Clinical Trial Directive (2001/20/EC).

8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child’s Assent or Caregiver’s Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor’s sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the “Consent Forms”) before IRB/EC
submission. The final IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to allow any remaining specimens to be used for exploratory research. Patients who decline to participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC–approved Consent Forms must be provided to the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient's legally authorized representative. All signed and dated Consent Forms must remain in each patient’s study file or in the site file and must be available for verification by study monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.
8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site’s study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which includes an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL VIOLATIONS

The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.

9.3 SITE INSPECTIONS

Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients' medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE

Steering Committee is established to provide the study Sponsor with recommendations related to any aspect of the trial, specifically study design, data interpretation, exploratory analyses, or alternate changes to the trial that may assist in patient accrual, data collection, analysis, and interpretation of the study results. The Sponsor is ultimately responsible for all decisions regarding the study.

The test for the study inclusion criteria of ALK-positive NSCLC will be performed at Sponsor’s designated central laboratories and assessed by Ventana IHC test.

An IDMC will be established to monitor the progress of the study and ensure that the safety of patients enrolled in the study is not compromised. Details of the composition, roles, and responsibilities, and processes of the IDMC are documented in a separate IDMC charter. The IDMC will review safety data and can make recommendations to the Sponsor to stop or amend the study on the basis of safety findings. The frequency of these reviews as well as the data to be reviewed will be agreed with the IDMC and outlined in the separate IDMC charter. No stopping for early proof of efficacy will result from any of these regular safety reviews. IDMC review meetings will be held in a blinded manner to the Sponsor.
An IRC will review the tumor assessments to determine the secondary endpoints of the overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1. In addition to the secondary endpoint of time to CNS progression together with C-ORR, C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the tumor assessments on the basis of RANO criteria.

The independent review of MRI and CT scans will NOT determine either eligibility OR patient treatment. All treatment decisions will be made by the investigator using local assessments.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the Sponsor prior to submission. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).
10. REFERENCES


Alectinib—F. Hoffmann-La Roche Ltd
Protocol BO28984, Version 1


Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.

## Appendix 1
### Schedule of Assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/ LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test(^a)</td>
<td>x</td>
<td></td>
<td>To be repeated as necessary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination(^b)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECOG PS</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>ECG(^c)</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Hematology, Coagulation</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x(^d)</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

\(^a\) To be repeated as necessary

\(^b\) Physical examination includes measurement of blood pressure, heart rate, respiratory rate, and temperature.

\(^c\) ECG (electrocardiogram) is performed at screening and on study day 14, 28, and then every 4 weeks until study completion.

\(^d\) Tests are performed only if there is a change in health status or symptoms.
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mandatory tumor sample for ALK testing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional tumor sample</td>
<td>x&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td>x&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for ALK fusion detection in circulating tumor cells (12 mL of blood)</td>
<td>x</td>
<td></td>
<td>x&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma for detection of ALK mutation status (20 mL of blood)</td>
<td>x</td>
<td></td>
<td>x&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 1
### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Days -28 to 0</th>
<th>Days -3 to 0</th>
<th>Days 0</th>
<th>Days 1</th>
<th>Days 5</th>
<th>Days 8</th>
<th>All Subsequent Visits (Every 8 weeks) Until PD, Death, or Withdrawal from Study prior to PD</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood sample for pharmacogenomics research at pre-dose (3 mL of blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor assessment</td>
<td>xI</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI scan of the brain</td>
<td>xI</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PK samples (2 mL blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>PRO (EORTC QLQ-C30/LC13; EQ-5D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td>xq</td>
</tr>
</tbody>
</table>
### Appendix 1

#### Schedule of Assessments (cont.)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening</th>
<th>Treatment Period</th>
<th>Post-Progression Visits on Treatment in Case of Isolated, Asymptomatic CNS Progression (Every 8 weeks) Until Systemic Progression and/or Symptomatic CNS Progression</th>
<th>Post-Treatment Visit (4 weeks after Permanent Treatment Discontinuation)</th>
<th>Subsequent Therapy for NSCLC; Survival follow-up and PRO (EORTC QLQ-C30/LC13; EQ-5D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total testosterone, albumin, and SHBG to calculate free testosterone, FSH, and LH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent therapy for NSCLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug dispensing and accountability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Sample for Roche Clinical Repository (10 mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire–Core; EQ-5D = EuroQoL 5 Dimension; FSH = follicle-stimulating hormone; LH = luteinizing
Appendix 1
Schedule of Assessments (cont.)

hormone; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NSCLC = non–small cell lung cancer; PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal.

Notes: First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided—within ≤ 24 hours. Post-baseline assessments are to be performed within ± 1 week for the first two 4 weekly and subsequent 8 weekly assessments.

a Urine or serum, to be repeated as necessary.

b Including an ophthalmologic examination if clinically indicated.

c At screening, Visit 0 (baseline), Visit 1 (Week 4), Visit 4 (Week 24), Visit 8 (Week 56), last treatment visit, and as clinically indicated throughout the study.

d Screening laboratory assessment done within 3 days can be counted as the baseline assessment.

e Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 10 to 15 unstained 5-µm slides are required. Tumor ALK status will be assessed by central laboratory before randomization.

f Optional tumor sample could be taken from the tumor block obtained at screening.

g At the time of disease progression from progressive lesions.

h Mandatory blood sample (12 mL) for CTCs should match in time to tumor progression (CNS progression and/or systemic disease progression) at discretion of the investigator.

i Blood sample (20 mL) to obtain plasma for exploratory biomarkers will be collected at Visit 0 (baseline), during the study every second visit (i.e., every 16 weeks) until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression.

j This sample is required in all patients in alectinib arm, and in those patients in the crizotinib arm who wish to participate in optional genomics sequencing.

k Tumor assessment consists at minimum of a CT/MRI scan of chest and abdomen (for imaging of liver and adrenal glands). Patients who are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP > 1.5 × ULN) of bone metastasis should undergo radionuclide bone scan. Post-baseline assessments are to be performed within ± 1 week for the 8 weekly assessments. If there is suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be performed as soon as possible before the next scheduled evaluation.

l Screening tumor assessment done within 14 days will be counted as the baseline assessment.

m Tumor assessment can be performed whenever clinically indicated. Brain assessment scans should be performed at every systemic imaging tumor assessment. Tumor assessment should continue until disease progression if a patient discontinues treatment prior to PD, regardless of whether they subsequently receive non-study, anti-cancer therapy (a use of subsequent non-study, anti-cancer therapy prior to disease progression would be considered a protocol violation).
Appendix 1
Schedule of Assessments (cont.)

n If treatment was permanently discontinued due to disease progression.

o Pre-dose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit. The pre-dose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits. Remind the patient not to take a daily dose at home on the day of scheduled study visit. For a subset of patients on alectinib treatment (10%–15%, at least n = 20) participating in serial/intensive PK sample collection, additional PK will be collected on Visits 0 (baseline) and 1 (Week 4) at pre-dose (within 60 min before intake of study medication), 1, 2, 4, 6, 8, 10, and 12 hours post-dose.

p PRO questionnaires are to be completed every 4 weeks until disease progression and during post-progression on treatment in case of isolated, asymptomatic CNS progression; at the post-treatment visit (4 weeks after permanent treatment discontinuation); and every follow up visit (every 8 weeks) after post-treatment visit for 6 months. Further guidelines on PRO questionnaire administration will be provided in the study manual.

q Performed every 8 weeks after post-treatment visit during the first 6 months and then every 12 weeks or performed as appropriate. The PRO assessments should be performed during the first 6 months.

r Male patients only, using institutional standard assay. The recommended time of day to have a blood sample taken for this test is between 7 a.m. and 10 a.m. Free testosterone calculator: http://www.issam.ch/freetesto.htm.

s Graded according to NCI CTCAE (version 4.0). Serious adverse events collection must start from first study-specific procedure.

t For details on drug dispensing and accountability, see Section 4.3.3.
## Appendix 2
### Schedule of Alectinib Pharmacokinetic Assessments

<table>
<thead>
<tr>
<th>Visit</th>
<th>Timepoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 0 (baseline)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 2 (Week 8)</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>All subsequent visits (every 8 weeks) until PD or death/withdrawal from study prior to PD</td>
<td>Pre-dose (within 2 hours before intake of alectinib)</td>
</tr>
<tr>
<td>Visit 0 (baseline) and Visit 1 (Week 4)</td>
<td>Pre-dose (within 2 hours before intake of alectinib), 1, 2, 4, 6, 8, 10, and 12 hours post-dose</td>
</tr>
</tbody>
</table>

PD = progressive disease; PK = Pharmacokinetic

a For patients participating in the serial/intensive PK sample collection only.
b A time window of ±1 hour may be considered for the 12-hour PK sample only
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters

This representative list is not intended to be an exhaustive list. Each patient’s concomitant medications should be carefully considered by the investigator with regard to the risk-benefit for the particular patient and appropriate monitoring, including any concomitant medication, dose adjustment, or therapeutic alternatives, which should be determined by the investigator caring for the patient.

<table>
<thead>
<tr>
<th>CYP3A Inducers</th>
<th>CYP3A Potent Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>avasimibe, aminogluthethimide, barbiturates, carbamazepine, dexamethasone, efavirenz, ethosuximide, garlic supplements, glucocorticoids, glutethimide, griseofulvin, modafinil, naftilin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, primidone, rifabutin, rifampin, rifapentine, St. John’s wort, troglitazone</td>
<td>aprepitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir, mibeferadi, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, treleandomycin, verapamil, voriconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-gp</th>
<th>Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>aliskiren, ambrisentan, colchicine, dabigatran, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, pravastatin, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan</td>
<td>amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir, quercetin, quinidine, ranolazine, verapamil</td>
<td>avasimibe, carbmazepine, phenytoin, rifampin, St John’s wort, tipranavir</td>
</tr>
</tbody>
</table>

Dual UGT1A1/CYP3A

<table>
<thead>
<tr>
<th>Substrates</th>
<th>Inhibitors</th>
<th>Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>buprenorphine, raltegravir</td>
<td>atazanavir</td>
<td>rifampin</td>
</tr>
</tbody>
</table>

Sensitive CYP3A and 2C8 substrates

| alfentanil, aprepitant, budesonide, buspirone, conivaptan, darifenacin, darunavir, dasatinib, dronedarone, eletriptan, eplerenone, everolimus, felodipine, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, quetiapine, saquinavir, sildenafil, simvastatin, sirolimus, tolvaptan, tipranavir, triazolam, ticagrelor, vardenafil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine, repaglinide, paclitaxol |
Appendix 3
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing Enzymes and Transporters (cont.)

This information in this appendix is adapted from Levien and Baker 2003\(^1\), Zhang 2010\(^2\), and FDA Guidance on Drug-Drug Interactions.

Also see:
- http://medicine.iupui.edu/clinpharm/ddis/table.aspx

Potent inhibitors of CYP3A are those considered to be "strong CYP3A inhibitors" previously shown to result in a $\geq 5$-fold increase in the AUC of a concomitantly administered CYP3A substrate. These are based on the available published literature and, thus, are not considered exhaustive or inclusive. See FDA Guidance on Drug-Drug Interactions for further detail.

---


Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1: Excerpt from Original Publication

Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, are presented below, with slight modifications and the addition of explanatory text as needed for clarity.

MEASURABILITY OF TUMOR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as described below.

**Measurable tumor lesions**

**Tumor lesions**
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size as follows:

- 10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than 5 mm)
- 10-mm caliper measurement by clinical examination (lesions that cannot be accurately measured with calipers should be recorded as non-measurable)
- 20 mm by chest X-ray

**Malignant lymph nodes**
To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in the short axis when assessed by CT scan (CT scan slice thickness is recommended to be no greater than 5 mm). At baseline and follow-up, only the short axis will be measured and followed. See also notes below on “Baseline Documentation of Target and Non-Target Lesions” for information on lymph node measurement.

**Non-Measurable tumor lesions**
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or pathological lymph nodes with ≥ 10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal

---

2. For consistency within this document, the section numbers and cross-references to other sections within the article have been deleted and minor formatting changes have been made.
mass/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques.

**Special considerations regarding lesion measurability**

Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.

**Bone lesions**

Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate imaging techniques for measuring bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.

Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques, such as CT or MRI, can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

Blastic bone lesions are non-measurable.

**Cystic lesions**

Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

**Lesions with prior local treatment**

Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.

**TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS**

**Measurement of lesions**

All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.
Method of assessment

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study. Imaging-based evaluation should always be the preferred option.

Clinical lesions

Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is suggested.

Chest X-Ray

Chest CT is preferred over chest X-Ray, particularly when progression is an important endpoint, because CT is more sensitive than X-Ray, particularly in identifying new lesions. However, lesions on chest X-Ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

CT, MRI

CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan on the basis of the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable.

If, prior to enrollment, it is known that a patient is unable to undergo CT scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the study should be guided by the tumor type under investigation and the anatomic location of the disease. For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible. Each case should be discussed with the radiologist to determine if the substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of target lesions on a different modality and interpretation of non-target disease or new lesions because the same lesion may appear to have a different size using a new modality.

Ultrasound

Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement.
Endoscopy, laparoscopy, tumor markers, cytology, histology
The utilization of these techniques for objective tumor evaluation cannot generally be advised.

TUMOR RESPONSE EVALUATION

ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE

To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable lesion, as detailed above.

BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS

When more than one measurable lesion is present at baseline, all lesions, up to a maximum of five lesions total and a maximum of two lesions per organ, representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline. This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions (albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size is >10 mm by CT scan).

Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but, in addition, the lesions should lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.

Lymph nodes merit special mention since they are normal anatomical structures that may be visible by imaging even if not involved by tumor. As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥10 mm but <15 mm) should be considered non-target lesions. Nodes that have a short axis of <10 mm are considered non-pathological and should not be recorded or followed.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum of diameters. If lymph nodes are to be included in the sum, then, as noted above, only the short axis is added into the sum. The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions or sites of disease, including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression”.

In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).

**RESPONSE CRITERIA**

**Evaluation of target lesions**

This section provides the definitions of the criteria used to determine objective tumor response for target lesions.

- **CR:** Disappearance of all target lesions
  
  Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

- **PR:** At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

- **PD:** At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
  
  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
  
  The appearance of one or more new lesions is also considered progression.

- **SD:** Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

**Special notes on the assessment of target lesions**

**Lymph nodes**

Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to < 10 mm on study. This means that when lymph nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm.
Target lesions that become too small to measure
During the study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as target lesions at baseline become so faint on the CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being too small to measure. When this occurs, it is important that a value be recorded on the CRF, as follows:

If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.

If the lesion is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned and BML (below measurable limit) should be ticked. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but is too small to measure, a default value of 5 mm should be assigned in this circumstance as well and BML should also be ticked).

To reiterate: if the radiologist is able to provide an actual measure, this measurement should be recorded, even if it is below 5 mm, and, in that case, BML should not be ticked.

Lesions that split or coalesce on treatment
When non-nodal lesions fragment, the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.

Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the group of non-target lesions. Whereas some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the timepoints specified in the protocol.

- **CR**: Disappearance of all non-target lesions and (if applicable) normalization of tumor marker level
  - All lymph nodes must be non-pathological in size (< 10 mm short axis).
- **Non-CR/Non-PD**: Persistence of one or more non-target lesions and/or (if applicable) maintenance of tumor marker level above the normal limits
Appendix 4
Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1: Excerpt from Original Publication (cont.)

- PD: Unequivocal progression of existing non-target lesions
  The appearance of one or more new lesions is also considered progression.

Special notes on assessment of progression of non-target disease

When the patient also has measurable disease
In this setting, to achieve unequivocal progression on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease in a magnitude that, even in the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

When the patient has only non-measurable disease
This circumstance arises in some Phase III trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden on the basis of the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic disease from localized to widespread. Examples may be described in protocols as “sufficient to require a change in therapy”. If unequivocal progression is seen, the patient should be considered to have had overall PD at that point. Though it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore, the increase must be substantial.

New lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly important when the patient’s baseline lesions show PR or CR (e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not).
A lesion identified during the study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.

If a new lesion is equivocal (e.g., because of its small size) continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.

EVALUATION OF RESPONSE

Timepoint response (overall response)

It is assumed that at each protocol-specified timepoint, a response assessment occurs. Table 1 provides a summary of the overall response status calculation at each timepoint for patients who have measurable disease at baseline.

When patients have non-measurable (therefore non-target) disease only, Table 2 is to be used.

Table 1  Timepoint Response: Patients with Target Lesions (with or without Non-Target Lesions)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.
Table 2  Timepoint Response: Patients with Non-Target Lesions Only

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD a</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or no</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease.

a  “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can be measured is not advised.

**Missing assessments and not-evaluable designation**

When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at that timepoint. If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response. This would be most likely to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three measured lesions and during the study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution of the missing lesion).

If one or more target lesions were not assessed either because the scan was not done or because the scan could not be assessed due to poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable. Similarly, if one or more non-target lesions are not assessed, the response for non-target lesions should be “unable to assess”, except where there is clear progression. Overall response would be “unable to assess” if either the target response or the non-target response is “unable to assess”, except where this is clear evidence of progression, as this equates with the case being not evaluable at that timepoint.
### Table 3  Best Overall Response When Confirmation Is Required

<table>
<thead>
<tr>
<th>Overall Response at First Timepoint</th>
<th>Overall Response at Subsequent Timepoint</th>
<th>Best Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR a</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD, provided minimum duration for SD was met; otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD, provided minimum duration for SD was met; otherwise, NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

a If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even disease meeting PR criteria relative to baseline, qualifies as PD at that point (since disease must have reappeared after CR). Best response would depend on whether the minimum duration for SD was met. However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint. Under these circumstances, the original CR should be changed to PR and the best response is PR.

**Special notes on response assessment**

When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (<10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document objective progression even after discontinuation of treatment. Symptomatic deterioration is not a
descriptor of an objective response; it is a reason for stopping study therapy. The objective response status of such patients is to be determined by evaluation of target and non-target disease as shown in Table 1 to Table 3.

For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non-target lesion, as appropriate. This is to avoid an incorrect assessment of complete response if the primary tumor is still present but not evaluated as a target or non-target lesion.
# Appendix 5

**Eastern Cooperative Oncology Group Performance Status Scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework or office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to a bed or chair &gt;50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>
# Appendix 6

**EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires**

**EORTC QLQ-C30 (version 3)**

We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no “right” or “wrong” answers. The information that you provide will remain strictly confidential.

Please fill in your initials:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Your birthdate (Day, Month, Year):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Today’s date (Day, Month, Year):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do you have any trouble doing strenuous activities,</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>like carrying a heavy shopping bag or a suitcase?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Do you have any trouble taking a long walk?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>3. Do you have any trouble taking a short walk outside of the house?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4. Do you need to stay in bed or a chair during the day?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5. Do you need help with eating, dressing, washing yourself or using the</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>toilet?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**During the past week:**

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Were you limited in doing either your work or other daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7. Were you limited in pursuing your hobbies or other leisure time activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>8. Were you short of breath?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>9. Have you had pain?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>10. Did you need to rest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>11. Have you had trouble sleeping?</td>
<td>1</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>12. Have you felt weak?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>13. Have you lacked appetite?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>14. Have you felt nauseated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>15. Have you vomited?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>16. Have you been constipated?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Please go on to the next page
### Appendix 6
### EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

#### During the past week:

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>17. Have you had diarrhea?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>18. Were you tired?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>19. Did pain interfere with your daily activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>21. Did you feel tense?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>22. Did you worry?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>23. Did you feel irritable?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>24. Did you feel depressed?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>25. Have you had difficulty remembering things?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>26. Has your physical condition or medical treatment interfered with your family life?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>27. Has your physical condition or medical treatment interfered with your social activities?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>28. Has your physical condition or medical treatment caused you financial difficulties?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

For the following questions please circle the number between 1 and 7 that best applies to you

29. How would you rate your overall health during the past week?  
   1 2 3 4 5 6 7  
   Very poor  Excellent

30. How would you rate your overall quality of life during the past week?  
   1 2 3 4 5 6 7  
   Very poor  Excellent
## Appendix 6
### EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

### EORTC QLQ - LC13

Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems **during the past week**. Please answer by circling the number that best applies to you.

<table>
<thead>
<tr>
<th>During the past week</th>
<th>Not at All</th>
<th>A Little</th>
<th>Quite a Bit</th>
<th>Very Much</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. How much did you cough?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>32. Did you cough up blood?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>33. Were you short of breath when you rested?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>34. Were you short of breath when you walked?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>35. Were you short of breath when you climbed stairs?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>36. Have you had a sore mouth or tongue?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>37. Have you had trouble swallowing?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>38. Have you had tingling hands or feet?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>39. Have you had hair loss?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>40. Have you had pain in your chest?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>41. Have you had pain in your arm or shoulder?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>42. Have you had pain in other parts of your body?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>If yes, where</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43. Did you take any medicine for pain?</td>
<td>1</td>
<td>No</td>
<td>2</td>
<td>Yes</td>
</tr>
<tr>
<td>If yes, how much did it help?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

EQ-5D

Health Questionnaire

(English version for the US)
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

**Mobility**
- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

**Self-Care**
- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

**Usual Activities (e.g. work, study, housework, family or leisure activities)**
- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

**Pain/Discomfort**
- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

**Anxiety/Depression**
- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 6
EORTC QLQ-C30/LC13 and EQ-5D-3L Questionnaires (cont.)

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Appendix 7
Modification of Diet in Renal Disease (MDRD) Formula

The estimating glomerular filtration rate (eGFR) will be calculated on the basis of the following formula:

$$eGFR = 175 \times SCRT - 1.154 \times AGE - 0.203 [\times 0.742 \text{ if female} ] [\times 1.212 \text{ if African American}]$$ (conventional units)

Appendix 8
Anaplastic Lymphoma Kinase (ALK) Immunohistochemistry

Overview
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA anti-ALK [D5F3]) IHC assay will be used to determine anaplastic lymphoma kinase (ALK) IHC status and to select patients with positive ALK for enrollment in Study BO28984. The anti-ALK (D5F3) rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib. For Study BO28984, the VENTANA anti-ALK (D5F3) assay will be used for investigational purposes only.

VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with using a VENTANA automated slide stainer. It is indicated as an aid in identifying patients eligible for treatment with alectinib.

Device Description
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary antibody, the BenchMark® automated slide staining platform, OptiView DAB detection kit, OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA anti-ALK 2-in-1 cell line control slides or other appropriate system run control.

Scoring System
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern. Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish non-specific staining from specific ALK positivity. Samples must be assessed for morphological damage and the presence of viable tumor versus necrosis. Light, granular, cytoplasmic stippling in alveolar macrophages can occur on anti-ALK (D5F3) and/or NRC slides as an artifact of the detection system. This staining artifact should be noted on the Slide Evaluation Form comment field but should NOT be interpreted as ALK-positive staining. Some background staining has also been observed on normal mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also should not be interpreted as ALK-positive staining. Case slide sets failing to show specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be considered ALK-positive. Refer to VENTANA ALK Scoring Interpretation Guide for non-small cell lung carcinoma (NSCLC) for additional information.
### Appendix 9
**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein</th>
<th>Enzyme</th>
<th>Transporter</th>
<th>Liver Injury Polymorphism</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>CHST13</td>
<td>CYP3A5</td>
<td>HNMT</td>
<td>SLC22A3</td>
</tr>
<tr>
<td>ABCB11</td>
<td>CHST2</td>
<td>CYP3A7</td>
<td>MAOA</td>
<td>SLC22A4</td>
</tr>
<tr>
<td>ABCB4</td>
<td>CHST3</td>
<td>CYP46A1</td>
<td>MAOB</td>
<td>SLC22A5</td>
</tr>
<tr>
<td>ABCB7</td>
<td>CHST4</td>
<td>CYP4A11</td>
<td>MAT1A</td>
<td>SLC22A6</td>
</tr>
<tr>
<td>ABCC1</td>
<td>CHST5</td>
<td>CYP4B1</td>
<td>METTL1</td>
<td>SLC22A7</td>
</tr>
<tr>
<td>ABCC2</td>
<td>CHST6</td>
<td>CYP4F11</td>
<td>NAT1</td>
<td>SLC22A8</td>
</tr>
<tr>
<td>ABCC3</td>
<td>CHST7</td>
<td>CYP4F12</td>
<td>NAT2</td>
<td>SLC25A27</td>
</tr>
<tr>
<td>ABCC4</td>
<td>CHST8</td>
<td>CYP4F2</td>
<td>NNMT</td>
<td>SLC28A1</td>
</tr>
<tr>
<td>ABCC5</td>
<td>CHST9</td>
<td>CYP4F3</td>
<td>NQO1</td>
<td>SLC28A2</td>
</tr>
<tr>
<td>ABCC6</td>
<td>COMT</td>
<td>CYP4F8</td>
<td>NR1I2</td>
<td>SLC28A3</td>
</tr>
<tr>
<td>ABCC8</td>
<td>CROT</td>
<td>CYP4Z1</td>
<td>NR1I3</td>
<td>SLC29A1</td>
</tr>
<tr>
<td>ABCC9</td>
<td>CYP11A1</td>
<td>CYP5A1</td>
<td>NR3C1</td>
<td>SLC29A2</td>
</tr>
<tr>
<td>ABCG1</td>
<td>CYP11B1</td>
<td>CYP7A1</td>
<td>ORM1</td>
<td>SLC5A6</td>
</tr>
<tr>
<td>ABCG2</td>
<td>CYP11B2</td>
<td>CYP7B1</td>
<td>ORM2</td>
<td>SLC6A6</td>
</tr>
<tr>
<td>ABP1</td>
<td>CYP17A1</td>
<td>CYP8B1</td>
<td>PGAP3</td>
<td>SLC7A5</td>
</tr>
<tr>
<td>ADH1A</td>
<td>CYP19A1</td>
<td>DCK</td>
<td>PNMT</td>
<td>SLC7A7</td>
</tr>
<tr>
<td>ADH1B</td>
<td>CYP1A1</td>
<td>DPYD</td>
<td>PON1</td>
<td>SLC7A8</td>
</tr>
<tr>
<td>ADH1C</td>
<td>CYP1A2</td>
<td>EPHX1</td>
<td>PON2</td>
<td>SLCO1A2</td>
</tr>
<tr>
<td>ADH4</td>
<td>CYP1B1</td>
<td>EPHX2</td>
<td>PON3</td>
<td>SLCO1B1</td>
</tr>
<tr>
<td>ADH5</td>
<td>CYP20A1</td>
<td>FAAH</td>
<td>POR</td>
<td>SLCO1B3</td>
</tr>
<tr>
<td>ADH6</td>
<td>CYP21A2</td>
<td>FMO1</td>
<td>PPARD</td>
<td>SLCO2B1</td>
</tr>
<tr>
<td>ADH7</td>
<td>CYP24A1</td>
<td>FMO2</td>
<td>PPARG</td>
<td>SLCO3A1</td>
</tr>
<tr>
<td>AHR</td>
<td>CYP26A1</td>
<td>FMO3</td>
<td>PPP1R9A</td>
<td>SLCO4A1</td>
</tr>
</tbody>
</table>
### Appendix 9

**Drug Metabolism Enzymes, Transporters (DMET), and Liver Injury Polymorphisms** (cont.)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Drug Metabolism Enzymes, Transporters (DMET)</th>
<th>Liver Injury Polymorphisms (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKAP9</td>
<td>CYP26C1</td>
<td>FMO4</td>
</tr>
<tr>
<td>ALB</td>
<td>CYP27A1</td>
<td>FMO5</td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>CYP27B1</td>
<td>FMO6</td>
</tr>
<tr>
<td>ALDH2</td>
<td>CYP2A13</td>
<td>G6PD</td>
</tr>
<tr>
<td>ALDH3A1</td>
<td>CYP2A6</td>
<td>GSTA1</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>CYP2A7</td>
<td>GSTA2</td>
</tr>
<tr>
<td>AOX1</td>
<td>CYP2B6</td>
<td>GSTA3</td>
</tr>
<tr>
<td>APOA2</td>
<td>CYP2B7P1</td>
<td>GSTA4</td>
</tr>
<tr>
<td>ARNT</td>
<td>CYP2C18</td>
<td>GSTA5</td>
</tr>
<tr>
<td>ARSA</td>
<td>CYP2C19</td>
<td>GSTM1</td>
</tr>
<tr>
<td>ATP7A</td>
<td>CYP2C8</td>
<td>GSTM2</td>
</tr>
<tr>
<td>ATP7B</td>
<td>CYP2C9</td>
<td>GSTM3</td>
</tr>
<tr>
<td>CA5P</td>
<td>CYP2D6</td>
<td>GSTM4</td>
</tr>
<tr>
<td>CBR1</td>
<td>CYP2E1</td>
<td>GSTM5</td>
</tr>
<tr>
<td>CBR3</td>
<td>CYP2F1</td>
<td>GSTO1</td>
</tr>
<tr>
<td>CDA</td>
<td>CYP2J2</td>
<td>GSTP1</td>
</tr>
<tr>
<td>CES2</td>
<td>CYP2S1</td>
<td>GSTT1</td>
</tr>
<tr>
<td>CHST1</td>
<td>CYP39A1</td>
<td>GSTT2</td>
</tr>
<tr>
<td>CHST10</td>
<td>CYP3A4</td>
<td>GSTZ1</td>
</tr>
<tr>
<td>CHST11</td>
<td>CYP3A43</td>
<td>HMGCR</td>
</tr>
</tbody>
</table>